"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,FR,A,FR 671850 A,138-882-260-630-714,1929-12-19,1929,FR 671850D A,1929-03-21,FR 671850T A,1929-03-21,Dispositif applicable aux automobiles et véhicules semblables en vue d'éviter des accidents,,,ROYSENTUL ADEL;;MOSS JOSEPH HENRY,,https://lens.org/138-882-260-630-714,Granted Patent,no,0,0,1,1,0,B60R19/26,B60R19/26,,0,0,,,,EXPIRED
2,WO,A1,WO 2020/120854 A1,144-035-472-962-69X,2020-06-18,2020,FR 2019052759 W,2019-11-19,FR 1872667 A,2018-12-11,METHOD FOR COMMANDING THE STARTING OF A HEAT ENGINE OF A HYBRID VEHICLE,"The present invention relates to a method for commanding the starting of a heat engine of a hybrid vehicle by means of an electric traction machine. According to the invention, the method involves, once a start request has been detected (31), determining (32) the energy power that can be delivered to said motive machine at the instant of detection of said request, when said energy power is above a predetermined threshold, initiating (33) a first start procedure, and when said power is below said threshold, initiating (40) a second start procedure consisting in turning over the heat engine by means of the motive machine until reaching a second engine target speed that is less than the first target speed of the first start procedure.",PSA AUTOMOBILES SA,TROJANI JOSEPH;;BOUCRAUT SEBASTIEN;;HARAKAT ADEL,,https://lens.org/144-035-472-962-69X,Patent Application,yes,5,0,6,6,0,B60K6/48;;B60W10/06;;B60W10/08;;B60W20/40;;B60W2510/242;;B60W2710/0644;;B60W2710/081;;B60W2710/083;;Y02T10/62;;B60K2006/268,B60K6/48;;B60W10/06;;B60W10/08;;B60W20/40,,0,0,,,,PENDING
3,AT,T1,AT E432339 T1,179-703-640-867-730,2009-06-15,2009,AT 97921106 T,1997-04-04,US 1490396 P;;US 9705685 W,1996-04-05,"VERWENDUNG VON ONKOFÖTAL-ANTIGEN SPEZIFISCHEN CD4,CD8 ZYTOTOXISCHEN, SUPPRESSOR T-ZELLEN UND INTERLEUKIN-10","The present invention provides a method of determining the success of a cancer therapy in an individual, comprising the step of measuring the frequency of occurence of an oncofetal antigen-specific subclasses in the individual's peripheral blood. Also provided is a method of determining whether protective immunity against a tumor will develop in an individual, comprising the step of measuring the frequency of oncofetal antigen-specific T cells, tumor cells and macrophages at the site of the tumor which secrete IL-10. Additionally, a method of determining whether an individual having a tumor will go into remission or remain in remission, comprising the step of measuring the frequency of oncofetal antigen-specific Th1 cells, Tc cells and Ts cells, IL-10 and interferon-gamma secreting T cells in the peripheral blood.",UNIV SOUTH ALABAMA,COGGIN JOSEPH;;BARSOUM ADEL;;ROHRER JAMES,,https://lens.org/179-703-640-867-730,Granted Patent,no,0,0,11,13,0,C07K16/244;;G01N33/57476;;Y10S435/975;;A61P35/00;;G01N33/57476;;C07K16/244;;Y10S435/975,A61K38/17;;C07K16/24;;G01N33/574,,0,0,,,,EXPIRED
4,FR,B1,FR 3089475 B1,171-208-296-729-70X,2020-11-13,2020,FR 1872667 A,2018-12-11,FR 1872667 A,2018-12-11,Procédé de commande du démarrage d’un moteur thermique de véhicule hybride,"Procédé de commande du démarrage d’un moteur thermique de véhicule hybride La présente invention a pour objet un procédé de commande du démarrage d’un moteur thermique de véhicule hybride au moyen d’une machine de traction électrique. Selon l’invention, le procédé comporte en cas de détection (31) d’une requête de démarrage, la détermination (32) de la puissance d’énergie délivrable à ladite machine motrice à l’instant de la détection de ladite requête, lorsque ladite puissance d’énergie est supérieure à un seuil prédéterminé, le déclenchement (33) d’une première procédure de démarrage, et lorsque ladite puissance est inférieure audit seuil, le déclenchement (40) d’une deuxième procédure de démarrage consistant à entrainer en rotation le moteur thermique par la machine motrice jusqu’à atteindre un deuxième régime cible moteur inférieur au premier régime cible de la première procédure de démarrage. Figure pour l’abrégé : figure 4",PSA AUTOMOBILES SA,TROJANI JOSEPH;;BOUCRAUT SEBASTIEN;;HARAKAT ADEL,,https://lens.org/171-208-296-729-70X,Granted Patent,no,0,0,6,6,0,B60K6/48;;B60W10/06;;B60W10/08;;B60W20/40;;B60W2510/242;;B60W2710/0644;;B60W2710/081;;B60W2710/083;;Y02T10/62;;B60K2006/268,B60W30/192;;B60K6/46;;B60W10/02;;B60W10/06;;B60W10/08;;F02N11/08,,0,0,,,,INACTIVE
5,EP,B1,EP 3894251 B1,004-997-625-015-492,2022-12-28,2022,EP 19823807 A,2019-11-19,FR 1872667 A;;FR 2019052759 W,2018-12-11,METHOD FOR COMMANDING THE STARTING OF A HEAT ENGINE OF A HYBRID VEHICLE,,PSA AUTOMOBILES SA,TROJANI JOSEPH;;BOUCRAUT SEBASTIEN;;HARAKAT ADEL,,https://lens.org/004-997-625-015-492,Granted Patent,yes,3,0,6,6,0,B60K6/48;;B60W10/06;;B60W10/08;;B60W20/40;;B60W2510/242;;B60W2710/0644;;B60W2710/081;;B60W2710/083;;Y02T10/62;;B60K2006/268,B60K6/48;;B60W10/06;;B60W10/08;;B60W20/40,,0,0,,,,ACTIVE
6,ES,T3,ES 2565578 T3,047-249-968-237-835,2016-04-05,2016,ES 03767221 T,2003-08-04,US 40085102 P;;US 0324518 W,2002-08-02,Vacunas contra el cáncer que contienen epítopos de antígeno oncofetal,"Una composición que comprende una pluralidad de fragmentos de antígeno oncofetal (AOF) distintos, no superpuestos que contienen epítopos que estimulan de manera específica los linfocitos T citotóxicos en un mamífero, y un transportador, en la que dicha composición no comprende ningún epítopo de AOF que estimule de manera específica los linfocitos T supresores.",SOUTH ALABAMA MEDICAL SCIENCE FOUND,COGGIN JOSEPH;;ROHRER JAMES;;BARSOUM ADEL,,https://lens.org/047-249-968-237-835,Granted Patent,no,0,0,14,14,0,A61K9/0019;;A61K9/127;;C07K14/4748;;A61P35/00;;A61K39/00118;;A61K9/127;;A61K9/0019;;C07K14/4748;;A61K39/00118,A01N37/18;;A61K39/00;;A61K/;;A61K9/00;;A61K9/127;;A61K38/08;;A61K38/10;;A61K38/17;;A61P35/00;;C07K14/47;;C12P21/00;;C12P21/06,,0,0,,,,EXPIRED
7,CN,A,CN 113165501 A,181-967-639-444-336,2021-07-23,2021,CN 201980082225 A,2019-11-19,FR 1872667 A;;FR 2019052759 W,2018-12-11,METHOD FOR COMMANDING THE STARTING OF A HEAT ENGINE OF A HYBRID VEHICLE,"The present invention relates to a method for commanding the starting of a heat engine of a hybrid vehicle by means of an electric traction machine. According to the invention, the method involves, once a start request has been detected (31), determining (32) the energy power that can be delivered to said motive machine at the instant of detection of said request, when said energy power is above a predetermined threshold, initiating (33) a first start procedure, and when said power is below said threshold, initiating (40) a second start procedure consisting in turning over the heat engine by means of the motive machine until reaching a second engine target speed that is less than the first target speed of the first start procedure.",PEUGEOT CITROEN AUTOMOBILES SA,TROJANI JOSEPH;;BOUCRAUT SEBASTIEN;;HARAKAT ADEL,,https://lens.org/181-967-639-444-336,Patent Application,no,5,0,6,6,0,B60K6/48;;B60W10/06;;B60W10/08;;B60W20/40;;B60W2510/242;;B60W2710/0644;;B60W2710/081;;B60W2710/083;;Y02T10/62;;B60K2006/268,B60K6/48;;B60W10/06;;B60W10/08;;B60W20/40,,0,0,,,,PENDING
8,FR,A1,FR 3089475 A1,168-493-599-863-559,2020-06-12,2020,FR 1872667 A,2018-12-11,FR 1872667 A,2018-12-11,Procédé de commande du démarrage d’un moteur thermique de véhicule hybride,"Procédé de commande du démarrage d’un moteur thermique de véhicule hybride La présente invention a pour objet un procédé de commande du démarrage d’un moteur thermique de véhicule hybride au moyen d’une machine de traction électrique. Selon l’invention, le procédé comporte en cas de détection (31) d’une requête de démarrage, la détermination (32) de la puissance d’énergie délivrable à ladite machine motrice à l’instant de la détection de ladite requête, lorsque ladite puissance d’énergie est supérieure à un seuil prédéterminé, le déclenchement (33) d’une première procédure de démarrage, et lorsque ladite puissance est inférieure audit seuil, le déclenchement (40) d’une deuxième procédure de démarrage consistant à entrainer en rotation le moteur thermique par la machine motrice jusqu’à atteindre un deuxième régime cible moteur inférieur au premier régime cible de la première procédure de démarrage. Figure pour l’abrégé : figure 4",PSA AUTOMOBILES SA,TROJANI JOSEPH;;BOUCRAUT SEBASTIEN;;HARAKAT ADEL,,https://lens.org/168-493-599-863-559,Patent Application,no,5,0,6,6,0,B60K6/48;;B60W10/06;;B60W10/08;;B60W20/40;;B60W2510/242;;B60W2710/0644;;B60W2710/081;;B60W2710/083;;Y02T10/62;;B60K2006/268,B60W30/192;;B60K6/46;;B60W10/02;;B60W10/06;;B60W10/08;;F02N11/08,,0,0,,,,INACTIVE
9,EP,A1,EP 3894251 A1,124-428-030-936-031,2021-10-20,2021,EP 19823807 A,2019-11-19,FR 1872667 A;;FR 2019052759 W,2018-12-11,METHOD FOR COMMANDING THE STARTING OF A HEAT ENGINE OF A HYBRID VEHICLE,,PSA AUTOMOBILES SA,TROJANI JOSEPH;;BOUCRAUT SEBASTIEN;;HARAKAT ADEL,,https://lens.org/124-428-030-936-031,Patent Application,yes,0,0,6,6,0,B60K6/48;;B60W10/06;;B60W10/08;;B60W20/40;;B60W2510/242;;B60W2710/0644;;B60W2710/081;;B60W2710/083;;Y02T10/62;;B60K2006/268,B60K6/48;;B60W10/06;;B60W10/08;;B60W20/40,,0,0,,,,ACTIVE
10,US,B2,US 11115455 B2,102-094-952-958-661,2021-09-07,2021,US 201817055505 A,2018-05-15,EP 2018062517 W,2018-05-15,Technique for monitoring activity in a content delivery network utilizing geohashing indexes,"A technique for monitoring activity in a content delivery network is disclosed. A method implementation of the technique is performed by a monitoring component associated with the content delivery network and comprises extracting (S 302 ), from one or more event logs of the content delivery network, a plurality of IP addresses and a plurality of events associated with the plurality of IP addresses, obtaining (S 304 ) geolocation information for each of the plurality of IP addresses, generating (S 306 ), for each of the plurality of IP addresses, a geohash based on the geolocation information, grouping (S 308 ) the plurality of IP addresses by their geohash to determine a plurality of geohash groups representative of IP addresses having a same geohash, creating (S 310 ) a geohash index including, for each of the plurality of geohash groups, the geohash of the respective geohash group along with a number of IP addresses included in the respective geohash group and cumulative event information associated with the IP addresses of the respective geohash group, and monitoring (S 312 ) activity in the content delivery network based on the geohash index.",ERICSSON TELEFON AB L M,BOUKHTOUTA AMINE;;BRUNNER RICHARD JOSEPH;;LARABI ADEL,TELEFONAKTIEBOLAGET LM ERICSSON (PUBL) (2018-06-07),https://lens.org/102-094-952-958-661,Granted Patent,yes,6,1,4,4,0,H04W4/021;;H04W4/025;;H04W4/029;;H04W4/08;;G06F16/958;;H04L63/1408;;H04L67/1001;;H04L67/535;;H04L67/52;;H04L61/2503;;H04L65/80,G06F15/173;;H04L29/06;;H04L29/12,,1,0,,,"International Search Report for PCT/EP2018/062517, dated Nov. 14, 2018; 10 pages.",ACTIVE
11,US,A1,US 2021/0227014 A1,009-293-708-871-100,2021-07-22,2021,US 201817055505 A,2018-05-15,EP 2018062517 W,2018-05-15,Technique for Monitoring Activity in a Content Delivery Network,"A technique for monitoring activity in a content delivery network is disclosed. A method implementation of the technique is performed by a monitoring component associated with the content delivery network and comprises extracting (S 302 ), from one or more event logs of the content delivery network, a plurality of IP addresses and a plurality of events associated with the plurality of IP addresses, obtaining (S 304 ) geolocation information for each of the plurality of IP addresses, generating (S 306 ), for each of the plurality of IP addresses, a geohash based on the geolocation information, grouping (S 308 ) the plurality of IP addresses by their geohash to determine a plurality of geohash groups representative of IP addresses having a same geohash, creating (S 310 ) a geohash index including, for each of the plurality of geohash groups, the geohash of the respective geohash group along with a number of IP addresses included in the respective geohash group and cumulative event information associated with the IP addresses of the respective geohash group, and monitoring (S 312 ) activity in the content delivery network based on the geohash index.",ERICSSON TELEFON AB L M,BOUKHTOUTA AMINE;;BRUNNER RICHARD JOSEPH;;LARABI ADEL,TELEFONAKTIEBOLAGET LM ERICSSON (PUBL) (2018-06-07),https://lens.org/009-293-708-871-100,Patent Application,yes,0,2,4,4,0,H04W4/021;;H04W4/025;;H04W4/029;;H04W4/08;;G06F16/958;;H04L63/1408;;H04L67/1001;;H04L67/535;;H04L67/52;;H04L61/2503;;H04L65/80,H04L29/06;;H04L29/12,,0,0,,,,ACTIVE
12,EP,A1,EP 3794789 A1,131-861-470-548-703,2021-03-24,2021,EP 18726753 A,2018-05-15,EP 2018062517 W,2018-05-15,TECHNIQUE FOR MONITORING ACTIVITY IN A CONTENT DELIVERY NETWORK,,ERICSSON TELEFON AB L M,BOUKHTOUTA AMINE;;BRUNNER RICHARD JOSEPH;;LARABI ADEL,,https://lens.org/131-861-470-548-703,Patent Application,yes,0,0,4,4,0,H04W4/021;;H04W4/025;;H04W4/029;;H04W4/08;;G06F16/958;;H04L63/1408;;H04L67/1001;;H04L67/535;;H04L67/52;;H04L61/2503;;H04L65/80,H04L29/06;;H04L29/08;;H04L29/12;;H04W4/02;;H04W4/021;;H04W4/029;;H04W4/08,,0,0,,,,DISCONTINUED
13,WO,A1,WO 2019/219172 A1,019-494-516-376-408,2019-11-21,2019,EP 2018062517 W,2018-05-15,EP 2018062517 W,2018-05-15,TECHNIQUE FOR MONITORING ACTIVITY IN A CONTENT DELIVERY NETWORK,"A technique for monitoring activity in a content delivery network is disclosed. A method implementation of the technique is performed by a monitoring component associated with the content delivery network and comprises extracting (S302), from one or more event logs of the content delivery network, a plurality of IP addresses and a plurality of events associated with the plurality of IP addresses, obtaining (S304) geolocation information for each of the plurality of IP addresses, generating (S306), for each of the plurality of IP addresses, a geohash based on the geolocation information, grouping (S308) the plurality of IP addresses by their geohash to determine a plurality of geohash groups representative of IP addresses having a same geohash, creating (S310) a geohash index including, for each of the plurality of geohash groups, the geohash of the respective geohash group along with a number of IP addresses included in the respective geohash group and cumulative event information associated with the IP addresses of the respective geohash group, and monitoring (S312) activity in the content delivery network based on the geohash index.",ERICSSON TELEFON AB L M,BOUKHTOUTA AMINE;;BRUNNER RICHARD JOSEPH;;LARABI ADEL,,https://lens.org/019-494-516-376-408,Patent Application,yes,3,0,4,4,0,H04W4/021;;H04W4/025;;H04W4/029;;H04W4/08;;G06F16/958;;H04L63/1408;;H04L67/1001;;H04L67/535;;H04L67/52;;H04L61/2503;;H04L65/80,H04L29/06;;H04L29/08;;H04L29/12;;H04W4/02;;H04W4/021;;H04W4/029;;H04W4/08;;H04W12/12,,0,0,,,,PENDING
14,FR,B1,FR 3063474 B1,189-846-475-342-797,2020-10-23,2020,FR 1751774 A,2017-03-06,FR 1751774 A,2017-03-06,PROCEDE DE DEMARRAGE D'UN MOTEUR THERMIQUE,"Procédé de démarrage d'un moteur thermique, comprenant une étape de mise en mouvement (T1) du moteur thermique par une machine électrique, puis une étape d'engagement (T2) de la combustion au sein du moteur thermique en mouvement, avant l'arrêt du pilotage de la machine électrique pour laisser le moteur thermique en mouvement sous l'effet de la combustion en son sein, le procédé comprenant une étape d'évaluation (T3) d'un couple fourni par la machine électrique, l'arrêt de pilotage étant effectué en réaction à une observation sur une durée prédéterminée, d'une valeur de couple fourni par la machine électrique inférieure à un seuil prédéterminé.",PEUGEOT CITROEN AUTOMOBILES SA,MARCHYLLIE ALEXIS;;BOUCRAUT SEBASTIEN;;HARAKAT ADEL;;TROJANI JOSEPH,,https://lens.org/189-846-475-342-797,Granted Patent,no,0,0,2,2,0,F02N11/0848;;F02N2200/042;;F02N2300/104;;F02P5/1506,B60W30/192;;B60K6/46;;B60W10/06;;B60W10/08;;B60W10/26;;B60W20/40;;F02D41/30;;F02N11/08,,0,0,,,,ACTIVE
15,FR,A1,FR 3063474 A1,094-358-165-010-124,2018-09-07,2018,FR 1751774 A,2017-03-06,FR 1751774 A,2017-03-06,PROCEDE DE DEMARRAGE D'UN MOTEUR THERMIQUE,"Procédé de démarrage d'un moteur thermique, comprenant une étape de mise en mouvement (T1) du moteur thermique par une machine électrique, puis une étape d'engagement (T2) de la combustion au sein du moteur thermique en mouvement, avant l'arrêt du pilotage de la machine électrique pour laisser le moteur thermique en mouvement sous l'effet de la combustion en son sein, le procédé comprenant une étape d'évaluation (T3) d'un couple fourni par la machine électrique, l'arrêt de pilotage étant effectué en réaction à une observation sur une durée prédéterminée, d'une valeur de couple fourni par la machine électrique inférieure à un seuil prédéterminé.",PEUGEOT CITROEN AUTOMOBILES SA,MARCHYLLIE ALEXIS;;BOUCRAUT SEBASTIEN;;HARAKAT ADEL;;TROJANI JOSEPH,,https://lens.org/094-358-165-010-124,Patent Application,no,3,0,2,2,0,F02N11/0848;;F02N2200/042;;F02N2300/104;;F02P5/1506,B60W30/192;;B60K6/46;;B60W10/06;;B60W10/08;;B60W10/26;;B60W20/40;;F02D41/30;;F02N11/08,,0,0,,,,ACTIVE
16,DE,D1,DE 69021360 D1,076-889-899-707-377,1995-09-07,1995,DE 69021360 T,1990-12-05,US 45806989 A,1989-12-28,Styrol-Isopren-Butadien-Terpolymerkautschuk und Reifen mit Laufflächen daraus.,,GOODYEAR TIRE & RUBBER,HALASA ADEL FARHAN;;BERGH JEAN;;FOURGON FERNAND ANTOINE JOSEPH,,https://lens.org/076-889-899-707-377,Granted Patent,no,0,0,12,13,0,B60C1/0016;;C08F236/10;;C08L7/00;;C08L9/00;;C08L9/06;;Y10T152/10495;;C08F212/00;;Y10T152/10495;;C08F236/10;;C08L9/00;;B60C1/0016;;C08L7/00;;C08L9/06,B29D30/00;;B29K9/06;;B60C1/00;;C08F236/04;;C08F236/10;;C08L9/06;;C08L21/00;;C08L47/00,,0,0,,,,EXPIRED
17,DE,D1,DE 69739423 D1,017-972-844-233-861,2009-07-09,2009,DE 69739423 T,1997-04-04,US 1490396 P;;US 9705685 W,1996-04-05,"VERWENDUNG VON ONKOFÖTAL-ANTIGEN SPEZIFISCHEN CD4, CD8 ZYTOTOXISCHEN, SUPPRESSOR T-ZELLEN UND INTERLEUKIN-10","The present invention provides a method of determining the success of a cancer therapy in an individual, comprising the step of measuring the frequency of occurence of an oncofetal antigen-specific subclasses in the individual's peripheral blood. Also provided is a method of determining whether protective immunity against a tumor will develop in an individual, comprising the step of measuring the frequency of oncofetal antigen-specific T cells, tumor cells and macrophages at the site of the tumor which secrete IL-10. Additionally, a method of determining whether an individual having a tumor will go into remission or remain in remission, comprising the step of measuring the frequency of oncofetal antigen-specific Th1 cells, Tc cells and Ts cells, IL-10 and interferon-gamma secreting T cells in the peripheral blood.",UNIV SOUTH ALABAMA,COGGIN JOSEPH H;;BARSOUM ADEL L;;ROHRER JAMES W,,https://lens.org/017-972-844-233-861,Granted Patent,no,0,0,11,13,0,C07K16/244;;G01N33/57476;;Y10S435/975;;A61P35/00;;G01N33/57476;;C07K16/244;;Y10S435/975,C12N5/00;;A01N63/00;;A61K35/14;;A61K38/17;;A61K39/00;;C07K16/24;;C12N5/02;;C12N5/06;;G01N33/574,,0,0,,,,EXPIRED
18,BR,A2,BR PI1105014 A2,043-144-682-375-582,2015-07-21,2015,BR PI1105014 A,2011-09-22,US 89220410 A,2010-09-28,Composições do revestimento do arame para artigos de borracha,"Composições do revestimento do arame para artigos de borracha. A presente invenção é baseada na descoberta inesperada que a lignina pode ser incorporada na composição da matéria prima do revestimento do arame para melhorar a adesão da borracha ao metal. Tem sido ainda constatado que a lignina pode ser empregada como uma restauração no todo ou em parte para promotores convencionais de adesão da borracha ao metal, tais como, materiais de cobalto os quais são convencionalmente empregados nas matérias primas do revestimento do arame para alcançar e manter as propriedades necessárias de adesão da borracha ao metal. Na verdade, as matérias primas do revestimento do arame que contém a lignina fornecem mais do que as características adequadas de adesão da borracha ao metal para as aplicações típicas, tal como, em pneus, e manter os níveis necessários de adesão durante longos períodos de serviço do produto. Por exemplo, os níveis elevados de adesão da borracha ao metal são mantidos sob condições adversas, tal como, exposição a temperaturas elevadas e os níveis elevados de umidade. A utilização de lignina nas formulações de matéria prima do revestimento do arame de acordo com esta invenção é, da mesma forma, economicamente vantajosa uma vez que a lignina é uma alternativa de baixo custo para agentes mais convencionais promotores de adesão. A lignina é, da mesma forma, ambientalmente amigável e não apresenta quaisquer riscos conhecidos para a saúde. A lignina é derivada da madeira e constitui cerca de 25 por cento a 33 por cento da massa seca da madeira. Por conseguinte, a lignina é um polímero orgânico abundante de ocorrência natural o qual é um recurso renovável uma vez que é derivado de árvores. Por conseguinte, lignina representa uma alternativa altamente eficaz, de baixo custo, abundante, e ambientalmente amigável para promotores convencionais de adesão da borracha ao metal. A presente invenção mais especificamente descreve uma composição da matéria prima do revestimento do arame a qual é compreendida de (1) um polímero de borracha, (2) de cerca de 40 phr a cerca de 80 phr de negro de fumo, e (3) de cerca de 2 phr a cerca de 30 phr de lignina",GOODYEAR TIRE & RUBBER,HALASA ADEL FARHAN;;VERTHE JOHN JOSEPH ANDRE;;LECHTENBOEHMER ANNETTE,,https://lens.org/043-144-682-375-582,Patent Application,no,0,0,5,5,0,B60C1/0008;;B60C1/0008;;B60C2009/0021;;B60C2009/0021;;C08K3/04;;C08K3/04;;C08L7/00;;C08L7/00;;C08L9/00;;C08L9/00;;C08L21/00;;C08L21/00;;C08L91/08;;C08L91/08;;C08L97/005;;C08L97/005;;D07B1/0666;;D07B1/0666,B60C15/00;;B60C9/18;;C08L97/00,,0,0,,,,DISCONTINUED
19,EP,A1,EP 0438966 A1,072-787-518-725-49X,1991-07-31,1991,EP 90630214 A,1990-12-05,US 45806989 A,1989-12-28,"Terpolymer rubber of styrene, isoprene and butadiene and tire with tread thereof.","A styrene, isoprene, butadiene terpolymer rubber with a characterization according to its glass transition temperatures and unit structure and a pneumatic tire with a tread composed of such terpolymer rubber specifically in combination with selected other rubber.",GOODYEAR TIRE & RUBBER,HALASA ADEL FARHAN;;BERGH JEAN;;FOURGON FERNAND ANTOINE JOSEPH,,https://lens.org/072-787-518-725-49X,Patent Application,yes,4,8,12,13,0,B60C1/0016;;C08F236/10;;C08L7/00;;C08L9/00;;C08L9/06;;Y10T152/10495;;C08F212/00;;Y10T152/10495;;C08F236/10;;C08L9/00;;B60C1/0016;;C08L7/00;;C08L9/06,B29D30/00;;B29K9/06;;B60C1/00;;C08F236/04;;C08F236/10;;C08L9/06;;C08L21/00;;C08L47/00,,0,0,,,,EXPIRED
20,US,A1,US 2012/0073720 A1,133-538-132-555-567,2012-03-29,2012,US 89220410 A,2010-09-28,US 89220410 A,2010-09-28,WIRE COAT COMPOSITIONS FOR RUBBER ARTICLES,"The present invention is based upon the unexpected finding that lignin can be incorporated into wire coat stock composition to improve metal to rubber adhesion. It has been further found that lignin can be used as a replacement in whole or in part for conventional rubber-to-metal adhesion promoters, such as cobalt materials which are conventionally used in wire coat stocks to attain and maintain needed rubber-to-wire adhesion properties. In fact, wire coat stocks that contain lignin provide more that adequate rubber-to-metal adhesion characteristics for typical applications, such as in tires, and maintain needed levels of adhesion over long periods of product service. For instance, high levels of rubber-to-metal adhesion are maintained under harsh conditions, such as exposure to elevated temperatures and high levels of humidity. The utilization of lignin in wire coat stock formulations in accordance with this invention is also economically advantageous since lignin is a low cost alternative to most conventional adhesion promoting agents. Lignin is also environmentally friendly and does not present any known health hazards. Lignin is derived from wood and constitutes about 25 percent to 33 percent of the dry mass of wood. Accordingly, lignin is an abundant naturally occurring organic polymer which is a renewable resource since it is derived from trees. Accordingly, lignin represents a low cost, abundant, environmentally friendly, and highly effective alternative to conventional rubber-to-metal adhesion promoters. The present invention more specifically discloses a wire coat stock composition which is comprised of (1) a rubbery polymer, (2) about 40 phr to about 80 phr of carbon black, and (3) about 2 phr to about 30 phr of lignin.",HALASA ADEL FARHAN;;VERTHE JOHN JOSEPH ANDRE;;LECHTENBOEHMER ANNETTE;;GOODYEAR TIRE & RUBBER,HALASA ADEL FARHAN;;VERTHE JOHN JOSEPH ANDRE;;LECHTENBOEHMER ANNETTE,,https://lens.org/133-538-132-555-567,Patent Application,yes,11,14,5,5,0,B60C1/0008;;B60C1/0008;;B60C2009/0021;;B60C2009/0021;;C08K3/04;;C08K3/04;;C08L7/00;;C08L7/00;;C08L9/00;;C08L9/00;;C08L21/00;;C08L21/00;;C08L91/08;;C08L91/08;;C08L97/005;;C08L97/005;;D07B1/0666;;D07B1/0666,B60C9/18;;B60C15/00;;C08L97/00,152/527;;524/76;;152/540;;152/532,2,0,,,"Machine translation of JP 2006-249361, 2006.;;https://monographs.iarc.fr/ENG/Monographs/vol93/mono93-6.pdf, no date.",DISCONTINUED
21,EP,A1,EP 0629640 A1,068-264-230-177-319,1994-12-21,1994,EP 94108554 A,1994-06-03,US 7763393 A,1993-06-17,Process for the synthesis of isoprene-butadiene rubber.,"The subject invention relates to a technique for synthesizing rubbery non-tapered, random, copolymers of 1,3-butadiene and isoprene. These rubbery copolymers exhibit an excellent combination of properties for utilization in tire sidewall rubber compounds for truck tires. By utilizing these isoprene-butadiene rubbers in tire sidewalls, tires having improved cut growth resistance can be built without sacrificing rolling resistance. Such rubbers can also be employed in tire tread compounds to improve tread wear characteristics and decrease rolling resistance without sacrificing traction characteristics. This invention more specifically discloses a process for the synthesis of isoprene-butadiene rubbers which comprises copolymerizing isoprene monomer and 1,3-butadiene monomer in an organic solvent in the presence of a catalyst system which is made by the sequential steps of (1) mixing (a) an organoaluminum hydride, (b) a member selected from the group consisting of aliphatic alcohols, cycloaliphatic alcohols, aliphatic thiols, cycloaliphatic thiols, trialkyl silanols, and triaryl silanols, and (c) optionally, 1,3-butadiene in an organic solvent to produce a modified organoaluminum catalyst component; (2) adding an organometallic compound which contains a metal from Group III-B of the Periodic System to the modified organoaluminum catalyst component to produce a Group III-B metal containing catalyst component; and (3) adding a compound which contains at least one labile halogen atom to the Group III-B metal containing catalyst component.",GOODYEAR TIRE & RUBBER,BELL ANTHONY JOSEPH;;MATRANA BARRY ALLEN;;HALASA ADEL FARHAN,,https://lens.org/068-264-230-177-319,Patent Application,yes,2,12,12,12,0,C08F236/04;;C08F236/04,C08F4/60;;C08F4/58;;C08F236/04;;C08F236/08,,1,0,,,"DATABASE WPI Week 8930, Derwent World Patents Index; AN 89-216511",EXPIRED
22,EP,A1,EP 2433813 A1,159-413-081-318-821,2012-03-28,2012,EP 11182786 A,2011-09-26,US 89220410 A,2010-09-28,Wire coat compositions for rubber articles,"The present invention is based upon the finding that lignin can be incorporated into wire coat stock composition to improve metal to rubber adhesion. It has been further found that lignin can be used as a replacement in whole or in part for conventional rubber-to-metal adhesion promoters, such as cobalt materials which are conventionally used in wire coat stocks to attain and maintain needed rubber-to-wire adhesion properties. In fact, wire coat stocks that contain lignin provide more that adequate rubber-to-metal adhesion characteristics for typical applications, such as in tires, and maintain needed levels of adhesion over long periods of product service. The utilization of lignin in wire coat stock formulations in accordance with this invention is also economically advantageous since lignin is a low cost alternative to most conventional adhesion promoting agents. The present invention more specifically discloses a wire coat stock composition which comprises a rubbery polymer, 40 phr to 80 phr of carbon black, and 2 phr to 30 phr of lignin.",GOODYEAR TIRE & RUBBER,HALASA ADEL FARHAN;;VERTHE JOHN JOSEPH ANDRE;;LECHTENBOEHMER ANNETTE,,https://lens.org/159-413-081-318-821,Patent Application,yes,20,15,5,5,0,B60C1/0008;;B60C1/0008;;B60C2009/0021;;B60C2009/0021;;C08K3/04;;C08K3/04;;C08L7/00;;C08L7/00;;C08L9/00;;C08L9/00;;C08L21/00;;C08L21/00;;C08L91/08;;C08L91/08;;C08L97/005;;C08L97/005;;D07B1/0666;;D07B1/0666,B60C1/00;;C08K3/04;;C08L7/00;;C08L21/00;;C08L91/08;;C08L97/00,,0,0,,,,ACTIVE
23,DE,D1,DE 69401386 D1,100-869-971-872-730,1997-02-20,1997,DE 69401386 T,1994-06-03,US 7763393 A,1993-06-17,Verfahren zur Herstellung eines Isopren-Butadien Kautschuks,,GOODYEAR TIRE & RUBBER,BELL ANTHONY JOSEPH;;MATRANA BARRY ALLEN;;HALASA ADEL FARHAN,,https://lens.org/100-869-971-872-730,Granted Patent,no,0,0,12,12,0,C08F236/04;;C08F236/04,C08F4/60;;C08F4/58;;C08F236/04;;C08F236/08,,0,0,,,,EXPIRED
24,NO,B,NO 151591 B,110-496-531-303-028,1985-01-21,1985,NO 782729 A,1978-08-10,US 82476777 A;;US 82478077 A;;US 86697378 A,1977-08-15,METALLARMERT GUMMILAMINAT HVOR GUMMIDELEN HAR FORBEDRET ADHESJON TIL EN METALLDEL I KONTAKT MED GUMMIBLANDINGEN,,FIRESTONE TIRE & RUBBER CO,RAVAGNANI FREDERICK JOSEPH;;SCHONFELD STEVEN EDWARD;;HALASA ADEL FARHAN,,https://lens.org/110-496-531-303-028,Unknown,no,0,0,16,21,0,B29C66/721;;B29C66/72141,B29C55/00;;B29C65/70;;C08K5/17;;B29C67/00;;B29D29/00;;B32B15/04;;B32B15/06;;B32B25/00;;B60C1/00;;C07C63/06;;C07C63/08;;C08J/;;C08J5/04;;C08J5/12;;C08K5/18;;C08L/;;C08L7/00;;C08L21/00;;C09J5/00,,0,0,,,,EXPIRED
25,WO,A2,WO 2011/006084 A2,138-844-959-845-156,2011-01-13,2011,US 2010/0041556 W,2010-07-09,US 27057009 P,2009-07-09,VACCINES WITH ONCOFETAL ANTIGEN/ILRP-LOADED AUTOLOGOUS DENDRITIC CELLS AND USES THEREOF,"Disclosed are compositions containing isolated monocyte-derived mature dendritic cells loaded with OFA/iLRP, or a fragment thereof that selectively stimulates T cytotoxic lymphocytes, and a carrier, vaccine compositions containing effective dosage amounts of the dendritic cells, methods of making the vaccines, and methods of cancer treatment or therapy that entail administration of the vaccines to cancer patients.",UNIV SOUTH ALABAMA;;ROHRER JAMES W;;COGGIN JOSEPH H;;BARSOUM ADEL L,ROHRER JAMES W;;COGGIN JOSEPH H;;BARSOUM ADEL L,,https://lens.org/138-844-959-845-156,Patent Application,yes,0,4,4,4,0,A61K35/26;;C12N5/0639;;C12N2501/02;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61P35/00;;A61P37/04;;A61K2239/49;;A61K2239/31;;A61K39/4615;;A61K39/4622;;A61K39/464402;;A61K39/46448;;A61K2239/38;;C12N5/0639;;A61K35/26;;A61K2039/5154;;C12N2501/23;;C12N2501/25;;C12N2501/22;;C12N2501/02;;A61K39/00118,A61K39/395;;A61K38/20;;A61K39/00;;A61P35/00,,0,0,,,,PENDING
26,US,A1,US 2003/0124125 A1,055-729-745-533-445,2003-07-03,2003,US 29452402 A,2002-11-14,US 29452402 A;;US 17391298 A;;US 83506997 A;;US 1490396 P,1996-04-05,"Oncofetal antigen specific T-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific CD4, CD8 cytotoxic and suppressor T cells and interleukin-10","
   Disclosed are methods for detecting cancer or determining the success of cancer therapy in an individual. These methods are based on analyzing the presence or frequency of cloned oncofetal antigen (OFA)- or immature laminin receptor protein (iLRP)-specific T lymphocyte subclasses obtained from the individual and which are stimulated with 44 kD OFA or iLRPA. A frequency of CD8 cytotoxic T cells relative to CD8 T suppressor cells indicates effectiveness of therapy, and a likelihood that protective immunity will develop. Also disclosed are kits for conducting these methods. Further disclosed are methods of rendering T suppressor lymphocytes cytotoxic, and methods of clonally expanding cytotoxic T lymphocytes in vivo. 
",UNIV SOUTH ALABAMA,COGGIN JOSEPH H;;ROHRER JAMES W;;BARSOUM ADEL L,,https://lens.org/055-729-745-533-445,Patent Application,yes,8,3,2,13,1,C07K16/244;;C07K16/2812;;C07K16/2815;;C07K16/2845;;C07K16/289;;C07K16/30;;G01N33/57476;;C07K2317/73;;C07K2317/76;;C07K16/2812;;G01N33/57476;;C07K16/2845;;C07K16/244;;C07K16/289;;C07K16/30;;C07K16/2815;;C07K2317/73;;C07K2317/76,A61K38/17;;A61K39/395;;C07K16/24;;C07K16/28;;C07K16/30;;C12N5/08;;G01N33/574,424/145.1;;435/372,0,0,,,,DISCONTINUED
27,EP,B1,EP 0438966 B1,099-824-360-582-993,1995-08-02,1995,EP 90630214 A,1990-12-05,US 45806989 A,1989-12-28,"Terpolymer rubber of styrene, isoprene and butadiene and tire with tread thereof.",,GOODYEAR TIRE & RUBBER,HALASA ADEL FARHAN;;BERGH JEAN;;FOURGON FERNAND ANTOINE JOSEPH,,https://lens.org/099-824-360-582-993,Granted Patent,yes,4,0,12,13,0,B60C1/0016;;C08F236/10;;C08L7/00;;C08L9/00;;C08L9/06;;Y10T152/10495;;C08F212/00;;Y10T152/10495;;C08F236/10;;C08L9/00;;B60C1/0016;;C08L7/00;;C08L9/06,B29D30/00;;B29K9/06;;B60C1/00;;C08F236/04;;C08F236/10;;C08L9/06;;C08L21/00;;C08L47/00,,0,0,,,,EXPIRED
28,AU,B2,AU 643960 B2,091-947-610-275-451,1993-12-02,1993,AU 1990/068392 A,1990-12-21,US 45806989 A,1989-12-28,"Terpolymer rubber of styrene, isoprene and butadiene and tire with tread thereof",,GOODYEAR TIRE & RUBBER,HALASA ADEL FARHAN;;BERGH JEAN;;FOURGON FERNAND ANTOINE JOSEPH,,https://lens.org/091-947-610-275-451,Granted Patent,no,1,0,12,13,0,B60C1/0016;;C08F236/10;;C08L7/00;;C08L9/00;;C08L9/06;;Y10T152/10495;;C08F212/00;;Y10T152/10495;;C08F236/10;;C08L9/00;;B60C1/0016;;C08L7/00;;C08L9/06,B29D30/00;;B29K9/06;;B60C1/00;;C08F236/04;;C08F236/10;;C08L9/06;;C08L21/00;;C08L47/00,,0,0,,,,EXPIRED
29,MX,A,MX 147498 A,108-390-123-269-943,1982-12-10,1982,MX 17451378 A,1978-08-14,US 82476777 A;;US 82478077 A;;US 86697378 A,1977-08-15,NUEVO USO INDUSTRIAL DEL ACIDO P-AMINOBENZOICO O SUS SALES DE METAL DE TRANSICION COMO AGENTES MEJORADORES DE LA ADHESION ENTRE COMPOSICIONES DE HULE Y ELEMENTOS METALICOS,,FIRESTONE TIRE & RUBBER CO,RAVAGNANI FREDERICK JOSEPH;;SCHONFELD STEVEN EDWARD;;HALASA ADEL FARHAN,,https://lens.org/108-390-123-269-943,Granted Patent,no,0,0,16,21,0,B29C66/721;;B29C66/72141,B29C55/00;;B29C65/70;;C08K5/17;;B29C67/00;;B29D29/00;;B32B15/04;;B32B15/06;;B32B25/00;;B60C1/00;;C07C63/06;;C07C63/08;;C08J/;;C08J5/04;;C08J5/12;;C08K5/18;;C08L/;;C08L7/00;;C08L21/00;;C09J5/00,09-6;;79-3,0,0,,,,EXPIRED
30,AU,A,AU 1978/038913 A,191-552-490-199-077,1980-02-21,1980,AU 1978/038913 A,1978-08-15,US 82476777 A,1977-08-15,RUBBER COMPOSITION,,FIRESTONE TIRE AND RUBBER CO THE,RAVAGNANI FREDERICK JOSEPH;;SCHONFELD STEVEN EDWARD;;HALASA ADEL FARHAN,,https://lens.org/191-552-490-199-077,Patent Application,no,0,0,4,21,0,B29C66/721;;B29C66/72141,C08K5/17;;B29C55/00;;B29C65/70;;B29C67/00;;B29D29/00;;B32B15/04;;B32B15/06;;B32B25/00;;B60C1/00;;C07C63/06;;C07C63/08;;C08J/;;C08J5/04;;C08J5/12;;C08K5/09;;C08K5/18;;C08L/;;C08L7/00;;C08L21/00;;C09J5/00,,0,0,,,,EXPIRED
31,DE,T2,DE 69401386 T2,085-666-238-490-375,1997-07-17,1997,DE 69401386 T,1994-06-03,US 7763393 A,1993-06-17,Verfahren zur Herstellung eines Isopren-Butadien Kautschuks,,GOODYEAR TIRE & RUBBER,BELL ANTHONY JOSEPH;;MATRANA BARRY ALLEN;;HALASA ADEL FARHAN,,https://lens.org/085-666-238-490-375,Granted Patent,no,0,0,12,12,0,C08F236/04;;C08F236/04,C08F4/60;;C08F4/58;;C08F236/04;;C08F236/08,,0,0,,,,EXPIRED
32,CA,A1,CA 2250164 A1,093-856-227-592-189,1997-10-16,1997,CA 2250164 A,1997-04-04,US 1490396 P;;US 9705685 W,1996-04-05,"USES OF ONCOFETAL ANTIGEN SPECIFIC CD4, CD8 CYTOTOXIC AND SUPPRESSOR T CELLS AND INTERLEUKIN-10","The present invention provides a method of determining the success of a cancer therapy in an individual, comprising the step of measuring the frequency of occurrence of an oncofetal antigen-specific subclasses in the individual's peripheral blood. Also provided is a method of determining whether protective immunity against a tumor will develop in an individual, comprising the step of measuring the frequency of oncofetal antigen-specific T cells, tumor cells and macrophages at the site of the tumor which secrete IL-10. Additionally, a method of determining whether an individual having a tumor will go into remission or remain in remission, comprising the step of measuring the frequency of oncofetal antigen-specific Th1 cells, Tc cells and Ts cells, IL10 and interferon-.gamma. secreting T cells in the peripheral blood.",UNIV SOUTH ALABAMA,BARSOUM ADEL L;;COGGIN JOSEPH H;;ROHRER JAMES W,,https://lens.org/093-856-227-592-189,Patent Application,no,0,0,11,13,0,C07K16/244;;G01N33/57476;;Y10S435/975;;A61P35/00;;G01N33/57476;;C07K16/244;;Y10S435/975,A61K38/17;;C07K16/24;;G01N33/574,,0,0,,,,EXPIRED
33,EP,B1,EP 0939796 B1,034-483-708-704-736,2009-05-27,2009,EP 97921106 A,1997-04-04,US 9705685 W;;US 1490396 P,1996-04-05,"USES OF ONCOFETAL ANTIGEN SPECIFIC CD4, CD8 CYTOTOXIC AND SUPPRESSOR T CELLS AND INTERLEUKIN-10","The present invention provides a method of determining the success of a cancer therapy in an individual, comprising the step of measuring the frequency of occurence of an oncofetal antigen-specific subclasses in the individual's peripheral blood. Also provided is a method of determining whether protective immunity against a tumor will develop in an individual, comprising the step of measuring the frequency of oncofetal antigen-specific T cells, tumor cells and macrophages at the site of the tumor which secrete IL-10. Additionally, a method of determining whether an individual having a tumor will go into remission or remain in remission, comprising the step of measuring the frequency of oncofetal antigen-specific Th1 cells, Tc cells and Ts cells, IL-10 and interferon-gamma secreting T cells in the peripheral blood.",UNIV SOUTH ALABAMA,COGGIN JOSEPH H;;BARSOUM ADEL L;;ROHRER JAMES W,,https://lens.org/034-483-708-704-736,Granted Patent,yes,0,1,11,13,0,C07K16/244;;G01N33/57476;;Y10S435/975;;A61P35/00;;G01N33/57476;;C07K16/244;;Y10S435/975,C12N5/00;;A01N63/00;;A61K35/14;;A61K38/17;;A61K39/00;;C07K16/24;;C12N5/02;;C12N5/06;;G01N33/574,,2,1,001-091-616-258-863,10697612,"COGGIN J.H. ET AL: ""37 kilodalton oncofetal antigen protein and immature laminin receptor are identical, universal T-cell inducing immunogens on primary rodent and human cancers"", ANTICANCER RESEARCH, vol. 19, 1999, pages 5535 - 5542, XP002981891;;ROHRER J.W. ET AL: ""The development of a new universal tumor rejection antigen expressed on human and rodent cancers for vaccination, prevention of cancer, and anti-tumor therapy"", MOD. ASP. IMMUNOBIOL., vol. 1, no. 5, 2001, pages 191 - 195",EXPIRED
34,WO,A3,WO 2011/006084 A3,048-304-137-413-629,2011-05-12,2011,US 2010/0041556 W,2010-07-09,US 27057009 P,2009-07-09,VACCINES WITH ONCOFETAL ANTIGEN/ILRP-LOADED AUTOLOGOUS DENDRITIC CELLS AND USES THEREOF,"Disclosed are compositions containing isolated monocyte-derived mature dendritic cells loaded with OFA/iLRP, or a fragment thereof that selectively stimulates T cytotoxic lymphocytes, and a carrier, vaccine compositions containing effective dosage amounts of the dendritic cells, methods of making the vaccines, and methods of cancer treatment or therapy that entail administration of the vaccines to cancer patients.",UNIV SOUTH ALABAMA;;ROHRER JAMES W;;COGGIN JOSEPH H;;BARSOUM ADEL L,ROHRER JAMES W;;COGGIN JOSEPH H;;BARSOUM ADEL L,,https://lens.org/048-304-137-413-629,Search Report,yes,3,0,4,4,0,A61K35/26;;C12N5/0639;;C12N2501/02;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61P35/00;;A61P37/04;;A61K2239/49;;A61K2239/31;;A61K39/4615;;A61K39/4622;;A61K39/464402;;A61K39/46448;;A61K2239/38;;C12N5/0639;;A61K35/26;;A61K2039/5154;;C12N2501/23;;C12N2501/25;;C12N2501/22;;C12N2501/02;;A61K39/00118,A61K39/395;;A61K38/20;;A61K39/00;;A61P35/00,,3,2,081-222-251-281-305;;066-975-326-005-050,12869512;;10.1182/blood-2003-01-0198;;pmc3775650;;10.1158/1078-0432.ccr-08-3240;;19622576,"SIEGEL, S. ET AL.: ""Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies."", BLOOD., vol. 102, no. 13, 17 July 2003 (2003-07-17), pages 4416 - 4423, XP007911735, DOI: doi:10.1182/blood-2003-01-0198;;JOSEPH, H. COGGIN JR. ET AL.: ""Cancer Vaccine Technology Update: The Immunobiology of 37 kDa Oncofetal Antigen/Immature Laminin Receptor Protein (OFA/iLRP) and RNA, a Universal Tumor Immunogen."", MOD. ASP. IMMUNOBIOL., vol. 16, 2005, pages 27 - 34;;SCHWAAB, T. ET AL.: ""Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients."", CLIN. CANCER RES., vol. 15, no. 15, 21 July 2009 (2009-07-21), pages 4986 - 4992",PENDING
35,BR,A,BR 9402389 A,054-672-219-321-222,1995-01-17,1995,BR 9402389 A,1994-06-13,US 7763393 A,1993-06-17,Processo para a síntese de borrachas isopreno-butadieno; processo para a preparação de um sistema catalítico e sistema catalítico,,GOODYEAR TIRE & RUBBER,BELL ANTHONY JOSEPH;;MATRANA BARRY ALLEN;;HALASA ADEL FARHAN,,https://lens.org/054-672-219-321-222,Patent Application,no,0,0,12,12,0,C08F236/04;;C08F236/04,C08F4/60;;C08F4/58;;C08F236/04;;C08F236/08,,0,0,,,,EXPIRED
36,EP,A1,EP 0939796 A1,062-640-824-565-237,1999-09-08,1999,EP 97921106 A,1997-04-04,US 9705685 W;;US 1490396 P,1996-04-05,"USES OF ONCOFETAL ANTIGEN SPECIFIC CD4, CD8 CYTOTOXIC AND SUPPRESSOR T CELLS AND INTERLEUKIN-10","The present invention provides a method of determining the success of a cancer therapy in an individual, comprising the step of measuring the frequency of occurence of an oncofetal antigen-specific subclasses in the individual's peripheral blood. Also provided is a method of determining whether protective immunity against a tumor will develop in an individual, comprising the step of measuring the frequency of oncofetal antigen-specific T cells, tumor cells and macrophages at the site of the tumor which secrete IL-10. Additionally, a method of determining whether an individual having a tumor will go into remission or remain in remission, comprising the step of measuring the frequency of oncofetal antigen-specific Th1 cells, Tc cells and Ts cells, IL-10 and interferon-gamma secreting T cells in the peripheral blood.",UNIV SOUTH ALABAMA,COGGIN JOSEPH H;;BARSOUM ADEL L;;ROHRER JAMES W,,https://lens.org/062-640-824-565-237,Patent Application,yes,0,0,11,13,0,C07K16/244;;G01N33/57476;;Y10S435/975;;A61P35/00;;G01N33/57476;;C07K16/244;;Y10S435/975,A61K38/17;;C07K16/24;;G01N33/574,,0,0,,,,EXPIRED
37,NO,L,NO 782729 L,128-281-630-684-175,1979-02-16,1979,NO 782729 A,1978-08-10,US 82476777 A;;US 82478077 A;;US 86697378 A,1977-08-15,GUMMIBLANDING EGNET FOR LAGVISE SAMMENSETNINGER MED METALL-FORSTERKNINGER,,FIRESTONE TIRE & RUBBER CO,RAVAGNANI FREDERICK JOSEPH;;SCHONFELD STEVEN EDWARD;;HALASA ADEL FARHAN,,https://lens.org/128-281-630-684-175,Abstract,no,0,0,16,21,0,B29C66/721;;B29C66/72141,B29C55/00;;C08K5/17;;B29C65/70;;B29C67/00;;B29D29/00;;B32B15/04;;B32B15/06;;B32B25/00;;B60C1/00;;C07C63/06;;C07C63/08;;C08J/;;C08J5/04;;C08J5/12;;C08K5/18;;C08L/;;C08L7/00;;C08L21/00;;C09J5/00,,0,0,,,,EXPIRED
38,DE,T2,DE 69021360 T2,132-578-661-084-617,1996-03-14,1996,DE 69021360 T,1990-12-05,US 45806989 A,1989-12-28,Styrol-Isopren-Butadien-Terpolymerkautschuk und Reifen mit Laufflächen daraus.,,GOODYEAR TIRE & RUBBER,HALASA ADEL FARHAN;;BERGH JEAN;;FOURGON FERNAND ANTOINE JOSEPH,,https://lens.org/132-578-661-084-617,Granted Patent,no,0,0,12,13,0,B60C1/0016;;C08F236/10;;C08L7/00;;C08L9/00;;C08L9/06;;Y10T152/10495;;C08F212/00;;Y10T152/10495;;C08F236/10;;C08L9/00;;B60C1/0016;;C08L7/00;;C08L9/06,B29D30/00;;B29K9/06;;B60C1/00;;C08F236/04;;C08F236/10;;C08L9/06;;C08L21/00;;C08L47/00,,0,0,,,,EXPIRED
39,EP,A4,EP 0939796 A4,102-138-072-828-908,2004-10-20,2004,EP 97921106 A,1997-04-04,US 9705685 W;;US 1490396 P,1996-04-05,"USES OF ONCOFETAL ANTIGEN SPECIFIC CD4, CD8 CYTOTOXIC AND SUPPRESSOR T CELLS AND INTERLEUKIN-10","The present invention provides a method of determining the success of a cancer therapy in an individual, comprising the step of measuring the frequency of occurence of an oncofetal antigen-specific subclasses in the individual's peripheral blood. Also provided is a method of determining whether protective immunity against a tumor will develop in an individual, comprising the step of measuring the frequency of oncofetal antigen-specific T cells, tumor cells and macrophages at the site of the tumor which secrete IL-10. Additionally, a method of determining whether an individual having a tumor will go into remission or remain in remission, comprising the step of measuring the frequency of oncofetal antigen-specific Th1 cells, Tc cells and Ts cells, IL-10 and interferon-gamma secreting T cells in the peripheral blood.",UNIV SOUTH ALABAMA,COGGIN JOSEPH H;;BARSOUM ADEL L;;ROHRER JAMES W,,https://lens.org/102-138-072-828-908,Search Report,no,0,0,11,13,0,C07K16/244;;G01N33/57476;;Y10S435/975;;A61P35/00;;G01N33/57476;;C07K16/244;;Y10S435/975,A61K38/17;;C07K16/24;;G01N33/574,,1,1,143-844-143-629-195,7499859,"ROHRER J W & COGGIN J H: ""CD8 T cell clones inhibit antitumor T cell function by secreting IL-10"", JOURNAL OF IMMUNOLOGY, vol. 155, no. 12, 15 December 1995 (1995-12-15), pages 5719 - 5727, XP002293749, ISSN: 0022-1767",EXPIRED
40,NO,C,NO 151591 C,187-670-389-711-454,1985-05-08,1985,NO 782729 A,1978-08-10,US 82476777 A;;US 82478077 A;;US 86697378 A,1977-08-15,METALLARMERT GUMMILAMINAT HVOR GUMMIDELEN HAR FORBEDRET ADHESJON TIL EN METALLDEL I KONTAKT MED GUMMIBLANDINGEN,,FIRESTONE TIRE & RUBBER CO,RAVAGNANI FREDERICK JOSEPH;;SCHONFELD STEVEN EDWARD;;HALASA ADEL FARHAN,,https://lens.org/187-670-389-711-454,Granted Patent,no,0,0,16,21,0,B29C66/721;;B29C66/72141,B29C55/00;;B29C65/70;;C08K5/17;;B29C67/00;;B29D29/00;;B32B15/04;;B32B15/06;;B32B25/00;;B60C1/00;;C07C63/06;;C07C63/08;;C08J/;;C08J5/04;;C08J5/12;;C08K5/18;;C08L/;;C08L7/00;;C08L21/00;;C09J5/00,,0,0,,,,EXPIRED
41,US,A1,US 2019/0232718 A1,017-739-697-347-437,2019-08-01,2019,US 201916381186 A,2019-04-11,US 201916381186 A;;US 89220410 A,2010-09-28,WIRE COAT COMPOSITIONS FOR RUBBER ARTICLES,"This invention reveals a pneumatic tire comprising a generally toroidal-shaped carcass with an outer circumferential tread, two spaced beads, at least one ply extending from bead to bead and sidewalls extending radially from and connecting said tread to said beads, and an innerliner which covers the inner surface and which is comprised of a halobutyl rubber, a filler and lignin. The incorporation of lignin into the innerliner prevents migration of moisture into the tire carcass which can lead to corrosion and consequential delamination of steel cords within the tire. Normally the lignin will be included in such innerliner formulations in an amount which is within the range of 1 phr to 20 phr. Lignin can also be used to protect the steel belts by incorporating it into other tire components located between the innerliner and the belts.",HALASA ADEL FARHAN;;VERTHE JOHN JOSEPH ANDRE;;LECHTENBOEHMER ANNETTE;;GOODYEAR TIRE & RUBBER,HALASA ADEL FARHAN;;VERTHE JOHN JOSEPH ANDRE;;LECHTENBOEHMER ANNETTE,THE GOODYEAR TIRE & RUBBER COMPANY (2010-09-20),https://lens.org/017-739-697-347-437,Patent Application,yes,0,0,5,5,0,B60C1/0008;;B60C1/0008;;B60C2009/0021;;B60C2009/0021;;C08K3/04;;C08K3/04;;C08L7/00;;C08L7/00;;C08L9/00;;C08L9/00;;C08L21/00;;C08L21/00;;C08L91/08;;C08L91/08;;C08L97/005;;C08L97/005;;D07B1/0666;;D07B1/0666,B60C1/00;;C08K3/04;;C08L21/00;;D07B1/06,,0,0,,,,DISCONTINUED
42,AU,B2,AU 633257 B2,037-129-741-507-045,1993-01-28,1993,AU 1989/037128 A,1989-06-28,US 21301988 A,1988-06-29,"STYRENE, ISOPRENE, BUTADIENE RUBBER AND TIRE WITH TREAD THEREOF",,THE GOODYEAR TIRE & RUBBER COMPANY,ADEL FARHAN HALASA;;JEAN BERGH;;FERNAND ANTOINE JOSEPH FOURGON,,https://lens.org/037-129-741-507-045,Granted Patent,no,3,1,9,10,0,B60C1/0016;;C08F236/10;;Y10T152/10495;;C08F236/08;;Y10T152/10495;;C08F236/10;;B60C1/0016,B60C1/00;;C08F236/06;;C08F236/08;;C08F236/10;;C08L9/00;;C08L21/00,,0,0,,,,EXPIRED
43,CA,C,CA 2250164 C,058-768-770-572-615,2011-12-06,2011,CA 2250164 A,1997-04-04,US 1490396 P;;US 9705685 W,1996-04-05,"ONCOFETAL ANTIGEN SPECIFIC T-LYMPHOCYTE MEDIATED IMMUNE RESPONSE: MANIPULATION AND USES OF ONCOFETAL ANTIGEN SPECIFIC CD4, CD8 CYTOTOXIC AND SUPPRESSOR T CELLS AND INTERLEUKIN-10","The present invention provides a method of determining the success of a cancer therapy in an individual, comprising the step of measuring the frequency of occurrence of an oncofetal antigen-specific subclasses in the individual's peripheral blood. Also provided is a method of determining whether protective immunity against a tumor will develop in an individual, comprising the step of measuring the frequency of oncofetal antigen-specific T cells, tumor cells and macrophages at the site of the tumor which secrete IL-10. Additionally, a method of determining whether an individual having a tumor will go into remission or remain in remission, comprising the step of measuring the frequency of oncofetal antigen-specific Th1 cells, Tc cells and Ts cells, IL-10 and interferon-.gamma. secreting T cells in the peripheral blood.",UNIV SOUTH ALABAMA,COGGIN JOSEPH H;;BARSOUM ADEL L;;ROHRER JAMES W,,https://lens.org/058-768-770-572-615,Granted Patent,no,0,0,11,13,0,C07K16/244;;G01N33/57476;;Y10S435/975;;A61P35/00;;G01N33/57476;;C07K16/244;;Y10S435/975,A61K39/00;;A61K38/17;;A61P35/00;;C07K16/24;;C12Q1/04;;G01N33/574,,0,0,,,,EXPIRED
44,EP,A1,EP 0349472 A1,094-911-652-185-58X,1990-01-03,1990,EP 89630106 A,1989-06-14,US 21301988 A,1988-06-29,"Styrene, isoprene, butadiene rubber and tire with tread thereof.","A styrene, isoprene, butadiene terpolymer rubber with a characterization according to its glass transition temperatures and unit structure and a pneumatic tire with a tread composed of such terpolymer rubber specifically in combination with selected other rubber which has been observed to provide such tread with enhanced physical properties.  ",GOODYEAR TIRE & RUBBER,HALASA ADEL FARHAN;;BERGH JEAN;;FOURGON FERNAND ANTOINE JOSEPH,,https://lens.org/094-911-652-185-58X,Patent Application,yes,3,12,9,10,0,B60C1/0016;;C08F236/10;;Y10T152/10495;;C08F236/08;;Y10T152/10495;;C08F236/10;;B60C1/0016,B60C1/00;;C08F236/06;;C08F236/08;;C08F236/10;;C08L9/00;;C08L21/00,,1,0,,,"PATENT ABSTRACTS OF JAPAN, vol. 8, no. 162 (C-235)[1599], 26th July 1984; & JP-A-59 64 645 (NIPPON GOSEI GOMU K.K.) 12-04-1984",DISCONTINUED
45,EP,B1,EP 2433813 B1,122-701-280-423-61X,2013-06-19,2013,EP 11182786 A,2011-09-26,US 89220410 A,2010-09-28,Wire coat compositions for rubber articles,,GOODYEAR TIRE & RUBBER,HALASA ADEL FARHAN;;VERTHE JOHN JOSEPH ANDRE;;LECHTENBOEHMER ANNETTE,,https://lens.org/122-701-280-423-61X,Granted Patent,yes,8,0,5,5,0,B60C1/0008;;B60C1/0008;;B60C2009/0021;;B60C2009/0021;;C08K3/04;;C08K3/04;;C08L7/00;;C08L7/00;;C08L9/00;;C08L9/00;;C08L21/00;;C08L21/00;;C08L91/08;;C08L91/08;;C08L97/005;;C08L97/005;;D07B1/0666;;D07B1/0666,B60C1/00;;C08K3/04;;C08L7/00;;C08L21/00;;C08L91/08;;C08L97/00,,0,0,,,,ACTIVE
46,AU,A,AU 1989/037128 A,063-028-370-698-857,1990-01-04,1990,AU 1989/037128 A,1989-06-28,US 21301988 A,1988-06-29,"STYRENE, ISOPRENE, BUTADIENE RUBBER AND TIRE WITH TREAD THEREOF",,GOODYEAR TIRE & RUBBER,HALASA ADEL FARHAN;;BERGH JEAN;;FOURGON FERNAND ANTOINE JOSEPH,,https://lens.org/063-028-370-698-857,Patent Application,no,0,0,9,10,0,B60C1/0016;;C08F236/10;;Y10T152/10495;;C08F236/08;;Y10T152/10495;;C08F236/10;;B60C1/0016,B60C1/00;;C08F236/06;;C08F236/08;;C08F236/10;;C08L9/00;;C08L21/00,,0,0,,,,EXPIRED
47,CA,A1,CA 2767595 A1,017-480-893-431-011,2011-01-13,2011,CA 2767595 A,2010-07-09,US 27057009 P;;US 2010/0041556 W,2009-07-09,VACCINES WITH ONCOFETAL ANTIGEN/ILRP-LOADED AUTOLOGOUS DENDRITIC CELLS AND USES THEREOF,"Disclosed are compositions containing isolated monocyte-derived mature dendritic cells loaded with OFA/iLRP, or a fragment thereof that selectively stimulates T cytotoxic lymphocytes, and a carrier, vaccine compositions containing effective dosage amounts of the dendritic cells, methods of making the vaccines, and methods of cancer treatment or therapy that entail administration of the vaccines to cancer patients.",UNIV SOUTH ALABAMA,ROHRER JAMES W;;COGGIN JOSEPH H;;BARSOUM ADEL L,,https://lens.org/017-480-893-431-011,Patent Application,no,0,0,4,4,0,A61K35/26;;C12N5/0639;;C12N2501/02;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61P35/00;;A61P37/04;;A61K2239/49;;A61K2239/31;;A61K39/4615;;A61K39/4622;;A61K39/464402;;A61K39/46448;;A61K2239/38;;C12N5/0639;;A61K35/26;;A61K2039/5154;;C12N2501/23;;C12N2501/25;;C12N2501/22;;C12N2501/02;;A61K39/00118,A61K39/395;;A61K38/20;;A61K39/00;;A61P35/00,,0,0,,,,DISCONTINUED
48,EP,B1,EP 0629640 B1,058-709-369-222-475,1997-01-08,1997,EP 94108554 A,1994-06-03,US 7763393 A,1993-06-17,Process for the synthesis of isoprene-butadiene rubber,,GOODYEAR TIRE & RUBBER,BELL ANTHONY JOSEPH;;MATRANA BARRY ALLEN;;HALASA ADEL FARHAN,,https://lens.org/058-709-369-222-475,Granted Patent,yes,2,0,12,12,0,C08F236/04;;C08F236/04,C08F4/60;;C08F4/58;;C08F236/04;;C08F236/08,,2,0,,,"DATABASE WPI Week 8930, Derwent Publications Ltd., London, GB; AN 89-216511 & JP-A-1 153 739 (JAPAN SYNTHETIC RUBBER) 15 June 1989;;DATABASE WPI Week 8930, Derwent Publications Ltd., London, GB; AN 89-216511 & JP-A-1 153 739",EXPIRED
49,ES,T3,ES 2077051 T3,086-485-808-935-035,1995-11-16,1995,ES 90630214 T,1990-12-05,US 45806989 A,1989-12-28,UNA CUBIERTA DE NEUMATICO QUE TIENE UNA HUELLA EXTERNA CIRCUNFERENCIAL.,"CAUCHO TERPOLIMERO DE ESTIRENO, ISOPROPENO Y BUTADIENO CON UNA CARACTERIZACION DE ACUERDO CON SUS TEMPERATURAS DE TRANSICION DEL ESTADO VITREO Y ESTRUCTURA UNITARIA Y UNA LLANTA NEUMATICA CON UNA BANDA DE RODADURA COMPUESTA DE TAL CAUCHO TERPOLIMERO ESPECIFICAMENTE EN COMBINACION CON OTROS CAUCHOS SELECCIONADOS.",GOODYEAR TIRE & RUBBER,HALASA ADEL FARHAN;;BERGH JEAN;;FOURGON FERNAND ANTOINE JOSEPH,,https://lens.org/086-485-808-935-035,Granted Patent,no,0,0,12,13,0,B60C1/0016;;C08F236/10;;C08L7/00;;C08L9/00;;C08L9/06;;Y10T152/10495;;C08F212/00;;Y10T152/10495;;C08F236/10;;C08L9/00;;B60C1/0016;;C08L7/00;;C08L9/06,B29D30/00;;B29K9/06;;B60C1/00;;C08F236/04;;C08F236/10;;C08L9/06;;C08L21/00;;C08L47/00,,0,0,,,,EXPIRED
50,WO,A1,WO 1997/038089 A1,168-567-659-072-038,1997-10-16,1997,US 9705685 W,1997-04-04,US 1490396 P,1996-04-05,"USES OF ONCOFETAL ANTIGEN SPECIFIC CD4, CD8 CYTOTOXIC AND SUPPRESSOR T CELLS AND INTERLEUKIN-10","The present invention provides a method of determining the success of a cancer therapy in an individual, comprising the step of measuring the frequency of occurrence of an oncofetal antigen-specific subclasses in the individual's peripheral blood. Also provided is a method of determining whether protective immunity against a tumor will develop in an individual, comprising the step of measuring the frequency of oncofetal antigen-specific T cells, tumor cells and macrophages at the site of the tumor which secrete IL-10. Additionally, a method of determining whether an individual having a tumor will go into remission or remain in remission, comprising the step of measuring the frequency of oncofetal antigen-specific Th1 cells, Tc cells and Ts cells, IL-10 and interferon-η secreting T cells in the peripheral blood.",UNIV SOUTH ALABAMA,COGGIN JOSEPH H;;BARSOUM ADEL L;;ROHRER JAMES W,,https://lens.org/168-567-659-072-038,Patent Application,yes,2,5,11,13,0,C07K16/244;;G01N33/57476;;Y10S435/975;;A61P35/00;;G01N33/57476;;C07K16/244;;Y10S435/975,A61K38/17;;C07K16/24;;G01N33/574,,7,7,041-782-669-795-463;;123-241-550-501-203;;168-546-333-978-048;;009-214-221-510-209;;020-753-499-798-965;;011-837-382-151-756;;129-775-065-815-860,10.1146/annurev.immunol.11.1.165;;8386517;;10.1146/annurev.iy.11.040193.001121;;7904290;;7868899;;1838908;;10.1111/j.1749-6632.1991.tb33444.x;;8450205;;10.1002/ijc.2910580304;;8050813;;2787679;;10.1182/blood.v74.2.786.786,"ANN. REV. IMMUNOL., 1993, Vol. 11, MOORE et al., ""Interleukin-10"", pages 165-190.;;J. IMMUNOL., January 1994, Vol. 152, ROHRER et al., ""Differential Recognition of Murine Tumor-Associated Oncofetal Transplantation Antigen and Individually Specific Tumor Transplantation Antigens by Syngenic Cloned BALB/c and RFM Mouse T Cells"", pages 754-764.;;J. IMMUNOL., March 1995, Vol. 154, ROHRER et al., ""Characterization of RFM Mouse T Lymphocyte Anti-Oncofetal Antigen Immunity in Apparent Tumor-Free, Long-Term Survivors of Sublethal X-Irradiation by Limiting Dilution T Lymphocyte Cloning"", pages 2266-2280.;;ANNALS NEW YORK ACAD. SCI., December 1991, Vol. 636, NAOR et al., ""Regulatory Interactions Among Autologous T Cell Clones"", pages 135-146.;;J. IMMUNOL., 15 March 1993, Vol. 150, No. 6, INOUE et al., ""Distinction of Mouse CD8+ Suppressor Effector T Cell Clones from Cytotoxic T Cell Clones by Cytokine Production and CD45 Isoforms"", pages 2121-2128.;;INT. J. CANCER., August 1994, Vol. 58, MAZZOCCHI et al., ""Frequency of Cytotoxic T Lymphocyte Precursors (CTLp) Interacting with Autologous Tumor Via the T-Cell Receptor: Limiting Dilution Analysis of Specific CTLp in Peripheral Blood and Tumor-Invaded Lymph Nodes of Melanoma Patients"", pages 330-339.;;BLOOD, 01 August 1989, Vol. 74, No. 2, TOTTERMAN et al., ""T-Cell Activation and Subset Patterns Are Altered in B-CLL and Correlate with the Stage of the Disease"", pages 786-792.",PENDING
51,AU,A,AU 1994/064765 A,092-293-832-543-235,1994-12-22,1994,AU 1994/064765 A,1994-06-16,US 7763393 A,1993-06-17,Process for the synthesis of isoprene-butadiene rubber,,GOODYEAR TIRE & RUBBER,BELL ANTHONY JOSEPH;;MATRANA BARRY ALLEN;;HALASA ADEL FARHAN,,https://lens.org/092-293-832-543-235,Patent Application,no,0,0,12,12,0,C08F236/04;;C08F236/04,C08F4/60;;C08F4/58;;C08F236/04;;C08F236/08,,0,0,,,,EXPIRED
52,AU,B2,AU 666619 B2,091-388-719-323-711,1996-02-15,1996,AU 1994/064765 A,1994-06-16,US 7763393 A,1993-06-17,Process for the synthesis of isoprene-butadiene rubber,,GOODYEAR TIRE & RUBBER,BELL ANTHONY JOSEPH;;MATRANA BARRY ALLEN;;HALASA ADEL FARHAN,,https://lens.org/091-388-719-323-711,Granted Patent,no,3,0,12,12,0,C08F236/04;;C08F236/04,C08F4/60;;C08F4/58;;C08F236/04;;C08F236/08,,0,0,,,,EXPIRED
53,CA,C,CA 1339637 C,113-171-525-837-967,1998-01-20,1998,CA 604167 A,1989-06-28,US 21301988 A,1988-06-29,"STYRENE, ISOPRENE, BUTADIENE TERPOLYMER RUBBER AND TIRE WITH TREAD THEREOF","A styrene, isoprene, butadiene terpolymer rubber with a characterization according to its glass transition temperatures and unit structure and a pneumatic tire with a tread composed of such terpolymer rubber specifically in combination with selected other rubber which has been observed to provide such tread with enhanced physical properties. , .",GOODYEAR TIRE & RUBBER,HALASA ADEL FARHAN;;BERGH JEAN;;FOURGON FERNAND ANTOINE JOSEPH,,https://lens.org/113-171-525-837-967,Granted Patent,no,0,0,9,10,0,B60C1/0016;;C08F236/10;;Y10T152/10495;;C08F236/08;;Y10T152/10495;;C08F236/10;;B60C1/0016,B60C1/00;;C08F236/06;;C08F236/08;;C08F236/10;;C08L9/00;;C08L21/00,D34020419    M;;D24006101    S,0,0,,,,EXPIRED
54,ES,T3,ES 2098077 T3,153-647-024-758-410,1997-04-16,1997,ES 94108554 T,1994-06-03,US 7763393 A,1993-06-17,UN PROCESO PARA LA SINTESIS DE CAUCHO ISOPRENO-BUTADIENO.,"LA PRESENTE INVENCION SE REFIERE A UNA TECNICA PARA SINTETIZAR COPOLIMEROS DE PROPIEDADES COMO EL CAUCHO, ALEATORIOS NO AHUSADOS, DE 1,3 PROPIEDADES COMO EL CAUCHO EXHIBEN UNA EXCELENTE COMBINACION DE PROPIEDADES PARA UTILIZACION EN COMPUESTOS DE CAUCHO DE COSTADOS DE NEUMATICOS PARA NEUMATICOS DE CAMIONES. UTILIZANDO ESTOS CAUCHOS DE ISOPRENOBUTADIENO EN LOS COSTADOS DE LOS NEUMATICOS, LOS NEUMATICOS CONSIGUEN RESISTENCIA MEJOR A LA APARICION DE CORTES Y PUEDEN FABRICARSE SIN DISMINUIR LA RESISTENCIA A LA RODADURA. TALES CAUCHOS PUEDEN UTILIZARSE TAMBIEN EN COMPUESTOS DE SUPERFICIE DE RODADURA DE NEUMATICOS, PARA MEJORAR LAS CARACTERISTICAS DE DESGASTE DE LA SUPERFICIE DE RODADURA Y DISMINUIR LA RESISTENCIA A LA RODADURA, SIN REDUCIR LAS CARACTERISTICAS DE TRACCION. LA INVENCION DESCRIBE MAS ESPECIFICAMENTE UN PROCESO PARA LA SINTESIS DE CAUCHOS DE ISOPRENOBUTADIENO, QUE COMPRENDE LA COPOLIMERIZACION DE MONOMERO DE ISOPRENO Y MONOMERO 1,3 UN SISTEMA CATALIZADOR, QUE SE CONSIGUE MEDIANTE LAS FASES SECUENCIALES DE: (1) MEZCLAR (A) UN HIDRURO DE ORGANOALUMINIO, (B) UN MIEMBRO SELECCIONADO DEL GRUPO FORMADO POR ALCOHOLES ALIFATICOS, ALCOHOLES CICLOALIFATICOS, TIOLES ALIFATICOS, TIOLES CICLOALIFATICOS, SILANOLES TRIALQUILOS Y SILANOLES TRIARILOS, Y (C), OPCIONALMENTE, 1.3 BUTADIENO EN UN DISOLVENTE ORGANICO, PARA OBTENER UN COMPONENTE CATALIZADOR DE ORGANOALUMINIO MODIFICADO; (2) AÑADIR UN COMPUESTO ORGANOMETALICO, QUE CONTIENE UN METAL DEL GRUPO III-B DEL SISTEMA PERIODICO, AL COMPONENTE CATALIZADOR DE ORGANOALUMINIO MODIFICADO, PARA OBTENER UN COMPONENTE CATALIZADOR CONTENIENDO METAL DEL GRUPO III-B; Y (3) AÑADIR UN COMPUESTO QUE CONTIENE AL MENOS UN ATOMO DE HALOGENO LABIL AL COMPONENTE CATALIZADOR CONTENIENDO METAL DEL GRUPO III-B.",GOODYEAR TIRE & RUBBER,BELL ANTHONY JOSEPH;;MATRANA BARRY ALLEN;;HALASA ADEL FARHAN,,https://lens.org/153-647-024-758-410,Granted Patent,no,0,0,12,12,0,C08F236/04;;C08F236/04,C08F4/60;;C08F4/58;;C08F236/04;;C08F236/08,,0,0,,,,EXPIRED
55,EP,B1,EP 1538900 B1,012-328-075-896-468,2016-01-06,2016,EP 03767221 A,2003-08-04,US 0324518 W;;US 40085102 P,2002-08-02,CANCER VACCINES CONTAINING EPITOPES OF ONCOFETAL ANTIGEN,,UNIV SOUTH ALABAMA,COGGIN JOSEPH H JR;;ROHRER JAMES W;;BARSOUM ADEL L,,https://lens.org/012-328-075-896-468,Granted Patent,yes,3,0,14,14,0,A61K9/0019;;A61K9/127;;C07K14/4748;;A61P35/00;;A61K39/00118;;A61K9/127;;A61K9/0019;;C07K14/4748;;A61K39/00118,A61K39/00;;A01N37/18;;A61K/;;A61K9/00;;A61K9/127;;A61K38/08;;A61K38/10;;A61K38/17;;A61P35/00;;C07K14/47;;C12P21/00;;C12P21/06,,7,0,,,"ROHRER J W ET AL: ""Human breast carcinoma patients develop clonable oncofetal antigen-specific effector and regulatory T lymphocytes."" JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 JUN 1999, vol. 162, no. 11, 1 June 1999 (1999-06-01), pages 6880-6892, XP002438875 ISSN: 0022-1767;;ROHRER J W & COGGIN J H: ""CD8 T cell clones inhibit antitumor T cell function by secreting IL-10"" JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 155, no. 12, 15 December 1995 (1995-12-15), pages 5719-5727, XP002293749 ISSN: 0022-1767;;ZELLE-RIESER ET AL: ""EXPRESSION AND IMMUNOGENICITY OF ONCOFETAL ANTIGEN-IMMATURE LAMININ RECEPTOR IN HUMAN RENAL CELL CARCINOMA"" JOURNAL OF UROLOGY, BALTIMORE, MD, US, vol. 165, no. 5, May 2001 (2001-05), pages 1705-1709, XP005545545 ISSN: 0022-5347;;COGGIN J H ET AL: ""Tumors express both unique TSTA and crossprotective 44 kDa oncofetal antigen"" IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 19, no. 9, September 1998 (1998-09), pages 405-408, XP004133960 ISSN: 0167-5699;;NUKAYA I. ET AL: 'Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte' INT. J. CANCER vol. 80, no. 1, January 1999, pages 92 - 97, XP002981879;;COGGIN JR ET AL: '37 Kilodalton oncofetal antigen protein and immature laminin receptor protein are identical, universal T-cell inducing immunogens on primary rodent and human cancers' ANTICANCER RES. vol. 19, no. 6C, November 1999 - December 1999, pages 5535 - 5542, XP002981891;;ARMSTRONG A:C. ET AL: 'Vaccines in Oncology: Background and clinical potential' BRITISH JOURNAL OF RADIOLOGY vol. 74, no. 887, November 2001, pages 991 - 1002, XP002981880",EXPIRED
56,DK,T3,DK 1116567 T3,041-306-797-495-927,2006-06-26,2006,DK 00311765 T,2000-12-29,US 47641199 A,1999-12-30,Gasunderstöttet formning af katetere i ét stykke,"An apparatus and a method are disclosed for manufacturing an integral one-piece catheter having a tube and a hub. The method comprises feeding molten material into a mold having a mold cavity. A fluid such as a gas is injected into an inlet of the mold. This causes the cavity to eject the molten central region of the polymer through an exit channel. In one embodiment, a gas is injected into the hub portion of the cavity. In another embodiment, a gas is injected into the catheter portion of the mold. The invention also involves forming a first portion of an intravascular device using a first material in a first mold. Thereafter the first portion of the intravascular device is inserted into a second mold to form a second portion using a second material. Gas is then introduced to form a hollow channel in the second portion. The invention also involves a first portion of the mold is injected with a first material, and a second portion of the cavity is injected with a second material at or around the same time that the first material is injected into the first portion of the cavity. Gas is then introduced to form a hollow channel in the second portion. <IMAGE>",MEDEX INC,GORAL DAVID;;KAFRAWY ADEL;;POLLEY WILLIAM F;;THOMAS JOSEPH R,,https://lens.org/041-306-797-495-927,Granted Patent,no,0,0,23,23,0,A61M25/0009;;B29C45/0013;;B29C45/1615;;B29C45/1704;;B29L2031/7542;;A61M25/0009;;B29C45/1704;;B29L2031/7542;;B29C45/1615;;B29C45/0013,B29C45/17;;A61M25/00;;B29C45/00;;B29C45/16,,0,0,,,,EXPIRED
57,US,A1,US 2010/0183643 A1,047-576-301-517-853,2010-07-22,2010,US 46251409 A,2009-08-05,US 46251409 A;;US 52327705 A;;US 0324518 W;;US 40085102 P,2002-08-02,Cancer vaccines containing epitopes of oncofetal antigen,"Disclosed are fragments of oncofetal antigen, otherwise known as immature laminin receptor protein that specifically stimulate one T cell subclass. The fragments may be formulated into compositions for potentiating T cell-mediated responses in mammalian cancer patients. They also have therapeutic uses in vitro.",UNIV SOUTH ALABAMA,COGGIN JR JOSEPH H;;ROHRER JAMES W;;BARSOUM ADEL L,SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION (2005-06-08),https://lens.org/047-576-301-517-853,Patent Application,yes,7,0,14,14,82,A61K9/0019;;A61K9/127;;C07K14/4748;;A61P35/00;;A61K39/00118;;A61K9/127;;A61K9/0019;;C07K14/4748;;A61K39/00118,A01N37/18;;A61K39/00;;A61K/;;A61K38/08;;A61K38/10;;A61K38/17;;A61P35/00;;C07K14/47;;C12P21/00;;C12P21/06,424/185.1;;424/277.1,1,1,007-721-243-922-080,pmc44831;;7524076;;10.1073/pnas.91.20.9456,"Mutis et al (PNAS, 1994, Vol. 91, pp. 9456-9460)",EXPIRED
58,AU,A8,AU 2003/258081 A8,077-414-202-957-999,2004-02-23,2004,AU 2003/258081 A,2003-08-04,US 40085102 P;;US 0324518 W,2002-08-02,Cancer vaccines containing epitopes of oncofetal antigen,,SOUTH ALABAMA MEDICAL SCIENCES,COGGIN JOSEPH H JR;;BARSOUM ADEL L;;ROHRER JAMES W,,https://lens.org/077-414-202-957-999,Patent Application,no,0,0,14,14,0,A61K9/0019;;A61K9/127;;C07K14/4748;;A61P35/00;;A61K39/00118;;A61K9/127;;A61K9/0019;;C07K14/4748;;A61K39/00118,A01N37/18;;A61K/;;A61K38/08;;A61K38/10;;A61K38/17;;A61K39/00;;A61P35/00;;C07K14/47;;C12P21/00;;C12P21/06,,0,0,,,,DISCONTINUED
59,AU,A1,AU 2003/258081 A1,140-633-740-709-135,2004-02-23,2004,AU 2003/258081 A,2003-08-04,US 40085102 P;;US 0324518 W,2002-08-02,CANCER VACCINES CONTAINING EPITOPES OF ONCOFETAL ANTIGEN,,SOUTH ALABAMA MEDICAL SCIENCES,COGGIN JOSEPH H JR;;ROHRER JAMES W;;BARSOUM ADEL L,,https://lens.org/140-633-740-709-135,Patent Application,no,0,0,14,14,0,A61K9/0019;;A61K9/127;;C07K14/4748;;A61P35/00;;A61K39/00118;;A61K9/127;;A61K9/0019;;C07K14/4748;;A61K39/00118,A01N37/18;;A61K/;;A61K38/08;;A61K38/10;;A61K38/17;;A61K39/00;;A61P35/00;;C07K14/47;;C12P21/00;;C12P21/06,,0,0,,,,DISCONTINUED
60,US,A1,US 2003/0044484 A1,175-258-982-550-954,2003-03-06,2003,US 26975702 A,2002-10-10,US 26975702 A;;US 47641199 A,1999-12-30,Gas assist molding of one-piece catheters,"
   An apparatus and a method are disclosed for manufacturing an integral one-piece catheter having a tube and a hub. The method comprises feeding molten material into a mold having a mold cavity. A fluid such as a gas is injected into an inlet of the mold. This causes the cavity to eject the molten central region of the polymer through an exit channel. In one embodiment, a gas is injected into the hub portion of the cavity. In another embodiment, a gas is injected into the catheter portion of the mold. 

   The invention also involves forming a first portion of an intravascular device using a first material in a first mold. Thereafter the first portion of the intravascular device is inserted into a second mold to form a second portion using a second material. Gas is then introduced to form a hollow channel in the second portion. 

   The invention also involves a first portion of the mold is injected with a first material, and a second portion of the cavity is injected with a second material at or around the same time that the first material is injected into the first portion of the cavity. Gas is then introduced to form a hollow channel in the second portion. 
",GORAL DAVID;;KAFRAWY ADEL;;POLLEY WILLIAM F.;;THOMAS JOSEPH R.,GORAL DAVID;;KAFRAWY ADEL;;POLLEY WILLIAM F;;THOMAS JOSEPH R,MEDEX INC (2004-08-13);;ETHICON ENDO SURGERY INC (2001-12-31),https://lens.org/175-258-982-550-954,Patent Application,yes,8,3,23,23,0,A61M25/0009;;B29C45/0013;;B29C45/1615;;B29C45/1704;;B29L2031/7542;;A61M25/0009;;B29C45/1704;;B29L2031/7542;;B29C45/1615;;B29C45/0013,A61M25/00;;B29C45/00;;B29C45/16;;B29C45/17,425/573;;425/588,0,0,,,,EXPIRED
61,DE,T2,DE 60026259 T2,077-063-402-005-480,2006-12-14,2006,DE 60026259 T,2000-12-29,US 47641199 A,1999-12-30,Durch Gas unterstütztes Formen von einteiligen Kathetern,"An apparatus and a method are disclosed for manufacturing an integral one-piece catheter having a tube and a hub. The method comprises feeding molten material into a mold having a mold cavity. A fluid such as a gas is injected into an inlet of the mold. This causes the cavity to eject the molten central region of the polymer through an exit channel. In one embodiment, a gas is injected into the hub portion of the cavity. In another embodiment, a gas is injected into the catheter portion of the mold. The invention also involves forming a first portion of an intravascular device using a first material in a first mold. Thereafter the first portion of the intravascular device is inserted into a second mold to form a second portion using a second material. Gas is then introduced to form a hollow channel in the second portion. The invention also involves a first portion of the mold is injected with a first material, and a second portion of the cavity is injected with a second material at or around the same time that the first material is injected into the first portion of the cavity. Gas is then introduced to form a hollow channel in the second portion. <IMAGE>",MEDEX INC,GORAL DAVID;;KAFRAWY ADEL;;POLLEY WILLIAM F;;THOMAS JOSEPH R,,https://lens.org/077-063-402-005-480,Granted Patent,no,0,0,23,23,0,A61M25/0009;;B29C45/0013;;B29C45/1615;;B29C45/1704;;B29L2031/7542;;A61M25/0009;;B29C45/1704;;B29L2031/7542;;B29C45/1615;;B29C45/0013,B29C45/17;;A61M25/00;;B29C45/00;;B29C45/16,,0,0,,,,EXPIRED
62,EP,A2,EP 1538900 A2,082-818-369-470-535,2005-06-15,2005,EP 03767221 A,2003-08-04,US 0324518 W;;US 40085102 P,2002-08-02,CANCER VACCINES CONTAINING EPITOPES OF ONCOFETAL ANTIGEN,,UNIV SOUTH ALABAMA,COGGIN JOSEPH H JR;;ROHRER JAMES W;;BARSOUM ADEL L,,https://lens.org/082-818-369-470-535,Patent Application,yes,0,0,14,14,0,A61K9/0019;;A61K9/127;;C07K14/4748;;A61P35/00;;A61K39/00118;;A61K9/127;;A61K9/0019;;C07K14/4748;;A61K39/00118,A01N37/18;;A61K/;;A61K9/00;;A61K39/00;;A61K9/127;;A61K38/08;;A61K38/10;;A61K38/17;;A61P35/00;;C07K14/47;;C12P21/00;;C12P21/06,,0,0,,,,EXPIRED
63,US,B1,US 6534060 B1,174-794-806-514-682,2003-03-18,2003,US 70296500 A,2000-10-31,US 70296500 A;;US 83506997 A;;US 1490396 P,1996-04-05,"Oncofetal antigen specific T-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific CD4, CD8 cytotoxic and suppressor T cells and interleukin-10","
    The present invention provides a method of determining the success of a cancer therapy in an individual, comprising the step of measuring the frequency of occurence of an oncofetal antigen-specific subclasses in the individual's peripheral blood. Also provided is a method of determining whether protective immunity against a tumor will develop in an individual, comprising the step of measuring the frequency of oncofetal antigen-specific T cells, tumor cells and macrophages at the site of the tumor which secrete IL-10. Additionally, a method of determining whether an individual having a tumor will go into remission or remain in remission, comprising the step of measuring the frequency of oncofetal antigen-specific Th1 cells, Tc cells and Ts cells, IL-10 and interferon- secreting T cells in the peripheral blood. 
",UNIV SOUTH ALABAMA,COGGIN JR JOSEPH H;;ROHRER JAMES W;;BARSOUM ADEL L,SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION (1996-05-22),https://lens.org/174-794-806-514-682,Granted Patent,yes,4,2,11,13,0,C07K16/244;;G01N33/57476;;Y10S435/975;;A61P35/00;;G01N33/57476;;C07K16/244;;Y10S435/975,A61K38/17;;C07K16/24;;G01N33/574,424/184.1;;424/277.1,88,73,006-892-054-524-630;;055-719-122-933-320;;114-908-372-687-178;;016-343-364-370-586;;012-040-060-717-946;;176-822-061-486-16X;;032-185-576-687-592;;030-951-377-995-426;;016-678-963-910-382;;117-516-581-351-087;;103-848-986-556-745;;001-091-616-258-863;;151-469-191-076-458;;120-346-815-753-417;;126-552-161-618-587;;011-239-499-409-415;;122-456-934-766-819;;056-550-012-449-568;;011-615-918-500-237;;056-819-026-657-252;;022-518-560-952-486;;006-750-394-354-486;;000-241-605-974-607;;106-006-901-149-170;;106-688-434-505-738;;062-371-823-108-410;;039-321-462-620-937;;039-129-895-811-317;;100-479-103-706-798;;105-044-211-640-879;;006-563-786-125-101;;028-675-365-661-816;;090-383-045-217-963;;006-402-611-958-876;;110-021-731-734-237;;097-181-136-899-612;;041-362-415-892-369;;149-569-811-994-37X;;137-565-953-035-314;;075-970-063-895-453;;044-647-253-422-118;;000-427-162-057-759;;121-959-388-556-256;;033-760-978-650-500;;103-105-275-022-678;;017-799-157-179-326;;117-898-627-488-043;;077-520-301-979-113;;087-731-686-512-620;;168-546-333-978-048;;123-241-550-501-203;;143-844-143-629-195;;141-588-737-283-723;;096-317-560-511-625;;046-383-261-887-720;;068-201-349-010-526;;050-260-243-107-473;;124-935-962-687-051;;069-390-941-471-614;;107-731-123-007-819;;050-298-576-176-059;;104-946-718-779-307;;027-368-947-278-992;;009-214-221-510-209;;020-753-499-798-965;;011-837-382-151-756;;129-775-065-815-860;;072-534-713-210-904;;102-128-410-091-322;;045-006-471-313-434;;083-548-250-351-706;;001-954-961-100-881;;045-113-894-537-329,3104476;;10.1016/0022-1759(87)90429-7;;5034143;;2600602;;1850386;;10.1002/ijc.2910480216;;1826699;;7814878;;14235685;;10.1038/204793a0;;10.1016/1040-8428(96)00194-1;;8793276;;10.1016/s0092-8674(05)80059-5;;1335364;;3337209;;pmc1880537;;10.1080/095530097144454;;9020967;;10697612;;10.1016/0167-5699(89)90229-6;;2742738;;2818874;;10.1001/archotol.1993.01880230105015;;8217085;;10.1172/jci105098;;pmc289652;;14234820;;10.1080/09553009414550081;;7905910;;1372018;;1940799;;pmc2119001;;10.1084/jem.174.5.1209;;7684412;;1578140;;7722288;;8103065;;1697873;;10.1084/jem.179.5.1597;;8163939;;pmc2191501;;2531194;;10.1084/jem.170.6.2081;;pmc2189521;;1827484;;5154596;;2967332;;10.1038/213674a0;;6031772;;1313950;;10.1038/356607a0;;5439527;;10.1111/j.1365-2141.1970.tb01436.x;;75855;;10.1002/ijc.2910210311;;8781270;;10.1016/s0065-2776(08)60431-9;;7506722;;10.1016/0022-1759(93)90158-4;;8445253;;8811309;;10.1016/s0889-8588(05)70376-2;;8809472;;10.1615/critrevimmunol.v16.i1.30;;7930605;;8202711;;10.1126/science.8202711;;10.1002/eji.1830210612;;1904359;;10.1111/j.1365-3083.1988.tb02344.x;;2965407;;pmc2180603;;401860;;10.1084/jem.145.2.275;;10.1093/jnci/75.3.527;;2411994;;10.1002/eji.1830230926;;8370402;;6975300;;8133535;;10.1093/jnci/86.7.515;;1907999;;pmc1950464;;1460278;;7868899;;7904290;;7499859;;7512591;;10.1126/science.2113314;;2113314;;8030748;;pmc1887307;;2928954;;5098546;;10.1159/000466675;;10.1111/j.1423-0410.1971.tb00469.x;;5121668;;160895;;10.1002/ijc.2910240510;;10.1093/jnci/44.4.955;;11515063;;pmc392661;;10.1073/pnas.75.6.2844;;351618;;325412;;10.1056/nejm197707212970301;;2524832;;10.1073/pnas.86.10.3758;;pmc287219;;1838908;;10.1111/j.1749-6632.1991.tb33444.x;;8450205;;10.1002/ijc.2910580304;;8050813;;2787679;;10.1182/blood.v74.2.786.786;;7994751;;10.1006/cimm.1994.1304;;7636270;;1356125;;7673726;;7561096;;8683120;;10.4049/jimmunol.157.1.231,"Abou-Zeid et al., J. Immunol. Methods 98:5 (1987).;;Bain and Pshyk, Transplantation Proc. 4:163 (1972).;;Barsoum et al., J. Biol. Resp. Modifiers 8:579-92 (1989).;;Barsoum et al., Inter. J. Cancer 48:248-52.;;Barsoum et al., Int. J. Biochem. 24:483-89 (1993).;;Berg et al., J. Immunol. 146:2865 (1991).;;Bost et al., J. Immunol. 154:718 (1995).;;Boyum, Nature 204:793 (1964).;;Chang et al., Critical Reviews in Oncology/Hematology 22:213-28 (1996).;;Chen et al., Cell 71:1093 (1992).;;Coggin et al., Am. J. Pathol. 130:136 (1988).;;Coggin et al., Int. J. Radiation Biol. 71:81 (1997).;;Coggin et al., Anti-Cancer Res. 19:5535 (1999).;;Coggin, Shared Cross-Protective OFAs on Chemically Induced Rodent Sarcomas, Immunol. Today 10(3):76-78 (1989).;;Coggin, Mol. Biother. 1(4):223-28 (1989).;;Coggin et al., Archives of Otolaryngology-Head and Neck Surgery 119:1257-66 (1993).;;Cone et al., J. Clin. Invest. 43:2241 (1964).;;Cox, Intern. J. Rad. Biol. 65:57-64 (1994).;;Damle et al., Immunol. 148:1985 (1992).;;Decker et al., Immunol. Methods 15:61 (1988).;;DeSantis et al., Eur. J. Immunol. 15:575 (1987).;;De Waal et al., J. Exp. Med. 174:1209 (1991).;;De Wall et al., J. Immunol. 150:4754 (1993).;;Ding et al., J. Immunol. 148:3133 (1992).;;Elson et al., J. Immunol. 154:4294 (1995).;;Enk et al., J. Immunol. 151:2390 (1993).;;Fairchild et al., J. Immunol. 145:2001 (1990).;;Ferguson et al., J. Exp. Med. 179:1597 (1994).;;Fiorentino et al., J. Exp. Med. 170:2081 (1989).;;Fiorentino et al., J. Immunol. 146:3444 (1991).;;Fotino et al., Ann. Clin. Lab. Sci. 1:131 (1971).;;Fotino et al., Vox Sang 21:469 (1971).;;Gajewski et al., J. Immunol. 140:4245 (1988).;;Gershon et al., Nature 213:674 (1967).;;Harding et al., Nature 356:607 (1992).;;Harris et al., Brit. J. Haematol. 18:229 (1970).;;Hellstrom et al., Int. J. Cancer 21:317 (1978).;;Henderson et al., Advances In Immunology 62:217-56 (1996).;;Johnson et al., J. Immunol. 152:429 (1994).;;Jung et al., J. Immunol. Methods 159:197 (1993).;;Kavanaugh et al., Hematology/Oncology Clinics of North America 4:927-51 (1996).;;Leffel et al., Cancer Res. 37:4112 (1977).;;Levy et al., Critical Reviews in Immunology 16:31-57 (1996).;;Li et al., J. Immunol. 153:3967 (1994).;;Lombardi et al., Science 264:1587 (1994).;;Lynch et al., Eur. J. Immunol. 21:1403 (1991).;;Moller, Scand. J. Immunol. 27:247 (1988).;;North et al., J. Exp. Med. 145:275 (1977).;;O'Garra et al., Eur. J. Immunol. 22:711 (1992).;;Payne et al., J. Natl. Cancer Inst. 75:527 (1985).;;Phillips, In: Tissue Culture: Methods and Applications. P.F. Kruse, Jr., ed. Academic Press, New York, 406-08 (1994).;;Portsman et al., J. Immunol. Methods 82:169 (1985).;;Powrie et al., Eur. J. Immunol. 23:2223 (1993).;;Rabin et al., J. Immunol. 127:1852 (1981).;;Rashid et al., J. Natl. Cancer Inst. 86:515-26 (1994).;;Renie et al., Sci. Amer. Sept: 57-59 (1996).;;Restifo et al., J. Immunol. 147:1453 (1991).;;Rivas et al., J. Immunol. 149:3865 (1992).;;Rogers et al., J. Immunol. Methods 15:61 (1991).;;Roher et al., J. Natl. Cancer Inst. 84:602-09 (1992).;;Roher et al., J. Immunol. 154:2266-80 (1995).;;Roher et al., J. Immunol. 152:754-64 (1994).;;Roher et al., J. Immunol. 155:5719-27 (1995).;;Schadene et al., J. Immunol. 152:4368 (1994).;;Schwartz, Science 248:1349 (1990).;;Smith et al., Am. J. Pathol. 145:18 (1994).;;Stranding et al., Biochem. Biophys. Acta 508:85 (1978).;;Stephenson et al., Surgery 105:523.;;Ting et al., Vox Sang. 20:561 (1971).;;Vaage, Cancer Res. 31:1655 (1971).;;Vikingson et al., J. Immunol. Methods 173:219 (1994).;;Vose et al., Int. J. Cancer 245:579 (1979).;;Wepsic et al., J. Natl. Cancer Inst. 44:955 (1970).;;Wybran et al., J. Immunol. 110:1157 (1973).;;Wysocki et al., Proc. Natl. Acad. Sci. USA 75:2844 (1978).;;Yu et al., N. Engl. J. Med. 297:121 (1977).;;Zheng et al., Proc. Natl. Acad. Sci. USA 86:3758 (1989).;;Zarling et al., Cancer Immun. Immunother. 7:243 (1980).;;Naor et al., Annals New York Acad. Sci. 636:135-46 (1991).;;Inoue et al., J. Immuno. 150(6):2121-28 (1993).;;Mazzocchi et al., Int. J. Cancer 58:330-39 (1994).;;Totterman et al., Blood. 74(2):786-92 (1989).;;Wang et al., Cell. Immunol. 159:152-69 (1994).;;Kim et al., J. Immunol. 155(4):2240-47 (1995).;;Yssel et al., J. Immunol. 149(7):2378-84 (1992).;;Giovarelli et al., J. Immunol. 155(6):3112-23.;;Yang et al., J. Immunol. 155(8):3897-03 (1995).;;Berman et al., J. Immunol. 157(1):231-38 (1996).",EXPIRED
64,US,A1,US 2005/0232922 A1,191-860-841-845-961,2005-10-20,2005,US 14503705 A,2005-06-03,US 14503705 A;;US 29452402 A;;US 17391298 A;;US 83506997 A;;US 1490396 P,1996-04-05,"Oncofetal antigen specific T-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific CD4, CD8 cytotoxic and suppressor T cells and interleukin-10","Disclosed are methods for detecting cancer or determining the success of cancer therapy in an individual. These methods are based on analyzing the presence or frequency of cloned oncofetal antigen (OFA)- or immature laminin receptor protein (iLRP)-specific T lymphocyte subclasses obtained from the individual and which are stimulated with 44 kD OFA or iLRPA. A frequency of CD8 cytotoxic T cells relative to CD8 T suppressor cells indicates effectiveness of therapy, and a likelihood that protective immunity will develop. Also disclosed are kits for conducting these methods. Further disclosed are methods of rendering T suppressor lymphocytes cytotoxic, and methods of clonally expanding cytotoxic T lymphocytes in vivo.",COGGIN JOSEPH H JR;;ROHRER JAMES W;;BARSOUM ADEL L,COGGIN JOSEPH H JR;;ROHRER JAMES W;;BARSOUM ADEL L,SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION (2005-05-05),https://lens.org/191-860-841-845-961,Patent Application,yes,8,4,2,13,1,C07K16/244;;C07K16/2812;;C07K16/2815;;C07K16/2845;;C07K16/289;;C07K16/30;;G01N33/57476;;C07K2317/73;;C07K2317/76;;C07K16/2812;;G01N33/57476;;C07K16/2845;;C07K16/244;;C07K16/289;;C07K16/30;;C07K16/2815;;C07K2317/73;;C07K2317/76,A61K38/17;;A61K39/395;;C07K16/24;;C07K16/28;;C07K16/30;;C12N5/08;;G01N33/574,424/145.1,0,0,,,,DISCONTINUED
65,AU,A,AU 2000/072578 A,194-977-629-439-032,2001-07-05,2001,AU 2000/072578 A,2000-12-29,US 47641199 A,1999-12-30,Gas assist molding of one-piece catheters,"An apparatus and a method are disclosed for manufacturing an integral one-piece catheter having a tube and a hub. The method comprises feeding molten material into a mold having a mold cavity. A fluid such as a gas is injected into an inlet of the mold. This causes the cavity to eject the molten central region of the polymer through an exit channel. In one embodiment, a gas is injected into the hub portion of the cavity. In another embodiment, a gas is injected into the catheter portion of the mold. The invention also involves forming a first portion of an intravascular device using a first material in a first mold. Thereafter the first portion of the intravascular device is inserted into a second mold to form a second portion using a second material. Gas is then introduced to form a hollow channel in the second portion. The invention also involves a first portion of the mold is injected with a first material, and a second portion of the cavity is injected with a second material at or around the same time that the first material is injected into the first portion of the cavity. Gas is then introduced to form a hollow channel in the second portion. <IMAGE>",MEDEX INC,GORAL DAVID;;KAFRAWY ADEL;;POLLEY WILLIAM F;;THOMAS JOSEPH R,,https://lens.org/194-977-629-439-032,Patent Application,no,0,0,23,23,0,A61M25/0009;;B29C45/0013;;B29C45/1615;;B29C45/1704;;B29L2031/7542;;A61M25/0009;;B29C45/1704;;B29L2031/7542;;B29C45/1615;;B29C45/0013,A61M25/00;;B29C45/00;;B29C45/16;;B29C45/17,,0,0,,,,EXPIRED
66,SG,A1,SG 98437 A1,034-046-313-823-452,2003-09-19,2003,SG 200007683 A,2000-12-28,US 47641199 A,1999-12-30,GAS ASSIST MOLDING OF ONE-PIECE CATHETERS,"An apparatus and a method are disclosed for manufacturing an integral one-piece catheter having a tube and a hub. The method comprises feeding molten material into a mold having a mold cavity. A fluid such as a gas is injected into an inlet of the mold. This causes the cavity to eject the molten central region of the polymer through an exit channel. In one embodiment, a gas is injected into the hub portion of the cavity. In another embodiment, a gas is injected into the catheter portion of the mold. The invention also involves forming a first portion of an intravascular device using a first material in a first mold. Thereafter the first portion of the intravascular device is inserted into a second mold to form a second portion using a second material. Gas is then introduced to form a hollow channel in the second portion. The invention also involves a first portion of the mold is injected with a first material, and a second portion of the cavity is injected with a second material at or around the same time that the first material is injected into the first portion of the cavity. Gas is then introduced to form a hollow channel in the second portion. <IMAGE>",ETHICON INC,DAVID GORAL;;ADEL KAFRAWY;;WILLIAM F POLLEY;;JOSEPH R THOMAS,,https://lens.org/034-046-313-823-452,Patent Application,no,1,0,23,23,0,A61M25/0009;;B29C45/0013;;B29C45/1615;;B29C45/1704;;B29L2031/7542;;A61M25/0009;;B29C45/1704;;B29L2031/7542;;B29C45/1615;;B29C45/0013,A61M25/00;;B29C45/00;;B29C45/16;;B29C45/17,,0,0,,,,PENDING
67,DE,T2,DE 69026465 T2,142-546-104-192-451,1996-08-08,1996,DE 69026465 T,1990-10-23,US 43004189 A,1989-11-01,Optischer Entzerrungsempfänger für Lichtwellenübertragungssystem,,AT & T CORP,CIMINI LEONARD JOSEPH;;GREENSTEIN LARRY J;;SALEH ADEL A M,,https://lens.org/142-546-104-192-451,Granted Patent,no,0,0,10,10,0,G02B6/29358;;G02B6/29394;;G02B6/4215;;H04B10/25133;;G02B6/4215;;G02B6/29358;;H04B10/25133;;G02B6/29394,G01J3/26;;G02B6/34;;H04B10/02;;H04B10/18,,0,0,,,,EXPIRED
68,PT,E,PT 1116567 E,064-022-419-399-284,2006-05-31,2006,PT 00311765 T,2000-12-29,US 47641199 A,1999-12-30,MOLDAGEM ASSISTIDA POR GAS DE CATETERES DE UMA PECA,"An apparatus and a method are disclosed for manufacturing an integral one-piece catheter having a tube and a hub. The method comprises feeding molten material into a mold having a mold cavity. A fluid such as a gas is injected into an inlet of the mold. This causes the cavity to eject the molten central region of the polymer through an exit channel. In one embodiment, a gas is injected into the hub portion of the cavity. In another embodiment, a gas is injected into the catheter portion of the mold. The invention also involves forming a first portion of an intravascular device using a first material in a first mold. Thereafter the first portion of the intravascular device is inserted into a second mold to form a second portion using a second material. Gas is then introduced to form a hollow channel in the second portion. The invention also involves a first portion of the mold is injected with a first material, and a second portion of the cavity is injected with a second material at or around the same time that the first material is injected into the first portion of the cavity. Gas is then introduced to form a hollow channel in the second portion. <IMAGE>",MEDEX INC,DAVID GORAL;;ADEL KAFRAWY;;POLLEY WILLIAM F;;THOMAS JOSEPH R,,https://lens.org/064-022-419-399-284,Granted Patent,no,0,0,23,23,0,A61M25/0009;;B29C45/0013;;B29C45/1615;;B29C45/1704;;B29L2031/7542;;A61M25/0009;;B29C45/1704;;B29L2031/7542;;B29C45/1615;;B29C45/0013,A61M25/00;;B29C45/00;;B29C45/16;;B29C45/17,,0,0,,,,EXPIRED
69,US,B2,US 8709405 B2,129-334-004-985-475,2014-04-29,2014,US 46251409 A,2009-08-05,US 46251409 A;;US 52327705 A;;US 0324518 W;;US 40085102 P,2002-08-02,Cancer vaccines containing epitopes of oncofetal antigen,"Disclosed are fragments of oncofetal antigen, otherwise known as immature laminin receptor protein that specifically stimulate one T cell subclass. The fragments may be formulated into compositions for potentiating T cell-mediated responses in mammalian cancer patients. They also have therapeutic uses in vitro.",COGGIN JR JOSEPH H;;ROHRER JAMES W;;BARSOUM ADEL L;;UNIV SOUTH ALABAMA,COGGIN JR JOSEPH H;;ROHRER JAMES W;;BARSOUM ADEL L,SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION (2005-06-08),https://lens.org/129-334-004-985-475,Granted Patent,yes,9,0,14,14,82,A61K9/0019;;A61K9/127;;C07K14/4748;;A61P35/00;;A61K39/00118;;A61K9/127;;A61K9/0019;;C07K14/4748;;A61K39/00118,A01N37/18;;A61K35/12;;A61K/;;A61K38/08;;A61K38/10;;A61K38/17;;A61K39/00;;A61P35/00;;C07K14/47;;C12N5/0784;;C12P21/00;;C12P21/06,424/93.71;;424/278.1;;435/375;;435/377,101,89,068-776-357-116-707;;007-721-243-922-080;;021-140-047-466-286;;001-091-616-258-863;;122-380-309-983-596;;025-616-693-471-094;;072-353-837-224-133;;015-573-463-771-956;;036-670-322-860-273;;073-743-409-298-371;;143-844-143-629-195;;008-722-616-989-992;;135-143-185-261-972;;056-522-114-356-583;;188-867-846-472-352;;071-241-199-775-770;;103-556-779-531-567;;120-346-815-753-417;;075-926-065-016-418;;045-711-346-412-488;;024-124-680-816-658;;033-798-202-369-352;;001-026-577-269-007;;019-786-857-266-199;;132-121-317-763-450;;127-128-919-672-872;;008-140-604-210-953;;027-846-935-842-908;;139-091-103-522-555;;045-676-911-168-166;;048-861-032-822-524;;047-962-740-795-340;;055-281-790-604-035;;005-521-702-082-318;;081-399-223-596-944;;102-283-491-932-209;;018-043-815-857-798;;065-954-201-877-42X;;044-551-639-775-171;;021-914-304-720-940;;003-341-151-880-629;;101-473-441-419-424;;121-644-187-021-339;;168-546-333-978-048;;117-516-581-351-087;;103-848-986-556-745;;072-353-837-224-133;;010-577-417-062-223;;033-760-978-650-500;;099-342-964-662-204;;029-661-731-577-913;;126-552-161-618-587;;028-697-309-251-510;;103-843-437-231-312;;118-487-476-701-416;;036-034-789-927-905;;004-567-599-435-628;;010-769-703-170-598;;026-626-612-779-878;;076-218-311-884-130;;079-756-586-352-456;;065-267-215-227-642;;050-458-364-566-821;;026-028-225-588-967;;044-518-451-836-169;;000-844-059-876-067;;008-660-712-324-869;;056-834-210-287-875;;010-058-174-809-534;;033-615-093-037-898;;070-475-487-024-440;;026-190-484-845-337;;062-333-814-343-796;;080-537-897-544-354;;124-257-229-162-56X;;013-328-986-731-118;;170-481-129-346-374;;039-309-144-579-439;;022-421-943-652-762;;019-246-072-356-162;;012-082-215-951-717;;112-613-940-739-511;;016-578-245-720-05X;;026-777-039-697-48X;;012-638-135-148-028;;005-795-969-557-480;;011-509-658-764-615;;030-955-335-211-791;;184-434-919-059-886,10389916;;pmc44831;;7524076;;10.1073/pnas.91.20.9456;;10.1002/(sici)1097-0215(19990105)80:1<92::aid-ijc18>3.0.co;2-m;;9935237;;10697612;;10.1259/bjr.74.887.740991;;11709463;;10.1093/jnci/63.2.367;;88539;;10352310;;10.1016/s0264-410x(97)00264-8;;9627940;;10.4049/jimmunol.176.5.2844;;16493041;;pmc384262;;6193515;;10.1073/pnas.80.17.5392;;7499859;;11342960;;10.1016/s0022-5347(05)66398-7;;10.1097/00005392-200105000-00085;;10.1016/s0140-6736(94)91454-0;;7906753;;3702918;;10.1056/nejm198605083141905;;3940657;;7834608;;908044;;2818874;;9368778;;10.1016/s0952-7915(97)80050-7;;7590825;;10.1111/j.1600-065x.1995.tb00081.x;;1853786;;10.1016/s0065-2776(08)60778-6;;8280701;;10.1097/00002371-199308000-00004;;9419443;;10.1615/critrevimmunol.v18.i1-2.20;;10.1016/s0167-5699(98)01305-x;;9745203;;10.1021/bi00035a037;;7669786;;8407208;;8198600;;10.1006/bbrc.1994.1713;;9328821;;10.1002/(sici)1097-4644(19971101)67:2<155::aid-jcb1>3.0.co;2-w;;10.1002/(sici)1097-4644(19971101)67:2<155::aid-jcb1>3.3.co;2-o;;2835781;;6505678;;10.1126/science.6505678;;8999943;;10.1074/jbc.272.4.2342;;10.3109/15419069409004438;;7827956;;1764767;;10.1007/bf00050795;;2156430;;pmc1877499;;pmc1886291;;1848041;;8257781;;10.1093/jnci/85.5.398;;8433393;;10.1093/jnci/89.16.1224;;9274918;;7647341;;10.1007/bf00668209;;pmc1969436;;7911032;;10.1038/bjc.1994.221;;10.1016/0014-5793(84)80863-7;;6734821;;8168177;;7074609;;7868899;;3337209;;pmc1880537;;10.1080/095530097144454;;9020967;;10352310;;10.1016/s0046-8177(96)90313-5;;8912829;;10.1093/jnci/75.3.527;;2411994;;10.1021/bi00444a047;;2531008;;pmc281978;;10.1073/pnas.85.17.6394;;2970639;;10.1001/archotol.1993.01880230105015;;8217085;;9286045;;10.1016/s0264-410x(97)00015-7;;10.1002/1521-4141(200011)30:11<3256::aid-immu3256>3.0.co;2-h;;11093141;;10.4049/jimmunol.165.1.566;;10861097;;10.1038/32588;;9521319;;pmc1782698;;11972639;;10.1046/j.1365-2567.2002.01396.x;;12127354;;10.1016/s1473-3099(02)00318-3;;10.1016/s0264-410x(00)00068-2;;10812228;;10.4049/jimmunol.167.11.6462;;11714813;;10861094;;10.4049/jimmunol.165.1.539;;8735547;;10.1016/0264-410x(95)00220-u;;10.4049/jimmunol.169.1.375;;12077267;;10.1128/jvi.74.4.1694-1703.2000;;pmc111644;;10644339;;10.1172/jci117662;;7814635;;pmc295437;;11741692;;10.1016/s0161-5890(01)00078-5;;10.1021/bc970183n;;9667946;;8585280;;10.1016/0264-410x(95)00011-o;;11544321;;10.4049/jimmunol.167.6.3324;;10.1073/pnas.96.16.9305;;10430938;;pmc17777;;11046050;;10.4049/jimmunol.165.9.5177;;10.1038/374546a0;;7700380;;9341778;;10.1002/eji.1830270931;;10.4049/jimmunol.164.2.900;;10623838;;10.1038/nm0697-625;;9176488;;11466332;;10.4049/jimmunol.167.3.1179;;11888923;;10065639;;10.1016/s0165-2478(98)00136-9;;pmc1422470;;11923611;;10.1097/00000658-200204000-00013;;12429623;;11160323;;10.4049/jimmunol.166.4.2610;;11888922;;10.1097/00002030-200107060-00005;;11426068;;11257408;;10.1016/s0264-410x(00)00499-0;;3276675;;10.1016/s0021-9258(19)77935-6;;9927689;;pmc15346;;10.1073/pnas.96.3.1036;;9841921;;10.1084/jem.188.11.2075;;pmc2212387;;10.1038/nm0398-321;;9500606;;pmc2064864;;10.1016/0264-410x(94)90245-3;;7839726,"Morse et al (Clinical Cancer Research, 1999, vol. 5, pp. 1331-1338).;;Mutis et al (PNAS, 1994, vol. 91, pp. 9456-9460).;;Rohrer, J. W., et al., Mod. Asp. Immunobiol. 1:191 (2001).;;Rohrer, J. W., et al., Mod. Asp. Immunobiol. 16: 27-34 (2005).;;Nukaya et al, Identification of the HLA-A24 Epitope Peptides of Carcinoembryonic Antigen Which Induce Tumor-Reactive Cytoxic T Lymphocyte. Int. J. Cancer, Jan. 1999, vol. 80, No. 1, pp. 92-97.;;Coggin Jr. et al, 37 KiloDalton Oncofetal Antigen Protein and Immature Laminin Receptor Protein are Identical, Universal T-Cell Indicing Immunogenes on Primary Rodent and Human Cancers. Anticancer Res.. Nov.-Dec. 1999. vol. 19, No. 6C, pp. 5535-5542.;;Armstrong et al, Vaccines in Oncoloogy: Background and Clinical Potential, British Journal of Radiology. Nov. 2001, vol. 74, No. 887, pp. 991-1002.;;Irie RF et al (J. Natl. Cancer Inst. 1979; 63(2):367-373).;;Rohrer JW et al (J. Immunol. 1999; 162(11):6880-6892.;;Oseroff et al (Vaccine 1999; 16(8):823-833).;;Rohrer et al., Journal of Immunology; 176; 2844-2856 (2006).;;Tai et al, Proc. Natl. Acad. Sci., 80:5392-5396 (Sep. 1983).;;Rohrer & Coggin, Journal of Immunology, The Williams and Wilkins Co. Baltimore, US, 155 (12); 5719-5727 (1995).;;Zelle-Rieser et al: Journal of Urology, Baltimore. MD, US., 165(5); 1705-1709 (2001).;;Astrow, A. B., Lancet 343:494 (1994).;;Bailar J. C., et al., N. Engl. J. Med. 314:1226 (1986).;;Gallagher, H. S., et al., Cancer 23:855 (1969).;;Spratt, J. S., et al., Cancer Res. 46:970 (1986).;;Zhuang, A., et al., Cancer Res. 55:467 (1995).;;Leffett, M. S., et al., Cancer Res. 37:4112 (1977).;;Coggin, J. H., Jr., Mol. Biother. 1:223 (1989).;;Van den Eynde, B. J., et al., Curr. Opinion Immunol. 9:684 (1997).;;Melief, C., et al., Immunol. Rev. 145:167 (1995).;;Greenberg, P. D., et al., Adv. Immunol. 49:281 (1991).;;Coulie, P. G., et al., J. Immunother. 14:104 (1993).;;Hellstrom, I., et al., Crit. Rev. Immunol. 18:1 (1998).;;Nabeta, Y. Mod., Asp. Immunobiol. 1:17 (2000).;;Coggin, J. H., Jr., et al., Immunol. Today 19:405 (1998).;;Seiter, S., et al., Mod. Asp. Immunobiol. 1:121 (2000).;;Landowski, T. H., et al., Biochem. 34:11276 (1995).;;Castronovo, V., Invasion Metastasis 13:1 (1993).;;van den Brule, F. A., et al., Biochem Biophys. Res. Commun. 201:388 (1994).;;Menard, S., et al., Biochem. 67:155 (1997).;;Coggin, J. H., Jr., et al., Anticancer Res. 19:1 (1999).;;Liotta, L. A., et al., Prog. Clin. Biol. Res. 256:3 (1988).;;Azavoorian, S., et al., Cancer 71:1368 (1993).;;Terranova, V. P., et al., Cancer Res. 42:2261 (1982).;;Terranova, V. P., et al., Science 226:982 (1984).;;Ardini, E., et al., J. Biol. Chem. 272:2342 (1997).;;Romanov, V., et al., Cell Adhes. Commun. 2:201 (1994).;;Turpeeniemi, H. T., et al., J. Biol. Chem. 261:1883 (1986).;;Sweeney, T. M., et al., Cancer Metastasis Rev. 10:245 (1991).;;D'Erico, A. S., et al., Mol. Pathol. 4:239 (1991).;;Monteagudo, C. M., et al., Am. J. Pathol. 136:585 (1990).;;Grigoni, W. F., et al., Am. J. Pathol. 138:647 (1991).;;Sobel, M. E., Semin. Cancer Biol. 4:311 (1993).;;Martignone, S., et al., J. Natl. Cancer Inst. 85:398 (1993).;;Waltregny, D., et al., J. Natl. Cancer Inst. 89:1224 (1997).;;Pellegrini, R., et al., Breast Cancer Res. Treat. 35:195 (1995).;;Menard, S., et al., Br. J. Cancer 69:1126 (1994).;;Vollmers, H. P., et al., Febs Letters 172:17 (1984).;;Wu, S. Chung-hua Ping Li Hsueh Tsa Chih 22:207 (1993).;;Terranova, V. P., et al., Cancer Res. 42:2265 (1982).;;Rohrer, J. W., et al., J. Immunol. 154:2266 (1995).;;Coggin, J. H., Jr., et al., Am. J. Pathol. 130:136 (1988).;;Coggin, J. H., Jr., et al., Int. J. Rad. Biol. 71:81 (1997).;;Rohrer, J. W., et al., J. Immunol. 162:6880 (1999).;;van den Brule, F. A., et al., Hum. Pathol. 27:1185 (1996).;;Payne, W. J., Jr., et al., J. Natl. Cancer Inst. 75:527 (1985).;;Rao, et al., Biochemistry 28:7476-7486 (1989).;;Yow, et al., Proc. Natl. Acad. Sci. USA 85:6394-6398 (1988).;;Coggin, et al., Arch. Otolaryngol Head Neck Surg. 119:1257-1266 (1993).;;Ambrosch, et al., Vaccine 15:1209-1213 (1997).;;Andrieu, et al., Eur. J. Immunol. 30:3256-65 (2000).;;B. Pulendran, et al., J. Immunol 165:566-572 (2000)).;;Banchereau, et al., Nature 392:245-52 (1998)).;;BenMohamed, et al., Immunology 106:113-121 (2002).;;BenMohamed, et al., The Lancet Infect. Dis. 2:425-31 (2002).;;BenMohamed, et al., Vaccine 18:2843-55 (2000).;;Boyum, Scand. J. Clin. Lab. Invest. 21:97:S77 (1968).;;Chikh, et al., J. Immunol. 167:6462-6470 (2001).;;Davila, E., E. Cells. 2000, J. Immunol. 165:539.;;Deprez, et al., Vaccine 14:375-382 (1996).;;E. Proietti, et al., J. Immunol. 169:375-383 (2002).;;Gahery-Segard, et al., J. Virol. 74:1694-1703 (2000).;;Vitello, et al., J. Clin. Invest. 95:341-349 (1995).;;Gras-Masse, Mol. Immunol. 38:423-431(2001).;;Guan, et al., Bioconjugate Chem. 9:451-458 (1998)).;;Gupta, et al., Vaccine 13:1263-76 (1995).;;Gursel, et al., J. Immunol. 167:3324-3328 (2001).;;Hartmann, G., G. J. Weiner, A. M. Krieg. 1999, Proc. Natl. Acad. Sci. USA 96:9305.;;I Krishnan, J. Immunol. 165:5177-5185 (2000)).;;Janeway, C. A., P. Travers, M. Walport, and M. Shlomchik. 2001. Immunobiology: The Immune System in Health and Disease. Garland Publishing, New York, pp. 307-309.;;Krieg, A. M., A. K. Yi, S. Matson, T. J. Waldschmidt, et al., Nature 374:546 (1995).;;Lipford, G. B., M. Bauer, C. Blank, et al. 1997. Eur. J. Immunol. 27:2340.;;Loing, et al., J. Immunol. 164:900-907 (2000).;;Lynch, D. H., E. Andreasen, E. Maraskovsky, et al. 1997, Nat. Med. 3:625.;;Mattei, et al., J. Immunol. 167:1179-1187 (2000).;;Mattner, et al., Cancer Res. 62:1477-1480 (2002).;;Mowat, Immunol. Lett. 65:133-40 (1999).;;Nair, et al., Annals of Surgery 235:540-549 (2002)).;;Nair, supra., Holtl, et al., Clin. Cancer Res. 8:3369-76 (2002).;;Nishiguchi, et al., J. Immunol. 166:2610-16 (2001).;;Ota, et al., Cancer Res. 62:1471-1476 (2002).;;Pialoux, et al., AIDS 15:1239-49 (2001).;;Podda, A. 2001, Vaccine 19:2673, Jun. 16, 2011.;;Posnett et al., J. Biol Chem. 263:1719-1725 (1988).;;Pulendran, B., J. L. Smith, G. Caspary, et al. 1999, Proc. Natl. Acad. Sci. USA 96:1036.;;Pulendran, B., J. L. Smith, M. Jenkins, et al. 1998, J. Exp. Med. 188:2075.;;Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, et al., Nat. Med. 4:321 (1998).;;Rouaix, et al., Vaccine 12:1209-14 (1994).",EXPIRED
70,DE,D1,DE 60026259 D1,193-195-183-013-092,2006-04-27,2006,DE 60026259 T,2000-12-29,US 47641199 A,1999-12-30,Durch Gas unterstütztes Formen von einteiligen Kathetern,"An apparatus and a method are disclosed for manufacturing an integral one-piece catheter having a tube and a hub. The method comprises feeding molten material into a mold having a mold cavity. A fluid such as a gas is injected into an inlet of the mold. This causes the cavity to eject the molten central region of the polymer through an exit channel. In one embodiment, a gas is injected into the hub portion of the cavity. In another embodiment, a gas is injected into the catheter portion of the mold. The invention also involves forming a first portion of an intravascular device using a first material in a first mold. Thereafter the first portion of the intravascular device is inserted into a second mold to form a second portion using a second material. Gas is then introduced to form a hollow channel in the second portion. The invention also involves a first portion of the mold is injected with a first material, and a second portion of the cavity is injected with a second material at or around the same time that the first material is injected into the first portion of the cavity. Gas is then introduced to form a hollow channel in the second portion. <IMAGE>",MEDEX INC,GORAL DAVID;;KAFRAWY ADEL;;POLLEY WILLIAM F;;THOMAS JOSEPH R,,https://lens.org/193-195-183-013-092,Granted Patent,no,0,0,23,23,0,A61M25/0009;;B29C45/0013;;B29C45/1615;;B29C45/1704;;B29L2031/7542;;A61M25/0009;;B29C45/1704;;B29L2031/7542;;B29C45/1615;;B29C45/0013,B29C45/17;;A61M25/00;;B29C45/00;;B29C45/16,,0,0,,,,EXPIRED
71,EP,A4,EP 1538900 A4,008-511-102-876-827,2008-09-24,2008,EP 03767221 A,2003-08-04,US 0324518 W;;US 40085102 P,2002-08-02,CANCER VACCINES CONTAINING EPITOPES OF ONCOFETAL ANTIGEN,,UNIV SOUTH ALABAMA,COGGIN JOSEPH H JR;;ROHRER JAMES W;;BARSOUM ADEL L,,https://lens.org/008-511-102-876-827,Search Report,no,2,0,14,14,0,A61K9/0019;;A61K9/127;;C07K14/4748;;A61P35/00;;A61K39/00118;;A61K9/127;;A61K9/0019;;C07K14/4748;;A61K39/00118,A01N37/18;;A61K/;;A61K38/08;;A61K38/10;;A61K38/17;;A61K39/00;;A61P35/00;;C07K14/47;;C12P21/00;;C12P21/06,,4,4,072-353-837-224-133;;143-844-143-629-195;;008-722-616-989-992;;019-786-857-266-199,10352310;;7499859;;11342960;;10.1016/s0022-5347(05)66398-7;;10.1097/00005392-200105000-00085;;10.1016/s0167-5699(98)01305-x;;9745203,"ROHRER J W ET AL: ""Human breast carcinoma patients develop clonable oncofetal antigen-specific effector and regulatory T lymphocytes."", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 JUN 1999, vol. 162, no. 11, 1 June 1999 (1999-06-01), pages 6880 - 6892, XP002438875, ISSN: 0022-1767;;ROHRER J W & COGGIN J H: ""CD8 T cell clones inhibit antitumor T cell function by secreting IL-10"", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 155, no. 12, 15 December 1995 (1995-12-15), pages 5719 - 5727, XP002293749, ISSN: 0022-1767;;ZELLE-RIESER ET AL: ""EXPRESSION AND IMMUNOGENICITY OF ONCOFETAL ANTIGEN-IMMATURE LAMININ RECEPTOR IN HUMAN RENAL CELL CARCINOMA"", JOURNAL OF UROLOGY, BALTIMORE, MD, US, vol. 165, no. 5, May 2001 (2001-05-01), pages 1705 - 1709, XP005545545, ISSN: 0022-5347;;COGGIN J H ET AL: ""Tumors express both unique TSTA and crossprotective 44 kDa oncofetal antigen"", IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 19, no. 9, September 1998 (1998-09-01), pages 405 - 408, XP004133960, ISSN: 0167-5699",EXPIRED
72,CA,C,CA 2329970 C,038-327-854-299-864,2008-02-05,2008,CA 2329970 A,2000-12-29,US 47641199 A,1999-12-30,GAS ASSIST MOLDING OF ONE-PIECE CATHETERS,"An apparatus and a method are disclosed for manufacturing an integral one--piece catheter having a tube and a hub. The method comprises feeding molten material into a mold having a mold cavity. A fluid such as a gas is injected into an inlet of the mold. This causes the cavity to eject the molten central region of the polym er through an exit channel. In one embodiment, a gas is injected into the hub portion o f the cavity. In another embodiment, a gas is injected into the catheter portion of the mold. The invention also involves forming a first portion of an intravascular devi ce using a first material in a first mold. Thereafter the first portion of the intravascular device is inserted into a second mold to form a second portion using a secon d material. Gas is then introduced to form a hollow channel in the second portion. The invention also involves a first portion of the mold is injected with a first material, and a second portion of the cavity is injected with a second material at or around the same time that the first material is injected into the first portion of the cavity. Gas is then introduced to form a hollow channel in the second portion.</SDOA B>",ETHICON INC,THOMAS JOSEPH R;;KAFRAWY ADEL;;POLLEY WILLIAM F;;GORAL DAVID,,https://lens.org/038-327-854-299-864,Granted Patent,no,0,0,23,23,0,A61M25/0009;;B29C45/0013;;B29C45/1615;;B29C45/1704;;B29L2031/7542;;A61M25/0009;;B29C45/1704;;B29L2031/7542;;B29C45/1615;;B29C45/0013,B29C45/10;;A61M25/00;;B29C45/00;;B29C45/16;;B29C45/17,,0,0,,,,EXPIRED
73,WO,A3,WO 2004/012681 A3,062-977-388-011-169,2004-11-11,2004,US 0324518 W,2003-08-04,US 40085102 P,2002-08-02,CANCER VACCINES CONTAINING EPITOPES OF ONCOFETAL ANTIGEN,"Disclosed are fragments of oncofetal antigen, otherwise known as immature laminin receptor protein that specifically stimulate one T cell subclass. The fragments may be formulated into compositions for potentiating T cell-mediated response in mammalian cancer patients. They also have therapeutic uses in vitro.",SOUTH ALABAMA MEDICAL SCIENCES;;COGGIN JOSEPH H JR;;ROHRER JAMES W;;BARSOUM ADEL L,COGGIN JOSEPH H JR;;ROHRER JAMES W;;BARSOUM ADEL L,,https://lens.org/062-977-388-011-169,Search Report,yes,1,0,14,14,0,A61K9/0019;;A61K9/127;;C07K14/4748;;A61P35/00;;A61K39/00118;;A61K9/127;;A61K9/0019;;C07K14/4748;;A61K39/00118,A01N37/18;;A61K/;;A61K38/08;;A61K38/10;;A61K38/17;;A61K39/00;;A61P35/00;;C07K14/47;;C12P21/00;;C12P21/06,,3,3,021-140-047-466-286;;001-091-616-258-863;;122-380-309-983-596,10.1002/(sici)1097-0215(19990105)80:1<92::aid-ijc18>3.0.co;2-m;;9935237;;10697612;;10.1259/bjr.74.887.740991;;11709463,"NUKAYA I. ET AL: ""Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte"", INT. J. CANCER, vol. 80, no. 1, January 1999 (1999-01-01), pages 92 - 97, XP002981879;;COGGIN JR ET AL: ""37 Kilodalton oncofetal antigen protein and immature laminin receptor protein are identical, universal T-cell inducing immunogens on primary rodent and human cancers"", ANTICANCER RES., vol. 19, no. 6C, November 1999 (1999-11-01) - December 1999 (1999-12-01), pages 5535 - 5542, XP002981891;;ARMSTRONG A:C. ET AL: ""Vaccines in Oncology: Background and clinical potential"", BRITISH JOURNAL OF RADIOLOGY, vol. 74, no. 887, November 2001 (2001-11-01), pages 991 - 1002, XP002981880",PENDING
74,US,B1,US 6630086 B1,005-998-179-040-161,2003-10-07,2003,US 47641199 A,1999-12-30,US 47641199 A,1999-12-30,Gas assist molding of one-piece catheters,"
    An apparatus and a method are disclosed for manufacturing an integral one piece catheter having a tube and a hub. The method comprises feeding molten material into a mold having a mold cavity. A fluid such as a gas is injected into an inlet of the mold. This causes the cavity to eject the molten central region of the polymer through an exit channel. In one embodiment, a gas is injected into the hub portion of the cavity. In another embodiment, a gas is injected into the catheter portion of the mold. 

    The invention also involves forming a first portion of an intravascular device using a first material in a first mold. Thereafter the first portion of the intravascular device is inserted into a second mold to form a second portion using a second material. Gas is then introduced to form a hollow channel in the second portion. 

    The invention also involves a first portion of the mold is injected with a first material, and a second portion of the cavity is injected with a second material at or around the same time that the first material is injected into the first portion of the cavity. Gas is then introduced to form a hollow channel in the second portion. 
",ETHICON INC,GORAL DAVID;;KAFRAWY ADEL;;POLLEY WILLIAM F;;THOMAS JOSEPH R,ETHICON INC (2000-02-10);;MEDEX INC (2003-05-21);;ETHICON ENDO SURGERY INC (2001-12-31),https://lens.org/005-998-179-040-161,Granted Patent,yes,13,44,23,23,0,A61M25/0009;;B29C45/0013;;B29C45/1615;;B29C45/1704;;B29L2031/7542;;A61M25/0009;;B29C45/1704;;B29L2031/7542;;B29C45/1615;;B29C45/0013,A61M25/00;;B29C45/00;;B29C45/16;;B29C45/17,264/40.4;;264/85;;264/572;;264/573,0,0,,,,EXPIRED
75,BR,A,BR 0100153 A,059-857-563-652-429,2001-08-28,2001,BR 0100153 A,2001-01-02,US 47641199 A,1999-12-30,"Método para fabricar um cateter e um cubo de uma peça, método de fabricar um cubo e um tubo cateter, método de fabricar um dispositivo intravascular, aparelho para forma um cateter de peça única e molde para forma um cubo e um tubo de peça única","An apparatus and a method are disclosed for manufacturing an integral one-piece catheter having a tube and a hub. The method comprises feeding molten material into a mold having a mold cavity. A fluid such as a gas is injected into an inlet of the mold. This causes the cavity to eject the molten central region of the polymer through an exit channel. In one embodiment, a gas is injected into the hub portion of the cavity. In another embodiment, a gas is injected into the catheter portion of the mold. The invention also involves forming a first portion of an intravascular device using a first material in a first mold. Thereafter the first portion of the intravascular device is inserted into a second mold to form a second portion using a second material. Gas is then introduced to form a hollow channel in the second portion. The invention also involves a first portion of the mold is injected with a first material, and a second portion of the cavity is injected with a second material at or around the same time that the first material is injected into the first portion of the cavity. Gas is then introduced to form a hollow channel in the second portion. <IMAGE>",JOHNSON & JOHNSON,GORAL DAVID;;KAFRAWY ADEL;;POLLEY WILLIAM F;;THOMAS JOSEPH R,JOHNSON AND JOHNSON (US) (2013-08-27),https://lens.org/059-857-563-652-429,Patent Application,no,0,0,23,23,0,A61M25/0009;;B29C45/0013;;B29C45/1615;;B29C45/1704;;B29L2031/7542;;A61M25/0009;;B29C45/1704;;B29L2031/7542;;B29C45/1615;;B29C45/0013,A61M25/00;;B29C45/00;;B29C45/16;;B29C45/17,,0,0,,,,DISCONTINUED
76,ZA,B,ZA 200100036 B,099-372-860-672-464,2002-07-02,2002,ZA 200100036 A,2001-01-02,US 47641199 A,1999-12-30,Gas assist molding of one-piece catheters.,"An apparatus and a method are disclosed for manufacturing an integral one-piece catheter having a tube and a hub. The method comprises feeding molten material into a mold having a mold cavity. A fluid such as a gas is injected into an inlet of the mold. This causes the cavity to eject the molten central region of the polymer through an exit channel. In one embodiment, a gas is injected into the hub portion of the cavity. In another embodiment, a gas is injected into the catheter portion of the mold. The invention also involves forming a first portion of an intravascular device using a first material in a first mold. Thereafter the first portion of the intravascular device is inserted into a second mold to form a second portion using a second material. Gas is then introduced to form a hollow channel in the second portion. The invention also involves a first portion of the mold is injected with a first material, and a second portion of the cavity is injected with a second material at or around the same time that the first material is injected into the first portion of the cavity. Gas is then introduced to form a hollow channel in the second portion. <IMAGE>",ETHICON INC,GORAL DAVID;;POLLEY WILLIAM F;;KAFRAWY ADEL;;THOMAS JOSEPH R,,https://lens.org/099-372-860-672-464,Granted Patent,no,0,0,23,23,0,A61M25/0009;;B29C45/0013;;B29C45/1615;;B29C45/1704;;B29L2031/7542;;A61M25/0009;;B29C45/1704;;B29L2031/7542;;B29C45/1615;;B29C45/0013,A61M25/00;;B29C45/00;;B29C45/16;;B29C45/17,,0,0,,,,EXPIRED
77,EP,A3,EP 1116567 A3,053-242-841-865-872,2003-01-02,2003,EP 00311765 A,2000-12-29,US 47641199 A,1999-12-30,Gas assist molding of one-piece catheters,"An apparatus and a method are disclosed for manufacturing an integral one-piece catheter having a tube and a hub. The method comprises feeding molten material into a mold having a mold cavity. A fluid such as a gas is injected into an inlet of the mold. This causes the cavity to eject the molten central region of the polymer through an exit channel. In one embodiment, a gas is injected into the hub portion of the cavity. In another embodiment, a gas is injected into the catheter portion of the mold. The invention also involves forming a first portion of an intravascular device using a first material in a first mold. Thereafter the first portion of the intravascular device is inserted into a second mold to form a second portion using a second material. Gas is then introduced to form a hollow channel in the second portion. The invention also involves a first portion of the mold is injected with a first material, and a second portion of the cavity is injected with a second material at or around the same time that the first material is injected into the first portion of the cavity. Gas is then introduced to form a hollow channel in the second portion.",ETHICON INC,GORAL DAVID;;KAFRAWY ADEL;;POLLEY WILLIAM F;;THOMAS JOSEPH R,"MEDEX, INC. (2005-05-11)",https://lens.org/053-242-841-865-872,Search Report,yes,8,0,23,23,0,A61M25/0009;;B29C45/0013;;B29C45/1615;;B29C45/1704;;B29L2031/7542;;A61M25/0009;;B29C45/1704;;B29L2031/7542;;B29C45/1615;;B29C45/0013,A61M25/00;;B29C45/00;;B29C45/16;;B29C45/17,,0,0,,,,EXPIRED
78,CA,C,CA 2492938 C,020-636-457-265-754,2012-05-22,2012,CA 2492938 A,2003-08-04,US 40085102 P;;US 0324518 W,2002-08-02,CANCER VACCINES CONTAINING EPITOPES OF ONCOFETAL ANTIGEN,"Disclosed are fragments of oncofetal antigen, otherwise known as immature laminin receptor protein that specifically stimulate one T cell subclass. The fragments may be formulated into compositions for potentiating T cell-mediated response in mammalian cancer patients. They also have therapeutic uses in vitro.",UNIV SOUTH ALABAMA,COGGIN JOSEPH H JR;;ROHRER JAMES W;;BARSOUM ADEL L,,https://lens.org/020-636-457-265-754,Granted Patent,no,0,0,14,14,82,A61K9/0019;;A61K9/127;;C07K14/4748;;A61P35/00;;A61K39/00118;;A61K9/127;;A61K9/0019;;C07K14/4748;;A61K39/00118,A61K39/00;;A01N37/18;;A61K/;;A61K38/08;;A61K38/10;;A61K38/17;;A61P35/00;;C07K14/47;;C12P21/00;;C12P21/06,,0,0,,,,EXPIRED
79,ES,T3,ES 2259595 T3,059-944-583-718-515,2006-10-16,2006,ES 00311765 T,2000-12-29,US 47641199 A,1999-12-30,MOLDEO ASISTIDO POR GAS DE CATETERES DE UNA PIEZA.,"An apparatus and a method are disclosed for manufacturing an integral one-piece catheter having a tube and a hub. The method comprises feeding molten material into a mold having a mold cavity. A fluid such as a gas is injected into an inlet of the mold. This causes the cavity to eject the molten central region of the polymer through an exit channel. In one embodiment, a gas is injected into the hub portion of the cavity. In another embodiment, a gas is injected into the catheter portion of the mold. The invention also involves forming a first portion of an intravascular device using a first material in a first mold. Thereafter the first portion of the intravascular device is inserted into a second mold to form a second portion using a second material. Gas is then introduced to form a hollow channel in the second portion. The invention also involves a first portion of the mold is injected with a first material, and a second portion of the cavity is injected with a second material at or around the same time that the first material is injected into the first portion of the cavity. Gas is then introduced to form a hollow channel in the second portion. <IMAGE>",MEDEX INC,GORAL DAVID;;KAFRAWY ADEL;;POLLEY WILLIAM F;;THOMAS JOSEPH R,,https://lens.org/059-944-583-718-515,Granted Patent,no,0,0,23,23,0,A61M25/0009;;B29C45/0013;;B29C45/1615;;B29C45/1704;;B29L2031/7542;;A61M25/0009;;B29C45/1704;;B29L2031/7542;;B29C45/1615;;B29C45/0013,A61M25/00;;B29C45/00;;B29C45/16;;B29C45/17,,0,0,,,,EXPIRED
80,US,B1,US 6335174 B1,072-584-222-995-36X,2002-01-01,2002,US 83506997 A,1997-04-04,US 83506997 A;;US 1490396 P,1996-04-05,"Oncofetal antigen specific t-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific CD4, CD8 cytotoxic and suppressor T cells and interleukin-10","
    The present invention provides a method of determining the success of a cancer therapy in an individual, comprising the step of measuring the frequency of occurence of an oncofetal antigen-specific subclasses in the individual's peripheral blood. Also provided is a method of determining whether protective immunity against a tumor will develop in an individual, comprising the step of measuring the frequency of oncofetal antigen-specific T cells, tumor cells and macrophages at the site of the tumor which secrete IL-10. Additionally, a method of determining whether an individual having a tumor will go into remission or remain in remission, comprising the step of measuring the frequency of oncofetal antigen-specific Th1 cells, Tc cells and Ts cells, IL-10 and interferon- secreting T cells in the peripheral blood. 
",UNIV SOUTH ALABAMA,COGGIN JOSEPH H JR;;BARSOUM ADEL L;;ROHRER JAMES W,SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION (2005-05-05),https://lens.org/072-584-222-995-36X,Granted Patent,yes,7,5,11,13,0,C07K16/244;;G01N33/57476;;Y10S435/975;;A61P35/00;;G01N33/57476;;C07K16/244;;Y10S435/975,A61K38/17;;C07K16/24;;G01N33/574,435/7.23;;435/7.24;;435/29;;435/372.3;;435/975;;530/351;;530/388.75,87,74,001-954-961-100-881;;006-892-054-524-630;;055-719-122-933-320;;114-908-372-687-178;;016-343-364-370-586;;070-546-138-582-036;;012-040-060-717-946;;176-822-061-486-16X;;032-185-576-687-592;;030-951-377-995-426;;016-678-963-910-382;;117-516-581-351-087;;103-848-986-556-745;;001-091-616-258-863;;151-469-191-076-458;;120-346-815-753-417;;126-552-161-618-587;;011-239-499-409-415;;122-456-934-766-819;;056-550-012-449-568;;011-615-918-500-237;;056-819-026-657-252;;106-006-901-149-170;;106-688-434-505-738;;062-371-823-108-410;;039-321-462-620-937;;039-129-895-811-317;;100-479-103-706-798;;105-044-211-640-879;;006-563-786-125-101;;028-675-365-661-816;;090-383-045-217-963;;006-402-611-958-876;;110-021-731-734-237;;097-181-136-899-612;;041-362-415-892-369;;149-569-811-994-37X;;137-565-953-035-314;;075-970-063-895-453;;044-647-253-422-118;;000-427-162-057-759;;121-959-388-556-256;;033-760-978-650-500;;103-105-275-022-678;;017-799-157-179-326;;117-898-627-488-043;;077-520-301-979-113;;087-731-686-512-620;;096-688-408-790-087;;123-241-550-501-203;;168-546-333-978-048;;143-844-143-629-195;;141-588-737-283-723;;096-317-560-511-625;;046-383-261-887-720;;068-201-349-010-526;;050-260-243-107-473;;124-935-962-687-051;;069-390-941-471-614;;107-731-123-007-819;;050-298-576-176-059;;104-946-718-779-307;;027-368-947-278-992;;009-214-221-510-209;;011-837-382-151-756;;045-113-894-537-329;;168-546-333-978-048;;072-534-713-210-904;;102-128-410-091-322;;045-006-471-313-434;;020-753-499-798-965;;129-775-065-815-860;;083-548-250-351-706;;001-954-961-100-881,7561096;;3104476;;10.1016/0022-1759(87)90429-7;;5034143;;2600602;;1850386;;10.1002/ijc.2910480216;;10.1016/0020-711x(93)90654-w;;8467950;;1826699;;7814878;;14235685;;10.1038/204793a0;;10.1016/1040-8428(96)00194-1;;8793276;;10.1016/s0092-8674(05)80059-5;;1335364;;3337209;;pmc1880537;;10.1080/095530097144454;;9020967;;10697612;;10.1016/0167-5699(89)90229-6;;2742738;;2818874;;10.1001/archotol.1993.01880230105015;;8217085;;10.1172/jci105098;;pmc289652;;14234820;;10.1080/09553009414550081;;7905910;;1372018;;1940799;;pmc2119001;;10.1084/jem.174.5.1209;;7684412;;1697873;;10.1084/jem.179.5.1597;;8163939;;pmc2191501;;2531194;;10.1084/jem.170.6.2081;;pmc2189521;;1827484;;5154596;;2967332;;10.1038/213674a0;;6031772;;1313950;;10.1038/356607a0;;5439527;;10.1111/j.1365-2141.1970.tb01436.x;;75855;;10.1002/ijc.2910210311;;8781270;;10.1016/s0065-2776(08)60431-9;;7506722;;10.1016/0022-1759(93)90158-4;;8445253;;8811309;;10.1016/s0889-8588(05)70376-2;;8809472;;10.1615/critrevimmunol.v16.i1.30;;7930605;;8202711;;10.1126/science.8202711;;10.1002/eji.1830210612;;1904359;;10.1111/j.1365-3083.1988.tb02344.x;;2965407;;pmc2180603;;401860;;10.1084/jem.145.2.275;;10.1093/jnci/75.3.527;;2411994;;10.1002/eji.1830230926;;8370402;;6975300;;8133535;;10.1093/jnci/86.7.515;;1907999;;pmc1950464;;1460278;;10.1093/jnci/84.8.602;;1556771;;7904290;;7868899;;7499859;;7512591;;10.1126/science.2113314;;2113314;;8030748;;pmc1887307;;2928954;;5098546;;10.1159/000466675;;10.1111/j.1423-0410.1971.tb00469.x;;5121668;;160895;;10.1002/ijc.2910240510;;10.1093/jnci/44.4.955;;11515063;;pmc392661;;10.1073/pnas.75.6.2844;;351618;;325412;;10.1056/nejm197707212970301;;2524832;;10.1073/pnas.86.10.3758;;pmc287219;;1838908;;10.1111/j.1749-6632.1991.tb33444.x;;10.1002/ijc.2910580304;;8050813;;8683120;;10.4049/jimmunol.157.1.231;;7868899;;7994751;;10.1006/cimm.1994.1304;;7636270;;1356125;;8450205;;2787679;;10.1182/blood.v74.2.786.786;;7673726;;7561096,"Berman, R. et al. J. Immunol. 155 (8): 3897-3903, Oct. 1993.;;Abou-Zeid, et al., J. Immunol. Methods 98:5 (1987).;;Bain and Pshyk, Transplantation Proc. 4:163 (1972).;;Barsoum et al., J. Biol. Resp. Modifiers 8:579 (1989).;;Barsoum et al., Inter. J. Cancer 48:248-252.;;Barsoum et al., Int. J. Biochem. 24:483-489 (1993).;;Berg, et al., J. Immunol. 146:2865 (1991).;;Bost, et al., J. Immunol. 154:718 (1995).;;Boyum, Nature 204:793 (1964).;;Chang, et al., Critical Reviews in Oncology/Hematology 22:213-228 (1996).;;Chen, et al., Cell 71:1093 (1992).;;Coggin, et al., Am J. Pathol 130:136 (1988).;;Coggin, et al., Internat. J. Rad. Biol. 71:81 (1997).;;Coggin, et al., Anti-Cancer Res. 19:5535 (1999).;;Coggin, Shared Cross-Protective OFAs on Chemically Induced Rodent Sarcomas. Immunology Today 10(3):76-78 (1989).;;Coggin, Molecular Biotheraphy 1(4):223-228 (1989).;;Coggin, et al., Archives of Otolaryngology-Head and Neck Surgery 119:1257-1266 (1993).;;Cone, et al., J. Clin. Invest. 43:2241 (1964).;;Cox, Intern. J. Rad. Biol. 65:57-64 (1994).;;Damle, et al., Immunol. 148:1985 (1992).;;Decker, et al., J. Immunol. Methods 15:61 (1988).;;DeSantis, et al., Eur. J. Immunol. 15:575 (1987).;;De Waal, et al., J. Exp. Med. 174:1209 (1991).;;De Waal, et al., J. Immunol. 150:4754 (1993).;;Fairchild, et al., J. Immunol. 145:2001 (1990).;;Ferguson, et al., J. Exp. Med. 179:1597 (1994).;;Fiorentino, et al., J. Exp. Med. 170:2081 (1989).;;Fiorentino, et al., J. Immunol. 146:3444 (1991).;;Fotino, et al., Ann. Clin. Lab. Sci. 1:131 (1971).;;Fotino, et al., Vox Sang 21:469 (1971).;;Gajewski, et al., J. Immunol. 140:4245 (1988).;;Gershon, et al., Nature 213:674 (1967).;;Harding, et al., Nature 356:607 (1992).;;Harris, et al., Brit. J. Haematol. 18:229 (1970).;;Hellstrom, et al., Int. J. Cancer 21:317 (1978).;;Henderson, et al., Advances in Immunology 62:217-256 (1996).;;Johnson, et al., J. Immunol. 152:429 (1994).;;Jung, et al., J. Immunol. Methods 159:197 (1993).;;Kavanaugh, et al., Hematology/Oncology Clinics of North America, 4:927-951 (1996).;;Leffel, et al., Cancer Res. 37:4112 (1977).;;Levy, et al., Critical Reviews in Immunology 16:31-57 (1996).;;Li, et al., J. Immunol. 153:3967 (1994).;;Lombardi, et al., Science 264:1587 (1994).;;Lynch, et al., Eur. J. Immunol. 21:1403 (1991).;;Moller, Scand. J. Immunol. 27:247 (1988).;;North, et al., J. Exp. Med. 145:275 (1977).;;O'Garra, et al., Eur. J. Immunol. 22:711 (1992).;;Payne, et al., J. Natl. Cancer Inst. 75:527 (1985).;;Phillips, In: Tissue Culture:Methods and Applications. P. F. Kruse, Jr., ed. Academic Press, New York, 406-408 (1994).;;Portsmann, et al., J. Immunol. Methods 82:169 (1985).;;Powrie, et al., Eur. J. Immunol. 23:2223 (1993).;;Rabin, et al., J. Immunol. 127:1852 (1981).;;Rashid, et al., J. Natl. Cancer Inst. 86:515-526 (1994).;;Renie, et al., Sci. Amer. Sep. 57-59 (1996).;;Restifo, et al., J. Immunol. 147:1453 (1993).;;Rivas, et al., J. Immunol. 149:3865 (1992).;;Rogers, et al., J. Immunol. Methods 15:61 (1991).;;Rohrer, et al., J. Natl. Cancer Inst. 84:602 (1992).;;Rohrer, et al., J. Immunol. 152:754-764 (1994).;;Rohrer, et al., J. Immunol. 154:2266 (1995).;;Rohrer, et al., J. Immunol. 155:5719 (1995).;;Schadene, et al., J. Immunol. 152:4368 (1994).;;Schwartz, Science 248:1349 (1990).;;Smith, et al., Am. J. Pathol. 145:18 (1994).;;Stranding, et al., Biochem. Biophys. Acta 508:85 (1978).;;Stephenson, et al., Surgery 105:523.;;Ting, et al., Vox Sang. 20:561 (1971).;;Vaage, Cancer Res. 31:1655 (1971).;;Vikingson, et al., J. Immunol. Methods 173:219 (1994).;;Vose, et al., Int. J. Cancer 245:579 (1979).;;Wepsic, et al., J. Natl. Cancer Inst. 44:955 (1970).;;Wybran, et al., J. Immunol. 110:1157 (1973).;;Wysocki, et al., Proc. Natl. Acad. Sci. USA 75:2844 (1978).;;Yu et al., N. Engl. J. Med. 297:121 (1977).;;Zheng, et al., Proc. Natl. acad. Sci USA 86:3758 (1989).;;Zarling, et al., Cancer Immun. Immunother. 7:243 (1980).;;Naor et al., Annals New York Acad. Sci. 636:135-146 (1991).;;Mazzocchi et al., Int. J. Cancer 58:330-339 (1994).;;Berman, et al., J. Immunol. 157(1) :231-238 (1996).;;Rohrer, J. W. et al. J. Immunol. 154 (5): 2266-2280, Mar. 1995.*;;Wang, L. et al. Cell. Immunol. 159: 152-169, Dec. 1994.*;;Kim, J. et al. J. Immunol. 155 (4): 2240-2247, Aug. 1995.*;;Yssel, H. et al. J. Immunol. 149 (7): 2378-2384, Oct. 1992.*;;Inoue, T. et al. J. Immunol. 150 (6): 2121-2138, Mar. 1993.*;;Totterman, T. et al. Blood 74 (2): 786-792, Aug. 1992.*;;Giovarelli, M. et al. J. Immunol. 155 (6): 3112-3123, Sep. 1995.*;;Yang, G. et al. J. Immunol. 155 (8): 3897-3903, Oct. 1995.*",EXPIRED
81,US,A1,US 2013/0052211 A1,130-579-584-194-450,2013-02-28,2013,US 201013383103 A,2010-07-09,US 201013383103 A;;US 27057009 P;;US 2010/0041556 W,2009-07-09,VACCINES WITH ONCOFETAL ANTIGEN/ILRP-LOADED AUTOLOGOUS DENDRITIC CELLS AND USES THEREOF,"Disclosed are compositions containing isolated monocyte-derived mature dendritic cells loaded with OFA/iLRP, or a fragment thereof that selectively stimulates T cytotoxic lymphocytes, and a carrier, vaccine compositions containing effective dosage amounts of the dendritic cells, methods of making the vaccines, and methods of cancer treatment or therapy that entail administration of the vaccines to cancer patients.",BARSOUM ADEL L;;ROHRER SUZANNE;;SEGERS CINDY C;;COGGIN KURT M;;UNIV SOUTH ALABAMA,BARSOUM ADEL L;;ROHRER JAMES W;;COGGIN JR JOSEPH H,SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION (2012-08-07),https://lens.org/130-579-584-194-450,Patent Application,yes,3,1,4,4,0,A61K35/26;;C12N5/0639;;C12N2501/02;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61P35/00;;A61P37/04;;A61K2239/49;;A61K2239/31;;A61K39/4615;;A61K39/4622;;A61K39/464402;;A61K39/46448;;A61K2239/38;;C12N5/0639;;A61K35/26;;A61K2039/5154;;C12N2501/23;;C12N2501/25;;C12N2501/22;;C12N2501/02;;A61K39/00118,A61K39/00;;A61P35/00;;A61P37/04;;C12N5/0784;;G01N33/569,424/184.1;;435/377;;435/374;;435/7.24,3,3,081-222-251-281-305;;094-310-089-281-72X;;072-353-837-224-133,12869512;;10.1182/blood-2003-01-0198;;17118612;;10.1016/j.jpba.2006.10.023;;10352310,"Siegel et al., Blood. 2003 Dec 15;102(13):4416-4423;;Jaber et al., Journal of Pharmaceutical and Biomedical analysis, vol. 43, no. 4, 23 Feb 2007, pages 1256-1261;;Rohrer et al., J Immunol, 1999 162(11): p. 6880-6892",DISCONTINUED
82,US,B2,US 7718762 B2,030-918-275-364-901,2010-05-18,2010,US 52327705 A,2005-09-22,US 52327705 A;;US 40085102 P;;US 0324518 W,2002-08-02,Cancer vaccines containing epitopes of oncofetal antigen,"Disclosed are fragments of oncofetal antigen, otherwise known as immature laminin receptor protein that specifically stimulate one T cell subclass. The fragments may be formulated into compositions for potentiating T cell-mediated responses in mammalian cancer patients. They also have therapeutic uses in vitro.",UNIV SOUTH ALABAMA,COGGIN JR JOSEPH H;;ROHRER JAMES W;;BARSOUM ADEL L,SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION (2005-06-08),https://lens.org/030-918-275-364-901,Granted Patent,yes,4,5,14,14,82,A61K9/0019;;A61K9/127;;C07K14/4748;;A61P35/00;;A61K39/00118;;A61K9/127;;A61K9/0019;;C07K14/4748;;A61K39/00118,A01N37/18;;C07K5/00;;A61K/;;A61K38/00;;A61K38/08;;A61K38/10;;A61K38/17;;A61K39/00;;A61P35/00;;C07K14/47;;C12P21/00;;C12P21/06,530/300;;514/2,100,87,025-616-693-471-094;;072-353-837-224-133;;015-573-463-771-956;;143-844-143-629-195;;008-722-616-989-992;;021-140-047-466-286;;001-091-616-258-863;;122-380-309-983-596;;036-670-322-860-273;;073-743-409-298-371;;135-143-185-261-972;;056-522-114-356-583;;188-867-846-472-352;;071-241-199-775-770;;103-556-779-531-567;;120-346-815-753-417;;075-926-065-016-418;;045-711-346-412-488;;024-124-680-816-658;;033-798-202-369-352;;001-026-577-269-007;;019-786-857-266-199;;132-121-317-763-450;;127-128-919-672-872;;008-140-604-210-953;;027-846-935-842-908;;139-091-103-522-555;;045-676-911-168-166;;048-861-032-822-524;;047-962-740-795-340;;055-281-790-604-035;;005-521-702-082-318;;081-399-223-596-944;;101-473-441-419-424;;028-697-309-251-510;;103-843-437-231-312;;118-487-476-701-416;;036-034-789-927-905;;004-567-599-435-628;;010-769-703-170-598;;026-626-612-779-878;;015-592-478-814-705;;076-218-311-884-130;;079-756-586-352-456;;065-267-215-227-642;;050-458-364-566-821;;026-028-225-588-967;;044-518-451-836-169;;000-844-059-876-067;;008-660-712-324-869;;056-834-210-287-875;;010-058-174-809-534;;033-615-093-037-898;;070-475-487-024-440;;026-190-484-845-337;;062-333-814-343-796;;080-537-897-544-354;;124-257-229-162-56X;;013-328-986-731-118;;170-481-129-346-374;;039-309-144-579-439;;022-421-943-652-762;;019-246-072-356-162;;012-082-215-951-717;;112-613-940-739-511;;016-578-245-720-05X;;026-777-039-697-48X;;012-638-135-148-028;;005-795-969-557-480;;011-509-658-764-615;;030-220-353-340-987;;030-955-335-211-791;;184-434-919-059-886;;003-773-931-590-365;;072-785-976-576-971;;110-835-202-698-472;;040-927-232-074-186;;024-569-814-204-203;;130-428-701-900-599;;110-509-109-698-351;;130-302-000-620-144;;044-196-745-940-261;;089-580-910-941-188;;050-298-576-176-059;;020-678-763-570-04X;;043-126-575-070-047;;066-272-193-056-071,10.1093/jnci/63.2.367;;88539;;10352310;;10.1016/s0264-410x(97)00264-8;;9627940;;7499859;;11342960;;10.1016/s0022-5347(05)66398-7;;10.1097/00005392-200105000-00085;;10.1002/(sici)1097-0215(19990105)80:1<92::aid-ijc18>3.0.co;2-m;;9935237;;10697612;;10.1259/bjr.74.887.740991;;11709463;;10.4049/jimmunol.176.5.2844;;16493041;;pmc384262;;6193515;;10.1073/pnas.80.17.5392;;10.1016/s0140-6736(94)91454-0;;7906753;;3702918;;10.1056/nejm198605083141905;;3940657;;7834608;;908044;;2818874;;9368778;;10.1016/s0952-7915(97)80050-7;;7590825;;10.1111/j.1600-065x.1995.tb00081.x;;1853786;;10.1016/s0065-2776(08)60778-6;;8280701;;10.1097/00002371-199308000-00004;;9419443;;10.1615/critrevimmunol.v18.i1-2.20;;10.1016/s0167-5699(98)01305-x;;9745203;;10.1021/bi00035a037;;7669786;;8407208;;8198600;;10.1006/bbrc.1994.1713;;9328821;;10.1002/(sici)1097-4644(19971101)67:2<155::aid-jcb1>3.0.co;2-w;;10.1002/(sici)1097-4644(19971101)67:2<155::aid-jcb1>3.3.co;2-o;;2835781;;6505678;;10.1126/science.6505678;;8999943;;10.1074/jbc.272.4.2342;;10.3109/15419069409004438;;7827956;;1764767;;10.1007/bf00050795;;2156430;;pmc1877499;;pmc1886291;;1848041;;8168177;;9286045;;10.1016/s0264-410x(97)00015-7;;10.1002/1521-4141(200011)30:11<3256::aid-immu3256>3.0.co;2-h;;11093141;;10.4049/jimmunol.165.1.566;;10861097;;10.1038/32588;;9521319;;pmc1782698;;11972639;;10.1046/j.1365-2567.2002.01396.x;;12127354;;10.1016/s1473-3099(02)00318-3;;10.1016/s0264-410x(00)00068-2;;10812228;;9411016;;pmc2199144;;10.1084/jem.186.10.1621;;10.4049/jimmunol.167.11.6462;;11714813;;10861094;;10.4049/jimmunol.165.1.539;;8735547;;10.1016/0264-410x(95)00220-u;;10.4049/jimmunol.169.1.375;;12077267;;10.1128/jvi.74.4.1694-1703.2000;;pmc111644;;10644339;;10.1172/jci117662;;7814635;;pmc295437;;11741692;;10.1016/s0161-5890(01)00078-5;;10.1021/bc970183n;;9667946;;8585280;;10.1016/0264-410x(95)00011-o;;11544321;;10.4049/jimmunol.167.6.3324;;10.1073/pnas.96.16.9305;;10430938;;pmc17777;;11046050;;10.4049/jimmunol.165.9.5177;;10.1038/374546a0;;7700380;;9341778;;10.1002/eji.1830270931;;10.4049/jimmunol.164.2.900;;10623838;;10.1038/nm0697-625;;9176488;;11466332;;10.4049/jimmunol.167.3.1179;;11888923;;10065639;;10.1016/s0165-2478(98)00136-9;;pmc1422470;;11923611;;10.1097/00000658-200204000-00013;;12429623;;11160323;;10.4049/jimmunol.166.4.2610;;11888922;;10.1097/00002030-200107060-00005;;11426068;;11257408;;10.1016/s0264-410x(00)00499-0;;3276675;;10.1016/s0021-9258(19)77935-6;;9927689;;pmc15346;;10.1073/pnas.96.3.1036;;9841921;;10.1084/jem.188.11.2075;;pmc2212387;;11599686;;10.1023/a:1017919305501;;10.1038/nm0398-321;;9500606;;pmc2064864;;10.1016/0264-410x(94)90245-3;;7839726;;pmc3240143;;12110131;;10.1186/ar567;;pmc2119046;;10.1084/jem.174.6.1665;;1744592;;9268501;;10.1006/cimm.1997.1152;;10.1002/(sici)1521-4141(199806)28:06<2045::aid-immu2045>3.0.co;2-8;;9645386;;11169401;;10.1002/1521-4141(200012)30:12<3591::aid-immu3591>3.0.co;2-j;;pmc1782729;;10.1046/j.1365-2567.2002.01438.x;;12100720;;10.1073/pnas.85.15.5409;;pmc281766;;3399498;;10067673;;10.1016/s0264-410x(98)00250-3;;10.4049/jimmunol.164.5.2372;;10679072;;7491819;;10.1016/0264-410x(94)00058-u;;pmc392661;;10.1073/pnas.75.6.2844;;351618;;10.1097/00002371-200105000-00002;;11395634;;11394496;;8082886;;10.1016/s0171-2985(11)80282-2;;12142552;;10.1097/00002371-200207000-00001,"Irie RF et al (J. Natl. Cancer Inst. 1979;63(2):367-373).;;Rohrer JW et al (J. Immunol. 1999 162(11):6880-6892).;;Oseroff et al (Vaccine 1999;16(8):823-833).;;Rohrer & Coggin, Journal of Immunology, The Williams and Wilkins Co. Baltimore, US, 155 (12); 5719-5727 (1995).;;Zelle-Rieser et al: Journal of Urology, Baltimore. MD, US., 165(5); 1705-1709 (2001).;;Supplementary European Search Report, EP 03 76 7221.;;Nukaya et al, Identification of the HLA-A24 Epitope Peptides of Carcinoembryonic Antigen Which Induce Tumor-Reactive Cytoxic T Lymphocyte. Int. J. Cancer, Jan. 1999, vol. 80, No. 1, pp. 92-97.;;Coggin Jr. et al, 37 KiloDalton Oncofetal Antigen Protein and Immature Laminin Receptor Protein are Identical, Universal T-Cell Indicing Immunogenes on Primary Rodent and Human Cancers. Anticancer Res . . . Nov.-Dec. 1999. vol. 19, No. 6C, pp. 5535-5542.;;Armstrong et al, Vaccines in Oncoloogy: Background and Clinical Potential, British Journal of Radiology. Nov. 2001, vol. 74, No. 887, pp. 991-1002.;;Rohrer et al., Journal of Immunology; 176; 2844-2856 (2006).;;Tai et al, Proc. Natl. Acad. Sci., 80:5392-5396 (Sep. 1983).;;Rohrer, J. W., et al., Mod. Asp. Immunobiol. 1:191 (2001).;;Rohrer, J. W., et al., Mod. Asp. Immunobiol. 16: 27-34 (2005).;;Astrow, A. B., Lancet 343:494 (1994).;;Bailar,, J. C., et al., N. Engl. J. Med. 314:1226 (1986).;;Gallagher, H. S., et al., Cancer 23:855 (1969).;;Spratt, J. S., et al., Cancer Res. 46:970 (1986).;;Zhuang, A., et al., Cancer Res. 55:467 (1995).;;Leffett, M. S., et al., Cancer Res. 37:4112 (1977).;;Coggin, J. H., Jr., Mol. Biother. 1:223 (1989).;;Van den Eynde, B. J., et al., Curr. Opinion Immunol. 9:684 (1997).;;Melief, C., et al., Immunol. Rev. 145:167 (1995).;;Greenberg, P. D., et al., Adv. Immunol. 49:281 (1991).;;Coulie, P. G., et al., J. Immunother. 14:104 (1993).;;Hellstrom, I., et al., Crit. Rev. Immunol. 18:1 (1998).;;Nabeta, Y. Mod., Asp. Immunobiol. 1:17 (2000).;;Coggin, J. H., Jr., et al., Immunol. Today 19:405 (1998).;;Seiter, S., et al., Mod. Asp. Immunobiol. 1:121 (2000).;;Landowski, T. H., et al., Biochem. 34:11276 (1995).;;Castronovo, V., Invasion Metastasis 13:1 (1993).;;van den Brule, F. A., et al., Biochem Biophys. Res. Commun. 201:388 (1994).;;Menard, S., et al., Biochem. 67:155 (1997).;;Coggin, J. H., Jr., et al., Anticancer Res. 19:1 (1999).;;Liotta, L. A., et al., Prog. Clin. Biol. Res. 256:3 (1988).;;Azavoorian, S., et al., Cancer 71:1368 (1993).;;Terranova, V. P., et al., Cancer Res. 42:2261 (1982).;;Terranova, V. P., et al., Science 226:982 (1984).;;Ardini, E., et al., J. Biol. Chem. 272:2342 (1997).;;Romanov, V., et al., Cell Adhes. Commun. 2:201 (1994).;;Turpeeniemi, H. T., et al., J. Biol. Chem. 261:1883 (1986).;;Sweeney, T. M., et al., Cancer Metastasis Rev. 10:245 (1991).;;D'Erico, A. S., et al., Mol. Pathol. 4:239 (1991).;;Monteagudo, C. M., et al., Am. J. Pathol. 136:585 (1990).;;Grigoni, W. F., et al., Am. J. Pathol. 138:647 (1991).;;Wu, S. Chung-hua Ping Li Hsueh Tsa Chih 22:207 (1993).;;Ambrosch, et al., Vaccine 15:1209-1213 (1997).;;Andrieu, et al., Eur. J. Immunol. 30:3256-65 (2000).;;B. Pulendran, et al., J. Immunol 165:566-572 (2000)).;;Banchereau, et al., Nature 392:245-52 (1998)).;;BenMohamed, et al., Immunology 106:113-121 (2002).;;BenMohamed, et al., The Lancet Infect. Dis. 2:425-31 (2002).;;BenMohamed, et al., Vaccine 18:2843-55 (2000).;;Boyum, Scand. J. Clin. Lab. Invest. 21:97:S77 (1968).;;Carson, D. A., E. Raz., 186:1621 (1997).;;Chikh, et al., J. Immunol. 167:6462-6470 (2001).;;Davila, E., E. Celis., J. Immunol. 165:539 ( 2000).;;Deprez, et al., Vaccine 14:375-382 (1996).;;E. Proietti, et al., J. Immunol. 169:375-383 (2002).;;Gahery-Segard, et al., J. Virol. 74:1694-1703 (2000).;;Vitello, et al., J. Clin. Invest. 95:341-349 (1995).;;Gras-Masse, Mol. Immunol. 38:423-431(2001);.;;Guan, et al., Bioconjugate Chem. 9:451-458 (1998)).;;Gupta, et al., Vaccine 13:1263-76 (1995).;;Gursel, et al., J. Immunol. 167:3324-3328 (2001).;;Hartmann, G., G. J. Weiner, A. M. Krieg., Proc. Natl. Acad. Sci. USA 96:9305 (1999).;;I Krishnan, J. Immunol. 165:5177-5185 (2000)).;;Janeway, C. A., P. Travers, M. Walport, and M. Shlomchik. 2001. Immunobiology: The Immune System in Health and Disease. Garland Publishing, New York, pp. 307-309.;;Krieg, A. M., A. K. Yi, S. Matson, T. J. Waldschmidt, et al., Nature 374:546 (1995).;;Lipford, G. B., M. Bauer, C. Blank, et al., Eur. J. Immunol. 27:2340 (1997).;;Loing, et al., J. Immunol. 164:900-907 (2000).;;Lynch, D. H., E. Andreasen, E. Maraskovsky, et al., Nat. Med. 3:625 (1997).;;Mattei, et al., J. Immunol. 167:1179-1187 (2000).;;Mattner, et al., Cancer Res. 62:1477-1480 (2002).;;Mowat, Immunol. Lett. 65:133-40 (1999).;;Nair, et al., Annals of Surgery 235:540-549 (2002)).;;Nair, supra., Holtl, et al., Clin. Cancer Res. 8:3369-76 (2002).;;Nishiguchi, et al., J. Immunol. 166:2610-16 (2001).;;Ota, et al., Cancer Res. 62:1471-1476 (2002).;;Pialoux, et al., AIDS 15:1239-49 (2001).;;Podda, A., Vaccine 19:2673 (2001).;;Posnett et al., J. Biol Chem. 263:1719-1725 (1988).;;Pulendran, B., J. L. Smith, G. Caspary, et al., Proc. Natl. Acad. Sci. USA 96:1036 (1999).;;Pulendran, B., J. L. Smith, M. Jenkins, et al., J. Exp. Med. 188:2075 (1998).;;R. Gasparini. T. Pozzi, E. Montomoli 17, 135-40 (2001).;;Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, et al., Nat. Med. 4:321 (1998).;;Rouaix, et al., Vaccine 12:1209-14 (1994).;;Sallusto, et al., Arthritis Res. 4 Suppl. 3:S127-132 (2002).;;Schild, et al., J. Exp. Med. 174:1665-1668 (1991).;;Shurin, M. R., P. P. Pandharipande, T. D. Zorina, et al., Cell. Immunol. 179:174 (1997).;;Sparwasser, T., E. S. Koch, R. M. Vabulas, et al., Eur. J. Immunol. 28:2045 (1998).;;Sparwasser, T., R. M. Vabulas, B. Villmow, et al., Eur. J. Immunol. 30:3591 (2000).;;Suen, et al., Immunol. 106:326-335 (2002).;;Tam, PNAS USA 85:5409-5413 (1988).;;Tsunoda, et al., Vaccine 17:675-685 (1999).;;Vabulas, R. M., H. Pircher, G. B. Lipford, et. al., J. Immunol. 164:2372 (2000).;;White, et al., Vaccine 13:1111-1122 (1995).;;Wysocki et al., Proc. Natl. Acad. Sci. (USA) 75:2844 (1978).;;Zeng, J. Immunother. 24:195-204 (2001).;;Zhou et al., Immunobiology 190:35-52 (1994).;;Zhou, et al., J. Immunother 25:289-303 (2002).",INACTIVE
83,JP,A,JP 2001224691 A,161-835-369-561-646,2001-08-21,2001,JP 2000402837 A,2000-12-28,US 47641199 A,1999-12-30,METHOD AND APPARATUS FOR GAS SUPPLEMENTAL TYPE MANUFACTURING INTEGRAL CATHETER,"PROBLEM TO BE SOLVED: To provide a method and an apparatus for manufacturing an integral catheter having a tube and a hub. SOLUTION: The method for manufacturing the integral catheter comprises a step of supplying a molten material into a mold having a molding porous part. In this case, a fluid like a gas is supplied into a supply port of the mold. A molten central part of a gas polymer is extruded from an outlet passage by this process. In one embodiment, the gas is supplied to a hub hart of the porous part. In another embodiment, the gas is supplied to a catheter part of the mold. The method also comprises a step of forming a first part of an intravascular unit by a first material in a first mold. Thereafter, a first part in the intravascular unit is inserted into a second mold, and a second part is formed of a second material. Thereafter, the gas is introduced, and a hollow passage is formed in the second part.",ETHICON INC,GORAL DAVID;;KAFRAWY ADEL;;POLLEY WILLIAM F;;THOMAS JOSEPH R,,https://lens.org/161-835-369-561-646,Patent Application,no,5,2,23,23,0,A61M25/0009;;B29C45/0013;;B29C45/1615;;B29C45/1704;;B29L2031/7542;;A61M25/0009;;B29C45/1704;;B29L2031/7542;;B29C45/1615;;B29C45/0013,A61M25/00;;B29C45/00;;B29C45/16;;B29C45/17,,0,0,,,,EXPIRED
84,EP,B1,EP 1116567 B1,116-362-493-500-913,2006-03-01,2006,EP 00311765 A,2000-12-29,US 47641199 A,1999-12-30,Gas assist molding of one-piece catheters,"An apparatus and a method are disclosed for manufacturing an integral one-piece catheter having a tube and a hub. The method comprises feeding molten material into a mold having a mold cavity. A fluid such as a gas is injected into an inlet of the mold. This causes the cavity to eject the molten central region of the polymer through an exit channel. In one embodiment, a gas is injected into the hub portion of the cavity. In another embodiment, a gas is injected into the catheter portion of the mold. The invention also involves forming a first portion of an intravascular device using a first material in a first mold. Thereafter the first portion of the intravascular device is inserted into a second mold to form a second portion using a second material. Gas is then introduced to form a hollow channel in the second portion. The invention also involves a first portion of the mold is injected with a first material, and a second portion of the cavity is injected with a second material at or around the same time that the first material is injected into the first portion of the cavity. Gas is then introduced to form a hollow channel in the second portion. <IMAGE>",MEDEX INC,GORAL DAVID;;KAFRAWY ADEL;;POLLEY WILLIAM F;;THOMAS JOSEPH R,"MEDEX, INC. (2005-05-11)",https://lens.org/116-362-493-500-913,Granted Patent,yes,0,4,23,23,0,A61M25/0009;;B29C45/0013;;B29C45/1615;;B29C45/1704;;B29L2031/7542;;A61M25/0009;;B29C45/1704;;B29L2031/7542;;B29C45/1615;;B29C45/0013,B29C45/17;;A61M25/00;;B29C45/00;;B29C45/16,,2,0,,,"HABERSTROH E.: ""Prozesssichere Verarbeitung von Flüssigsilikonkautschuk (LSR) zu technischen Formteilen"", KUNSTSTOFFE, CARL HANSER VERLAG, vol. 89, no. 1, January 1999 (1999-01-01), MONCHEN, pages 68 - 72, XP000958199;;RAHNHÖFER K.: ""Gasinnendruckprozess ist mehr als eine Alternative"", KUNSTSTOFFVERARBEITER, KUNSTSTOFF VERLAG, vol. 41, no. 9, September 1996 (1996-09-01), ISERNHAGEN, pages 24 - 27, XP000625474",EXPIRED
85,DE,D1,DE 69026465 D1,126-902-008-663-40X,1996-05-15,1996,DE 69026465 T,1990-10-23,US 43004189 A,1989-11-01,Optischer Entzerrungsempfänger für Lichtwellenübertragungssystem,,AT & T CORP,CIMINI LEONARD JOSEPH;;GREENSTEIN LARRY J;;SALEH ADEL A M,,https://lens.org/126-902-008-663-40X,Granted Patent,no,0,0,10,10,0,G02B6/29358;;G02B6/29394;;G02B6/4215;;H04B10/25133;;G02B6/4215;;G02B6/29358;;H04B10/25133;;G02B6/29394,G01J3/26;;G02B6/34;;H04B10/02;;H04B10/18,,0,0,,,,EXPIRED
86,US,B2,US 6779998 B2,124-130-704-335-207,2004-08-24,2004,US 26975702 A,2002-10-10,US 26975702 A;;US 47641199 A,1999-12-30,Gas assist molding of one-piece catheters,"
    An apparatus is disclosed for manufacturing an integral one-piece catheter having a tube and a hub. A mold having a mold cavity into which molten polymer is fed to form the hub and tube, and into which gas is injected into an inlet of the mold. 
",MEDEX INC,GORAL DAVID;;KAFRAWY ADEL;;POLLEY WILLIAM F;;THOMAS JOSEPH R,MEDEX INC (2004-08-13);;ETHICON ENDO SURGERY INC (2001-12-31),https://lens.org/124-130-704-335-207,Granted Patent,yes,8,7,23,23,0,A61M25/0009;;B29C45/0013;;B29C45/1615;;B29C45/1704;;B29L2031/7542;;A61M25/0009;;B29C45/1704;;B29L2031/7542;;B29C45/1615;;B29C45/0013,A61M25/00;;B29C45/00;;B29C45/16;;B29C45/17,425/112;;425/120;;425/130,0,0,,,,EXPIRED
87,CO,A1,CO 5300431 A1,010-968-623-525-100,2003-07-31,2003,CO 00098176 A,2000-12-28,US 47641199 A,1999-12-30,METODO PARA ELABORAR UN CATETER DE UNA PIEZA MEDIANTE MOLDEO ASISTIDO Y APARATO PARA FORMAR DICHO CATETER,"An apparatus and a method are disclosed for manufacturing an integral one-piece catheter having a tube and a hub. The method comprises feeding molten material into a mold having a mold cavity. A fluid such as a gas is injected into an inlet of the mold. This causes the cavity to eject the molten central region of the polymer through an exit channel. In one embodiment, a gas is injected into the hub portion of the cavity. In another embodiment, a gas is injected into the catheter portion of the mold. The invention also involves forming a first portion of an intravascular device using a first material in a first mold. Thereafter the first portion of the intravascular device is inserted into a second mold to form a second portion using a second material. Gas is then introduced to form a hollow channel in the second portion. The invention also involves a first portion of the mold is injected with a first material, and a second portion of the cavity is injected with a second material at or around the same time that the first material is injected into the first portion of the cavity. Gas is then introduced to form a hollow channel in the second portion. <IMAGE>",ETHICON INC,GORAL DAVID;;KAFRAWY ADEL;;POLLEY WILLIAM F;;THOMAS JOSEPH R,,https://lens.org/010-968-623-525-100,Patent Application,no,0,0,23,23,0,A61M25/0009;;B29C45/0013;;B29C45/1615;;B29C45/1704;;B29L2031/7542;;A61M25/0009;;B29C45/1704;;B29L2031/7542;;B29C45/1615;;B29C45/0013,A61M25/00;;B29C45/00;;B29C45/16;;B29C45/17,,0,0,,,,EXPIRED
88,WO,A2,WO 2004/012681 A2,025-638-853-451-226,2004-02-12,2004,US 0324518 W,2003-08-04,US 40085102 P,2002-08-02,CANCER VACCINES CONTAINING EPITOPES OF ONCOFETAL ANTIGEN,"Disclosed are fragments of oncofetal antigen, otherwise known as immature laminin receptor protein that specifically stimulate one T cell subclass. The fragments may be formulated into compositions for potentiating T cell-mediated response in mammalian cancer patients. They also have therapeutic uses in vitro.",SOUTH ALABAMA MEDICAL SCIENCES;;COGGIN JOSEPH H JR;;ROHRER JAMES W;;BARSOUM ADEL L,COGGIN JOSEPH H JR;;ROHRER JAMES W;;BARSOUM ADEL L,,https://lens.org/025-638-853-451-226,Patent Application,yes,0,20,14,14,0,A61K9/0019;;A61K9/127;;C07K14/4748;;A61P35/00;;A61K39/00118;;A61K9/127;;A61K9/0019;;C07K14/4748;;A61K39/00118,A01N37/18;;A61K/;;A61K38/08;;A61K38/10;;A61K38/17;;A61K39/00;;A61P35/00;;C07K14/47;;C12P21/00;;C12P21/06,,0,0,,,,PENDING
89,AU,B2,AU 774205 B2,037-266-960-774-961,2004-06-17,2004,AU 2000/072578 A,2000-12-29,US 47641199 A,1999-12-30,Gas assist molding of one-piece catheters,"An apparatus and a method are disclosed for manufacturing an integral one-piece catheter having a tube and a hub. The method comprises feeding molten material into a mold having a mold cavity. A fluid such as a gas is injected into an inlet of the mold. This causes the cavity to eject the molten central region of the polymer through an exit channel. In one embodiment, a gas is injected into the hub portion of the cavity. In another embodiment, a gas is injected into the catheter portion of the mold. The invention also involves forming a first portion of an intravascular device using a first material in a first mold. Thereafter the first portion of the intravascular device is inserted into a second mold to form a second portion using a second material. Gas is then introduced to form a hollow channel in the second portion. The invention also involves a first portion of the mold is injected with a first material, and a second portion of the cavity is injected with a second material at or around the same time that the first material is injected into the first portion of the cavity. Gas is then introduced to form a hollow channel in the second portion. <IMAGE>",ETHICON INC,GORAL DAVID;;KAFRAWY ADEL;;POLLEY WILLIAM F;;THOMAS JOSEPH R,,https://lens.org/037-266-960-774-961,Granted Patent,no,0,0,23,23,0,A61M25/0009;;B29C45/0013;;B29C45/1615;;B29C45/1704;;B29L2031/7542;;A61M25/0009;;B29C45/1704;;B29L2031/7542;;B29C45/1615;;B29C45/0013,A61M25/00;;B29C45/00;;B29C45/16;;B29C45/17,,0,0,,,,EXPIRED
90,CA,A1,CA 2492938 A1,071-337-883-478-031,2004-02-12,2004,CA 2492938 A,2003-08-04,US 40085102 P;;US 0324518 W,2002-08-02,CANCER VACCINES CONTAINING EPITOPES OF ONCOFETAL ANTIGEN,"Disclosed are fragments of oncofetal antigen, otherwise known as immature laminin receptor protein that specifically stimulate one T cell subclass. Th e fragments may be formulated into compositions for potentiating T cell-mediat ed response in mammalian cancer patients. They also have therapeutic uses in vitro.",SOUTH ALABAMA MEDICAL SCIENCES,BARSOUM ADEL L;;ROHRER JAMES W;;COGGIN JOSEPH H JR,,https://lens.org/071-337-883-478-031,Patent Application,no,0,0,14,14,82,A61K9/0019;;A61K9/127;;C07K14/4748;;A61P35/00;;A61K39/00118;;A61K9/127;;A61K9/0019;;C07K14/4748;;A61K39/00118,A01N37/18;;A61K/;;A61K38/08;;A61K38/10;;A61K38/17;;A61K39/00;;A61P35/00;;C07K14/47;;C12P21/00;;C12P21/06,,0,0,,,,EXPIRED
91,AU,A,AU 1997/027235 A,090-040-598-977-44X,1997-10-29,1997,AU 1997/027235 A,1997-04-04,US 1490396 P;;US 9705685 W,1996-04-05,"Uses of oncofetal antigen specific cd4, cd8 cytotoxic and suppressor t cells and interleukin-10","The present invention provides a method of determining the success of a cancer therapy in an individual, comprising the step of measuring the frequency of occurence of an oncofetal antigen-specific subclasses in the individual's peripheral blood. Also provided is a method of determining whether protective immunity against a tumor will develop in an individual, comprising the step of measuring the frequency of oncofetal antigen-specific T cells, tumor cells and macrophages at the site of the tumor which secrete IL-10. Additionally, a method of determining whether an individual having a tumor will go into remission or remain in remission, comprising the step of measuring the frequency of oncofetal antigen-specific Th1 cells, Tc cells and Ts cells, IL-10 and interferon-gamma secreting T cells in the peripheral blood.",SOUTH ALABAMA MEDICAL SCIENCE FOUND,COGGIN JOSEPH H JR;;BARSOUM ADEL L;;ROHRER JAMES W,,https://lens.org/090-040-598-977-44X,Patent Application,no,0,0,11,13,0,C07K16/244;;G01N33/57476;;Y10S435/975;;A61P35/00;;G01N33/57476;;C07K16/244;;Y10S435/975,A61K38/17;;C07K16/24;;G01N33/574,,0,0,,,,PENDING
92,AT,T1,AT E318687 T1,025-907-877-805-351,2006-03-15,2006,AT 00311765 T,2000-12-29,US 47641199 A,1999-12-30,DURCH GAS UNTERSTÜTZTES FORMEN VON EINTEILIGEN KATHETERN,"An apparatus and a method are disclosed for manufacturing an integral one-piece catheter having a tube and a hub. The method comprises feeding molten material into a mold having a mold cavity. A fluid such as a gas is injected into an inlet of the mold. This causes the cavity to eject the molten central region of the polymer through an exit channel. In one embodiment, a gas is injected into the hub portion of the cavity. In another embodiment, a gas is injected into the catheter portion of the mold. The invention also involves forming a first portion of an intravascular device using a first material in a first mold. Thereafter the first portion of the intravascular device is inserted into a second mold to form a second portion using a second material. Gas is then introduced to form a hollow channel in the second portion. The invention also involves a first portion of the mold is injected with a first material, and a second portion of the cavity is injected with a second material at or around the same time that the first material is injected into the first portion of the cavity. Gas is then introduced to form a hollow channel in the second portion. <IMAGE>",MEDEX INC,GORAL DAVID;;KAFRAWY ADEL;;POLLEY WILLIAM F;;THOMAS JOSEPH R,,https://lens.org/025-907-877-805-351,Granted Patent,no,0,0,23,23,0,A61M25/0009;;B29C45/0013;;B29C45/1615;;B29C45/1704;;B29L2031/7542;;A61M25/0009;;B29C45/1704;;B29L2031/7542;;B29C45/1615;;B29C45/0013,A61M25/00;;B29C45/00;;B29C45/16;;B29C45/17,,0,0,,,,EXPIRED
93,US,A1,US 2006/0165709 A1,143-217-592-549-569,2006-07-27,2006,US 52327705 A,2005-09-22,US 52327705 A;;US 40085102 P;;US 0324518 W,2002-08-02,Cancer vaccines containing epitopes of oncofetal antigen,"Disclosed are fragments of oncofetal antigen, otherwise known as immature laminin receptor protein that specifically stimulate one T cell subclass. The fragments may be formulated into compositions for potentiating T cell-mediated response in mammalian cancer patients. They also have therapeutic uses in vitro.",SOUTH ALABAMA MEDICAL SCIENCES,COGGIN JOSEPH H JR;;ROHRER JAMES W;;BARSOUM ADEL L,SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION (2005-06-08),https://lens.org/143-217-592-549-569,Patent Application,yes,3,6,14,14,82,A61K9/0019;;A61K9/127;;C07K14/4748;;A61P35/00;;A61K39/00118;;A61K9/127;;A61K9/0019;;C07K14/4748;;A61K39/00118,A01N37/18;;A61K39/00;;A61K/;;A61K9/127;;A61K38/08;;A61K38/10;;A61K38/17;;A61P35/00;;C07K14/47;;C12P21/00;;C12P21/06,424/185.1;;424/450,0,0,,,,EXPIRED
94,CA,A1,CA 2329970 A1,161-269-076-617-534,2001-06-30,2001,CA 2329970 A,2000-12-29,US 47641199 A,1999-12-30,GAS ASSIST MOLDING OF ONE-PIECE CATHETERS,"An apparatus and a method are disclosed for manufacturing an integral on e- piece catheter having a tube and a hub. The method comprises feeding molten material into a mold having a mold cavity. A fluid such as a gas is injected into an inlet of the mold. This causes the cavity to eject the molten central region of the polym er through an exit channel. In one embodiment, a gas is injected into the hub portion o f the cavity. In another embodiment, a gas is injected into the catheter portion of the mold. The invention also involves forming a first portion of an intravascular devi ce using a first material in a first mold. Thereafter the first portion of the intravascular device is inserted into a second mold to form a second portion using a secon d material. Gas is then introduced to form a hollow channel in the second portion. The invention also involves a first portion of the mold is injected with a first material, and a second portion of the cavity is injected with a second material at or around the same time that the first material is injected into the first portion of the cavity. Gas is then introduced to form a hollow channel in the second portion.< /SDOAB>",ETHICON INC,KAFRAWY ADEL;;GORAL DAVID;;THOMAS JOSEPH R;;POLLEY WILLIAM F,,https://lens.org/161-269-076-617-534,Patent Application,no,0,0,23,23,0,A61M25/0009;;B29C45/0013;;B29C45/1615;;B29C45/1704;;B29L2031/7542;;A61M25/0009;;B29C45/1704;;B29L2031/7542;;B29C45/1615;;B29C45/0013,A61M25/00;;B29C45/00;;B29C45/16;;B29C45/17,,0,0,,,,EXPIRED
95,EP,A2,EP 1116567 A2,199-534-513-837-724,2001-07-18,2001,EP 00311765 A,2000-12-29,US 47641199 A,1999-12-30,Gas assist molding of one-piece catheters,"An apparatus and a method are disclosed for manufacturing an integral one-piece catheter having a tube and a hub. The method comprises feeding molten material into a mold having a mold cavity. A fluid such as a gas is injected into an inlet of the mold. This causes the cavity to eject the molten central region of the polymer through an exit channel. In one embodiment, a gas is injected into the hub portion of the cavity. In another embodiment, a gas is injected into the catheter portion of the mold. The invention also involves forming a first portion of an intravascular device using a first material in a first mold. Thereafter the first portion of the intravascular device is inserted into a second mold to form a second portion using a second material. Gas is then introduced to form a hollow channel in the second portion. The invention also involves a first portion of the mold is injected with a first material, and a second portion of the cavity is injected with a second material at or around the same time that the first material is injected into the first portion of the cavity. Gas is then introduced to form a hollow channel in the second portion.",ETHICON INC,GORAL DAVID;;KAFRAWY ADEL;;POLLEY WILLIAM F;;THOMAS JOSEPH R,"MEDEX, INC. (2005-05-11)",https://lens.org/199-534-513-837-724,Patent Application,yes,0,14,23,23,0,A61M25/0009;;B29C45/0013;;B29C45/1615;;B29C45/1704;;B29L2031/7542;;A61M25/0009;;B29C45/1704;;B29L2031/7542;;B29C45/1615;;B29C45/0013,A61M25/00;;B29C45/00;;B29C45/16;;B29C45/17,,0,0,,,,EXPIRED
96,EP,A1,EP 0402303 A1,139-398-338-841-290,1990-12-12,1990,EP 90630116 A,1990-06-08,US 36381189 A,1989-06-09,Pneumatic tire.,"A pneumatic tire has a radial ply carcass structure (11) and an aspect ratio in the range of .35 to .65. The tire has a directional type tread design, and in a preferred embodiment employs a particular tread pitching arrangement and a particular type of tread compound. The tire has a greater tread radius (TR₁) in a central portion (CP) of the tread than the tread radii (TR₂, TR₃ in the other portions (OP₁,OP₂) of the tread.  ",GOODYEAR TIRE & RUBBER,HALASA ADEL FARHAN;;BERGH JEAN;;FOURGON FERNAND ANTOINE JOSEPH;;GRAAS MAURICE;;HITZKY LEO JOSEPH,,https://lens.org/139-398-338-841-290,Patent Application,yes,4,34,3,3,0,B60C11/11;;B60C1/0016;;B60C3/04;;B60C9/2009;;B60C11/0083;;B60C11/0302;;B60C11/0306;;B60C11/04;;B60C2011/0383,B60C1/00;;B60C3/04;;B60C9/18;;B60C9/20;;B60C9/22;;B60C11/00;;B60C11/03;;B60C11/04;;B60C11/11;;B60C15/06;;C08L9/00;;C08L21/00,,0,0,,,,DISCONTINUED
97,EP,B1,EP 0426357 B1,109-338-988-726-750,1996-04-10,1996,EP 90311579 A,1990-10-23,US 43004189 A,1989-11-01,Optical equalization receiver for lightwave communication systems,,AT & T CORP,CIMINI LEONARD JOSEPH JR;;GREENSTEIN LARRY J;;SALEH ADEL A M,AT&T CORP. (1994-06-22),https://lens.org/109-338-988-726-750,Granted Patent,yes,1,2,10,10,0,G02B6/29358;;G02B6/29394;;G02B6/4215;;H04B10/25133;;G02B6/4215;;G02B6/29358;;H04B10/25133;;G02B6/29394,G01J3/26;;G02B6/34;;H04B10/02;;H04B10/18,,3,0,,,"12TH EUROPEAN CONFERENCE ON OPTICAL COMMUNICATION vol. 1, September 1986, BARCELONA, SPAIN pages 209 - 212; FUJII ET AL: 'NONLINEAR SEPARATION OF OPTICAL PULSES';;OPTICS LETTERS. vol. 14, no. 9, 1 May 1989, NEW YORK US pages 450 - 452; LI ET AL: 'Broadband cubic-phase compensation with resonant Gires-Tournois interferometers';;PATENT ABSTRACTS OF JAPAN vol. 5, no. 129 (E-70)(801) 19 August 1981 & JP-A-56 065 541",EXPIRED
98,ZA,B,ZA 876713 B,008-564-452-107-859,1988-04-27,1988,ZA 876713 A,1987-09-08,US 91003586 A,1986-09-22,REACTIVE END GROUP POLYMERS,,GOODYEAR TIRE & RUBBER,BELL ANTHONY JOSEPH;;ANTHONY JOSEPH BELL;;HALASA ADEL FARHAN;;ADEL FARHAN HALASA;;CASTNER KENNETH FLOYD;;KENNETH FLOYD CASTNER;;BALOGH GEORGE FRANK;;GEORGE FRANK BALOGH,,https://lens.org/008-564-452-107-859,Granted Patent,no,0,0,9,9,0,C08C19/44;;C08C19/44;;C08F36/02,C08F8/18;;C08C19/12;;C08C19/42;;C08C19/44;;C08F8/20;;C08F8/34,,0,0,,,,EXPIRED
99,WO,A1,WO 2021/079350 A1,087-762-960-380-221,2021-04-29,2021,IB 2020060002 W,2020-10-23,US 201916664228 A,2019-10-25,METHOD FOR SERVICE PLACEMENT IN A MULTI-ACCESS/MOBILE EDGE COMPUTING (MEC) SYSTEM,"The disclosure relates to a method, an apparatus and a non-transitory computer readable media for service placement in a multi-access/mobile edge computing (MEC) system, comprising: iteratively, for each subset of services or applications S u of each type u, u being element of a set of U of unique V2X services or applications sorted in order of latency requirement: calculating an average latency for the subset of services or applications S u ; selecting a node c providing a latency smaller than or equal to the calculated average latency and providing enough capacity to run the subset of services or applications S u ; placing the subset of services or applications S u on the node c ; and updating a list of available nodes.",ERICSSON TELEFON AB L M;;MOUBAYED ABDALLAH;;SHAMI ABDALLAH;;HEIDARI PARISA;;LARABI ADEL;;BRUNNER RICHARD JOSEPH,MOUBAYED ABDALLAH;;SHAMI ABDALLAH;;HEIDARI PARISA;;LARABI ADEL;;BRUNNER RICHARD JOSEPH,,https://lens.org/087-762-960-380-221,Patent Application,yes,1,1,4,4,0,G06F9/5066;;H04W4/40;;G06F9/45558;;G06F17/11;;G06F2009/45595;;H04L67/10;;H04W24/08,G06F9/50,,2,2,018-031-519-295-809;;062-188-280-455-399,10.1109/nana.2019.00015;;10.1109/mnet.2018.1700105,"HONG GAOFENG ET AL: ""An Optimal Resource Allocation Mechanism in Vehicular MEC Systems"", 2019 INTERNATIONAL CONFERENCE ON NETWORKING AND NETWORK APPLICATIONS (NANA), IEEE, 10 October 2019 (2019-10-10), pages 34 - 38, XP033731724, DOI: 10.1109/NANA.2019.00015;;YUAN QUAN ET AL: ""Toward Efficient Content Delivery for Automated Driving Services: An Edge Computing Solution"", IEEE NETWORK, IEEE SERVICE CENTER, NEW YORK, NY, US, vol. 32, no. 1, 1 January 2018 (2018-01-01), pages 80 - 86, XP011676328, ISSN: 0890-8044, [retrieved on 20180125], DOI: 10.1109/MNET.2018.1700105",PENDING
100,US,A1,US 2021/0127241 A1,130-875-350-787-639,2021-04-29,2021,US 201916664228 A,2019-10-25,US 201916664228 A,2019-10-25,METHOD FOR SERVICE PLACEMENT IN A MULTI-ACCESS/MOBILE EDGE COMPUTING (MEC) SYSTEM,"The disclosure relates to a method, an apparatus and a non-transitory computer readable media for service placement in a multi-access/mobile edge computing (MEC) system, comprising: iteratively, for each subset of services or applications s u of each type u, u being element of a set of U of unique V2X services or applications sorted in order of latency requirement: calculating an average latency for the subset of services or applications s u ; selecting a node c providing a latency smaller than or equal to the calculated average latency and providing enough capacity to run the subset of services or applications s u ; placing the subset of services or applications s u on the node c; and updating a list of available nodes.",MOUBAYED ABDALLAH;;SHAMI ABDALLAH;;HEIDARI PARISA;;LARABI ADEL;;BRUNNER RICHARD JOSEPH,MOUBAYED ABDALLAH;;SHAMI ABDALLAH;;HEIDARI PARISA;;LARABI ADEL;;BRUNNER RICHARD JOSEPH,TELEFONAKTIEBOLAGET LM ERICSSON (PUBL) (2020-02-06),https://lens.org/130-875-350-787-639,Patent Application,yes,12,8,4,4,0,G06F9/5066;;H04W4/40;;G06F9/45558;;G06F17/11;;G06F2009/45595;;H04L67/10;;H04W24/08,H04W4/40;;G06F17/11;;H04L29/08;;H04W24/08,,4,4,002-891-920-893-847;;061-109-047-376-454;;087-666-949-162-258;;045-197-203-743-619,10.1109/access.2018.2888478;;10.1109/glocom.2018.8647858;;10.1109/cloudnet.2017.8071527;;10.1109/infocom.2019.8737543,"YU XIANG; GUAN MAOLIN; LIAO MINGXIA; FAN XIA: ""Pre-Migration of Vehicle to Network Services Based on Priority in Mobile Edge Computing"", IEEE ACCESS, IEEE, USA, vol. 7, 1 January 1900 (1900-01-01), USA, pages 3722 - 3730, XP011696460, DOI: 10.1109/ACCESS.2018.2888478;;YALA LOUIZA; FRANGOUDIS PANTELIS A.; KSENTINI ADLEN: ""Latency and Availability Driven VNF Placement in a MEC-NFV Environment"", 2018 IEEE GLOBAL COMMUNICATIONS CONFERENCE (GLOBECOM), IEEE, 9 December 2018 (2018-12-09), pages 1 - 7, XP033520017, DOI: 10.1109/GLOCOM.2018.8647858;;WANG WEI; ZHAO YONGLI; TORNATORE MASSIMO; GUPTA ABHISHEK; ZHANG JIE; MUKHERJEE BISWANATH: ""Virtual machine placement and workload assignment for mobile edge computing"", 2017 IEEE 6TH INTERNATIONAL CONFERENCE ON CLOUD NETWORKING (CLOUDNET), IEEE, 25 September 2017 (2017-09-25), pages 1 - 6, XP033230712, DOI: 10.1109/CloudNet.2017.8071527;;GAO BIN; ZHOU ZHI; LIU FANGMING; XU FEI: ""Winning at the Starting Line: Joint Network Selection and Service Placement for Mobile Edge Computing"", IEEE INFOCOM 2019 - IEEE CONFERENCE ON COMPUTER COMMUNICATIONS, IEEE, 29 April 2019 (2019-04-29), pages 1459 - 1467, XP033561272, DOI: 10.1109/INFOCOM.2019.8737543",ACTIVE
101,US,B2,US 11102630 B2,147-980-939-846-920,2021-08-24,2021,US 201916664228 A,2019-10-25,US 201916664228 A,2019-10-25,Method for service placement in a multi-access/mobile edge computing (MEC) system,"The disclosure relates to a method, an apparatus and a non-transitory computer readable media for service placement in a multi-access/mobile edge computing (MEC) system, comprising: iteratively, for each subset of services or applications s u of each type u, u being element of a set of U of unique V2X services or applications sorted in order of latency requirement: calculating an average latency for the subset of services or applications s u ; selecting a node c providing a latency smaller than or equal to the calculated average latency and providing enough capacity to run the subset of services or applications s u ; placing the subset of services or applications s u on the node c; and updating a list of available nodes.",MOUBAYED ABDALLAH;;SHAMI ABDALLAH;;HEIDARI PARISA;;LARABI ADEL;;BRUNNER RICHARD JOSEPH;;ERICSSON TELEFON AB L M,MOUBAYED ABDALLAH;;SHAMI ABDALLAH;;HEIDARI PARISA;;LARABI ADEL;;BRUNNER RICHARD JOSEPH,TELEFONAKTIEBOLAGET LM ERICSSON (PUBL) (2020-02-06),https://lens.org/147-980-939-846-920,Granted Patent,yes,16,0,4,4,0,G06F9/5066;;H04W4/40;;G06F9/45558;;G06F17/11;;G06F2009/45595;;H04L67/10;;H04W24/08,H04W4/40;;G06F9/455;;G06F17/11;;H04L29/08;;H04W24/08,,28,14,002-891-920-893-847;;061-109-047-376-454;;087-666-949-162-258;;045-197-203-743-619;;111-939-292-638-125;;138-627-696-930-71X;;086-805-216-166-666;;117-890-058-950-149;;075-447-550-820-102;;012-768-733-851-392;;007-356-956-395-310;;119-614-688-349-149;;018-031-519-295-809;;062-188-280-455-399,10.1109/access.2018.2888478;;10.1109/glocom.2018.8647858;;10.1109/cloudnet.2017.8071527;;10.1109/infocom.2019.8737543;;10.1109/comst.2018.2808444;;10.1109/vtcspring.2018.8417826;;10.1109/tits.2017.2741507;;10.1109/wcnc.2018.8377183;;10.1109/ivs.2018.8500531;;10.1007/978-1-4684-2001-2_9;;10.1109/access.2017.2731777;;10.1109/tvt.2017.2665480;;10.1109/nana.2019.00015;;10.1109/mnet.2018.1700105,"X. Yu, M. Guan, M. Liao and X. Fan, “Pre-Migration of Vehicle to Network Services Based on Priority in Mobile Edge Computing,” in IEEE Access, vol. 7, pp. 3722-3730, 2019, Date of Publication: Dec. 25, 2018 (Year: 2018).;;L. Yala, P. A. Frangoudis and A. Ksentini, “Latency and Availability Driven VNF Placement in a MEC-NFV Environment,” 2018 IEEE Global Communications Conference (GLOBECOM), Abu Dhabi, United Arab Emirates, 2018, pp. 1-7 (Year: 2018).;;W. Wang, Y. Zhao, M. Tornatore, A. Gupta, J. Zhang and B. Mukherjee, “Virtual machine placement and workload assignment for mobile edge computing,” 2017 IEEE 6th International Conference on Cloud Networking (CloudNet), Prague, 2017, pp. 1-6 (Year: 2017).;;B. Gao, Z. Zhou, F. Liu and F. Xu, “Winning at the Starting Line: Joint Network Selection and Service Placement for Mobile Edge Computing,” IEEE INFOCOM 2019—IEEE Conference on Computer Communications, Paris, France, 2019, pp. 1459-1467 (Year: 2019).;;Z. Machardy et al.: “V2X Access Technologies: Regulation, Research, and Remaining Challenges”, IEEE Communications Surveys & Tutorials, vol. 20, No. 3, Third Quarter 2018.;;3GPP TR 22.885 V14.0.0 (Dec. 2015): “3rd Generation Partnership Project; Technical Specification Group Services and System Aspects; Study on LTE support for Vehicle to Everything (V2X) services”, 50 pages.;;ETSI TR 102 638 V1.1.1 (Jun. 2009): “Intelligent Transport Systems (ITS); Vehicular Communications; Basic Set of Applications; Definitions”, 81 pages.;;D. Sabella et al.: “A Hierarchical MEC Architecture: Experimenting the RAVEN Use-Case”, 2018 IEEE 87th. Vehicular Technology Conference (VTC Spring), Jun. 2018, 5 pages.;;W. Balid et al.: “Intelligent Vehicle Counting and Classification Sensor for Real-Time Traffic Surveillance”, IEEE Transactions on Intelligent Transportation Systems, vol. 19, No. 6, pp. 1784-1794, 2018.;;N. Bissmeyer: “Security in Hybrid Vehicular Communication based on ITS-G5, LTE-V, and Mobile Edge Computing”, AmE 2018-Automotive meets Electronics; 9th GMM-Symposium. VDE, 2018, pp. 1-6.;;A. Moubayed et al.: “Edge-enabled V2X Service Placement for Intelligent Transportation Systems”, Submitted to EEE Transactions on Mobile Computing, 2019, 12 pages.;;D. Martin-Sacristan et al.: “Evaluation of LTE-Advanced Connectivity Options for the Provisioning of V2X Services”, 2018 IEEE Wireless Communications and Networking Conference (WCNC), Apr. 2018, pp. 1-6.;;ETSI EN 302 637-2 V1.3.2 (Nov. 2014): Intelligent Transport Systems (ITS); Vehicular Communications; Basic Set of Applications; Part 2: Specification of Cooperative Awareness Basic Service, 44 pages.;;Z. Amjad et al.: “Low Latency V2X Applications and Network Requirements: Performance Evaluation”, 2018 IEEE Intelligent Vehicles Symposium (IV), Jun. 2018, pp. 220-225.;;Final draft, ETSI EN 302 637-3 V1.2.1 (Sep. 2014): “Intelligent Transport Systems (ITS); Vehicular Communications Basic Set of Applications; Part 3: Specifications of Decentralized Environmental Notification Basic Service”, 650 Route des Lucioles F-06921 Sophia Antipolis Cedex—France, Tech. Rep.,2010.73 pages.;;ETSI TS 122 185 V14.3.0 (Mar. 2017): “LTE; Service requirements for V2X services (3GPP TS 22.185 version 14.3.0 Release 14)”, 650 Route des Lucioles F-06921 Sophia Antipolis Cedex—France, Tech. Rep., 2017, 16 pages.;;Mux: “The Low Latency Live Streaming Landscape in 2019”, Jan. 23, 2019, 17 pages.;;R. M. Karp: “Reducibility Among Combinatorial Problems”, Complexity of computer computations. Springer, 1972, pp. 35-103.;;Microsoft, “How to: Change the Size of a Windows Azure Virtual Machine”, Aug. 8, 2013, 3 pages.;;K. Lee: “Latency of Cellular-Based V2X: Perspectives on TTI-Proportional Latency and TTI-Independent Latency”, EEE Access, vol. 5, p. 15800-15809, 2017.;;D. Dyachuk: “Buy or Rent? The Cost Model of Hosting in the Cloud and in a Colo!”, Nov. 14, 2017, 8 pages.;;Federal Communications Commission (FCC): “A Broadband Network Cost Model: A Basis for Public Funding Essential To Bringing Nationwide Interoperable Communications To America 's First Responders”, OBI Technical Paper No. 2, May 2010, 22 pages.;;N. Nikookaran et al.: “Combining Capital and Operating Expenditure Costs in Vehicular Roadside Unit Placement”, IEEE Transactions on Vehicular Technology, vol. 66, No. 8, pp. 7317-7331, Aug. 2017.;;Ericsson: “Cloud evolution: The era of intent-aware clouds”, May 20, 2019. Uploaded from the Internet on Apr. 13, 2021, 7 pages.;;C. V. S. C. Consortium et al., “Vehicle Safety Communications Project: Task 3 final report: Identify Intelligent Vehicle Safety Applications Enabled by DSRC”, National Highway Traffic Safety Administration, US Department of Transportation, Washington DC, Mar. 2005.;;G. Hong et al.: “An Optimal Resource Allocation Mechanism in Vehicular MEC Systems”, 2019 International Conference on Networking and Network Applications (NaNA), pp. 34-38.;;Q. Yuan et al.: “Toward Efficient Content Delivery for Automated Driving Services: An Edge Computing Solution”, IEEE Network, IEEE Service Center, New York, NY, US, vol. 32, No. 1, Jan. 1, 2018, pp. 80-86.;;International Search Report and Written Opinion for PCT/IB2020/060002, dated Feb. 5, 2021, 11 pages.",ACTIVE
102,EP,A3,EP 0426357 A3,090-358-495-950-076,1992-08-12,1992,EP 90311579 A,1990-10-23,US 43004189 A,1989-11-01,OPTICAL EQUALIZATION RECEIVER FOR LIGHTWAVE COMMUNICATION SYSTEMS,"An optical equalization receiver for countering the effects of delay distortion is realized by utilizing dynamically controllable Fabry-Perot etalon structures. By dynamically adjusting the frequency response of an etalon that is in a feedback loop configuration, the associated delay characteristic of the etalon may be used to counter the effects of delay distortion, thereby allowing higher transmission rates and transmission distances to be achieved. In one exemplary embodiment, an optical receiver comprising a reflective Fabry-Perot etalon and a piezoelectric transducer is used in a feedback loop configuration wherein a feedback control circuit monitors an output signal from the etalon for generating a control signal representing the amount of delay needed to compensate for distortion in an optical signal incident on the etalon. Specifically, the control signal causes a change in the optical path length of the etalon that results in a shift in its frequency response for producing a delay substantially equal and opposite to the associated delay distortion.  ",AMERICAN TELEPHONE AND TELEGRAPH COMPANY,"CIMINI, LEONARD JOSEPH, JR.;;GREENSTEIN, LARRY J.;;SALEH, ADEL A. M.",AT&T CORP. (1994-06-22),https://lens.org/090-358-495-950-076,Search Report,yes,1,0,10,10,0,G02B6/29358;;G02B6/29394;;G02B6/4215;;H04B10/25133;;G02B6/4215;;G02B6/29358;;H04B10/25133;;G02B6/29394,G01J3/26;;G02B6/34;;H04B10/02;;H04B10/18,,3,1,028-442-308-435-284,10.1364/ol.14.000450;;19749949,"12TH EUROPEAN CONFERENCE ON OPTICAL COMMUNICATION vol. 1, September 1986, BARCELONA, SPAIN pages 209 - 212; FUJII ET AL: 'NONLINEAR SEPARATION OF OPTICAL PULSES';;OPTICS LETTERS. vol. 14, no. 9, 1 May 1989, NEW YORK US pages 450 - 452; LI ET AL: 'Broadband cubic-phase compensation with resonant Gires-Tournois interferometers';;PATENT ABSTRACTS OF JAPAN vol. 5, no. 129 (E-70)(801) 19 August 1981 & JP-A-56 065 541 ( FUJITSU ) 3 June 1981",EXPIRED
103,EP,A1,EP 4049137 A1,153-528-870-348-582,2022-08-31,2022,EP 20801020 A,2020-10-23,US 201916664228 A;;IB 2020060002 W,2019-10-25,METHOD FOR SERVICE PLACEMENT IN A MULTI-ACCESS/MOBILE EDGE COMPUTING (MEC) SYSTEM,,ERICSSON TELEFON AB L M,MOUBAYED ABDALLAH;;SHAMI ABDALLAH;;HEIDARI PARISA;;LARABI ADEL;;BRUNNER RICHARD JOSEPH,,https://lens.org/153-528-870-348-582,Patent Application,yes,0,0,4,4,0,G06F9/5066;;H04W4/40;;G06F9/45558;;G06F17/11;;G06F2009/45595;;H04L67/10;;H04W24/08,G06F9/50,,0,0,,,,PENDING
104,EP,A2,EP 0426357 A2,160-406-930-714-758,1991-05-08,1991,EP 90311579 A,1990-10-23,US 43004189 A,1989-11-01,Optical equalization receiver for lightwave communication systems.,"An optical equalization receiver for countering the effects of delay distortion is realized by utilizing dynamically controllable Fabry-Perot etalon structures. By dynamically adjusting the frequency response of an etalon that is in a feedback loop configuration, the associated delay characteristic of the etalon may be used to counter the effects of delay distortion, thereby allowing higher transmission rates and transmission distances to be achieved. In one exemplary embodiment, an optical receiver comprising a reflective Fabry-Perot etalon and a piezoelectric transducer is used in a feedback loop configuration wherein a feedback control circuit monitors an output signal from the etalon for generating a control signal representing the amount of delay needed to compensate for distortion in an optical signal incident on the etalon. Specifically, the control signal causes a change in the optical path length of the etalon that results in a shift in its frequency response for producing a delay substantially equal and opposite to the associated delay distortion.  ",AMERICAN TELEPHONE & TELEGRAPH,CIMINI LEONARD JOSEPH JR;;GREENSTEIN LARRY J;;SALEH ADEL A M,AT&T CORP. (1994-06-22),https://lens.org/160-406-930-714-758,Patent Application,yes,0,14,10,10,0,G02B6/29358;;G02B6/29394;;G02B6/4215;;H04B10/25133;;G02B6/4215;;G02B6/29358;;H04B10/25133;;G02B6/29394,G01J3/26;;G02B6/34;;H04B10/02;;H04B10/18,,0,0,,,,EXPIRED
105,BR,A,BR 8704819 A,020-141-453-602-069,1988-05-17,1988,BR 8704819 A,1987-09-18,US 91003586 A,1986-09-22,PROCESSO PARA PREPARACAO DE POLIDIENO TERMINALMENTE LIGAVEL;PROCESSO PARA LIGAR TERMINALMENTE UM POLIDIENO CONTENDO GRUPOS TERMINAIS DIALQUILDITIO CARBAMILA;PROCESSO PARA LIGAR TERMINALMENTE POLIDIENO TERMINADO POR METAL;POLIDIENO TERMINALMENTE LIGAVEL E PROCESSO PARA PREPARAR UM POLIDIENO TERMINALMENTE LIGAVEL,,GOODYEAR TIRE & RUBBER,BELL ANTHONY JOSEPH;;HALASA ADEL FARHAN;;CASTNER KENNETH FLOYD;;BALOGH GEORGE FRANK,,https://lens.org/020-141-453-602-069,Patent Application,no,0,0,9,9,0,C08C19/44;;C08C19/44;;C08F36/02,C08F8/18;;C08C19/12;;C08C19/42;;C08C19/44;;C08F8/20;;C08F8/34,,0,0,,,,DISCONTINUED
106,AU,B2,AU 591425 B2,199-860-845-573-538,1989-11-30,1989,AU 1987/078692 A,1987-09-21,US 91003586 A,1986-09-22,HEXACHLOROCYCLOPENTADIENE END GROUP POLYMERS,,GOODYEAR TIRE & RUBBER,BELL ANTHONY JOSEPH;;HALASA ADEL FARHAN;;CASTNER KENNETH FLOYD;;BALOGH GEORGE FRANK,,https://lens.org/199-860-845-573-538,Granted Patent,no,0,0,9,9,0,C08C19/44;;C08C19/44;;C08F36/02,C08F8/18;;C08C19/12;;C08C19/42;;C08C19/44;;C08F8/20;;C08F8/34,,0,0,,,,EXPIRED
107,BR,A,BR 8801053 A,117-242-453-999-596,1988-10-18,1988,BR 8801053 A,1988-03-10,US 2553387 A,1987-03-13,PROCESSO PARA PREPARAR UMA MISTURA DE BORRACHA DE POLIDIENO,,GOODYEAR TIRE & RUBBER,HALASA ADEL FARHAN;;ROBERTSON SYLVIA EILEEN;;ZANZIG DAVID JOHN;;ARCONTI RICHARD JOSEPH,,https://lens.org/117-242-453-999-596,Patent Application,no,0,0,18,18,0,C08C19/44;;C08F36/04;;C08L21/00;;C08F36/04;;C08F4/44;;C08F36/04;;C08C19/44;;C08L21/00,C08F8/00;;C08C19/44;;C08F2/00;;C08F4/44;;C08F36/04;;C08L9/00;;C08L21/00,,0,0,,,,EXPIRED
108,AU,A,AU 1987/078692 A,125-473-472-313-519,1988-03-24,1988,AU 1987/078692 A,1987-09-21,US 91003586 A,1986-09-22,ENDCAPPING DIENE POLYMERS,,GOODYEAR TIRE & RUBBER,BELL ANTHONY JOSEPH;;HALASA ADEL FARHAN;;CASTNER KENNETH FLOYD;;BALOGH GEORGE FRANK,,https://lens.org/125-473-472-313-519,Patent Application,no,0,0,9,9,0,C08C19/44;;C08C19/44;;C08F36/02,C08F8/18;;C08C19/12;;C08C19/42;;C08C19/44;;C08F8/20;;C08F8/34,,0,0,,,,EXPIRED
109,KR,B1,KR 920006252 B1,082-116-706-751-885,1992-08-01,1992,KR 890701861 A,1989-10-10,US 15375088 A;;US 8804693 W,1988-02-08,ANALOG-TO-DIGITAL CONVERTER MADE WITH FOCUSED ION BEAM TECHNOLOGY,,HUGHES AIRCRAFT CO,LARSON LAWRENCE E;;JENSON JOSEPH F;;WOLDEN ROBERT H;;SCHMITZ ADEL I,,https://lens.org/082-116-706-751-885,Granted Patent,no,0,0,10,10,0,H01L27/12;;H01L29/0692;;H01L29/7838;;H01L29/78612;;H01L29/78657;;H01L29/78696;;H03M1/361;;H03M1/36;;H01L29/78696;;H01L29/78612;;H01L29/78657;;H01L27/12;;H03M1/361;;H01L29/7838;;H01L29/0692,H01L27/12;;H01L21/265;;H01L29/06;;H01L29/78;;H01L29/786;;H03M1/00;;H03M1/36,,0,0,,,,EXPIRED
110,EP,A2,EP 0262077 A2,065-414-415-530-133,1988-03-30,1988,EP 87630190 A,1987-09-15,US 91003586 A,1986-09-22,Reactive end group polymers.,"Metals from Groups I and II of the periodic table are commonly used to initiate the polymerization of conjugated diolefin monomers into polymers. The polymers formed in such polymerizations are terminated with the metal used to initiate the polymerization and are sometimes referred to as living polymers. Reactive end groups can be affixed to the chain ends of such polymers by utilizing the process of this invention. Such reactive end groups can subsequently be reacted with the backbone of other polymer chains. This results in the formation of a polymer having a reduced number of dangling chain ends. The functionalizing agents which can be utilized in the preparation of such polymers include hexachlorocyclopentadiene, tetra­alkylthiuram disulfides, and chlorinated phenyl fulvenes.  ",GOODYEAR TIRE & RUBBER,BELL ANTHONY JOSEPH;;HALASA ADEL FARHAN;;CASTNER KENNETH FLOYD;;BALOGH GEORGE FRANK,,https://lens.org/065-414-415-530-133,Patent Application,yes,0,0,9,9,0,C08C19/44;;C08C19/44;;C08F36/02,C08F8/18;;C08C19/12;;C08C19/42;;C08C19/44;;C08F8/20;;C08F8/34,,0,0,,,,DISCONTINUED
111,EP,A3,EP 0262077 A3,070-293-347-397-141,1988-06-22,1988,EP 87630190 A,1987-09-15,US 91003586 A,1986-09-22,REACTIVE END GROUP POLYMERS,"Metals from Groups I and II of the periodic table are commonly used to initiate the polymerization of conjugated diolefin monomers into polymers. The polymers formed in such polymerizations are terminated with the metal used to initiate the polymerization and are sometimes referred to as living polymers. Reactive end groups can be affixed to the chain ends of such polymers by utilizing the process of this invention. Such reactive end groups can subsequently be reacted with the backbone of other polymer chains. This results in the formation of a polymer having a reduced number of dangling chain ends. The functionalizing agents which can be utilized in the preparation of such polymers include hexachlorocyclopentadiene, tetra­alkylthiuram disulfides, and chlorinated phenyl fulvenes.  ",THE GOODYEAR TIRE & RUBBER COMPANY,"BELL, ANTHONY JOSEPH;;HALASA, ADEL FARHAN;;CASTNER, KENNETH FLOYD;;BALOGH, GEORGE FRANK",,https://lens.org/070-293-347-397-141,Search Report,yes,3,0,9,9,0,C08C19/44;;C08C19/44;;C08F36/02,C08F8/18;;C08C19/12;;C08C19/42;;C08C19/44;;C08F8/20;;C08F8/34,,0,0,,,,DISCONTINUED
112,US,A1,US 2017/0021146 A1,113-041-467-726-218,2017-01-26,2017,US 201615289790 A,2016-10-10,US 201615289790 A;;US 201615195139 A;;US 201615065766 A;;US 201514929066 A;;US 201562156152 P;;US 201562142895 P;;US 201462073766 P,2014-10-31,METHODS AND SYSTEMS FOR TREATING HYDROCEPHALUS,"Methods for treating hydrocephalus using a shunt, the shunt having one or more CSF intake openings in a distal portion, a valve disposed in a proximal portion of the shunt, and a lumen extending between the one or more CSF intake openings and the valve, the method comprises deploying the shunt in a body of a patient so that the distal portion of the shunt is at least partially disposed within a CP angle cistern, a body of the shunt is at least partially disposed within an IPS of the patient, and the proximal portion of the shunt is at least partially disposed within or proximate to a JV of the patient, wherein, after deployment of the shunt, CSF flows from the CP angle cistern to the JV via the shunt lumen at a flow rate in a range of 5 ml per hour to 15 ml per hour.",CEREVASC LLC,HEILMAN CARL;;MALEK ADEL M;;REZAC DAVID A;;ROBINSON TIMOTHY W;;TING JOSEPH,CEREVASC INC (2015-05-12),https://lens.org/113-041-467-726-218,Patent Application,yes,0,0,30,30,0,A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M27/006;;A61M39/24;;A61M2210/06;;A61M2039/2426;;A61M2039/242;;A61M27/006;;A61B17/3401;;A61B17/3478;;A61M27/006;;A61B6/12;;A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M25/10;;A61M39/24;;A61M2039/242;;A61B34/20;;A61B18/14;;A61B2018/1425;;A61B18/1477;;A61B2018/00446;;A61B2018/00619;;A61M2210/06;;A61B18/1492;;A61M2039/2426,A61M27/00;;A61B6/12;;A61B34/20;;A61M25/00;;A61M25/01;;A61M25/09;;A61M39/24,,0,0,,,,ACTIVE
113,US,A1,US 2016/0303356 A1,193-612-298-914-573,2016-10-20,2016,US 201615195453 A,2016-06-28,US 201615195453 A;;US 201615065766 A;;US 201514929066 A;;US 201462073766 P;;US 201562142895 P;;US 201562156152 P,2014-10-31,METHODS AND SYSTEMS FOR TREATING HYDROCEPHALUS,"Methods for treating hydrocephalus using a shunt, the shunt having one or more CSF intake openings in a distal portion, a valve disposed in a proximal portion of the shunt, and a lumen extending between the one or more CSF intake openings and the valve, the method comprises deploying the shunt in a body of a patient so that the distal portion of the shunt is at least partially disposed within a CP angle cistern, a body of the shunt is at least partially disposed within an IPS of the patient, and the proximal portion of the shunt is at least partially disposed within or proximate to a JV of the patient, wherein, after deployment of the shunt, CSF flows from the CP angle cistern to the JV via the shunt lumen at a flow rate in a range of 5 ml per hour to 15 ml per hour.",CEREVASC LLC,HEILMAN CARL;;MALEK ADEL M;;REZAC DAVID A;;ROBINSON TIMOTHY W;;TING JOSEPH,CEREVASC INC (2015-05-12),https://lens.org/193-612-298-914-573,Patent Application,yes,0,10,30,30,0,A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M27/006;;A61M39/24;;A61M2210/06;;A61M2039/2426;;A61M2039/242;;A61M27/006;;A61B17/3401;;A61B17/3478;;A61M27/006;;A61B6/12;;A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M25/10;;A61M39/24;;A61M2039/242;;A61B34/20;;A61B18/14;;A61B2018/1425;;A61B18/1477;;A61B2018/00446;;A61B2018/00619;;A61M2210/06;;A61B18/1492;;A61M2039/2426,A61M27/00;;A61B18/14;;A61M25/01;;A61M25/09;;A61M39/24,,0,0,,,,ACTIVE
114,AT,T1,AT E227571 T1,198-463-005-724-211,2002-11-15,2002,AT 97937175 T,1997-08-08,GB 9625311 A;;US 2382996 P;;US 9714019 W,1996-08-12,THROMBIN INHIBITOREN,"A compound which inhibits human thrombin and which has structure (A), such as formula (a).",MERCK & CO INC,FRALEY MARK E;;HUNGATE RANDALL W;;NAYLOR-OLSEN ADEL M;;VACCA JOSEPH P,,https://lens.org/198-463-005-724-211,Granted Patent,no,0,0,12,14,0,C07D213/74;;C07D405/12;;A61P43/00;;A61P7/02,A61K31/4409;;A61K31/4433;;A61P7/02;;A61P43/00;;C07D213/74;;C07D405/12,,0,0,,,,DISCONTINUED
115,US,B2,US 10058686 B2,042-690-492-418-969,2018-08-28,2018,US 201815862120 A,2018-01-04,US 201815862120 A;;US 201715668657 A;;US 201715432818 A;;US 201615289790 A;;US 201615195139 A;;US 201615065766 A;;US 201514929066 A;;US 201562156152 P;;US 201562142895 P;;US 201462073766 P,2014-10-31,Methods and systems for treating hydrocephalus,"Methods for treating hydrocephalus using a shunt, the shunt having one or more CSF intake openings in a distal portion, a valve disposed in a proximal portion of the shunt, and a lumen extending between the one or more CSF intake openings and the valve, the method comprises deploying the shunt in a body of a patient so that the distal portion of the shunt is at least partially disposed within a CP angle cistern, a body of the shunt is at least partially disposed within an IPS of the patient, and the proximal portion of the shunt is at least partially disposed within or proximate to a JV of the patient, wherein, after deployment of the shunt, CSF flows from the CP angle cistern to the JV via the shunt lumen at a flow rate in a range of 5 ml per hour to 15 ml per hour.",CEREVASC LLC,HEILMAN CARL;;MALEK ADEL M;;REZAC DAVID A;;ROBINSON TIMOTHY W;;TING JOSEPH,CEREVASC INC (2015-05-12),https://lens.org/042-690-492-418-969,Granted Patent,yes,204,10,30,30,0,A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M27/006;;A61M39/24;;A61M2210/06;;A61M2039/2426;;A61M2039/242;;A61M27/006;;A61B17/3401;;A61B17/3478;;A61M27/006;;A61B6/12;;A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M25/10;;A61M39/24;;A61M2039/242;;A61B34/20;;A61B18/14;;A61B2018/1425;;A61B18/1477;;A61B2018/00446;;A61B2018/00619;;A61M2210/06;;A61B18/1492;;A61M2039/2426,A61M5/00;;A61B34/20;;A61M25/00;;A61M25/01;;A61M25/09;;A61M27/00;;A61M39/24,,11,0,,,"PCT International Search Report and Written Opinion for International Appln. No. PCT/US2017/056227, Applicant Cerevasc, LLC, Forms PCT/ISA/210, 220, and 237, dated Mar. 29, 2018 (24 pages).;;PCT International Search Report and Written Opinion for International Application No. PCT/2015/011317, Applicant Tufts Medical Center, Inc., Forms PCT/ISA/210, 220, and 237, dated Mar. 26, 2015 (15 pages).;;Non-Final Office Action for U.S. Appl. No. 14/179,622, dated May 13, 2015 (13 pages).;;PCT Notification of Transmittal of the International Search Report and Written Opinion, dated Feb. 17, 2016, for PCT/US2015/058505, Applicant CereVasc, LLC., international filing date Oct. 30, 2015 (16 pages).;;Non-Final Office Action for U.S. Appl. No. 14/596,335, dated Jul. 7, 2016 (16 pages).;;PCT International Search Report and Written Opinion for International Appln. No. PCT/US2016/069280, applicant CEREVASC, LLC, dated Mar. 27, 2017 (80 pages).;;Non-Final Office Action for U.S. Appl. No. 15/294,000, dated Feb. 16, 2017 (26 pages).;;Final Office Action for U.S. Appl. No. 14/596,335, dated Oct. 26, 2016 (19 pages).;;Interview Summary for U.S. Appl. No. 14/596,335, dated Oct. 11, 2016 (3 pages).;;PCT Notification of Transmittal of the International Search Report and Written Opinion of the I.S.A. for PCT/US2016/0595952, dated Jan. 20, 2017, 14 pages.;;PCT Invitation to Pay Additional Fees for International Appln. No. PCT/US2018/020667, dated May 29, 2018 (17 pages).",ACTIVE
116,MX,B,MX 166113 B,180-272-435-682-909,1992-12-21,1992,MX 1068088 A,1988-03-07,US 2553387 A,1987-03-13,PROCEDIMIENTO DE POLIMERIZACION,"La presente invención se refiere a un procedimiento para preparar una mezcla de caucho de polidieno que está caracterizado porque: (1) se polimeriza cuando menos un monómero de dieno utilizando cuando menos un catalizador que se selecciona del grupo que consiste de los metales del grupo I, los metales del grupo II, los compuestos organometálicos que contienen un metal del grupo I y los compuestos organometálicos que contienen un metal del grupo II, hasta una conversión que queda dentro de la escala del 30 por ciento al 70 por ciento, a fin de producir cadenas de polidieno de bajo peso molecular; (2) unir del 20 al 70 por ciento de las cadenas de polidieno de bajo peso molecular con un agente de ramificación apropiado; y (3) permitir que la polimerización continua a producir las mezclas de caucho de polidieno.",GOODYEAR TIRE & RUBBER,ARCONTI RICHARD JOSEPH;;HALASA ADEL FARHAN;;ROBERTSON-WILCOX SYLVIA EILEEN;;ZANZIG DAVID JOHN,,https://lens.org/180-272-435-682-909,Granted Patent,no,0,0,18,18,0,C08C19/44;;C08F36/04;;C08L21/00;;C08F36/04;;C08F4/44;;C08F36/04;;C08C19/44;;C08L21/00,C08C19/44;;C08F2/00;;C08F8/00;;C08F4/44;;C08F36/04;;C08L9/00;;C08L21/00,,0,0,,,,EXPIRED
117,EP,A3,EP 0282437 A3,005-486-531-102-626,1989-12-20,1989,EP 88630046 A,1988-03-08,US 2553387 A,1987-03-13,POLYMERIZATION PROCESS,"Metals from Groups I and II and organometallic compounds thereof can be used to catalyze the polymerization of diene monomers into polymers. The polymers formed in such polymerizations are terminated with the metal used to catalyze the polymerization and are sometimes referred to as living polymers. Very useful blends of such polymers can be made by utilizing the process of the present invention. More specifically, the present invention discloses a process for preparing a polydiene rubber blend comprising: (1) polymerizing at least one diene monomer utilizing at least one catalyst selected from the group consisting of Group I metals, Group II metals, organometallic compounds containing a Group I metal, and organometallic compounds containing a Group II metal, to a conversion which is within the range of 30% to 70% to produce low molecular weight polydiene chains; (2) joining from 20% to 70% of said low molecular weight polydiene chains with a suitable branching agent; and (3) allowing the polymerization to continue so as to produce said polydiene rubber blends.  ",THE GOODYEAR TIRE & RUBBER COMPANY,"HALASA, ADEL FARHAN;;ROBERTSON-WILCOX, SYLVIA EILEEN;;ZANZIG, DAVID JOHN;;ARCONTI, RICHARD JOSEPH",,https://lens.org/005-486-531-102-626,Search Report,yes,3,0,18,18,0,C08C19/44;;C08F36/04;;C08L21/00;;C08F36/04;;C08F4/44;;C08F36/04;;C08C19/44;;C08L21/00,C08F8/00;;C08C19/44;;C08F2/00;;C08F4/44;;C08F36/04;;C08L9/00;;C08L21/00,,0,0,,,,EXPIRED
118,EP,A1,EP 0949921 A1,019-819-118-338-177,1999-10-20,1999,EP 97937175 A,1997-08-08,GB 9625311 A;;US 9714019 W;;US 2382996 P,1996-08-12,THROMBIN INHIBITORS,"A compound which inhibits human thrombin and which has structure (A), such as formula (a).",MERCK & CO INC,FRALEY MARK E;;HUNGATE RANDALL W;;NAYLOR-OLSEN ADEL M;;VACCA JOSEPH P,,https://lens.org/019-819-118-338-177,Patent Application,yes,0,0,12,14,0,C07D213/74;;C07D405/12;;A61P43/00;;A61P7/02,A61K31/4409;;A61K31/4433;;A61P7/02;;A61P43/00;;C07D213/74;;C07D405/12,,0,0,,,,EXPIRED
119,US,B2,US 9669195 B2,023-912-072-185-902,2017-06-06,2017,US 201615289790 A,2016-10-10,US 201615289790 A;;US 201615195139 A;;US 201615065766 A;;US 201514929066 A;;US 201562156152 P;;US 201562142895 P;;US 201462073766 P,2014-10-31,Methods and systems for treating hydrocephalus,"Methods for treating hydrocephalus using a shunt, the shunt having one or more CSF intake openings in a distal portion, a valve disposed in a proximal portion of the shunt, and a lumen extending between the one or more CSF intake openings and the valve, the method comprises deploying the shunt in a body of a patient so that the distal portion of the shunt is at least partially disposed within a CP angle cistern, a body of the shunt is at least partially disposed within an IPS of the patient, and the proximal portion of the shunt is at least partially disposed within or proximate to a JV of the patient, wherein, after deployment of the shunt, CSF flows from the CP angle cistern to the JV via the shunt lumen at a flow rate in a range of 5 ml per hour to 15 ml per hour.",CEREVASC LLC,HEILMAN CARL;;MALEK ADEL M;;REZAC DAVID A;;ROBINSON TIMOTHY W;;TING JOSEPH,CEREVASC INC (2015-05-12),https://lens.org/023-912-072-185-902,Granted Patent,yes,164,17,30,30,0,A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M27/006;;A61M39/24;;A61M2210/06;;A61M2039/2426;;A61M2039/242;;A61M27/006;;A61B17/3401;;A61B17/3478;;A61M27/006;;A61B6/12;;A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M25/10;;A61M39/24;;A61M2039/242;;A61B34/20;;A61B18/14;;A61B2018/1425;;A61B18/1477;;A61B2018/00446;;A61B2018/00619;;A61M2210/06;;A61B18/1492;;A61M2039/2426,A61M5/00;;A61B6/12;;A61B18/00;;A61B18/14;;A61B34/20;;A61M25/00;;A61M25/01;;A61M25/09;;A61M25/10;;A61M27/00;;A61M39/24,,8,0,,,"Final Office Action for U.S. Appl. No. 14/596,335, dated Oct. 26, 2016 (19 pages).;;Interview Summary for U.S. Appl. No. 14/596,335, dated Oct. 11, 2016 (3 pages).;;PCT International Search Report and Written Opinion for International Application No. PCT/2015/011317, Applicant Tufts Medical Center, Inc., Forms PCT/ISA/210, 220, and 237, dated Mar. 26, 2015 (15 pages).;;Non-Final Office Action for U.S. Appl. No. 14/179,622, mailed on May 13, 2015 (13 pages).;;PCT Notification of Transmittal of the International Search Report and Written Opinion, mailed Feb. 17, 2016, for PCT/US2015/058505, Applicant CereVasc, LLC., international filing date Oct. 30, 2015 (16 pages).;;Non-Final Office Action for U.S. Appl. No. 14/596,335, dated Jul. 7, 2016 (16 pages).;;PCT International Search Report and Written Opinion for International Appln. No. PCT/U52016/069280, applicant CEREVASC, LLC, dated Mar. 27, 2017 (80 pages).;;Non-Final Office Action for U.S. Appl. No. 15/294,000, filed Feb. 16, 2017 (26 pages).",ACTIVE
120,EP,B1,EP 0282437 B1,029-987-238-729-469,1993-03-03,1993,EP 88630046 A,1988-03-08,US 2553387 A,1987-03-13,POLYMERIZATION PROCESS,,THE GOODYEAR TIRE & RUBBER COMPANY,"HALASA, ADEL FARHAN;;ROBERTSON-WILCOX, SYLVIA EILEEN;;ZANZIG, DAVID JOHN;;ARCONTI, RICHARD JOSEPH",,https://lens.org/029-987-238-729-469,Granted Patent,yes,3,0,18,18,0,C08C19/44;;C08F36/04;;C08L21/00;;C08F36/04;;C08F4/44;;C08F36/04;;C08C19/44;;C08L21/00,C08F8/00;;C08C19/44;;C08F2/00;;C08F4/44;;C08F36/04;;C08L9/00;;C08L21/00,,0,0,,,,EXPIRED
121,DE,D1,DE 3878705 D1,097-815-766-227-986,1993-04-08,1993,DE 3878705 T,1988-03-08,US 2553387 A,1987-03-13,POLYMERISATIONSVERFAHREN.,,GOODYEAR TIRE & RUBBER,HALASA ADEL FARHAN;;ROBERTSON-WILCOX SYLVIA EILEEN;;ZANZIG DAVID JOHN;;ARCONTI RICHARD JOSEPH,,https://lens.org/097-815-766-227-986,Granted Patent,no,0,0,18,18,0,C08C19/44;;C08F36/04;;C08L21/00;;C08F36/04;;C08F4/44;;C08F36/04;;C08C19/44;;C08L21/00,C08F8/00;;C08C19/44;;C08F2/00;;C08F4/44;;C08F36/04;;C08L9/00;;C08L21/00,,0,0,,,,EXPIRED
122,AU,A,AU 1997/039749 A,129-953-088-912-873,1998-03-06,1998,AU 1997/039749 A,1997-08-08,GB 9625311 A;;US 2382996 P;;US 9714019 W,1996-08-12,Thrombin inhibitors,"A compound which inhibits human thrombin and which has structure (A), such as formula (a).",MERCK & CO INC,FRALEY MARK E;;HUNGATE RANDALL W;;NAYLOR-OLSEN ADEL M;;VACCA JOSEPH P,,https://lens.org/129-953-088-912-873,Patent Application,no,0,0,12,14,0,C07D213/74;;C07D405/12;;A61P43/00;;A61P7/02,A61K31/4409;;A61K31/4433;;A61P7/02;;A61P43/00;;C07D213/74;;C07D405/12,,0,0,,,,EXPIRED
123,ES,T3,ES 2185042 T3,014-792-529-058-875,2003-04-16,2003,ES 97937175 T,1997-08-08,GB 9625311 A;;US 2382996 P,1996-08-12,INHIBIDORES DE LA TROMBINA.,"A compound which inhibits human thrombin and which has structure (A), such as formula (a).",MERCK & CO INC,FRALEY MARK E;;HUNGATE RANDALL W;;NAYLOR-OLSEN ADEL M;;VACCA JOSEPH P,,https://lens.org/014-792-529-058-875,Granted Patent,no,0,0,12,14,0,C07D213/74;;C07D405/12;;A61P43/00;;A61P7/02,A61K31/4409;;A61K31/4433;;A61P7/02;;A61P43/00;;C07D213/74;;C07D405/12,,0,0,,,,EXPIRED
124,US,A1,US 2020/0376239 A1,024-141-189-806-614,2020-12-03,2020,US 202016998606 A,2020-08-20,US 202016998606 A;;US 201815981118 A;;US 201815862120 A;;US 201715668657 A;;US 201715432818 A;;US 201615289790 A;;US 201615195139 A;;US 201615065766 A;;US 201514929066 A;;US 201562156152 P;;US 201562142895 P;;US 201462073766 P,2014-10-31,METHODS AND SYSTEMS FOR DRAINING CEREBROSPINAL FLUID INTO THE VENOUS SYSTEM,"Methods for treating hydrocephalus using a shunt, the shunt having one or more CSF intake openings in a distal portion, a valve disposed in a proximal portion of the shunt, and a lumen extending between the one or more CSF intake openings and the valve, the method comprises deploying the shunt in a body of a patient so that the distal portion of the shunt is at least partially disposed within a CP angle cistern, a body of the shunt is at least partially disposed within an IPS of the patient, and the proximal portion of the shunt is at least partially disposed within or proximate to a JV of the patient, wherein, after deployment of the shunt, CSF flows from the CP angle cistern to the JV via the shunt lumen at a flow rate in a range of 5 ml per hour to 15 ml per hour.",CEREVASC INC,HEILMAN CARL;;MALEK ADEL M;;REZAC DAVID A;;ROBINSON TIMOTHY W;;TING JOSEPH,CEREVASC INC (2015-05-12),https://lens.org/024-141-189-806-614,Patent Application,yes,8,0,30,30,0,A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M27/006;;A61M39/24;;A61M2210/06;;A61M2039/2426;;A61M2039/242;;A61M27/006;;A61B17/3401;;A61B17/3478;;A61M27/006;;A61B6/12;;A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M25/10;;A61M39/24;;A61M2039/242;;A61B34/20;;A61B18/14;;A61B2018/1425;;A61B18/1477;;A61B2018/00446;;A61B2018/00619;;A61M2210/06;;A61B18/1492;;A61M2039/2426,A61M27/00;;A61B6/12;;A61B18/14;;A61B34/20;;A61M25/00;;A61M25/01;;A61M25/09;;A61M25/10;;A61M39/24,,0,0,,,,PENDING
125,US,A1,US 2018/0264240 A1,056-205-950-952-728,2018-09-20,2018,US 201815981118 A,2018-05-16,US 201815981118 A;;US 201815862120 A;;US 201715668657 A;;US 201715432818 A;;US 201615289790 A;;US 201615195139 A;;US 201615065766 A;;US 201514929066 A;;US 201562156152 P;;US 201562142895 P;;US 201462073766 P,2014-10-31,METHODS AND SYSTEMS FOR TREATING HYDROCEPHALUS,"Methods for treating hydrocephalus using a shunt, the shunt having one or more CSF intake openings in a distal portion, a valve disposed in a proximal portion of the shunt, and a lumen extending between the one or more CSF intake openings and the valve, the method comprises deploying the shunt in a body of a patient so that the distal portion of the shunt is at least partially disposed within a CP angle cistern, a body of the shunt is at least partially disposed within an IPS of the patient, and the proximal portion of the shunt is at least partially disposed within or proximate to a JV of the patient, wherein, after deployment of the shunt, CSF flows from the CP angle cistern to the JV via the shunt lumen at a flow rate in a range of 5 ml per hour to 15 ml per hour.",CEREVASC LLC,HEILMAN CARL;;MALEK ADEL M;;REZAC DAVID A;;ROBINSON TIMOTHY W;;TING JOSEPH,CEREVASC INC (2015-05-12),https://lens.org/056-205-950-952-728,Patent Application,yes,10,4,30,30,0,A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M27/006;;A61M39/24;;A61M2210/06;;A61M2039/2426;;A61M2039/242;;A61M27/006;;A61B17/3401;;A61B17/3478;;A61M27/006;;A61B6/12;;A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M25/10;;A61M39/24;;A61M2039/242;;A61B34/20;;A61B18/14;;A61B2018/1425;;A61B18/1477;;A61B2018/00446;;A61B2018/00619;;A61M2210/06;;A61B18/1492;;A61M2039/2426,A61M27/00;;A61B34/20;;A61M25/00;;A61M25/01;;A61M25/09;;A61M39/24,,0,0,,,,ACTIVE
126,AU,B2,AU 604622 B2,070-154-606-260-933,1990-12-20,1990,AU 1988/013025 A,1988-03-11,US 2553387 A,1987-03-13,PROCESS FOR PREPARING POLYDIENE RUBBER BLENDS,,GOODYEAR TIRE & RUBBER,HALASA ADEL FARHAN;;ROBERTSON-WILCOX SYLVIA EILEEN;;ZANZIG DAVID JOHN;;ARCONTI RICHARD JOSEPH,,https://lens.org/070-154-606-260-933,Granted Patent,no,0,0,18,18,0,C08C19/44;;C08F36/04;;C08L21/00;;C08F36/04;;C08F4/44;;C08F36/04;;C08C19/44;;C08L21/00,C08F8/00;;C08C19/44;;C08F2/00;;C08F4/44;;C08F36/04;;C08L9/00;;C08L21/00,,0,0,,,,EXPIRED
127,ES,T3,ES 2038333 T3,104-051-845-602-726,1993-07-16,1993,ES 88630046 T,1988-03-08,US 2553387 A,1987-03-13,PROCEDIMIENTO DE POLIMERIZACION.,"LOS METALES DE LOS GRUPOS I Y II Y SUS COMPUESTOS ORGANOMETALICOS PUENEN USARSE PARA LA POLIMERIZACION DE MONOMEROS DIENICOS A POLIMEROS. LOS POLIMEROS FORMADOS EN TALES POLIMERIZACIONES ESTAN TERMINADOS CON LOS METALES USADOS PARA CATALIZAR LA POLIMERIZACION Y, A VECES, SE DESIGNAN COMO POLIMEROS VIVIENTES. SE REIVINDICA EL PROCESO DE PREPARACION DE UNA MEZCLA DE CAUCHO DE POLIDIENO QUE CONSISTE EN: 1) POLIMERIZACION DE, AL MENOS, UN MONOMERO DIENICO UTILIZANDO LOS CATALIZADORES INDICADOS HASTA UNA CONVERSION DENTRO DE LA GAMA ENTRE 30 Y 70% PARA PRODUCIR CADENAS DE POLIDIENO DE BAJO PESO MOLECULAR; (2) UNIR DESDE EL 20% HASTA EL 70% DE DICHAS CADENAS DE BAJO PESO MOLECULAR CON UN AGENTE DE RAMIFICACION ADECUADO; Y 3) PERMITIR QUE LA POLIMERIZACION CONTINUE HASTA PRODUCIR DICHAS MEZCLAS DE CAUCHO DE POLIDIENO.",THE GOODYEAR TIRE & RUBBER COMPANY,"HALASA, ADEL FARHAN;;ROBERTSON-WILCOX, SYLVIA EILEEN;;ZANZIG, DAVID JOHN;;ARCONTI, RICHARD JOSEPH",,https://lens.org/104-051-845-602-726,Granted Patent,no,0,0,18,18,0,C08C19/44;;C08F36/04;;C08L21/00;;C08F36/04;;C08F4/44;;C08F36/04;;C08C19/44;;C08L21/00,C08C19/44;;C08F2/00;;C08F4/44;;C08F36/04;;C08L9/00;;C08L21/00;;C08F8/00,,0,0,,,,EXPIRED
128,US,B2,US 9545505 B2,020-442-998-095-633,2017-01-17,2017,US 201615195453 A,2016-06-28,US 201615195453 A;;US 201615065766 A;;US 201514929066 A;;US 201462073766 P;;US 201562142895 P;;US 201562156152 P,2014-10-31,Methods and systems for treating hydrocephalus,"Methods for treating hydrocephalus using a shunt, the shunt having one or more CSF intake openings in a distal portion, a valve disposed in a proximal portion of the shunt, and a lumen extending between the one or more CSF intake openings and the valve, the method comprises deploying the shunt in a body of a patient so that the distal portion of the shunt is at least partially disposed within a CP angle cistern, a body of the shunt is at least partially disposed within an IPS of the patient, and the proximal portion of the shunt is at least partially disposed within or proximate to a JV of the patient, wherein, after deployment of the shunt, CSF flows from the CP angle cistern to the JV via the shunt lumen at a flow rate in a range of 5 ml per hour to 15 ml per hour.",CEREVASC LLC,HEILMAN CARL;;MALEK ADEL M;;REZAC DAVID A;;ROBINSON TIMOTHY W;;TING JOSEPH,CEREVASC INC (2015-05-12),https://lens.org/020-442-998-095-633,Granted Patent,yes,102,21,30,30,0,A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M27/006;;A61M39/24;;A61M2210/06;;A61M2039/2426;;A61M2039/242;;A61M27/006;;A61B17/3401;;A61B17/3478;;A61M27/006;;A61B6/12;;A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M25/10;;A61M39/24;;A61M2039/242;;A61B34/20;;A61B18/14;;A61B2018/1425;;A61B18/1477;;A61B2018/00446;;A61B2018/00619;;A61M2210/06;;A61B18/1492;;A61M2039/2426,A61M5/00;;A61B6/12;;A61B18/00;;A61B18/14;;A61M25/01;;A61M25/09;;A61M27/00;;A61M39/24,,5,0,,,"Non-Final Office Action for U.S. Appl. No. 14/596,335, dated Jul. 7, 2016.;;Non-Final Office Action for U.S. Appl. No. 14/179,622, mailed on May 13, 2015 (13 pages).;;PCT Notification of Transmittal of the International Search Report and Written Opinion, mailed Feb. 17, 2016, for PCT/US2015/058505, Applicant CereVasc, LLC., international filing date Oct. 30, 2015 (16 pages).;;Final Office Action for U.S. Appl. No. 14/596,335, dated Oct. 26, 2016 (19 pages).;;Interview Summary for U.S. Appl. No. 14/596,335, dated Oct. 11, 2016 (3 pages).",ACTIVE
129,AU,B2,AU 713527 B2,033-996-663-527-197,1999-12-02,1999,AU 1997/039749 A,1997-08-08,GB 9625311 A;;US 2382996 P;;US 9714019 W,1996-08-12,Thrombin inhibitors,"A compound which inhibits human thrombin and which has structure (A), such as formula (a).",MERCK & CO INC,FRALEY MARK E;;HUNGATE RANDALL W;;NAYLOR-OLSEN ADEL M;;VACCA JOSEPH P,,https://lens.org/033-996-663-527-197,Granted Patent,no,0,0,12,14,0,C07D213/74;;C07D405/12;;A61P43/00;;A61P7/02,A61K31/4409;;A61K31/4433;;A61P7/02;;A61P43/00;;C07D213/74;;C07D405/12,,0,0,,,,EXPIRED
130,US,B1,US 9387311 B1,093-225-844-290-900,2016-07-12,2016,US 201615065766 A,2016-03-09,US 201615065766 A;;US 201514929066 A;;US 201462073766 P;;US 201562142895 P;;US 201562156152 P,2014-10-31,Methods and systems for treating hydrocephalus,"Methods for treating hydrocephalus using a shunt, the shunt having one or more CSF intake openings in a distal portion, a valve disposed in a proximal portion of the shunt, and a lumen extending between the one or more CSF intake openings and the valve, the method comprises deploying the shunt in a body of a patient so that the distal portion of the shunt is at least partially disposed within a CP angle cistern, a body of the shunt is at least partially disposed within an IPS of the patient, and the proximal portion of the shunt is at least partially disposed within or proximate to a JV of the patient, wherein, after deployment of the shunt, CSF flows from the CP angle cistern to the JV via the shunt lumen at a flow rate in a range of 5 ml per hour to 15 ml per hour.",CEREVASC LLC,HEILMAN CARL;;MALEK ADEL M;;REZAC DAVID A;;ROBINSON TIMOTHY W;;TING JOSEPH,CEREVASC INC (2015-05-12),https://lens.org/093-225-844-290-900,Granted Patent,yes,101,34,30,30,0,A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M27/006;;A61M39/24;;A61M2210/06;;A61M2039/2426;;A61M2039/242;;A61M27/006;;A61B17/3401;;A61B17/3478;;A61M27/006;;A61B6/12;;A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M25/10;;A61M39/24;;A61M2039/242;;A61B34/20;;A61B18/14;;A61B2018/1425;;A61B18/1477;;A61B2018/00446;;A61B2018/00619;;A61M2210/06;;A61B18/1492;;A61M2039/2426,A61M5/00;;A61B18/14;;A61M25/00;;A61M25/01;;A61M25/10;;A61M27/00,,10,2,156-065-109-977-179;;002-633-141-477-914,10.1007/s10143-010-0242-0;;20177727;;8559335;;10.1227/00006123-199511000-00005;;10.1097/00006123-199511000-00005,"Oh, J., ""Implantable Microdevice for the Treatment of Hydrocephalus"", Drexel University, Mar. 2011, 155 pages.;;Toma, A., et al., ""Ventriculosinus Shunt"", Neurosurg Review, dated Feb. 23, 2010, 7 pages.;;Weiner, H., et al., ""Current Treatment of Normal-Pressure Hydrocephalus: Comparison of Flow-Regulated and Differential-Pressure Shunt Valves"", Neurosurgery vol. 37(5), dated Nov. 1995, 13 pages.;;Final Office Action for U.S. Appl. No. 12/362,152 dated Mar. 8, 2012.;;Non-Final Office Action for U.S. Appl. No. 12/362,152 dated Aug. 5, 2011.;;Final Office Action for U.S. Appl. No. 13/569,212 dated Jul. 17, 2013.;;Non-Final Office Action for U.S. Appl. No. 13/569,212 dated Jan. 10, 2013.;;PCT International Search Report and Written Opinion for International Application No. PCT/2015/011317, Applicant Tufts Medical Center, Inc., Forms PCT/ISA/210, 220, and 237, dated Mar. 26, 2015 (15 pages).;;Non-Final Office Action for U.S. Appl. No. 14/179,622, mailed on May 13, 2015 (13 pages).;;PCT Notification of Transmittal of the International Search Report and Written Opinion, mailed Feb. 17, 2016, for PCT/US2015/058505, Applicant CereVasc, LLC., international filing date Oct. 30, 2015 (16 pages).",ACTIVE
131,US,A1,US 2019/0105477 A1,159-413-216-534-362,2019-04-11,2019,US 201816212511 A,2018-12-06,US 201816212511 A;;US 201715668657 A;;US 201715432818 A;;US 201615289790 A;;US 201615195139 A;;US 201615065766 A;;US 201514929066 A;;US 201562156152 P;;US 201562142895 P;;US 201462073766 P,2014-10-31,SYSTEMS AND METHODS FOR DEPLOYING AN IMPLANT IN THE VASCULATURE,"Methods for treating hydrocephalus using a shunt, the shunt having one or more CSF intake openings in a distal portion, a valve disposed in a proximal portion of the shunt, and a lumen extending between the one or more CSF intake openings and the valve, the method comprises deploying the shunt in a body of a patient so that the distal portion of the shunt is at least partially disposed within a CP angle cistern, a body of the shunt is at least partially disposed within an IPS of the patient, and the proximal portion of the shunt is at least partially disposed within or proximate to a JV of the patient, wherein, after deployment of the shunt, CSF flows from the CP angle cistern to the JV via the shunt lumen at a flow rate in a range of 5 ml per hour to 15 ml per hour.",CEREVASC LLC,HEILMAN CARL;;MALEK ADEL M;;REZAC DAVID A;;ROBINSON TIMOTHY W;;TING JOSEPH,CEREVASC INC (2015-05-12),https://lens.org/159-413-216-534-362,Patent Application,yes,7,24,30,30,0,A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M27/006;;A61M39/24;;A61M2210/06;;A61M2039/2426;;A61M2039/242;;A61M27/006;;A61B17/3401;;A61B17/3478;;A61M27/006;;A61B6/12;;A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M25/10;;A61M39/24;;A61M2039/242;;A61B34/20;;A61B18/14;;A61B2018/1425;;A61B18/1477;;A61B2018/00446;;A61B2018/00619;;A61M2210/06;;A61B18/1492;;A61M2039/2426,A61M27/00;;A61B6/12;;A61B18/14;;A61B34/20;;A61M25/00;;A61M25/01;;A61M25/09;;A61M25/10;;A61M39/24,,0,0,,,,ACTIVE
132,US,A1,US 2016/0199627 A1,035-292-513-740-045,2016-07-14,2016,US 201615065766 A,2016-03-09,US 201615065766 A;;US 201514929066 A;;US 201462073766 P;;US 201562142895 P;;US 201562156152 P,2014-10-31,METHODS AND SYSTEMS FOR TREATING HYDROCEPHALUS,"Methods for treating hydrocephalus using a shunt, the shunt having one or more CSF intake openings in a distal portion, a valve disposed in a proximal portion of the shunt, and a lumen extending between the one or more CSF intake openings and the valve, the method comprises deploying the shunt in a body of a patient so that the distal portion of the shunt is at least partially disposed within a CP angle cistern, a body of the shunt is at least partially disposed within an IPS of the patient, and the proximal portion of the shunt is at least partially disposed within or proximate to a JV of the patient, wherein, after deployment of the shunt, CSF flows from the CP angle cistern to the JV via the shunt lumen at a flow rate in a range of 5 ml per hour to 15 ml per hour.",CEREVASC LLC,HEILMAN CARL;;MALEK ADEL M;;REZAC DAVID A;;ROBINSON TIMOTHY W;;TING JOSEPH,CEREVASC INC (2015-05-12),https://lens.org/035-292-513-740-045,Patent Application,yes,0,0,30,30,0,A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M27/006;;A61M39/24;;A61M2210/06;;A61M2039/2426;;A61M2039/242;;A61M27/006;;A61B17/3401;;A61B17/3478;;A61M27/006;;A61B6/12;;A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M25/10;;A61M39/24;;A61M2039/242;;A61B34/20;;A61B18/14;;A61B2018/1425;;A61B18/1477;;A61B2018/00446;;A61B2018/00619;;A61M2210/06;;A61B18/1492;;A61M2039/2426,A61M27/00;;A61B18/14;;A61B34/20;;A61M25/00;;A61M25/01;;A61M25/10,,0,0,,,,ACTIVE
133,DE,T2,DE 3878705 T2,086-046-300-722-202,1993-09-09,1993,DE 3878705 T,1988-03-08,US 2553387 A,1987-03-13,POLYMERISATIONSVERFAHREN.,,GOODYEAR TIRE & RUBBER,HALASA ADEL FARHAN;;ROBERTSON-WILCOX SYLVIA EILEEN;;ZANZIG DAVID JOHN;;ARCONTI RICHARD JOSEPH,,https://lens.org/086-046-300-722-202,Granted Patent,no,0,0,18,18,0,C08C19/44;;C08F36/04;;C08L21/00;;C08F36/04;;C08F4/44;;C08F36/04;;C08C19/44;;C08L21/00,C08F8/00;;C08C19/44;;C08F2/00;;C08F4/44;;C08F36/04;;C08L9/00;;C08L21/00,,0,0,,,,EXPIRED
134,AU,A,AU 1988/013025 A,102-904-309-036-109,1988-09-15,1988,AU 1988/013025 A,1988-03-11,US 2553387 A,1987-03-13,PROCESS FOR PREPARING POLYDIENE RUBBER BLENDS,,GOODYEAR TIRE & RUBBER,HALASA ADEL FARHAN;;ROBERTSON-WILCOX SYLVIA EILEEN;;ZANZIG DAVID JOHN;;ARCONTI RICHARD JOSEPH,,https://lens.org/102-904-309-036-109,Patent Application,no,0,0,18,18,0,C08C19/44;;C08F36/04;;C08L21/00;;C08F36/04;;C08F4/44;;C08F36/04;;C08C19/44;;C08L21/00,C08F8/00;;C08C19/44;;C08F2/00;;C08F4/44;;C08F36/04;;C08L9/00;;C08L21/00,,0,0,,,,EXPIRED
135,EP,A2,EP 0282437 A2,110-036-693-699-435,1988-09-14,1988,EP 88630046 A,1988-03-08,US 2553387 A,1987-03-13,Polymerization process.,"Metals from Groups I and II and organometallic compounds thereof can be used to catalyze the polymerization of diene monomers into polymers. The polymers formed in such polymerizations are terminated with the metal used to catalyze the polymerization and are sometimes referred to as living polymers. Very useful blends of such polymers can be made by utilizing the process of the present invention. More specifically, the present invention discloses a process for preparing a polydiene rubber blend comprising: (1) polymerizing at least one diene monomer utilizing at least one catalyst selected from the group consisting of Group I metals, Group II metals, organometallic compounds containing a Group I metal, and organometallic compounds containing a Group II metal, to a conversion which is within the range of 30% to 70% to produce low molecular weight polydiene chains; (2) joining from 20% to 70% of said low molecular weight polydiene chains with a suitable branching agent; and (3) allowing the polymerization to continue so as to produce said polydiene rubber blends.  ",GOODYEAR TIRE & RUBBER,HALASA ADEL FARHAN;;ROBERTSON-WILCOX SYLVIA EILEEN;;ZANZIG DAVID JOHN;;ARCONTI RICHARD JOSEPH,,https://lens.org/110-036-693-699-435,Patent Application,yes,0,46,18,18,0,C08C19/44;;C08F36/04;;C08L21/00;;C08F36/04;;C08F4/44;;C08F36/04;;C08C19/44;;C08L21/00,C08F8/00;;C08C19/44;;C08F2/00;;C08F4/44;;C08F36/04;;C08L9/00;;C08L21/00,,0,0,,,,EXPIRED
136,EP,B1,EP 0949921 B1,185-771-029-937-847,2002-11-13,2002,EP 97937175 A,1997-08-08,GB 9625311 A;;US 9714019 W;;US 2382996 P,1996-08-12,THROMBIN INHIBITORS,"A compound which inhibits human thrombin and which has structure (A), such as formula (a).",MERCK & CO INC,FRALEY MARK E;;HUNGATE RANDALL W;;NAYLOR-OLSEN ADEL M;;VACCA JOSEPH P,,https://lens.org/185-771-029-937-847,Granted Patent,yes,7,0,12,14,0,C07D213/74;;C07D405/12;;A61P43/00;;A61P7/02,A61K31/4409;;A61K31/4433;;A61P7/02;;A61P43/00;;C07D213/74;;C07D405/12,,0,0,,,,EXPIRED
137,US,A1,US 2017/0157375 A1,105-865-845-598-682,2017-06-08,2017,US 201715432818 A,2017-02-14,US 201715432818 A;;US 201615289790 A;;US 201615195139 A;;US 201615065766 A;;US 201514929066 A;;US 201562142895 P;;US 201562156152 P;;US 201462073766 P,2014-10-31,METHODS AND SYSTEMS FOR TREATING HYDROCEPHALUS,"Methods for treating hydrocephalus using a shunt, the shunt having one or more CSF intake openings in a distal portion, a valve disposed in a proximal portion of the shunt, and a lumen extending between the one or more CSF intake openings and the valve, the method comprises deploying the shunt in a body of a patient so that the distal portion of the shunt is at least partially disposed within a CP angle cistern, a body of the shunt is at least partially disposed within an IPS of the patient, and the proximal portion of the shunt is at least partially disposed within or proximate to a JV of the patient, wherein, after deployment of the shunt, CSF flows from the CP angle cistern to the JV via the shunt lumen at a flow rate in a range of 5 ml per hour to 15 ml per hour.",CEREVASC LLC,HEILMAN CARL;;MALEK ADEL M;;REZAC DAVID A;;ROBINSON TIMOTHY W;;TING JOSEPH,CEREVASC INC (2015-05-12),https://lens.org/105-865-845-598-682,Patent Application,yes,4,4,30,30,0,A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M27/006;;A61M39/24;;A61M2210/06;;A61M2039/2426;;A61M2039/242;;A61M27/006;;A61B17/3401;;A61B17/3478;;A61M27/006;;A61B6/12;;A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M25/10;;A61M39/24;;A61M2039/242;;A61B34/20;;A61B18/14;;A61B2018/1425;;A61B18/1477;;A61B2018/00446;;A61B2018/00619;;A61M2210/06;;A61B18/1492;;A61M2039/2426,A61M27/00;;A61B34/20;;A61M25/00;;A61M25/01;;A61M25/09;;A61M39/24,,0,0,,,,ACTIVE
138,CA,A1,CA 2262686 A1,130-677-580-357-741,1998-02-19,1998,CA 2262686 A,1997-08-08,GB 9625311 A;;US 2382996 P;;US 9714019 W,1996-08-12,THROMBIN INHIBITORS,"A compound which inhibits human thrombin and which has structure (A), such as formula (a).",MERCK & CO INC,VACCA JOSEPH P;;FRALEY MARK E;;HUNGATE RANDALL W;;NAYLOR-OLSEN ADEL M,,https://lens.org/130-677-580-357-741,Patent Application,no,0,0,12,14,0,C07D213/74;;C07D405/12;;A61P43/00;;A61P7/02,A61K31/4409;;A61K31/4433;;A61P7/02;;A61P43/00;;C07D213/74;;C07D405/12,,0,0,,,,DISCONTINUED
139,US,A1,US 2018/0015267 A1,061-637-055-515-759,2018-01-18,2018,US 201715668657 A,2017-08-03,US 201715668657 A;;US 201715432818 A;;US 201615289790 A;;US 201615195139 A;;US 201615065766 A;;US 201514929066 A;;US 201562156152 P;;US 201562142895 P;;US 201462073766 P,2014-10-31,METHODS AND SYSTEMS FOR TREATING HYDROCEPHALUS,"Methods for treating hydrocephalus using a shunt, the shunt having one or more CSF intake openings in a distal portion, a valve disposed in a proximal portion of the shunt, and a lumen extending between the one or more CSF intake openings and the valve, the method comprises deploying the shunt in a body of a patient so that the distal portion of the shunt is at least partially disposed within a CP angle cistern, a body of the shunt is at least partially disposed within an IPS of the patient, and the proximal portion of the shunt is at least partially disposed within or proximate to a JV of the patient, wherein, after deployment of the shunt, CSF flows from the CP angle cistern to the JV via the shunt lumen at a flow rate in a range of 5 ml per hour to 15 ml per hour.",CEREVASC LLC,HEILMAN CARL;;MALEK ADEL M;;REZAC DAVID A;;ROBINSON TIMOTHY W;;TING JOSEPH,CEREVASC INC (2015-05-12),https://lens.org/061-637-055-515-759,Patent Application,yes,12,9,30,30,0,A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M27/006;;A61M39/24;;A61M2210/06;;A61M2039/2426;;A61M2039/242;;A61M27/006;;A61B17/3401;;A61B17/3478;;A61M27/006;;A61B6/12;;A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M25/10;;A61M39/24;;A61M2039/242;;A61B34/20;;A61B18/14;;A61B2018/1425;;A61B18/1477;;A61B2018/00446;;A61B2018/00619;;A61M2210/06;;A61B18/1492;;A61M2039/2426,A61M27/00;;A61M25/00;;A61M25/01;;A61M25/09;;A61M39/24,,0,0,,,,ACTIVE
140,US,B2,US 9724501 B2,113-748-814-647-645,2017-08-08,2017,US 201715432818 A,2017-02-14,US 201715432818 A;;US 201615289790 A;;US 201615195139 A;;US 201615065766 A;;US 201514929066 A;;US 201562142895 P;;US 201562156152 P;;US 201462073766 P,2014-10-31,Methods and systems for treating hydrocephalus,"Methods for treating hydrocephalus using a shunt, the shunt having one or more CSF intake openings in a distal portion, a valve disposed in a proximal portion of the shunt, and a lumen extending between the one or more CSF intake openings and the valve, the method comprises deploying the shunt in a body of a patient so that the distal portion of the shunt is at least partially disposed within a CP angle cistern, a body of the shunt is at least partially disposed within an IPS of the patient, and the proximal portion of the shunt is at least partially disposed within or proximate to a JV of the patient, wherein, after deployment of the shunt, CSF flows from the CP angle cistern to the JV via the shunt lumen at a flow rate in a range of 5 ml per hour to 15 ml per hour.",CEREVASC LLC,HEILMAN CARL;;MALEK ADEL M;;REZAC DAVID A;;ROBINSON TIMOTHY W;;TING JOSEPH,CEREVASC INC (2015-05-12),https://lens.org/113-748-814-647-645,Granted Patent,yes,163,17,30,30,0,A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M27/006;;A61M39/24;;A61M2210/06;;A61M2039/2426;;A61M2039/242;;A61M27/006;;A61B17/3401;;A61B17/3478;;A61M27/006;;A61B6/12;;A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M25/10;;A61M39/24;;A61M2039/242;;A61B34/20;;A61B18/14;;A61B2018/1425;;A61B18/1477;;A61B2018/00446;;A61B2018/00619;;A61M2210/06;;A61B18/1492;;A61M2039/2426,A61M5/00;;A61B34/20;;A61M25/00;;A61M25/01;;A61M25/09;;A61M27/00;;A61M39/24,,8,0,,,"PCT International Search Report and Written Opinion for International Application No. PCT/2015/011317, Applicant Tufts Medical Center, Inc., Forms PCT/ISA/210, 220, and 237, dated Mar. 26, 2015 (15 pages).;;Non-Final Office Action for U.S. Appl. No. 14/179,622, mailed on May 13, 2015 (13 pages).;;PCT Notification of Transmittal of the International Search Report and Written Opinion, mailed Feb. 17, 2016, for PCT/US2015/058505, Applicant CereVasc, LLC., international filing date Oct. 30, 2015 (16 pages).;;Non-Final Office Action for U.S. Appl. No. 14/596,335, dated Jul. 7, 2016 (16 pages).;;Final Office Action for U.S. Appl. No. 14/596,335, dated Oct. 26, 2016 (19 pages).;;Interview Summary for U.S. Appl. No. 14/596,335, dated Oct. 11, 2016 (3 pages).;;PCT International Search Report and Written Opinion for International Appln. No. PCT/US2016/069280, applicant Cerevasc LLC, dated Mar. 27, 2017 (80 pages).;;Non-Final Office Action for U.S. Appl. No. 15/294,000, filed Feb. 16, 2017 (26 pages).",ACTIVE
141,US,A1,US 2016/0303355 A1,152-116-682-910-606,2016-10-20,2016,US 201615195139 A,2016-06-28,US 201615195139 A;;US 201615065766 A;;US 201514929066 A;;US 201462073766 P;;US 201562142895 P;;US 201562156152 P,2014-10-31,METHODS AND SYSTEMS FOR TREATING HYDROCEPHALUS,"Methods for treating hydrocephalus using a shunt, the shunt having one or more CSF intake openings in a distal portion, a valve disposed in a proximal portion of the shunt, and a lumen extending between the one or more CSF intake openings and the valve, the method comprises deploying the shunt in a body of a patient so that the distal portion of the shunt is at least partially disposed within a CP angle cistern, a body of the shunt is at least partially disposed within an IPS of the patient, and the proximal portion of the shunt is at least partially disposed within or proximate to a JV of the patient, wherein, after deployment of the shunt, CSF flows from the CP angle cistern to the JV via the shunt lumen at a flow rate in a range of 5 ml per hour to 15 ml per hour.",CEREVASC LLC,HEILMAN CARL;;MALEK ADEL M;;REZAC DAVID A;;ROBINSON TIMOTHY W;;TING JOSEPH,CEREVASC INC (2015-05-12),https://lens.org/152-116-682-910-606,Patent Application,yes,0,11,30,30,0,A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M27/006;;A61M39/24;;A61M2210/06;;A61M2039/2426;;A61M2039/242;;A61M27/006;;A61B17/3401;;A61B17/3478;;A61M27/006;;A61B6/12;;A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M25/10;;A61M39/24;;A61M2039/242;;A61B34/20;;A61B18/14;;A61B2018/1425;;A61B18/1477;;A61B2018/00446;;A61B2018/00619;;A61M2210/06;;A61B18/1492;;A61M2039/2426,A61M27/00;;A61B6/12;;A61B18/14;;A61M25/00;;A61M25/01;;A61M25/09;;A61M39/24,,0,0,,,,ACTIVE
142,US,A1,US 2018/0126132 A1,196-548-251-921-544,2018-05-10,2018,US 201815862120 A,2018-01-04,US 201815862120 A;;US 201715668657 A;;US 201715432818 A;;US 201615289790 A;;US 201615195139 A;;US 201615065766 A;;US 201514929066 A;;US 201562156152 P;;US 201562142895 P;;US 201462073766 P,2014-10-31,METHODS AND SYSTEMS FOR TREATING HYDROCEPHALUS,"Methods for treating hydrocephalus using a shunt, the shunt having one or more CSF intake openings in a distal portion, a valve disposed in a proximal portion of the shunt, and a lumen extending between the one or more CSF intake openings and the valve, the method comprises deploying the shunt in a body of a patient so that the distal portion of the shunt is at least partially disposed within a CP angle cistern, a body of the shunt is at least partially disposed within an IPS of the patient, and the proximal portion of the shunt is at least partially disposed within or proximate to a JV of the patient, wherein, after deployment of the shunt, CSF flows from the CP angle cistern to the JV via the shunt lumen at a flow rate in a range of 5 ml per hour to 15 ml per hour.",CEREVASC LLC,HEILMAN CARL;;MALEK ADEL M;;REZAC DAVID A;;ROBINSON TIMOTHY W;;TING JOSEPH,CEREVASC INC (2015-05-12),https://lens.org/196-548-251-921-544,Patent Application,yes,0,14,30,30,0,A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M27/006;;A61M39/24;;A61M2210/06;;A61M2039/2426;;A61M2039/242;;A61M27/006;;A61B17/3401;;A61B17/3478;;A61M27/006;;A61B6/12;;A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M25/10;;A61M39/24;;A61M2039/242;;A61B34/20;;A61B18/14;;A61B2018/1425;;A61B18/1477;;A61B2018/00446;;A61B2018/00619;;A61M2210/06;;A61B18/1492;;A61M2039/2426,A61M27/00;;A61B34/20;;A61M25/00;;A61M25/01;;A61M25/09;;A61M39/24,,0,0,,,,ACTIVE
143,US,B2,US 10307576 B2,018-539-298-487-870,2019-06-04,2019,US 201816212511 A,2018-12-06,US 201816212511 A;;US 201715668657 A;;US 201715432818 A;;US 201615289790 A;;US 201615195139 A;;US 201615065766 A;;US 201514929066 A;;US 201562156152 P;;US 201562142895 P;;US 201462073766 P,2014-10-31,Systems and methods for deploying an implant in the vasculature,"Methods for treating hydrocephalus using a shunt, the shunt having one or more CSF intake openings in a distal portion, a valve disposed in a proximal portion of the shunt, and a lumen extending between the one or more CSF intake openings and the valve, the method comprises deploying the shunt in a body of a patient so that the distal portion of the shunt is at least partially disposed within a CP angle cistern, a body of the shunt is at least partially disposed within an IPS of the patient, and the proximal portion of the shunt is at least partially disposed within or proximate to a JV of the patient, wherein, after deployment of the shunt, CSF flows from the CP angle cistern to the JV via the shunt lumen at a flow rate in a range of 5 ml per hour to 15 ml per hour.",CEREVASC LLC,HEILMAN CARL;;MALEK ADEL M;;REZAC DAVID A;;ROBINSON TIMOTHY W;;TING JOSEPH,CEREVASC INC (2015-05-12),https://lens.org/018-539-298-487-870,Granted Patent,yes,227,9,30,30,0,A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M27/006;;A61M39/24;;A61M2210/06;;A61M2039/2426;;A61M2039/242;;A61M27/006;;A61B17/3401;;A61B17/3478;;A61M27/006;;A61B6/12;;A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M25/10;;A61M39/24;;A61M2039/242;;A61B34/20;;A61B18/14;;A61B2018/1425;;A61B18/1477;;A61B2018/00446;;A61B2018/00619;;A61M2210/06;;A61B18/1492;;A61M2039/2426,A61M27/00;;A61B6/12;;A61B18/00;;A61B18/14;;A61B34/20;;A61M25/00;;A61M25/01;;A61M25/09;;A61M25/10;;A61M39/24,,18,0,,,"Examination Report dated Jan. 25, 2019 for EP Appln. No. 15791220.5.;;PCT International Search Report and Written Opinion for International Application No. PCT/2015/011317, Applicant Tufts Medical Center, Inc., Forms PCT/ISA/210, 220, and 237, dated Mar. 26, 2015 (15 pages).;;Non-Final Office Action for U.S. Appl. No. 14/179,622, dated May 13, 2015 (13 pages).;;PCT Notification of Transmittal of the International Search Report and Written Opinion, dated Feb. 17, 2016, for PCT/US2015/058505, Applicant CereVasc, LLC., international filing date Oct. 30, 2015 (16 pages).;;Non-Final Office Action for U.S. Appl. No. 14/596,335, dated Jul. 7, 2016 (16 pages).;;PCT International Search Report and Written Opinion for International Appln. No. PCTIUS2016/069280, applicant Cerevasc, LLC, dated Mar. 27, 2017 (80 pages).;;Non-Final Office Action for U.S. Appl. No. 15/294,000, dated Feb. 16, 2017 (26 pages).;;Final Office Action for U.S. Appl. No. 14/596,335, dated Oct. 26, 2016 (19 pages).;;Interview Summary for U.S. Appl. No. 14/596,335, dated Oct. 11, 2016 (3 pages).;;PCT Notification of Transmittal of the International Search Report and Written Opinion of the I.S.A. for PCT/US2016/0595952, dated Jan. 20, 2017, 14 pages.;;PCT International Search Report and Written Opinion for International Appln. No. PCT/US2017/056227, Applicant Cerevasc, LLC, Forms PCT/ISA/210, 220, and 237, dated Mar. 29, 2018 (24 pages).;;Non-Final Office Action for U.S. Appl. No. 15/862,120, dated Apr. 19, 2018.;;Amendment Response to Office Action for U.S. Appl. No. 15/862,120 dated May 1, 2018.;;Supplemental Amendment for U.S. Appl. No. 15/862,120 dated May 7, 2018.;;PCT Invitation to Pay Additional Fees for International Appln. No. PCT/US2018/020667, dated May 29, 2018 (17 pages).;;PCT International Search Report and Written Opinion for International Appln. No. PCT/US2018/020667, dated Aug. 1, 2018 (21 pages).;;Non-Final Office Action dated Nov. 6, 2018 for U.S. Appl. No. 15/668,657.;;Response to Non Final Office Action filed Nov. 14, 2018 for U.S. Appl. No. 15/668,657.",ACTIVE
144,US,A,US 5792761 A,137-525-705-937-240,1998-08-11,1998,US 90744697 A,1997-08-08,US 90744697 A;;US 2382996 P,1996-08-12,Thrombin inhibitors,A compound which inhibits human thrombin and where has the structure ##STR1##,MERCK & CO INC,FRALEY MARK E;;NAYLOR-OLSEN ADEL M;;HUNGATE RANDALL W;;VACCA JOSEPH P,MERCK & CO. INC (1996-09-24),https://lens.org/137-525-705-937-240,Granted Patent,yes,7,16,1,14,0,C07D213/74;;C07D401/12;;C07D405/12;;C07D213/74;;C07D401/12;;C07D405/12,C07D213/74;;C07D401/12;;C07D405/12,514/212;;514/314;;514/337;;514/339;;514/352;;540/593;;546/165;;546/166;;546/277.4;;546/281.7;;546/282.7;;546/284.1;;546/304,1,1,140-841-663-813-882,10.1021/ja00031a046,"Edwards et al., Design, Synthesis, and Kinetic Evaluation of a Unique Class of Elastase Inhibitors, the piptidyl alpha ketobenzoxazoles, J. Am. Chem. Soc., vol. 114, No. 1, pp. 1854 1863, 1992.",EXPIRED
145,US,B2,US 10765846 B2,156-999-420-200-564,2020-09-08,2020,US 201815981118 A,2018-05-16,US 201815981118 A;;US 201815862120 A;;US 201715668657 A;;US 201715432818 A;;US 201615289790 A;;US 201615195139 A;;US 201615065766 A;;US 201514929066 A;;US 201562156152 P;;US 201562142895 P;;US 201462073766 P,2014-10-31,Methods and systems for draining cerebrospinal fluid into the venous system,"Methods for treating hydrocephalus using a shunt, the shunt having one or more CSF intake openings in a distal portion, a valve disposed in a proximal portion of the shunt, and a lumen extending between the one or more CSF intake openings and the valve, the method comprises deploying the shunt in a body of a patient so that the distal portion of the shunt is at least partially disposed within a CP angle cistern, a body of the shunt is at least partially disposed within an IPS of the patient, and the proximal portion of the shunt is at least partially disposed within or proximate to a JV of the patient, wherein, after deployment of the shunt, CSF flows from the CP angle cistern to the JV via the shunt lumen at a flow rate in a range of 5 ml per hour to 15 ml per hour.",CEREVASC LLC;;CEREVASC INC,HEILMAN CARL;;MALEK ADEL M;;REZAC DAVID A;;ROBINSON TIMOTHY W;;TING JOSEPH,CEREVASC INC (2015-05-12),https://lens.org/156-999-420-200-564,Granted Patent,yes,241,2,30,30,0,A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M27/006;;A61M39/24;;A61M2210/06;;A61M2039/2426;;A61M2039/242;;A61M27/006;;A61B17/3401;;A61B17/3478;;A61M27/006;;A61B6/12;;A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M25/10;;A61M39/24;;A61M2039/242;;A61B34/20;;A61B18/14;;A61B2018/1425;;A61B18/1477;;A61B2018/00446;;A61B2018/00619;;A61M2210/06;;A61B18/1492;;A61M2039/2426,A61M27/00;;A61B6/12;;A61B18/00;;A61B18/14;;A61B34/20;;A61M25/00;;A61M25/01;;A61M25/09;;A61M25/10;;A61M39/24,,34,0,,,"Examination Report dated Jan. 25, 2019 for EP Appln. No. 15791220.5.;;Amendment Response to Office Action for U.S. Appl. No. 15/862,120 dated May 1, 2018.;;Supplemental Amendment for U.S. Appl. No. 15/862,120 dated May 7, 2018.;;PCT Invitation to Pay Additional Fees for International Appln. No. PCT/US2018/020667, dated May 29, 2018 (17 pages).;;PCT International Search Report and Written Opinion for International Application No. PCT/2015/011317, Applicant Tufts Medical Center, Inc., Forms PCT/ISA/210, 220, and 237, dated Mar. 26, 2015 (15 pages).;;Non-Final Office Action for U.S. Appl. No. 14/179,622, dated May 13, 2015 (13 pages).;;PCT Notification of Transmittal of the International Search Report and Written Opinion, dated Feb. 17, 2016, for PCT/US2015/058505, Applicant CereVasc, LLC., international filing date Oct. 30, 2015 (16 pages).;;Non-Final Office Action for U.S. Appl. No. 14/596,335, dated Jul. 7, 2016 (16 pages).;;PCT International Search Report and Written Opinion for International Appln. No. PCT/US2016/069280, applicant Cerevasc, LLC, dated Mar. 27, 2017 (80 pages).;;Non-Final Office Action for U.S. Appl. No. 15/294,000, dated Feb. 16, 2017 (26 pages).;;Final Office Action for U.S. Appl. No. 14/596,335, dated Oct. 26, 2016 (19 pages).;;Interview Summary for U.S. Appl. No. 14/596,335, dated Oct. 11, 2016 (3 pages).;;PCT Notification of Transmittal of the International Search Report and Written Opinion of the I.S.A. for PCT/US2016/0595952, dated Jan. 20, 2017, 14 pages.;;PCT International Search Report and Written Opinion for International Appln. No. PCT/US2017/056227, Applicant Cerevasc, LLC, Forms PCT/ISA/210, 220, and 237, dated Mar. 29, 2018 (24 pages).;;Non-Final Office Action for U.S. Appl. No. 15/862,120, dated Apr. 19, 2018.;;Non-Final Office Action dated Nov. 6, 2018 for U.S. Appl. No. 15/668,657.;;Response to Non Final Office Action filed Nov. 14, 2018 for U.S. Appl. No. 15/668,657.;;Notice of Allowance dated Dec. 14, 2018 for U.S. Appl. No. 15/668,657.;;Notice of Allowance dated Dec. 14, 2018 for U.S. Appl. No. 15/745,961.;;Non-final office action dated Mar. 21, 2019 for U.S. Appl. No. 16/212,511.;;Amendment Response to Office Action for U.S. Appl. No. 16/212,547 dated Mar. 4, 2019.;;Notice of Allowance dated Apr. 17, 2019 for U.S. Appl. No. 16/212,511.;;Notice of Rejection for JP International Patent Appln. No. 2017-542811 dated Nov. 13, 2018.;;Office Action dated Mar. 5, 2019 for Japanese Patent Appln. No. 2017-542811, with English translation provided by Foreign Associate.;;Notice of Allowance dated Apr. 9, 2019 for U.S. Appl. No. 16/212,547l;;PCT Invitation to Pay Additional Fees for International Appln. No. PCT/US2019/021471, dated Jun. 28, 2019 (10 pages).;;PCT International Search Report and Written Opinion dated Aug. 20, 2019 for PCT Appln. No. PCT/US2019/021471, 17 pages.;;Office action and search report dated Jul. 29, 2019 for Chinese Application No. 2015800588073, in Chinese with English translation provided by foreign associate.;;Response to Examination Report filed Jun. 4, 2019 for EP Appln. No. 15791220.5.;;Response to Foreign Office Action filed Jun. 24, 2019 for JP Patent Appln. No. 2017-542811.;;PCT Invitation to Pay Additional Fees mailed Jan. 5, 2018 for PCT/US2017/056227, Applicant Cerevasc, LLC, 17 pages.;;Response to Office action filed Oct. 29, 2019 for Chinese Application No. 2015800588073.;;EPO communication Rule 71(3) allowance dated Nov. 7, 2019 for European patent application No. 15791220.5.;;International Search Report and Written Opinion for International Appln. No. PCT/US2018/020667 [dated Aug. 1, 2018 (21 pages)].",ACTIVE
146,US,B2,US 9662479 B2,117-582-636-945-583,2017-05-30,2017,US 201615195139 A,2016-06-28,US 201615195139 A;;US 201615065766 A;;US 201514929066 A;;US 201462073766 P;;US 201562142895 P;;US 201562156152 P,2014-10-31,Methods and systems for treating hydrocephalus,"Methods for treating hydrocephalus using a shunt, the shunt having one or more CSF intake openings in a distal portion, a valve disposed in a proximal portion of the shunt, and a lumen extending between the one or more CSF intake openings and the valve, the method comprises deploying the shunt in a body of a patient so that the distal portion of the shunt is at least partially disposed within a CP angle cistern, a body of the shunt is at least partially disposed within an IPS of the patient, and the proximal portion of the shunt is at least partially disposed within or proximate to a JV of the patient, wherein, after deployment of the shunt, CSF flows from the CP angle cistern to the JV via the shunt lumen at a flow rate in a range of 5 ml per hour to 15 ml per hour.",CEREVASC LLC,HEILMAN CARL;;MALEK ADEL M;;REZAC DAVID A;;ROBINSON TIMOTHY W;;TING JOSEPH,CEREVASC INC (2015-05-12),https://lens.org/117-582-636-945-583,Granted Patent,yes,162,5,30,30,0,A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M27/006;;A61M39/24;;A61M2210/06;;A61M2039/2426;;A61M2039/242;;A61M27/006;;A61B17/3401;;A61B17/3478;;A61M27/006;;A61B6/12;;A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M25/10;;A61M39/24;;A61M2039/242;;A61B34/20;;A61B18/14;;A61B2018/1425;;A61B18/1477;;A61B2018/00446;;A61B2018/00619;;A61M2210/06;;A61B18/1492;;A61M2039/2426,A61M5/00;;A61B6/12;;A61B18/00;;A61B18/14;;A61M25/00;;A61M25/01;;A61M25/09;;A61M27/00;;A61M39/24,,8,0,,,"Non-Final Office Action for U.S. Appl. No. 14/596,335, dated Jul. 7, 2016.;;PCT International Search Report and Written Opinion for International Application No. PCT/2015/011317, Applicant Tufts Medical Center, Inc., Forms PCT/ISA/210, 220, and 237, dated Mar. 26, 2015 (15 pages).;;Non-Final Office Action for U.S. Appl. No. 14/179,622, mailed on May 13, 2015 (13 pages).;;PCT Notification of Transmittal of the International Search Report and Written Opinion, mailed Feb. 17, 2016, for PCT/US2015/058505, Applicant CereVasc, LLC., international filing date Oct. 30, 2015 (16 pages).;;Final Office Action for U.S. Appl. No. 14/596,335, dated Oct. 26, 2016 (19 pages).;;Interview Summary for U.S. Appl. No. 14/596,335, dated Oct. 11, 2016 (3 pages).;;Non-Final Office Action for U.S. Appl. No. 15/294,000, filed Feb. 16, 2017 (26 pages).;;PCT International Search Report and Written Opinion for International Appln. No. PCT/US2016/069280, applicant CEREVASC, LLC, dated Mar. 27, 2017 (80 pages).",ACTIVE
147,WO,A1,WO 1998/006396 A1,122-708-677-985-217,1998-02-19,1998,US 9714019 W,1997-08-08,GB 9625311 A;;US 2382996 P,1996-08-12,THROMBIN INHIBITORS,"A compound which inhibits human thrombin and which has structure (A), such as formula (a).",MERCK & CO INC;;FRALEY MARK E;;HUNGATE RANDALL W;;NAYLOR OLSEN ADEL M;;VACCA JOSEPH P,FRALEY MARK E;;HUNGATE RANDALL W;;NAYLOR-OLSEN ADEL M;;VACCA JOSEPH P,,https://lens.org/122-708-677-985-217,Patent Application,yes,5,1,12,14,0,C07D213/74;;C07D405/12;;A61P43/00;;A61P7/02,A61K31/4409;;A61K31/4433;;A61P7/02;;A61P43/00;;C07D213/74;;C07D405/12,,0,0,,,,PATENTED
148,US,B2,US 10279154 B2,199-818-028-000-554,2019-05-07,2019,US 201715668657 A,2017-08-03,US 201715668657 A;;US 201715432818 A;;US 201615289790 A;;US 201615195139 A;;US 201615065766 A;;US 201514929066 A;;US 201562156152 P;;US 201562142895 P;;US 201462073766 P,2014-10-31,Methods and systems for treating hydrocephalus,"Methods for treating hydrocephalus using a shunt, the shunt having one or more CSF intake openings in a distal portion, a valve disposed in a proximal portion of the shunt, and a lumen extending between the one or more CSF intake openings and the valve, the method comprises deploying the shunt in a body of a patient so that the distal portion of the shunt is at least partially disposed within a CP angle cistern, a body of the shunt is at least partially disposed within an IPS of the patient, and the proximal portion of the shunt is at least partially disposed within or proximate to a JV of the patient, wherein, after deployment of the shunt, CSF flows from the CP angle cistern to the JV via the shunt lumen at a flow rate in a range of 5 ml per hour to 15 ml per hour.",CEREVASC LLC,HEILMAN CARL;;MALEK ADEL M;;REZAC DAVID A;;ROBINSON TIMOTHY W;;TING JOSEPH,CEREVASC INC (2015-05-12),https://lens.org/199-818-028-000-554,Granted Patent,yes,225,9,30,30,0,A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M27/006;;A61M39/24;;A61M2210/06;;A61M2039/2426;;A61M2039/242;;A61M27/006;;A61B17/3401;;A61B17/3478;;A61M27/006;;A61B6/12;;A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M25/10;;A61M39/24;;A61M2039/242;;A61B34/20;;A61B18/14;;A61B2018/1425;;A61B18/1477;;A61B2018/00446;;A61B2018/00619;;A61M2210/06;;A61B18/1492;;A61M2039/2426,A61M27/00;;A61B6/12;;A61B18/00;;A61B18/14;;A61B34/20;;A61M25/00;;A61M25/01;;A61M25/09;;A61M25/10;;A61M39/24,,17,0,,,"PCT International Search Report and Written Opinion for International Appln. No. PCT/US2017/056227, Applicant Cerevasc, LLC, Forms PCT/ISA/210, 220, and 237, dated Mar. 29, 2018 (24 pages).;;Non-Final Office Action for U.S. Appl. No. 15/862,120, dated Apr. 19, 2018.;;Amendment Response to Office Action for U.S. Appl. No. 15/862,120 dated May 1, 2018.;;Supplemental Amendment for U.S. Appl. No. 15/862,120 dated May 7, 2018.;;PCT Invitation to Pay Additional Fees for International Appln. No. PCT/US2018/020667, dated May 29, 2018 (17 pages).;;PCT International Search Report and Written Opinion for International Application No. PCT/2015/011317, Applicant Tufts Medical Center, Inc., Forms PCT/ISA/210, 220, and 237, dated Mar. 26, 2015 (15 pages).;;Non-Final Office Action for U.S. Appl. No. 14/179,622, dated May 13, 2015 (13 pages).;;PCT Notification of Transmittal of the International Search Report and Written Opinion, dated Feb. 17, 2016, for PCT/US2015/058505, Applicant CereVasc, LLC., international filing date Oct. 30, 2015 (16 pages).;;Non-Final Office Action for U.S. Appl. No. 14/596,335, dated Jul. 7, 2016 (16 pages).;;PCT International Search Report and Written Opinion for International Appln. No. PCT/US2016/069280, applicant Cerevasc, LLC, dated Mar. 27, 2017 (80 pages).;;Non-Final Office Action for U.S. Appl. No. 15/294,000, dated Feb. 16, 2017 (26 pages).;;Final Office Action for U.S. Appl. No. 14/596,335, dated Oct. 26, 2016 (19 pages).;;Interview Summary for U.S. Appl. No. 14/596,335, dated Oct. 11, 2016 (3 pages).;;PCT International Search Report and Written Opinion for International Appln. No. PCT/US2018/020667, dated Aug. 1, 2018 (21 pages).;;PCT Notification of Transmittal of the International Search Report and Written Opinion of the I.S.A. for PCT/US2016/0595952, dated Jan. 20, 2017, 14 pages.;;Notice of Allowance dated Dec. 14, 2018 for U.S. Appl. No. 15/745,961.;;European Office Action for EP Appln. No. 15791220.5 dated Jan. 25, 2019 (6 pages).",ACTIVE
149,EP,A4,EP 4088284 A4,005-740-090-040-909,2024-01-17,2024,EP 22723958 A,2022-02-18,US 202163165078 P;;IB 2022000096 W,2021-03-23,"DEVICES, SYSTEMS, AND METHODS FOR MONITORING FLUID INTAKE, HEALTHCARE GAMIFICATION, AND HEALTH PREDICTION",,CME FZ LLC;;CME OFFSHORE SAL,TRAD JAD MOUNIR;;HASSAN BASSEL ADEL;;YOUSSEF WISSAM MICHEL;;WAKIM ELIE JOSEPH;;OLLEIK ALI,,https://lens.org/005-740-090-040-909,Search Report,no,4,0,4,4,0,A47G23/16;;G01F3/00;;G01F15/0755;;A47G19/2227;;A47G23/16;;A61B5/4875;;G01F15/068,G16H10/60;;A47G19/22;;A61B5/00;;G16H50/20;;G16H50/30,,1,0,,,See also references of WO 2022200855A1,PENDING
150,EP,A1,EP 0614291 A1,027-138-852-228-681,1994-09-07,1994,EP 94301120 A,1994-02-16,US 2465593 A,1993-03-01,All-optical network architecture.,"There is disclosed the architecture for an all-optical network which employs a three level hierarchy using wavelength division multiplexing. At the lowest level of the hierarchy are Level-0 all-optical networks (36, 37, 38, 39). The Level-0 networks are ""local"" broadcast networks each of which supports a plurality of access ports and in which each access port can ""hear"" all the local traffic transmitted by all other access ports in the same Level-0 network. Each Level-0 network shares wavelengths internally, but there is extensive reuse of wavelengths among different Level-0 networks. The next higher level (62, 64), which is the intermediate level, Level-1, is essentially a wavelength router coupled with one or more of the Level-0 networks to provide a wavelength path to one or more directly connected Level-0 networks or, in combination with a Level-2 network (80), a light path to one or more Level-0 networks outside itself. The Level-2 are second level wavelength routing networks which provide light paths, as opposed to wavelength paths, between Level-1 networks. The Level-2 networks may be as simple as fiber trunks alone or they may employ frequency changing devices in addition to wavelength routers and/or spatial switches.",AT & T CORP;;DIGITAL EQUIPMENT CORP;;MASSACHUSETTS INST TECHNOLOGY,CHAN VINCENT W S;;GALLAGER ROBERT G;;KIRBY ALAN JOSEPH;;SALEH ADEL ABDEL MONEIM,,https://lens.org/027-138-852-228-681,Patent Application,yes,2,22,3,3,0,H04J14/0227;;H04J14/028;;H04J14/0282;;H04Q11/0001;;H04J14/0238;;H04J14/0241;;H04J14/0228;;H04Q11/0001;;H04J14/028;;H04J14/0282;;H04J14/0227;;H04J14/0241;;H04J14/0238;;H04J14/0228,H04B10/27;;H04B10/272;;H04B10/278;;H04J14/02;;H04Q11/00,,1,0,,,"HAYES ET AL: ""Local optical distribution"", PROCEEDINGS OF THE CONFERENCE ON COMPUTER COMMUNICATIONS (INFOCOM), May 1992 (1992-05-01), NEW YORK, US, pages 68 - 74, XP000300047, DOI: doi:10.1109/INFCOM.1992.263570",DISCONTINUED
151,US,A1,US 2022/0312997 A1,047-317-240-867-262,2022-10-06,2022,US 202217685241 A,2022-03-02,US 202217685241 A;;US 202163165078 P,2021-03-23,"DEVICES, SYSTEMS, AND METHODS FOR MONITORING FLUID INTAKE, HEALTHCARE GAMIFICATION, AND HEALTH PREDICTION","Devices, systems, and methods are provided for monitoring water or other fluid consumption. For example, a fluid intake measurement device may provide highly accurate fluid consumption, which can be directly attached to a variety of fluid containers. The systems and methods herein also relate to the application of game psychology and mechanics to predict potential health issues and drive behavioral change for a healthier lifestyle and/or support motivational techniques for better healthcare conduct.",CME OFFSHORE SAL,YOUSSEF WISSAM MICHEL;;TRAD JAD MOUNIR;;HASSAN BASSEL ADEL;;WAKIM ELIE JOSEPH;;OLLEIK ALI,,https://lens.org/047-317-240-867-262,Patent Application,yes,0,0,4,4,0,A47G23/16;;G01F3/00;;G01F15/0755;;A47G19/2227;;A47G23/16;;A61B5/4875;;G01F15/068,A47G23/16;;A61B5/00;;G01F15/06,,0,0,,,,PENDING
152,US,B1,US 6686420 B1,160-688-726-977-217,2004-02-03,2004,US 32443802 A,2002-12-19,US 32443802 A,2002-12-19,Pneumatic tire having a component containing high trans styrene-isoprene-butadiene rubber,"
    The invention is directed to a pneumatic tire having at least one component comprising a vulcanizable rubber composition, wherein the vulcanizable rubber composition comprises, based on 100 parts by weight of elastomer (phr), from about 30 to 100 phr of high trans random SIBR, and from about zero to about 70 phr of at least one additional elastomer, wherein the high trans random SIBR comprises from about 3 to about 30 percent by weight of styrene. 
",GOODYEAR TIRE & RUBBER,ZANZIG DAVID JOHN;;HALASA ADEL FARHAN;;ZUPPO III JOHN ROBERT;;VERTHE JOHN JOSEPH ANDRE,GOODYEAR TIRE & RUBBER COMPANY THE (2003-04-24),https://lens.org/160-688-726-977-217,Granted Patent,yes,4,2,1,1,0,C08L9/06;;C08L9/06;;C08L21/00;;C08L21/00,C08L9/06;;C08L21/00,525/332.9;;526/173;;526/335;;526/337;;526/340;;526/347;;525/241;;525/331.9;;525/332.8;;525/342;;525/365;;525/367,0,0,,,,EXPIRED
153,EP,A1,EP 4088284 A1,053-284-730-106-641,2022-11-16,2022,EP 22723958 A,2022-02-18,US 202163165078 P;;IB 2022000096 W,2021-03-23,"DEVICES, SYSTEMS, AND METHODS FOR MONITORING FLUID INTAKE, HEALTHCARE GAMIFICATION, AND HEALTH PREDICTION",,CME FZ LLC;;CME OFFSHORE SAL,TRAD JAD MOUNIR;;HASSAN BASSEL ADEL;;YOUSSEF WISSAM MICHEL;;WAKIM ELIE JOSEPH;;OLLEIK ALI,,https://lens.org/053-284-730-106-641,Patent Application,yes,0,0,4,4,0,A47G23/16;;G01F3/00;;G01F15/0755;;A47G19/2227;;A47G23/16;;A61B5/4875;;G01F15/068,G16H10/60;;A61B5/00;;G16H50/20;;G16H50/30,,0,0,,,,PENDING
154,US,A1,US 2016/0229918 A1,192-304-752-515-791,2016-08-11,2016,US 201414904312 A,2014-07-11,US 201414904312 A;;US 201361845155 P;;US 2014/0046424 W,2013-07-11,TUMOR SELECTIVE ANTIBODIES SPECIFIC TO ONCOFETAL ANTIGEN/IMMATURE LAMININ RECEPTOR PROTEIN,"Disclosed are high affinity antibodies or antigen binding fragments thereof, which bind an epitope that lies within the C terminal region of oncofetal antigen (OFA)/immature laminin receptor protein (iLRP), and which do not substantially cross-react with mature OFA/LRP. The antibodies may be conjugated to cytotoxic moieties to enhance their therapeutic efficacy. Methods of making the antibodies and therapeutic and diagnostic uses thereof are also disclosed.",BENOVUS BIO INC;;SOUTH ALABAMA MEDICAL SCIENCE FOUND,JOHNSON KENT J;;MORGAN ALTON C;;SINKULE JOSEPH A;;VARANI JAMES;;COGGIN JOSEPH H;;ROHRER JAMES W;;BARSOUM ADEL L,,https://lens.org/192-304-752-515-791,Patent Application,yes,0,0,5,5,70,A61K2039/505;;C07K2317/33;;C07K2317/34;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/30;;A61P35/00;;A61P35/04;;C07K2317/34;;C07K2317/73;;C07K2317/92;;A61K2039/505;;C07K2317/76;;C07K2317/33;;C07K16/30;;C07K16/3061;;C07K2317/20;;C07K2317/565;;G01N33/57426;;G01N2333/705;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3046;;C07K16/3069;;G01N33/57476,G01N33/574;;C07K16/30,,0,0,,,,DISCONTINUED
155,US,A1,US 2015/0218287 A1,126-386-138-483-011,2015-08-06,2015,US 201514614331 A,2015-02-04,US 201514614331 A;;US 2014/0046424 W;;US 201361845155 P,2013-07-11,TUMOR SELECTIVE ANTIBODIES SPECIFIC TO ONCOFETAL ANTIGEN/IMMATURE LAMININ RECEPTOR PROTEIN,"Disclosed are high affinity antibodies or antigen-binding fragments thereof, which bind an epitope that lies within the C-terminal region of oncofetal antigen (OFA)/immature laminin receptor protein (iLRP), and which do not substantially cross-react with mature OFA/LRP. The antibodies may be conjugated to cytotoxic moieties to enhance their therapeutic efficacy. Methods of making the antibodies and therapeutic and diagnostic uses thereof are also disclosed.",BENOVUS BIO INC;;UNIV SOUTH ALABAMA,JOHNSON KENT J;;MORGAN ALTON C;;SINKULE JOSEPH A;;VARANI JAMES;;COGGIN JR JOSEPH H;;ROHRER JAMES W;;BARSOUM ADEL L,,https://lens.org/126-386-138-483-011,Patent Application,yes,0,2,5,5,70,A61K2039/505;;C07K2317/33;;C07K2317/34;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/30;;A61P35/00;;A61P35/04;;C07K2317/34;;C07K2317/73;;C07K2317/92;;A61K2039/505;;C07K2317/76;;C07K2317/33;;C07K16/30;;C07K16/3061;;C07K2317/20;;C07K2317/565;;G01N33/57426;;G01N2333/705;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3046;;C07K16/3069;;G01N33/57476,G01N33/574;;C07K16/30,,1,1,001-870-890-004-842,10.1080/15384047.2015.1026484;;25799942;;pmc4622506,McClintock et al. (Cancer Biol. Ther. 16:724-732 (2015); Abstract),DISCONTINUED
156,WO,A3,WO 2015/017113 A3,003-070-656-253-549,2015-04-09,2015,US 2014/0046424 W,2014-07-11,US 201361845155 P,2013-07-11,TUMOR SELECTIVE ANTIBODIES SPECIFIC TO ONCOFETAL ANTIGEN / IMMATURE LAMININ RECEPTOR PROTEIN,"Disclosed are high affinity antibodies or antigen binding fragments thereof, which bind an epitope that lies within the C terminal region of oncofetal antigen (OFA)/immature laminin receptor protein (iLRP), and which do not substantially cross-react with mature OFA/LRP. The antibodies may be conjugated to cytotoxic moieties to enhance their therapeutic efficacy. Methods of making the antibodies and therapeutic and diagnostic uses thereof are also disclosed.",BENOVUS BIO INC;;UNIV SOUTH ALABAMA,JOHNSON KENT J;;MORGAN ALTON C;;VARANI JAMES;;ROHRER JAMES W;;BARSOUM ADEL L;;SINKULE JOSEPH A;;COGGIN JOSEPH H JR,,https://lens.org/003-070-656-253-549,Search Report,yes,1,0,5,5,0,A61K2039/505;;C07K2317/33;;C07K2317/34;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/30;;A61P35/00;;A61P35/04;;C07K2317/34;;C07K2317/73;;C07K2317/92;;A61K2039/505;;C07K2317/76;;C07K2317/33;;C07K16/30;;C07K16/3061;;C07K2317/20;;C07K2317/565;;G01N33/57426;;G01N2333/705;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3046;;C07K16/3069;;G01N33/57476,A61K39/00;;C07K16/28;;A61P35/00;;A61P35/04;;C07K16/30,,2,1,081-222-251-281-305,12869512;;10.1182/blood-2003-01-0198,"ROHRER J W ET AL: ""Development of a new universal tumor rejection antigen expressed on hu"", MODERN ASPECTS OF IMMUNOBIOLOGY, XX, XX, vol. 1, no. 5, 1 January 2001 (2001-01-01), pages 191 - 195, XP008080480;;SANDRA SIEGEL ET AL: ""Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies"", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 102, no. 13, 15 December 2003 (2003-12-15), pages 4416 - 4423, XP007911735, ISSN: 0006-4971, [retrieved on 20030717], DOI: 10.1182/BLOOD-2003-01-0198",PENDING
157,WO,A9,WO 2015/017113 A9,003-364-364-388-234,2015-06-25,2015,US 2014/0046424 W,2014-07-11,US 201361845155 P,2013-07-11,TUMOR SELECTIVE ANTIBODIES SPECIFIC TO ONCOFETAL ANTIGEN / IMMATURE LAMININ RECEPTOR PROTEIN,"Disclosed are high affinity antibodies or antigen binding fragments thereof, which bind an epitope that lies within the C terminal region of oncofetal antigen (OFA)/immature laminin receptor protein (iLRP), and which do not substantially cross-react with mature OFA/LRP. The antibodies may be conjugated to cytotoxic moieties to enhance their therapeutic efficacy. Methods of making the antibodies and therapeutic and diagnostic uses thereof are also disclosed.",BENOVUS BIO INC;;UNIV SOUTH ALABAMA,JOHNSON KENT J;;MORGAN ALTON C;;VARANI JAMES;;ROHRER JAMES W;;BARSOUM ADEL L;;SINKULE JOSEPH A;;COGGIN JOSEPH H JR,,https://lens.org/003-364-364-388-234,Search Report,yes,0,0,5,5,0,A61K2039/505;;C07K2317/33;;C07K2317/34;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/30;;A61P35/00;;A61P35/04;;C07K2317/34;;C07K2317/73;;C07K2317/92;;A61K2039/505;;C07K2317/76;;C07K2317/33;;C07K16/30;;C07K16/3061;;C07K2317/20;;C07K2317/565;;G01N33/57426;;G01N2333/705;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3046;;C07K16/3069;;G01N33/57476,C07K16/28;;A61K39/00;;A61P35/00;;A61P35/04;;C07K16/30,,0,0,,,,PENDING
158,EP,A1,EP 1593529 A1,082-870-456-892-806,2005-11-09,2005,EP 05103530 A,2005-04-28,US 83774004 A;;US 85952404 A,2004-05-03,Natural rubber-rich composition and tire with tread thereof,"This invention relates to a natural rubber-rich rubber composition and tire with a tread thereof. A partial replacement of the natural rubber in the natural rubber-rich tire tread is accomplished by an inclusion of a specialized trans 1,4-styrene/butadiene copolymer rubber characterized by having a combination of bound styrene content and microstructure limitations. The tire tread rubber composition is comprised of a blend of the specialized trans 1,4-styrene/butadiene rubber and cis 1,4-polyisoprene natural rubber optionally together with at least one additional diene-based elastomer in which the natural rubber remains a major portion of the elastomers in the tread rubber composition. The specialized trans 1,4-styrene/butadiene rubber has a bound styrene content in a range of from 15 to 35 percent and a microstructure of its polybutadiene portion composed of from 50 to 80 percent trans 1,4-isomeric units, from 10 to 20 percent cis 1,4- isomeric units and from 2 to 10 percent vinyl 1,2- isomeric units.",GOODYEAR TIRE & RUBBER,SANDSTROM PAUL HARRY;;HALASA ADEL FARHAN;;HSU WEN-LIANG;;VERTHE JOHN JOSEPH ANDRE;;JASIUNAS CHAD AARON,,https://lens.org/082-870-456-892-806,Patent Application,yes,4,0,8,14,0,B60C1/0016;;C08K5/548;;C08L7/00;;C08L9/00;;C08L9/06;;C08L21/00;;C08K3/013,B60C1/00;;C08K3/00;;C08K5/548;;C08L7/00;;C08L9/00;;C08L9/06;;C08L21/00,,0,0,,,,ACTIVE
159,JP,A,JP 2005344111 A,152-231-906-564-41X,2005-12-15,2005,JP 2005146500 A,2005-05-19,US 85952404 A,2004-06-02,TIRE HAVING TREAD OF RUBBER COMPOSITION HAVING HIGH NATURAL RUBBER CONTENT,"<P>PROBLEM TO BE SOLVED: To provide a rubber composition having the nearly same physical characteristics by substituting a part of a natural cis-1,4-polyisoprene rubber with a synthetic polymer or a synthetic elastomer in a rubber composition for a tire tread, having high natural rubber content. <P>SOLUTION: The substitution of the natural rubber in the tire tread having the high natural rubber content is achieved by the incorporation of a specified trans-1,4-styrene/butadiene copolymer rubber characterized by the combination of a restriction condition of bonding styrene content and a restriction condition of microstructure. The tire tread rubber composition contains both of a blend of the specified trans-1,4-styrene/butadiene rubber and the cis-1,4-polyisoprene natural rubber, and at least one kind of an additional diene-based elastomer, while allowing the natural rubber to occupy the majority amount of the elastomer in the tread rubber composition. <P>COPYRIGHT: (C)2006,JPO&NCIPI",GOODYEAR TIRE & RUBBER,SANDSTROM PAUL HARRY;;HALASA ADEL FARHAN;;HSU WEN-LIANG;;VERTHE JOHN JOSEPH ANDRE;;JASIUNAS CHAD AARON,,https://lens.org/152-231-906-564-41X,Patent Application,no,3,5,4,14,0,B60C1/0016;;C08K3/04;;C08K3/36;;C08L7/00;;C08L9/06;;C08L21/00;;C08L7/00;;C08K3/36;;B60C1/0016;;C08L9/06;;C08L21/00;;C08K3/04,C08F4/56;;C08K3/04;;C08K3/36;;C08L7/00;;C08L9/06;;C08L21/00;;B60C1/00,,0,0,,,,PENDING
160,WO,A2,WO 2015/017113 A2,058-911-661-395-364,2015-02-05,2015,US 2014/0046424 W,2014-07-11,US 201361845155 P,2013-07-11,TUMOR SELECTIVE ANTIBODIES SPECIFIC TO ONCOFETAL ANTIGEN / IMMATURE LAMININ RECEPTOR PROTEIN,"Disclosed are high affinity antibodies or antigen binding fragments thereof, which bind an epitope that lies within the C terminal region of oncofetal antigen (OFA)/immature laminin receptor protein (iLRP), and which do not substantially cross-react with mature OFA/LRP. The antibodies may be conjugated to cytotoxic moieties to enhance their therapeutic efficacy. Methods of making the antibodies and therapeutic and diagnostic uses thereof are also disclosed.",BENOVUS BIO INC;;UNIV SOUTH ALABAMA,JOHNSON KENT J;;MORGAN ALTON C;;VARANI JAMES;;ROHRER JAMES W;;BARSOUM ADEL L;;SINKULE JOSEPH A;;COGGIN JOSEPH H JR,,https://lens.org/058-911-661-395-364,Patent Application,yes,0,1,5,5,0,A61K2039/505;;C07K2317/33;;C07K2317/34;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/30;;A61P35/00;;A61P35/04;;C07K2317/34;;C07K2317/73;;C07K2317/92;;A61K2039/505;;C07K2317/76;;C07K2317/33;;C07K16/30;;C07K16/3061;;C07K2317/20;;C07K2317/565;;G01N33/57426;;G01N2333/705;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3046;;C07K16/3069;;G01N33/57476,A61K39/395,,0,0,,,,PENDING
161,US,A1,US 2019/0154910 A1,041-693-564-141-645,2019-05-23,2019,US 201716094244 A,2017-03-17,US 201716094244 A;;US 201662324785 P;;EP 2017056338 W,2016-04-19,BROAD SPECTRUM RADIATION BY SUPERCONTINUUM GENERATION USING A TAPERED OPTICAL FIBER,"A measurement apparatus, including: a tapered optical fiber, the tapered optical fiber having an input to receive radiation and having an output to provide spectrally broadened output radiation toward a measurement target, the tapered optical fiber configured to spectrally broaden the radiation received at the input; and a detector system configured to receive a redirected portion of the output radiation from the measurement target.",ASML HOLDING NV,LEUNG KING PUI;;CHEN TAO;;HAVELIN JAMES RONAN;;AARTS IGOR MATHEUS PETRONELLA;;JOOBEUR ADEL;;CARBONE JOSEPH,ASML HOLDING N.V (2015-04-26),https://lens.org/041-693-564-141-645,Patent Application,yes,3,3,15,15,0,G02F1/365;;G03F9/7065;;G01B11/02;;G01B2210/56;;G02F1/3528;;G03F9/7065;;G02F1/365;;G02B6/02004;;G01B2210/56;;G02B6/29377;;G02B6/2746;;G02F1/3528;;G02B6/1228;;G01B11/02;;G02F1/365;;G03F7/7055;;G03F9/7065;;G02F1/365;;G03F9/7065;;G01B2210/56;;G01B11/02;;G02F1/3528;;G02B6/02004;;G02B6/1228;;G02B6/2746;;G02B6/29377,G02B6/02;;G02B6/122;;G02B6/27;;G02B6/293;;G02F1/365,,1,1,042-390-036-026-836,18066233;;10.1364/ol.25.001415,"Birks Supercontinuum generation in tapered fibers; Optics Letters, October 2000, Vol. 25, no 19, pp. 1415-1417",ACTIVE
162,NL,A,NL 2018536 A,035-080-596-101-841,2017-10-31,2017,NL 2018536 A,2017-03-17,US 201662324785 P,2016-04-19,BROAD SPECTRUM RADIATION BY SUPERCONTINUUM GENERATION USING A TAPERED OPTICAL FIBER,"A measurement apparatus, including: a tapered optical fiber, the tapered optical fiber having an input to receive radiation and having an output to provide spectrally broadened output radiation toward a measurement target, the tapered optical fiber configured to spectrally broaden the radiation received at the input; and a detector system configured to receive a redirected portion of the output radiation from the measurement target.",ASML HOLDING NV,KING PUI LEUNG;;TAO CHEN;;RONAN JAMES HAVELIN;;IGOR MATHEUS PETRONELLA AARTS;;ADEL JOOBEUR;;JOSEPH CARBONE,,https://lens.org/035-080-596-101-841,Patent Application,no,0,0,15,15,0,G02F1/365;;G03F9/7065;;G01B11/02;;G01B2210/56;;G02F1/3528;;G03F9/7065;;G02F1/365;;G02B6/02004;;G01B2210/56;;G02B6/29377;;G02B6/2746;;G02F1/3528;;G02B6/1228;;G01B11/02;;G02F1/365;;G03F7/7055;;G03F9/7065;;G02F1/365;;G03F9/7065;;G01B2210/56;;G01B11/02;;G02F1/3528;;G02B6/02004;;G02B6/1228;;G02B6/2746;;G02B6/29377,G03F7/20,,0,0,,,,PENDING
163,WO,A1,WO 2017/182204 A1,040-570-869-498-382,2017-10-26,2017,EP 2017056338 W,2017-03-17,US 201662324785 P,2016-04-19,BROAD SPECTRUM RADIATION BY SUPERCONTINUUM GENERATION USING A TAPERED OPTICAL FIBER,"A measurement apparatus, including: a tapered optical fiber, the tapered optical fiber having an input to receive radiation and having an output to provide spectrally broadened output radiation toward a measurement target, the tapered optical fiber configured to spectrally broaden the radiation received at the input; and a detector system configured to receive a redirected portion of the output radiation from the measurement target.",ASML HOLDING NV,LEUNG KING PUI;;CHEN TAO;;HAVELIN RONAN JAMES;;AARTS IGOR MATHEUS PETRONELLA;;JOOBEUR ADEL;;CARBONE JOSEPH,,https://lens.org/040-570-869-498-382,Patent Application,yes,9,2,15,15,0,G02F1/365;;G03F9/7065;;G01B11/02;;G01B2210/56;;G02F1/3528;;G03F9/7065;;G02F1/365;;G02B6/02004;;G01B2210/56;;G02B6/29377;;G02B6/2746;;G02F1/3528;;G02B6/1228;;G01B11/02;;G02F1/365;;G03F7/7055;;G03F9/7065;;G02F1/365;;G03F9/7065;;G01B2210/56;;G01B11/02;;G02F1/3528;;G02B6/02004;;G02B6/1228;;G02B6/2746;;G02B6/29377,G03F9/00;;G02F1/365,,0,0,,,,PENDING
164,BR,A,BR PI0502260 A,120-683-145-793-571,2006-01-24,2006,BR PI0502260 A,2005-05-30,US 85952404 A,2004-06-02,Composição rica em borracha natural e pneu com banda de rodagem dessa composição,"""COMPOSIçãO RICA EM BORRACHA NATURAL E PNEU COM BANDA DE RODAGEM DESSA COMPOSIçãO"". Esta invenção se refere a uma composição de borracha rica em borracha natural e a um pneu com banda de rodagem dessa composição. Uma substituição parcial da borracha natural na banda de rodagem de pneu rica em borracha natural é realizada pela inclusão de uma borracha copolimérica de trans 1,4-estireno/butadieno especializada, caracterizada por ter uma combinação de teor de estireno ligado e limitações de microestrutura. A composição de borracha para banda de rodagem de pneus é composta por uma mescla da borracha de trans 1,4-estireno/butadieno especializada e borracha natural de cis 1,4-poliisopreno, opcionalmente com pelo menos um elastómero à base de dieno adicional, em que a borracha natural permanece como a maior parte dos elastómeros na composição de borracha para banda de rodagem. Um aspecto significativo da invenção é uma substituição parcial da borracha de cis 1,4-poliisopreno natural na composição de borracha para banda de rodagem. A borracha de trans 1,4-estireno/butadieno especializada tem um teor de estireno ligado na faixa de 15 a 35 por cento e uma microestrutura de sua parte polibutadieno composta por 50 a 80 por cento de unidades isoméricas trans 1,4, 10 a 20 por cento de unidades isoméricas cis 1,4 e 2 a 10 por cento de unidades isoméricas vinila 1, 2; de preferência, um valor de viscosidade Mooney (ML1+4) a 100<198>C na faixa de 50 a 100, alternativamente de 50 a 85 e, de preferência, uma temperatura de transição de vidro (Tg) na faixa de -60<198>C a -90<198>C.",GOODYEAR TIRE & RUBBER,SANDSTROM PAUL HARRY;;HALASA ADEL FARHAN;;HSU WEN-LIANG;;VERTHE JOHN JOSEPH ANDRE;;JASIUNAS CHAD AARON,,https://lens.org/120-683-145-793-571,Patent Application,no,0,0,4,14,0,B60C1/0016;;C08K3/04;;C08K3/36;;C08L7/00;;C08L9/06;;C08L21/00;;C08L7/00;;C08K3/36;;B60C1/0016;;C08L9/06;;C08L21/00;;C08K3/04,B60C1/00;;C08F4/56;;C08K3/04;;C08K3/36;;C08L7/00;;C08L9/06;;C08L21/00,,0,0,,,,DISCONTINUED
165,KR,A,KR 20180133466 A,044-592-720-872-084,2018-12-14,2018,KR 20187032238 A,2017-03-17,US 201662324785 P;;EP 2017056338 W,2016-04-19,테이퍼드 광섬유를 이용한 초연속체 발생에 의한 광폭 스펙트럼 방사선,"방사선을 수신하기 위한 입력을 가지며 측정 타겟을 향해 스펙트럼 확장된 출력 방사선을 제공하기 위한 출력을 갖는 테이퍼드(tapered) 광섬유로서, 상기 입력에서 수신된 방사선을 스펙트럼 확장시키도록 구성된 상기 테이퍼드 광섬유; 및 상기 측정 타겟으로부터 상기 출력 방사선의 재지향된 부분을 수신하도록 구성된 검출기 시스템을 포함하는, 측정 장치.",ASML HOLDING NV,LEUNG KING PUI;;CHEN TAO;;HAVELIN RONAN JAMES;;AARTS IGOR MATHEUS PETRONELLA;;JOOBEUR ADEL;;CARBONE JOSEPH,,https://lens.org/044-592-720-872-084,Patent Application,no,2,0,15,15,0,G02F1/365;;G03F9/7065;;G01B11/02;;G01B2210/56;;G02F1/3528;;G03F9/7065;;G02F1/365;;G02B6/02004;;G01B2210/56;;G02B6/29377;;G02B6/2746;;G02F1/3528;;G02B6/1228;;G01B11/02;;G02F1/365;;G03F7/7055;;G03F9/7065;;G02F1/365;;G03F9/7065;;G01B2210/56;;G01B11/02;;G02F1/3528;;G02B6/02004;;G02B6/1228;;G02B6/2746;;G02B6/29377,G02F1/365;;G03F7/20;;G03F9/00,,0,0,,,,ACTIVE
166,EP,A1,EP 3446181 A1,058-760-030-244-10X,2019-02-27,2019,EP 17712441 A,2017-03-17,US 201662324785 P;;EP 2017056338 W,2016-04-19,BROAD SPECTRUM RADIATION BY SUPERCONTINUUM GENERATION USING A TAPERED OPTICAL FIBER,,ASML HOLDING NV,LEUNG KING PUI;;CHEN TAO;;HAVELIN RONAN JAMES;;AARTS IGOR MATHEUS PETRONELLA;;JOOBEUR ADEL;;CARBONE JOSEPH,,https://lens.org/058-760-030-244-10X,Patent Application,yes,0,0,15,15,0,G02F1/365;;G03F9/7065;;G01B11/02;;G01B2210/56;;G02F1/3528;;G03F9/7065;;G02F1/365;;G02B6/02004;;G01B2210/56;;G02B6/29377;;G02B6/2746;;G02F1/3528;;G02B6/1228;;G01B11/02;;G02F1/365;;G03F7/7055;;G03F9/7065;;G02F1/365;;G03F9/7065;;G01B2210/56;;G01B11/02;;G02F1/3528;;G02B6/02004;;G02B6/1228;;G02B6/2746;;G02B6/29377,G03F9/00;;G02F1/365,,0,0,,,,PENDING
167,DE,D1,DE 602005001969 D1,142-119-648-857-363,2007-09-27,2007,DE 602005001969 T,2005-04-28,US 85952404 A;;US 83774004 A,2004-05-03,Naturkautschukreiche Zusammensetzung und Reifen mit daraus hergestellter Lauffläche,,GOODYEAR TIRE & RUBBER,SANDSTROM PAUL HARRY;;HALASA ADEL FARHAN;;HSU WEN-LIANG;;VERTHE JOHN JOSEPH ANDRE;;JASIUNAS CHAD AARON,,https://lens.org/142-119-648-857-363,Granted Patent,no,0,0,8,14,0,B60C1/0016;;C08K3/013;;C08K5/548;;C08L7/00;;C08L9/00;;C08L9/06;;C08L21/00,B60C1/00;;C08K3/00;;C08K5/548;;C08L7/00;;C08L9/00;;C08L9/06;;C08L21/00,,0,0,,,,ACTIVE
168,US,A1,US 2021/0033779 A1,043-010-272-748-709,2021-02-04,2021,US 202017066524 A,2020-10-09,US 202017066524 A;;US 201816094244 A;;EP 2017056338 W;;US 201662324785 P,2016-04-19,BROAD SPECTRUM RADIATION BY SUPERCONTINUUM GENERATION USING A TAPERED OPTICAL FIBER,"A measurement apparatus, including: a tapered optical fiber, the tapered optical fiber having an input to receive radiation and having an output to provide spectrally broadened output radiation toward a measurement target, the tapered optical fiber configured to spectrally broaden the radiation received at the input; and a detector system configured to receive a redirected portion of the output radiation from the measurement target.",ASML HOLDING NV,LEUNG KING PUI;;CHEN TAO;;HAVELIN RONAN JAMES;;AARTS IGOR MATHEUS PETRONELLA;;JOOBEUR ADEL;;CARBONE JOSEPH,ASML HOLDING N.V (2016-04-26),https://lens.org/043-010-272-748-709,Patent Application,yes,2,0,15,15,0,G02F1/365;;G03F9/7065;;G01B11/02;;G01B2210/56;;G02F1/3528;;G03F9/7065;;G02F1/365;;G02B6/02004;;G01B2210/56;;G02B6/29377;;G02B6/2746;;G02F1/3528;;G02B6/1228;;G01B11/02;;G02F1/365;;G03F7/7055;;G03F9/7065;;G02F1/365;;G03F9/7065;;G01B2210/56;;G01B11/02;;G02F1/3528;;G02B6/02004;;G02B6/1228;;G02B6/2746;;G02B6/29377,G02B6/02;;G01B11/02;;G02B6/122;;G02B6/27;;G02B6/293;;G02F1/365;;G03F9/00,,0,0,,,,ACTIVE
169,DE,T2,DE 602005001969 T2,186-263-597-620-579,2008-05-15,2008,DE 602005001969 T,2005-04-28,US 85952404 A;;US 83774004 A,2004-05-03,Naturkautschukreiche Zusammensetzung und Reifen mit daraus hergestellter Lauffläche,,GOODYEAR TIRE & RUBBER,SANDSTROM PAUL HARRY;;HALASA ADEL FARHAN;;HSU WEN-LIANG;;VERTHE JOHN JOSEPH ANDRE;;JASIUNAS CHAD AARON,,https://lens.org/186-263-597-620-579,Granted Patent,no,0,0,8,14,0,B60C1/0016;;C08K3/013;;C08K5/548;;C08L7/00;;C08L9/00;;C08L9/06;;C08L21/00,B60C1/00;;C08K3/00;;C08K5/548;;C08L7/00;;C08L9/00;;C08L9/06;;C08L21/00,,0,0,,,,ACTIVE
170,CN,A,CN 109606312 A,121-775-485-922-522,2019-04-12,2019,CN 201811123337 A,2018-09-26,US 201715723514 A,2017-10-03,VEHICLE COMPONENT OPERATION,"A system includes a computer including a processor and a memory, the memory including instructions executable by the processor to detect a service controller connected to a vehicle, upon authenticating the service controller, receive an operation mode for a vehicle component from the service controller, and actuate the vehicle component within operating limits based on the operation mode.",FORD GLOBAL TECH LLC,STANEK JOSEPH F;;RHODE DOUGLAS SCOTT;;NAHLE WASSIM MAHMOUD;;AWAD ALLA MICHAEL ADEL;;HANSEN CHERI LYN,,https://lens.org/121-775-485-922-522,Patent Application,no,0,0,4,4,0,B60R25/01;;B60R25/10;;B60R25/20;;G07C9/00174;;G07C9/00571;;H04L67/12;;H04L63/0823;;G05D1/0088;;G05D1/0022;;B62D1/28;;G07C5/008;;G07C5/0808;;H04L2012/40273;;H04L67/12;;G07C9/00174;;H04L63/0823;;G07C9/00571;;H04L63/00,B60R25/20;;B60R25/01;;B60R25/10,,0,0,,,,PENDING
171,US,A1,US 2019/0100231 A1,016-210-635-605-406,2019-04-04,2019,US 201715723514 A,2017-10-03,US 201715723514 A,2017-10-03,VEHICLE COMPONENT OPERATION,"A system includes a computer including a processor and a memory, the memory including instructions executable by the processor to detect a service controller connected to a vehicle, upon authenticating the service controller, receive an operation mode for a vehicle component from the service controller, and actuate the vehicle component within operating limits based on the operation mode.",FORD GLOBAL TECH LLC,STANEK JOSEPH F;;RHODE DOUGLAS SCOTT;;NAHLE WASSIM MAHMOUD;;AWAD ALLA MICHAEL ADEL;;HANSEN CHERI LYN,FORD GLOBAL TECHNOLOGIES LLC (2017-09-27),https://lens.org/016-210-635-605-406,Patent Application,yes,14,1,4,4,0,B60R25/01;;B60R25/10;;B60R25/20;;G07C9/00174;;G07C9/00571;;H04L67/12;;H04L63/0823;;G05D1/0088;;G05D1/0022;;B62D1/28;;G07C5/008;;G07C5/0808;;H04L2012/40273;;H04L67/12;;G07C9/00174;;H04L63/0823;;G07C9/00571;;H04L63/00,B62D1/28;;G05D1/00;;G07C5/00;;G07C5/08;;H04L29/08,,0,0,,,,ACTIVE
172,US,B2,US 11835752 B2,121-990-459-664-074,2023-12-05,2023,US 202017066524 A,2020-10-09,US 202017066524 A;;US 201816094244 A;;EP 2017056338 W;;US 201662324785 P,2016-04-19,Broad spectrum radiation by supercontinuum generation using a tapered optical fiber,"A measurement apparatus, including: a tapered optical fiber, the tapered optical fiber having an input to receive radiation and having an output to provide spectrally broadened output radiation toward a measurement target, the tapered optical fiber configured to spectrally broaden the radiation received at the input; and a detector system configured to receive a redirected portion of the output radiation from the measurement target.",ASML HOLDING NV,LEUNG KING PUI;;CHEN TAO;;HAVELIN RONAN JAMES;;PETRONELLA AARTS IGOR MATHEUS;;JOOBEUR ADEL;;CARBONE JOSEPH,ASML HOLDING N.V (2016-04-26),https://lens.org/121-990-459-664-074,Granted Patent,yes,28,0,15,15,0,G02F1/365;;G03F9/7065;;G01B11/02;;G01B2210/56;;G02F1/3528;;G03F9/7065;;G02F1/365;;G02B6/02004;;G01B2210/56;;G02B6/29377;;G02B6/2746;;G02F1/3528;;G02B6/1228;;G01B11/02;;G02F1/365;;G03F7/7055;;G03F9/7065;;G02F1/365;;G03F9/7065;;G01B2210/56;;G01B11/02;;G02F1/3528;;G02B6/02004;;G02B6/1228;;G02B6/2746;;G02B6/29377,G02B6/02;;G01B11/02;;G02B6/122;;G02B6/27;;G02B6/293;;G02F1/35;;G02F1/365;;G03F9/00,,8,2,064-164-348-042-053;;042-390-036-026-836,10.1007/s00340-003-1218-3;;18066233;;10.1364/ol.25.001415,"International Search Report and Written Opinion issued in corresponding PCT Patent Application No. PCT/EP2017/056338, dated Jul. 7, 2017.;;Teipel, J, et al.: “Characteristics of supercontinuum generation in tapered fibers using femtosecond laser pulses”, Applied Physics B—Lasers and Optics, vol. 77, No. 2-3, 2003, pp. 245-251.;;Korean Office Action issued in corresponding Korean Patent Application No. 10-2018-7032238, dated Sep. 5, 2019.;;Japanese Office Action issued in corresponding Japanese Patent Application No. 2018-553464, dated Nov. 6, 2019.;;Wang, Zhaoyang et al.: “Supercontinuum Spectrum Generation in Tapered Fiber Using Femtosecond Laser Pulses”, Memoirs of the Muroran Institute of Technology, Nov. 2006, No. 56, pp. 1-7.;;Birks et al., “Supercontinuum generation in tapered fibers”, Optics Letters, vol. 25, Issue 19, pp. 1415-1417 (2000).;;Japanese Office Action issued in corresponding Japanese Patent Application No. 2018-553464, dated Feb. 28, 2020.;;Chinese Office Action issued in corresponding Chinese Patent Application No. 201780034762.5, dated Jun. 1, 2020.",ACTIVE
173,CN,A,CN 109313403 A,146-079-767-292-15X,2019-02-05,2019,CN 201780034762 A,2017-03-17,US 201662324785 P;;EP 2017056338 W,2016-04-19,BROAD SPECTRUM RADIATION BY SUPERCONTINUUM GENERATION USING A TAPERED OPTICAL FIBER,"Provided is a measurement apparatus, including: a tapered optical fiber, the tapered optical fiber having an input to receive radiation and having an output to provide spectrally broadened output radiation toward a measurement target, the tapered optical fiber configured to spectrally broaden the radiation received at the input; and a detector system configured to receive a redirected portion of the output radiation from the measurement target.",ASML HOLDING NV,LEUNG KING PUI;;CHEN TAO;;HAVELIN RONAN JAMES;;AARTS IGOR MATHEUS PETRONELLA;;JOOBEUR ADEL;;CARBONE JOSEPH,,https://lens.org/146-079-767-292-15X,Patent Application,no,6,2,15,15,0,G02F1/365;;G03F9/7065;;G01B11/02;;G01B2210/56;;G02F1/3528;;G03F9/7065;;G02F1/365;;G02B6/02004;;G01B2210/56;;G02B6/29377;;G02B6/2746;;G02F1/3528;;G02B6/1228;;G01B11/02;;G02F1/365;;G03F7/7055;;G03F9/7065;;G02F1/365;;G03F9/7065;;G01B2210/56;;G01B11/02;;G02F1/3528;;G02B6/02004;;G02B6/1228;;G02B6/2746;;G02B6/29377,G03F9/00;;G02F1/365,,0,0,,,,PENDING
174,US,B2,US 10759466 B2,024-231-425-531-843,2020-09-01,2020,US 201715723514 A,2017-10-03,US 201715723514 A,2017-10-03,Vehicle component operation,"A system includes a computer including a processor and a memory, the memory including instructions executable by the processor to detect a service controller connected to a vehicle, upon authenticating the service controller, receive an operation mode for a vehicle component from the service controller, and actuate the vehicle component within operating limits based on the operation mode.",FORD GLOBAL TECH LLC,STANEK JOSEPH F;;RHODE DOUGLAS SCOTT;;NAHLE WASSIM MAHMOUD;;AWAD ALLA MICHAEL ADEL;;HANSEN CHERI LYN,FORD GLOBAL TECHNOLOGIES LLC (2017-09-27),https://lens.org/024-231-425-531-843,Granted Patent,yes,21,0,4,4,0,B60R25/01;;B60R25/10;;B60R25/20;;G07C9/00174;;G07C9/00571;;H04L67/12;;H04L63/0823;;G05D1/0088;;G05D1/0022;;B62D1/28;;G07C5/008;;G07C5/0808;;H04L2012/40273;;H04L67/12;;G07C9/00174;;H04L63/0823;;G07C9/00571;;H04L63/00,B62D1/28;;G05D1/00;;G07C5/00;;G07C5/08;;G07C9/00;;H04L12/40;;H04L29/06;;H04L29/08,,2,0,,,"DE-102015013318-A1 Machine translation (Year: 2017).;;Torchinsky article entitled “Autonomous Cars Must Let Us Wander and Explore Without a Destination in Mind,” dated May 23, 2017 5:11pm (4 pages).",ACTIVE
175,US,B2,US 10737666 B2,039-860-068-258-194,2020-08-11,2020,US 201715826030 A,2017-11-29,US 201715826030 A,2017-11-29,Automotive control,"A system includes a switch biased to a neutral position, a camera, and a computer communicatively coupled to the switch and the camera. The computer is programmed to activate a vehicle brake upon receiving data from the switch that the switch is in the neutral position and to activate the vehicle brake upon determining that an operator of the switch is in an inattentive state based on data received from the camera.",FORD GLOBAL TECH LLC,AWAD ALLA MICHAEL ADEL;;HANSEN CHERI LYN;;HU JEFFREY YIZHOU;;STANEK JOSEPH F;;RHODE DOUGLAS SCOTT,FORD GLOBAL TECHNOLOGIES LLC (2017-11-09),https://lens.org/039-860-068-258-194,Granted Patent,yes,8,0,4,4,0,B60T7/14;;B60T2220/00;;G01C23/00;;B62D15/025;;B62D1/00;;G06V20/56;;G06V20/597;;G05D1/0016;;B60T7/12;;B60T7/02;;B60T2220/00;;B60T7/14,B60T7/12;;B60T7/02;;B60T7/14;;G05D1/00,,2,0,,,"H Scientific Inc. entitled “Joystick Remote Control”.;;Edelstein article entitled “Tesla Adds Safety Provisions to ‘Summon’ Self Driving Feature,” Green Car Reports dated Feb. 16, 2016.",ACTIVE
176,US,A1,US 2019/0161063 A1,072-806-187-261-248,2019-05-30,2019,US 201715826030 A,2017-11-29,US 201715826030 A,2017-11-29,AUTOMOTIVE CONTROL,"A system includes a switch biased to a neutral position, a camera, and a computer communicatively coupled to the switch and the camera. The computer is programmed to activate a vehicle brake upon receiving data from the switch that the switch is in the neutral position and to activate the vehicle brake upon determining that an operator of the switch is in an inattentive state based on data received from the camera.",FORD GLOBAL TECH LLC,AWAD ALLA MICHAEL ADEL;;HANSEN CHERI LYN;;HU JEFFREY YIZHOU;;STANEK JOSEPH F;;RHODE DOUGLAS SCOTT,FORD GLOBAL TECHNOLOGIES LLC (2017-11-09),https://lens.org/072-806-187-261-248,Patent Application,yes,2,2,4,4,0,B60T7/14;;B60T2220/00;;G01C23/00;;B62D15/025;;B62D1/00;;G06V20/56;;G06V20/597;;G05D1/0016;;B60T7/12;;B60T7/02;;B60T2220/00;;B60T7/14,B60T7/12;;B60T7/02;;G05D1/00,,0,0,,,,ACTIVE
177,CN,A,CN 109839923 A,014-486-089-823-768,2019-06-04,2019,CN 201811407901 A,2018-11-23,US 201715826030 A,2017-11-29,AUTOMOTIVE CONTROL,"The invention provides automotive control. A system includes a switch biased to a neutral position, a camera, and a computer communicatively coupled to the switch and the camera. The computer is programmed to activate a vehicle brake upon receiving data from the switch that the switch is in the neutral position and to activate the vehicle brake upon determining that an operator of the switch is inan inattentive state based on data received from the camera.",FORD GLOBAL TECH LLC,AWAD ALLA MICHAEL ADEL;;HANSEN CHERI LYN;;HU JEFFREY YIZHOU;;STANEK JOSEPH F;;RHODE DOUGLAS SCOTT,,https://lens.org/014-486-089-823-768,Patent Application,no,0,0,4,4,0,B60T7/14;;B60T2220/00;;G01C23/00;;B62D15/025;;B62D1/00;;G06V20/56;;G06V20/597;;G05D1/0016;;B60T7/12;;B60T7/02;;B60T2220/00;;B60T7/14,G05D1/00,,0,0,,,,PENDING
178,DE,A1,DE 102018124144 A1,079-795-181-456-988,2019-04-04,2019,DE 102018124144 A,2018-09-28,US 201715723514 A,2017-10-03,FAHRZEUGKOMPONENTENBETRIEB,"Ein System beinhaltet einen Computer, der einen Prozessor und einen Speicher beinhaltet, wobei der Speicher Anweisungen beinhaltet, die durch den Prozessor ausgeführt werden können, um eine Servicesteuerung zu erfassen, die mit einem Fahrzeug verbunden ist, einen Betriebsmodus für eine Fahrzeugkomponente von der Servicesteuerung bei Authentifizieren der Servicesteuerung zu empfangen und die Fahrzeugkomponente innerhalb von Betriebsgrenzen auf Grundlage des Betriebsmodus zu betätigen.",FORD GLOBAL TECH LLC,STANEK JOSEPH F;;RHODE DOUGLAS SCOTT;;NAHLE WASSIM MAHMOUD;;AWAD ALLA MICHAEL ADEL;;HANSEN CHERI LYN,,https://lens.org/079-795-181-456-988,Patent Application,no,0,0,4,4,0,B60R25/01;;B60R25/10;;B60R25/20;;G07C9/00174;;G07C9/00571;;H04L67/12;;H04L63/0823;;G05D1/0088;;G05D1/0022;;B62D1/28;;G07C5/008;;G07C5/0808;;H04L2012/40273;;H04L67/12;;G07C9/00174;;H04L63/0823;;G07C9/00571;;H04L63/00,B60W30/182;;B60R25/04;;B60W50/00,,0,0,,,,PENDING
179,US,B2,US 10802208 B2,065-244-741-922-504,2020-10-13,2020,US 201716094244 A,2017-03-17,US 201716094244 A;;US 201662324785 P;;EP 2017056338 W,2016-04-19,Broad spectrum radiation by supercontinuum generation using a tapered optical fiber,"A measurement apparatus, including: a tapered optical fiber, the tapered optical fiber having an input to receive radiation and having an output to provide spectrally broadened output radiation toward a measurement target, the tapered optical fiber configured to spectrally broaden the radiation received at the input; and a detector system configured to receive a redirected portion of the output radiation from the measurement target.",ASML HOLDING NV,LEUNG KING PUI;;CHEN TAO;;HAVELIN RONAN JAMES;;AARTS IGOR MATHEUS PETRONELLA;;JOOBEUR ADEL;;CARBONE JOSEPH,ASML HOLDING N.V (2015-04-26),https://lens.org/065-244-741-922-504,Granted Patent,yes,26,2,15,15,0,G02F1/365;;G03F9/7065;;G01B11/02;;G01B2210/56;;G02F1/3528;;G03F9/7065;;G02F1/365;;G02B6/02004;;G01B2210/56;;G02B6/29377;;G02B6/2746;;G02F1/3528;;G02B6/1228;;G01B11/02;;G02F1/365;;G03F7/7055;;G03F9/7065;;G02F1/365;;G03F9/7065;;G01B2210/56;;G01B11/02;;G02F1/3528;;G02B6/02004;;G02B6/1228;;G02B6/2746;;G02B6/29377,G02B6/02;;G01B11/02;;G02B6/122;;G02B6/27;;G02B6/293;;G02F1/35;;G02F1/365;;G03F9/00,,8,2,042-390-036-026-836;;064-164-348-042-053,18066233;;10.1364/ol.25.001415;;10.1007/s00340-003-1218-3,"Birks et al., “Supercontinuunn generation in tapered fibers”; Optics Letters, Oct. 2000, vol. 25, No. 19, pp. 1415-1417.;;Japanese Office Action issued in corresponding Japanese Patent Application No. 2018-553464, dated Nov. 6, 2019.;;Wang, Zhaoyang et al.: “Supercontinuum Spectrum Generation in Tapered Fiber Using Femtosecond Laser Pulses”, Memoirs of the Muroran Institute of Technology, Nov. 2006, No. 56, pp. 1-7.;;Korean Office Action issued in corresponding Korean Patent Application No. 10-2018-7032238, dated Sep. 5, 2019.;;International Search Report and Written Opinion issued in corresponding PCT Patent Application No. PCT/EP2017/056338, dated Jul. 7, 2017.;;Teipel, J, et al.: “Characteristics of supercontinuum generation in tapered fibers using femtosecond laser pulses”, Applied Physics B—Lasers and Optics, vol. 77, No. 2-3, 2003, pp. 245-251.;;Japanese Office Action issued in corresponding Japanese Patent Application No. 2018-553464, dated Feb. 28. 2020.;;Chinese Office Action issued in corresponding Chinese Patent Application No. 201780034762.5, dated Jun. 1, 2020.",ACTIVE
180,EP,B1,EP 1593529 B1,049-809-494-267-789,2007-08-15,2007,EP 05103530 A,2005-04-28,US 83774004 A;;US 85952404 A,2004-05-03,Natural rubber-rich composition and tire with tread thereof,,GOODYEAR TIRE & RUBBER,SANDSTROM PAUL HARRY;;HALASA ADEL FARHAN;;HSU WEN-LIANG;;VERTHE JOHN JOSEPH ANDRE;;JASIUNAS CHAD AARON,,https://lens.org/049-809-494-267-789,Granted Patent,yes,4,0,8,14,0,B60C1/0016;;C08K3/013;;C08K5/548;;C08L7/00;;C08L9/00;;C08L9/06;;C08L21/00,B60C1/00;;C08K3/00;;C08K5/548;;C08L7/00;;C08L9/00;;C08L9/06;;C08L21/00,,0,0,,,,ACTIVE
181,DE,A1,DE 102018129840 A1,173-097-314-848-82X,2019-05-29,2019,DE 102018129840 A,2018-11-26,US 201715826030 A,2017-11-29,AUTOMOTIVE STEUERUNG,"Ein System beinhaltet einen Schalter, der in eine neutrale Position vorgespannt ist, eine Kamera und einen Computer, der kommunikativ an den Schalter und die Kamera gekoppelt ist. Der Computer ist programmiert, um bei Empfangen von Daten von dem Schalter, dass sich der Schalter in der neutralen Position befindet, eine Fahrzeugbremse zu aktivieren und um bei Bestimmen, dass sich ein Bediener des Schalters in einem unaufmerksamen Zustand befindet, auf Grundlage von Daten, die von der Kamera empfangen wurden, die Fahrzeugbremse zu aktivieren.",FORD GLOBAL TECH LLC,AWAD ALLA MICHAEL ADEL;;HANSEN CHERI LYN;;HU JEFFREY YIZHOU;;STANEK JOSEPH F;;RHODE DOUGLAS SCOTT,,https://lens.org/173-097-314-848-82X,Patent Application,no,0,0,4,4,0,B60T7/14;;B60T2220/00;;G01C23/00;;B62D15/025;;B62D1/00;;G06V20/56;;G06V20/597;;G05D1/0016;;B60T7/12;;B60T7/02;;B60T2220/00;;B60T7/14,B60R16/02;;B60R25/08;;B60T13/66;;B60W50/08,,0,0,,,,PENDING
182,AU,A1,AU 2020/259906 A1,047-793-545-546-213,2021-11-11,2021,AU 2020/259906 A,2020-04-15,AU 2019/901294 A;;AU 2020/050372 W,2019-04-15,Metal organic frameworks and methods of preparation thereof,"A method of preparing a Metal Organic Framework (MOF) with an acoustically-driven microfluidic platform, the method comprising: depositing a liquid comprising MOF precursors on a piezoelectric substrate of an acoustic microfluidic platform, the MOF precursors comprising a metal ion and an organic ligand, applying acoustic irradiation to the liquid to induce azimuthal liquid recirculation, which causes formation of the MOF within the liquid, and isolating the MOF.",MELBOURNE INST TECH,AHMED HEBA ADEL ALY ELSAYED ELSAYED;;REZK AMGAD REZK NOSHI;;RICHARDSON JOSEPH J;;YEO LESLIE YU-MING,,https://lens.org/047-793-545-546-213,Patent Application,no,0,0,5,5,0,B01J19/0093;;C07F1/08;;C07F15/025;;B01L3/502723;;H03H9/14552;;B01J2219/00889;;B01J2219/00932;;B01L2400/0436;;B01L2400/0439;;B01F33/3012;;B01F33/3034;;B01F35/3201;;B01L3/502707;;B01L2400/0436;;B01L3/50273;;B01J19/0093;;B01J2219/00932;;B01J2219/00889;;B01F31/80;;B01F33/3021;;B01J19/0093;;B01J20/226;;B01J2219/00932;;B01L3/50273;;B01L2400/0436;;B01L2400/0439;;C01B37/00;;C07F1/08;;C07F15/025,C07F1/08;;B01F13/00;;B01F15/00;;B01J19/00;;B01L3/00;;C07F15/02;;H03H9/145,,0,0,,,,PENDING
183,WO,A1,WO 1997/027286 A1,160-958-923-474-915,1997-07-31,1997,US 9700767 W,1997-01-21,US 58991596 A;;US 61895796 A;;US 71329696 A,1996-01-23,METHODS FOR USING THE OBESE GENE AND ITS GENE PRODUCT TO STIMULATE HEMATOPOIETIC DEVELOPMENT,"The present invention relates to the expression of various forms of a novel receptor in hematopoietic and endothelial cells. A variant form of this receptor has been detected in brain cells and shown to bind to the obese gene product, leptin. In particular, the present invention relates to methods of using leptin to stimulate the growth and development of receptor-positive hematopoietic and endothelial cells in vitro and in vivo. In addition, this receptor is selectively expressed in hematopoietic progenitor cells with long-term repopulating potential. Thus, agents that specifically bind to this receptor may be used to identify and isolate progenitor cells for a variety of clinical applications.",PROGENITOR INC,SNODGRASS H RALPH;;CIOFFI JOSEPH;;ZUPANCIC THOMAS J;;SHAFER ALAN W;;MIKHAIL ADEL A;;BARUT BRUCE A,,https://lens.org/160-958-923-474-915,Patent Application,yes,0,56,18,46,0,A61K38/2264;;A61K48/00;;C07K14/5759;;C07K14/715;;C12N5/0641;;C12N5/0645;;C12N5/0647;;C12N2501/125;;C12N2501/14;;C12N2501/355;;C12N2506/02;;A61P17/02;;A61P35/00;;A61P37/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/00,C12N15/09;;A61K38/00;;A61K38/22;;A61K48/00;;A61P7/00;;A61P7/06;;A61P9/00;;A61P17/02;;A61P35/00;;A61P37/00;;C07K14/575;;C07K14/715;;C12N5/078;;C12N5/0786;;C12N5/0789;;C12Q1/68,,4,3,074-176-125-758-741;;043-216-149-257-326;;038-624-516-538-608,10.1016/s0960-9822(02)70684-2;;8805376;;8962092;;pmc26173;;10.1073/pnas.93.25.14564;;8616721;;10.1038/nm0596-585,"CURRENT BIOLOGY, 01 September 1996, Vol. 6, No. 9, BENNETT et al., ""A Role for Leptin and Its Cognate Receptor in Hematopoiesis"", pages 1170-1180.;;PROC. NATL. ACAD. SCI. U.S.A., 10 December 1996, Vol. 93, GAINSFORD et al., ""Leptin Can Induce Proliferation, Differentiation and Functional Activation of Hematopoietic Cells"", pages 14564-14568.;;NATURE MEDICINE, May 1996, Vol. 2, No. 5, CIOFFI et al., ""Novel B219/OB Receptor Isoforms: Possible Role of Leptin in Hematopoiesis and Reproduction"", pages 585-589.;;See also references of EP 0892849A4",PATENTED
184,US,A1,US 2022/0033425 A1,055-839-004-208-597,2022-02-03,2022,US 202117501742 A,2021-10-14,AU 2019/901294 A;;AU 2020/050372 W,2019-04-15,METAL ORGANIC FRAMEWORKS AND METHODS OF PREPARATION THEREOF,"A method of preparing a Metal Organic Framework (MOF) with an acoustically-driven microfluidic platform, the method comprising: depositing a liquid comprising MOF precursors on a piezoelectric substrate of an acoustic microfluidic platform, the MOF precursors comprising a metal ion and an organic ligand, applying acoustic irradiation to the liquid to induce azimuthal liquid recirculation, which causes formation of the MOF within the liquid, and isolating the MOF.",MELBOURNE INST TECH,AHMED HEBA ADEL ALY ELSAYED ELSAYED;;REZK AMGAD REZK NOSHI;;RICHARDSON JOSEPH J;;YEO LESLIE YU-MING,ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (2021-10-27),https://lens.org/055-839-004-208-597,Patent Application,yes,0,1,5,5,0,B01J19/0093;;C07F1/08;;C07F15/025;;B01L3/502723;;H03H9/14552;;B01J2219/00889;;B01J2219/00932;;B01L2400/0436;;B01L2400/0439;;B01F33/3012;;B01F33/3034;;B01F35/3201;;B01L3/502707;;B01L2400/0436;;B01L3/50273;;B01J19/0093;;B01J2219/00932;;B01J2219/00889;;B01F31/80;;B01F33/3021;;B01J19/0093;;B01J20/226;;B01J2219/00932;;B01L3/50273;;B01L2400/0436;;B01L2400/0439;;C01B37/00;;C07F1/08;;C07F15/025,C07F15/02;;B01J19/00;;B01J20/22;;B01L3/00;;C01B37/00;;C07F1/08,,1,1,017-659-457-109-915,10.1021/cr200304e;;22098087,"N. Stock, et al., Synthesis of metal-organic frameworks (MOFs): Routes to various MOF topologies, morphologies, and composites, 112 Chemical Reviews, 933–969 (2012) (Year: 2012)",PENDING
185,AU,B2,AU 731685 B2,130-339-573-795-960,2001-04-05,2001,AU 1997/018311 A,1997-01-21,US 58991596 A;;US 61895796 A;;US 71329696 A;;US 9700767 W,1996-01-23,Methods for using the obese gene and its gene product to stimulate hematopoietic development,,PROGENITOR INC,SNODGRASS H RALPH;;CIOFFI JOSEPH;;ZUPANCIC THOMAS J;;SHAFER ALAN W;;MIKHAIL ADEL A;;BARUT BRUCE A,,https://lens.org/130-339-573-795-960,Granted Patent,no,0,0,18,46,0,A61K38/2264;;A61K48/00;;C07K14/5759;;C07K14/715;;C12N5/0641;;C12N5/0645;;C12N5/0647;;C12N2501/125;;C12N2501/14;;C12N2501/355;;C12N2506/02;;A61P17/02;;A61P35/00;;A61P37/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/00,C12N15/09;;A61K38/00;;A61K38/22;;A61K48/00;;A61P7/00;;A61P7/06;;A61P9/00;;A61P17/02;;A61P35/00;;A61P37/00;;C07K14/575;;C07K14/715;;C12N5/078;;C12N5/0786;;C12N5/0789;;C12Q1/68,,0,0,,,,EXPIRED
186,DE,A1,DE 102019122757 A1,143-165-375-437-913,2020-02-27,2020,DE 102019122757 A,2019-08-23,US 201816111658 A,2018-08-24,FAHRZEUGGESCHWINDIGKEITSSTEUERUNG,"Diese Offenbarung stellt eine Fahrzeuggeschwindigkeitssteuerung bereit. Ein erstes Fahrzeuggeschwindigkeitsziel ist auf Grundlage einer Geschwindigkeit eines zweiten Fahrzeugs und mindestens einem von einer Krümmung einer Straße, einer Neigung der Straße, einem Querneigungswinkel der Straße, Sicht oder einem Reibungskoeffizienten auf einer Straßenoberfläche bestimmt.",FORD GLOBAL TECH LLC,FERNANDO RAVEEN;;NEMEC BARNABAS JOSEPH;;AWAD ALLA MICHAEL ADEL;;TSAI TSUNG-HAN;;HAMILTON KATHRYN;;SICIAK RAY C,,https://lens.org/143-165-375-437-913,Patent Application,no,0,0,4,4,0,B60W30/143;;B60W30/143;;B60W30/188;;B60K2031/005;;B60W40/105;;B60W2520/10;;B60W2552/15;;B60W2552/15;;B60W2552/20;;B60W2552/30;;B60W2552/30;;B60W2552/40;;B60W2552/40;;B60W2554/4042;;B60W2554/80;;B60W2554/801;;B60W2554/802;;B60W2555/20;;H04W4/44;;H04W4/46,B60W30/165;;B60W10/04;;B60W10/18;;B60W10/20;;B60W40/02;;B60W40/068;;B60W40/072;;B60W40/076;;B60W50/08;;G08G1/0965;;G08G1/0967;;H04W4/44;;H04W4/46,,0,0,,,,PENDING
187,AU,C,AU 731685 C,182-160-966-144-145,2002-08-22,2002,AU 1997/018311 A,1997-01-21,US 58991596 A;;US 61895796 A;;US 71329696 A;;US 9700767 W,1996-01-23,Methods for using the obese gene and its gene product to stimulate hematopoietic development,,PROGENITOR INC,SNODGRASS H RALPH;;CIOFFI JOSEPH;;ZUPANCIC THOMAS J;;SHAFER ALAN W;;MIKHAIL ADEL A;;BARUT BRUCE A,,https://lens.org/182-160-966-144-145,Amended Patent,no,0,0,18,46,0,A61K38/2264;;A61K48/00;;C07K14/5759;;C07K14/715;;C12N5/0641;;C12N5/0645;;C12N5/0647;;C12N2501/125;;C12N2501/14;;C12N2501/355;;C12N2506/02;;A61P17/02;;A61P35/00;;A61P37/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/00,C12N15/09;;A61K38/00;;A61K38/22;;A61K48/00;;A61P7/00;;A61P7/06;;A61P9/00;;A61P17/02;;A61P35/00;;A61P37/00;;C07K14/575;;C07K14/715;;C12N5/078;;C12N5/0786;;C12N5/0789;;C12Q1/68,,0,0,,,,EXPIRED
188,ES,T3,ES 2260784 T3,174-906-421-372-509,2006-11-01,2006,ES 97903840 T,1997-01-21,US 58991596 A;;US 61895796 A;;US 71329696 A,1996-01-23,METODOS DE UTILIZACION DEL GEN OBESE Y SU PRODUCTO GENICO PARA ESTIMULAR EL DESARROLO HEMATOPOYETICO.,"LA PRESENTE INVENCION SE REFIERE A LA EXPRESION DE DIVERSAS FORMAS DE UN NUEVO RECEPTOR EN CELULAS HEMATOPOYETICAS Y ENDOTELIALES. SE HA DETECTADO UNA FORMA VARIANTE DE ESTE RECEPTOR EN CELULAS CEREBRALES, COMPROBANDOSE QUE SE FIJA AL PRODUCTO DEL GEN DE LA OBESIDAD, LA LEPTINA. EN PARTICULAR, LA PRESENTE INVENCION SE REFIERE A PROCEDIMIENTOS PARA EL USO DE LA LEPTINA A FIN DE ESTIMULAR EL CRECIMIENTO Y DESARROLLO DE CELULAS HEMATOPOYETICAS Y ENDOTELIALES RECEPTORES - POSITIVAS IN VITRO E IN VIVO. ADEMAS, ESTE RECEPTOR SE EXPRESA SELECTIVAMENTE EN CELULAS PROGENITORAS HEMATOPOYETICAS CON POTENCIAL DE REPOBLACION A LARGO PLAZO. ASI PUES, SE PUEDEN UTILIZAR AGENTES QUE SE FIJAN ESPECIFICAMENTE A ESTE RECEPTOR PARA IDENTIFICAR Y AISLAR LAS CELULAS PROGENITORAS, PARA UNA GRAN VARIEDAD DE APLICACIONES CLINICAS.",INDEVUS PHARMACEUTICALS INC,SNODGRASS H RALPH;;CIOFFI JOSEPH;;ZUPANCIC THOMAS J;;SHAFER ALAN W;;MIKHAIL ADEL A;;BARUT BRUCE A,,https://lens.org/174-906-421-372-509,Granted Patent,no,0,0,18,46,0,A61K38/2264;;A61K48/00;;C07K14/5759;;C07K14/715;;C12N5/0641;;C12N5/0645;;C12N5/0647;;C12N2501/125;;C12N2501/14;;C12N2501/355;;C12N2506/02;;A61P17/02;;A61P35/00;;A61P37/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/00,C12N15/09;;A61K38/00;;A61K38/22;;A61K48/00;;A61P7/00;;A61P7/06;;A61P9/00;;A61P17/02;;A61P35/00;;A61P37/00;;C07K14/575;;C07K14/715;;C12N5/078;;C12N5/0786;;C12N5/0789;;C12Q1/68,,0,0,,,,EXPIRED
189,JP,A,JP 2007163502 A,040-746-415-171-509,2007-06-28,2007,JP 2006355150 A,2006-12-28,US 58991596 A;;US 61895796 A;;US 71329696 A,1996-01-23,"OBESE GENE FOR STIMULATING HEMATOPOIETIC DEVELOPMENT, AND USE OF PRODUCT THEREOF","<P>PROBLEM TO BE SOLVED: To provide a novel using method for leptin. <P>SOLUTION: The present invention provides a medicine containing leptin, and for curing a cancer developing a leptin receptor, and the propagation of the cancer is restrained by the medicine. <P>COPYRIGHT: (C)2007,JPO&INPIT",INDEVUS PHARMACEUTICALS INC,SNODGRASS H RALPH;;CIOFFI JOSEPH;;ZUPANCIC THOMAS J;;SHAFER ALAN W;;MIKHAIL ADEL A;;BARUT BRUCE A,,https://lens.org/040-746-415-171-509,Patent Application,no,0,0,18,46,33,A61K38/2264;;A61K48/00;;C07K14/5759;;C07K14/715;;C12N5/0641;;C12N5/0645;;C12N5/0647;;C12N2501/125;;C12N2501/14;;C12N2501/355;;C12N2506/02;;A61P17/02;;A61P35/00;;A61P37/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/00,C12N15/09;;G01N33/574;;A61K38/00;;A61K38/22;;A61K48/00;;A61P7/00;;A61P7/06;;A61P9/00;;A61P17/02;;A61P35/00;;A61P37/00;;A61P43/00;;C07K14/575;;C07K14/715;;C12N5/078;;C12N5/0786;;C12N5/0789;;C12Q1/68,,0,0,,,,PENDING
190,EP,A1,EP 1731164 A1,048-964-715-524-851,2006-12-13,2006,EP 06004170 A,1997-01-21,EP 97903840 A;;US 58991596 A;;US 61895796 A;;US 71329696 A,1996-01-23,Methods for using the obese gene and its gene product to stimulate hematopoietic development,"The present invention relates to the expression of various forms of a novel receptor in hematopoietic and endothelial cells. A variant form of this receptor has been detected in brain cells and shown to bind to the obese gene product, leptin. In particular, the present invention relates to methods of using leptin to stimulate the growth and development of receptor-positive hematopoietic and endothelial cells  in vitro  and  in vivo . In addition, this receptor is selectively expressed in hematopoietic progenitor cells with long-term repopulating potential. Thus, agents that specifically bind to this receptor may be used to identify and isolate progenitor cells for a variety of clinical applications.",INDEVUS PHARMACEUTICALS INC,SNODGRASS H RALPH;;CIOFFI JOSEPH;;ZUPANCIC THOMAS J;;SHAFER ALAN W;;MIKHAIL ADEL A;;BARUT BRUCE A,,https://lens.org/048-964-715-524-851,Patent Application,yes,1,0,18,46,31,A61K38/2264;;A61K48/00;;C07K14/5759;;C07K14/715;;C12N5/0641;;C12N5/0645;;C12N5/0647;;C12N2501/125;;C12N2501/14;;C12N2501/355;;C12N2506/02;;A61P17/02;;A61P35/00;;A61P37/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/00,A61K38/22;;C12N15/09;;A61K38/00;;A61K48/00;;A61P7/00;;A61P7/06;;A61P9/00;;A61P17/02;;A61P35/00;;A61P37/00;;C07K14/575;;C07K14/715;;C12N5/078;;C12N5/0786;;C12N5/0789;;C12Q1/68,,1,1,058-358-091-684-488,10.1016/0092-8674(95)90151-5;;8548812;;08548812,"TARTAGLIA L A ET AL: ""IDENTIFICATION AND EXPRESSION CLONING OF A LEPTIN RECEPTOR, OB-R"", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 83, no. 7, 29 December 1995 (1995-12-29), pages 1263 - 1271, XP000602068, ISSN: 0092-8674",DISCONTINUED
191,EP,A1,EP 0892849 A1,064-270-007-558-173,1999-01-27,1999,EP 97903840 A,1997-01-21,US 9700767 W;;US 58991596 A;;US 61895796 A;;US 71329696 A,1996-01-23,METHODS FOR USING THE OBESE GENE AND ITS GENE PRODUCT TO STIMULATE HEMATOPOIETIC DEVELOPMENT,,PROGENITOR INC,SNODGRASS H RALPH;;CIOFFI JOSEPH;;ZUPANCIC THOMAS J;;SHAFER ALAN W;;MIKHAIL ADEL A;;BARUT BRUCE A,"INDEVUS PHARMACEUTICALS, INC. (2005-09-07)",https://lens.org/064-270-007-558-173,Patent Application,yes,0,0,18,46,0,A61K38/2264;;A61K48/00;;C07K14/5759;;C07K14/715;;C12N5/0641;;C12N5/0645;;C12N5/0647;;C12N2501/125;;C12N2501/14;;C12N2501/355;;C12N2506/02;;A61P17/02;;A61P35/00;;A61P37/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/00,C12N15/09;;A61K38/00;;A61K38/22;;A61K48/00;;A61P7/00;;A61P7/06;;A61P9/00;;A61P17/02;;A61P35/00;;A61P37/00;;C07K14/575;;C07K14/715;;C12N5/078;;C12N5/0786;;C12N5/0789;;C12Q1/68,,0,0,,,,EXPIRED
192,CN,A,CN 110857091 A,051-797-685-562-314,2020-03-03,2020,CN 201910783603 A,2019-08-23,US 201816111658 A,2018-08-24,VEHICLE VELOCITY CONTROL,"The present invention provides a vehicle velocity control. A first vehicle velocity target is determined based on a velocity of a proximate second vehicle and at least one of a curvature of a road, agradient of the road, a bank angle of the road, visibility, and a coefficient of friction on a surface of the road.",FORD GLOBAL TECH LLC,RAVEEN FERNANDO;;BARNABAS JOSEPH NEMEC;;MICHAEL ADEL AWAD ALLA;;TSUNG-HAN TSAI;;KATHRYN HAMILTON;;RAY C SICIAK,,https://lens.org/051-797-685-562-314,Patent Application,no,0,1,4,4,0,B60W30/143;;B60W30/143;;B60W30/188;;B60K2031/005;;B60W40/105;;B60W2520/10;;B60W2552/15;;B60W2552/15;;B60W2552/20;;B60W2552/30;;B60W2552/30;;B60W2552/40;;B60W2552/40;;B60W2554/4042;;B60W2554/80;;B60W2554/801;;B60W2554/802;;B60W2555/20;;H04W4/44;;H04W4/46,B60W30/14;;B60W40/105;;H04W4/44;;H04W4/46,,0,0,,,,PENDING
193,US,A1,US 2020/0062255 A1,064-868-370-884-412,2020-02-27,2020,US 201816111658 A,2018-08-24,US 201816111658 A,2018-08-24,VEHICLE VELOCITY CONTROL,"A first vehicle velocity target is determined based on a velocity of a proximate second vehicle and at least one of a curvature of a road, a gradient of the road, a bank angle of the road, visibility, and a coefficient of friction on a surface of the road.",FORD GLOBAL TECH LLC,FERNANDO RAVEEN;;NEMEC BARNABAS JOSEPH;;AWAD ALLA MICHAEL ADEL;;TSAI TSUNG-HAN;;HAMILTON KATHRYN;;SICIAK RAY C,FORD GLOBAL TECHNOLOGIES LLC (2018-08-17),https://lens.org/064-868-370-884-412,Patent Application,yes,2,8,4,4,0,B60W30/143;;B60W30/143;;B60W30/188;;B60K2031/005;;B60W40/105;;B60W2520/10;;B60W2552/15;;B60W2552/15;;B60W2552/20;;B60W2552/30;;B60W2552/30;;B60W2552/40;;B60W2552/40;;B60W2554/4042;;B60W2554/80;;B60W2554/801;;B60W2554/802;;B60W2555/20;;H04W4/44;;H04W4/46,B60W30/188,,0,0,,,,ACTIVE
194,US,B2,US 10703373 B2,095-811-241-023-39X,2020-07-07,2020,US 201816111658 A,2018-08-24,US 201816111658 A,2018-08-24,Vehicle velocity control,"A first vehicle velocity target is determined based on a velocity of a proximate second vehicle and at least one of a curvature of a road, a gradient of the road, a bank angle of the road, visibility, and a coefficient of friction on a surface of the road.",FORD GLOBAL TECH LLC,FERNANDO RAVEEN;;NEMEC BARNABAS JOSEPH;;AWAD ALLA MICHAEL ADEL;;TSAI TSUNG-HAN;;HAMILTON KATHRYN;;SICIAK RAY C,FORD GLOBAL TECHNOLOGIES LLC (2018-08-17),https://lens.org/095-811-241-023-39X,Granted Patent,yes,20,2,4,4,0,B60W30/143;;B60W30/143;;B60W30/188;;B60K2031/005;;B60W40/105;;B60W2520/10;;B60W2552/15;;B60W2552/15;;B60W2552/20;;B60W2552/30;;B60W2552/30;;B60W2552/40;;B60W2552/40;;B60W2554/4042;;B60W2554/80;;B60W2554/801;;B60W2554/802;;B60W2555/20;;H04W4/44;;H04W4/46,B60W30/188,,2,0,,,"Paul Ingrassia, Reuters Technology News, “Look No Hand Test Driving a Google Car”, Aug. 17, 2014 retrieved from Internet URL: https://uk.reuters.com/article/us-google-driverless/look-no-hands-test-driving-a-google-car (7 pages).;;Joe Miller, BBC Technology Reporter, “Google Driverless Cars Designed to Exceed Speed Limit”, Aug. 19, 2014, retrieved from Internet URL: http://www.bbc.com/news/echnology-28851996 (3 pages).",ACTIVE
195,AU,A,AU 1997/018311 A,181-503-860-808-121,1997-08-20,1997,AU 1997/018311 A,1997-01-21,US 58991596 A;;US 61895796 A;;US 71329696 A;;US 9700767 W,1996-01-23,Methods for using the obese gene and its gene product to stimulate hematopoietic development,,INDEVUS PHARMACEUTICALS INC,SNODGRASS H RALPH;;CIOFFI JOSEPH;;ZUPANCIC THOMAS J;;SHAFER ALAN W;;MIKHAIL ADEL A;;BARUT BRUCE A,,https://lens.org/181-503-860-808-121,Patent Application,no,0,0,18,46,0,A61K38/2264;;A61K48/00;;C07K14/5759;;C07K14/715;;C12N5/0641;;C12N5/0645;;C12N5/0647;;C12N2501/125;;C12N2501/14;;C12N2501/355;;C12N2506/02;;A61P17/02;;A61P35/00;;A61P37/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/00,C12N15/09;;A61K38/00;;A61K38/22;;A61K48/00;;A61P7/00;;A61P7/06;;A61P9/00;;A61P17/02;;A61P35/00;;A61P37/00;;C07K14/575;;C07K14/715;;C12N5/078;;C12N5/0786;;C12N5/0789;;C12Q1/68,,0,0,,,,EXPIRED
196,DK,T3,DK 0892849 T3,162-900-435-694-442,2006-07-24,2006,DK 97903840 T,1997-01-21,US 58991596 A;;US 61895796 A;;US 71329696 A,1996-01-23,Fremgangsmåde til anvendelse af obese-genet og dets genprodukt til stimulering af hæmatopoietisk udvikling,,INDEVUS PHARMACEUTICALS INC,SNODGRASS H RALPH;;CIOFFI JOSEPH;;ZUPANCIC THOMAS J;;SHAFER ALAN W;;MIKHAIL ADEL A;;BARUT BRUCE A,,https://lens.org/162-900-435-694-442,Granted Patent,no,0,0,18,46,0,A61K38/2264;;A61K48/00;;C07K14/5759;;C07K14/715;;C12N5/0641;;C12N5/0645;;C12N5/0647;;C12N2501/125;;C12N2501/14;;C12N2501/355;;C12N2506/02;;A61P17/02;;A61P35/00;;A61P37/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/00,C12N5/00;;C12N15/09;;A61K38/00;;A61K38/22;;A61K48/00;;A61P7/00;;A61P7/06;;A61P9/00;;A61P17/02;;A61P35/00;;A61P37/00;;C07K14/575;;C07K14/715;;C12N5/078;;C12N5/0786;;C12N5/0789;;C12Q1/68,,0,0,,,,EXPIRED
197,EP,A4,EP 0892849 A4,180-029-803-749-24X,2004-08-25,2004,EP 97903840 A,1997-01-21,US 9700767 W;;US 58991596 A;;US 61895796 A;;US 71329696 A,1996-01-23,METHODS FOR USING THE OBESE GENE AND ITS GENE PRODUCT TO STIMULATE HEMATOPOIETIC DEVELOPMENT,,PROGENITOR INC,SNODGRASS H RALPH;;CIOFFI JOSEPH;;ZUPANCIC THOMAS J;;SHAFER ALAN W;;MIKHAIL ADEL A;;BARUT BRUCE A,"INDEVUS PHARMACEUTICALS, INC. (2005-09-07)",https://lens.org/180-029-803-749-24X,Search Report,no,0,0,18,46,0,A61K38/2264;;A61K48/00;;C07K14/5759;;C07K14/715;;C12N5/0641;;C12N5/0645;;C12N5/0647;;C12N2501/125;;C12N2501/14;;C12N2501/355;;C12N2506/02;;A61P17/02;;A61P35/00;;A61P37/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/00,C12N15/09;;A61K38/00;;A61K38/22;;A61K48/00;;A61P7/00;;A61P7/06;;A61P9/00;;A61P17/02;;A61P35/00;;A61P37/00;;C07K14/575;;C07K14/715;;C12N5/078;;C12N5/0786;;C12N5/0789;;C12Q1/68,,3,2,058-358-091-684-488;;010-744-497-659-171,10.1016/0092-8674(95)90151-5;;8548812;;08548812;;8539591;;10.1126/science.271.5245.29,"TARTAGLIA L A ET AL: ""IDENTIFICATION AND EXPRESSION CLONING OF A LEPTIN RECEPTOR, OB-R"", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 83, no. 7, 29 December 1995 (1995-12-29), pages 1263 - 1271, XP000602068, ISSN: 0092-8674;;BARINAGA M: ""OBESITY: LEPTIN RECEPTOR WEIGHS IN"", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 271, 5 January 1996 (1996-01-05), pages 29, XP002029643, ISSN: 0036-8075;;See also references of WO 9727286A1",EXPIRED
198,CA,A1,CA 2244693 A1,000-625-956-439-959,1997-07-31,1997,CA 2244693 A,1997-01-21,US 58991596 A;;US 61895796 A;;US 71329696 A,1996-01-23,METHODS FOR USING THE OBESE GENE AND ITS GENE PRODUCT TO STIMULATE HEMATOPOIETIC DEVELOPMENT,"The present invention relates to the expression of various forms of a novel receptor in hematopoietic and endothelial cells. A variant form of this receptor has been detected in brain cells and shown to bind to the obese gene product, leptin. In particular, the present invention relates to methods of using leptin to stimulate the growth and development of receptor-positive hematopoietic and endothelial cells in vitro and in vivo. In addition, this receptor is selectively expressed in hematopoietic progenitor cells with long-term repopulating potential. Thus, agents that specifically bind to this receptor may be used to identify and isolate progenitor cells for a variety of clinical applications.",PROGENITOR INC,ZUPANCIC THOMAS J;;CIOFFI JOSEPH;;SHAFER ALAN W;;BARUT BRUCE A;;SNODGRASS H RALPH;;MIKHAIL ADEL A,,https://lens.org/000-625-956-439-959,Patent Application,no,0,0,18,46,29,A61K38/2264;;A61K48/00;;C07K14/5759;;C07K14/715;;C12N5/0641;;C12N5/0645;;C12N5/0647;;C12N2501/125;;C12N2501/14;;C12N2501/355;;C12N2506/02;;A61P17/02;;A61P35/00;;A61P37/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/00,C12N15/09;;A61K38/00;;A61K38/22;;A61K48/00;;A61P7/00;;A61P7/06;;A61P9/00;;A61P17/02;;A61P35/00;;A61P37/00;;C07K14/575;;C07K14/715;;C12N5/078;;C12N5/0786;;C12N5/0789;;C12Q1/68,,0,0,,,,DISCONTINUED
199,EP,A1,EP 3956333 A1,145-388-521-932-092,2022-02-23,2022,EP 20790993 A,2020-04-15,AU 2019/901294 A;;AU 2020/050372 W,2019-04-15,METAL ORGANIC FRAMEWORKS AND METHODS OF PREPARATION THEREOF,,MELBOURNE INST TECH,AHMED HEBA ADEL ALY ELSAYED ELSAYED;;REZK AMGAD REZK NOSHI;;RICHARDSON JOSEPH J;;YEO LESLIE YU-MING,,https://lens.org/145-388-521-932-092,Patent Application,yes,0,0,5,5,0,B01J19/0093;;C07F1/08;;C07F15/025;;B01L3/502723;;H03H9/14552;;B01J2219/00889;;B01J2219/00932;;B01L2400/0436;;B01L2400/0439;;B01F33/3012;;B01F33/3034;;B01F35/3201;;B01L3/502707;;B01L2400/0436;;B01L3/50273;;B01J19/0093;;B01J2219/00932;;B01J2219/00889;;B01F31/80;;B01F33/3021;;B01J19/0093;;B01J20/226;;B01J2219/00932;;B01L3/50273;;B01L2400/0436;;B01L2400/0439;;C01B37/00;;C07F1/08;;C07F15/025,C07F1/08;;B01J19/00;;B01L3/00;;C07F15/02;;H03H9/145,,0,0,,,,PENDING
200,EP,B1,EP 0892849 B1,002-992-646-522-359,2006-03-15,2006,EP 97903840 A,1997-01-21,US 9700767 W;;US 58991596 A;;US 61895796 A;;US 71329696 A,1996-01-23,METHODS FOR USING THE OBESE GENE AND ITS GENE PRODUCT TO STIMULATE HEMATOPOIETIC DEVELOPMENT,,INDEVUS PHARMACEUTICALS INC,SNODGRASS H RALPH;;CIOFFI JOSEPH;;ZUPANCIC THOMAS J;;SHAFER ALAN W;;MIKHAIL ADEL A;;BARUT BRUCE A,"INDEVUS PHARMACEUTICALS, INC. (2005-09-07)",https://lens.org/002-992-646-522-359,Granted Patent,yes,0,0,18,46,0,A61K38/2264;;A61K48/00;;C07K14/5759;;C07K14/715;;C12N5/0641;;C12N5/0645;;C12N5/0647;;C12N2501/125;;C12N2501/14;;C12N2501/355;;C12N2506/02;;A61P17/02;;A61P35/00;;A61P37/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/00,C12N5/00;;C12N15/09;;A61K38/00;;A61K38/22;;A61K48/00;;A61P7/00;;A61P7/06;;A61P9/00;;A61P17/02;;A61P35/00;;A61P37/00;;C07K14/575;;C07K14/715;;C12N5/078;;C12N5/0786;;C12N5/0789;;C12Q1/68,,5,0,,,"TARTAGLIA L A ET AL: ""IDENTIFICATION AND EXPRESSION CLONING OF A LEPTIN RECEPTOR, OB-R"" CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 83, no. 7, 29 December 1995 (1995-12-29), pages 1263-1271, XP000602068 ISSN: 0092-8674;;BARINAGA M: ""OBESITY: LEPTIN RECEPTOR WEIGHS IN"" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 271, 5 January 1996 (1996-01-05), page 29, XP002029643 ISSN: 0036-8075;;CURRENT BIOLOGY, 01 September 1996, Vol. 6, No. 9, BENNETT et al., ""A Role for Leptin and Its Cognate Receptor in Hematopoiesis"", pages 1170-1180.;;PROC. NATL. ACAD. SCI. U.S.A., 10 December 1996, Vol. 93, GAINSFORD et al., ""Leptin Can Induce Proliferation, Differentiation and Functional Activation of Hematopoietic Cells"", pages 14564-14568.;;NATURE MEDICINE, May 1996, Vol. 2, No. 5, CIOFFI et al., ""Novel B219/OB Receptor Isoforms: Possible Role of Leptin in Hematopoiesis and Reproduction"", pages 585-589.",EXPIRED
201,EP,A4,EP 3956333 A4,145-162-560-447-450,2023-01-11,2023,EP 20790993 A,2020-04-15,AU 2019/901294 A;;AU 2020/050372 W,2019-04-15,METAL ORGANIC FRAMEWORKS AND METHODS OF PREPARATION THEREOF,,MELBOURNE INST TECH,AHMED HEBA ADEL ALY ELSAYED ELSAYED;;REZK AMGAD REZK NOSHI;;RICHARDSON JOSEPH J;;YEO LESLIE YU-MING,,https://lens.org/145-162-560-447-450,Search Report,no,0,0,5,5,0,B01J19/0093;;C07F1/08;;C07F15/025;;B01L3/502723;;H03H9/14552;;B01J2219/00889;;B01J2219/00932;;B01L2400/0436;;B01L2400/0439;;B01F33/3012;;B01F33/3034;;B01F35/3201;;B01L3/502707;;B01L2400/0436;;B01L3/50273;;B01J19/0093;;B01J2219/00932;;B01J2219/00889;;B01F31/80;;B01F33/3021;;B01J19/0093;;B01J20/226;;B01J2219/00932;;B01L3/50273;;B01L2400/0436;;B01L2400/0439;;C01B37/00;;C07F1/08;;C07F15/025,C07F1/08;;B01J19/00;;B01L3/00;;C07F15/02;;H03H9/145,,1,0,,,No further relevant documents disclosed,PENDING
202,PT,E,PT 892849 E,097-913-448-371-519,2006-08-31,2006,PT 97903840 T,1997-01-21,US 58991596 A;;US 61895796 A;;US 71329696 A,1996-01-23,METODO PARA UTILIZACAO DO GENE OBESO E SEU PRODUTO GENICO PARA ESTIMULAR O DESENVOLVIMENTO HEMATOPOIETICO,,INDEVUS PHARMACEUTICALS INC,RALPH SNODGRASS H;;JOSEPH CIOFFI;;ZUPANCIC THOMAS J;;SHAFER ALAN W;;MIKHAIL ADEL A;;BARUT BRUCE A,,https://lens.org/097-913-448-371-519,Granted Patent,no,0,0,18,46,0,A61K38/2264;;A61K48/00;;C07K14/5759;;C07K14/715;;C12N5/0641;;C12N5/0645;;C12N5/0647;;C12N2501/125;;C12N2501/14;;C12N2501/355;;C12N2506/02;;A61P17/02;;A61P35/00;;A61P37/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/00,C12N15/09;;A61K38/00;;A61K38/22;;A61K48/00;;A61P7/00;;A61P7/06;;A61P9/00;;A61P17/02;;A61P35/00;;A61P37/00;;C07K14/575;;C07K14/715;;C12N5/078;;C12N5/0786;;C12N5/0789;;C12Q1/68,,0,0,,,,EXPIRED
203,WO,A1,WO 2020/210868 A1,099-591-943-014-352,2020-10-22,2020,AU 2020/050372 W,2020-04-15,AU 2019/901294 A,2019-04-15,METAL ORGANIC FRAMEWORKS AND METHODS OF PREPARATION THEREOF,"A method of preparing a Metal Organic Framework (MOF) with an acoustically-driven microfluidic platform, the method comprising: depositing a liquid comprising MOF precursors on a piezoelectric substrate of an acoustic microfluidic platform, the MOF precursors comprising a metal ion and an organic ligand, applying acoustic irradiation to the liquid to induce azimuthal liquid recirculation, which causes formation of the MOF within the liquid, and isolating the MOF.",MELBOURNE INST TECH,AHMED HEBA ADEL ALY ELSAYED ELSAYED;;REZK AMGAD REZK NOSHI;;RICHARDSON JOSEPH J;;YEO LESLIE YU-MING,,https://lens.org/099-591-943-014-352,Patent Application,yes,6,1,5,5,0,B01J19/0093;;C07F1/08;;C07F15/025;;B01L3/502723;;H03H9/14552;;B01J2219/00889;;B01J2219/00932;;B01L2400/0436;;B01L2400/0439;;B01F33/3012;;B01F33/3034;;B01F35/3201;;B01L3/502707;;B01L2400/0436;;B01L3/50273;;B01J19/0093;;B01J2219/00932;;B01J2219/00889;;B01F31/80;;B01F33/3021;;B01J19/0093;;B01J20/226;;B01J2219/00932;;B01L3/50273;;B01L2400/0436;;B01L2400/0439;;C01B37/00;;C07F1/08;;C07F15/025,C07F1/08;;B01F13/00;;B01F15/00;;B01J19/00;;B01L3/00;;C07F15/02;;H03H9/145,,3,2,004-333-817-150-881;;004-333-817-150-881,10.1039/c8ce01144c;;10.1039/c8ce01144c,"XU, CHAOPING ET AL.: ""Surface acoustic wave (SAW)-induced synthesis of HKUST-1 with different morphologies and sizes"", CRYSTENGCOMM, vol. 20, no. 45, 2018, pages 7275 - 7280, XP055749857, DOI: 10.1039/C8CE01144C;;XU, CHAOPING ET AL.: ""Surface acoustic wave (SAW)-induced synthesis of HKUST-1 with different morphologies and sizes"", CRYSTENGCOMM, vol. 20, no. 45, 2018, pages 7275 - 7280, XP055749857, DOI: 10.1039/C8CE01144C;;See also references of EP 3956333A4",PENDING
204,AT,T1,AT E320479 T1,097-698-679-077-422,2006-04-15,2006,AT 97903840 T,1997-01-21,US 58991596 A;;US 61895796 A;;US 71329696 A,1996-01-23,PROCESS ZUR VERWENDUNG DES OBESE-GENS UND SEINES GENPRODUKTS ZUR STIMULIERUNG DER ENTWICKLUNG VON HAEMOTOPOIETISCHEN ZELLEN,,INDEVUS PHARMACEUTICALS INC,SNODGRASS H RALPH;;CIOFFI JOSEPH;;ZUPANCIC THOMAS J;;SHAFER ALAN W;;MIKHAIL ADEL A;;BARUT BRUCE A,,https://lens.org/097-698-679-077-422,Granted Patent,no,0,0,18,46,0,A61K38/2264;;A61K48/00;;C07K14/5759;;C07K14/715;;C12N5/0641;;C12N5/0645;;C12N5/0647;;C12N2501/125;;C12N2501/14;;C12N2501/355;;C12N2506/02;;A61P17/02;;A61P35/00;;A61P37/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/00,C12N15/09;;A61K38/00;;A61K38/22;;A61K48/00;;A61P7/00;;A61P7/06;;A61P9/00;;A61P17/02;;A61P35/00;;A61P37/00;;C07K14/575;;C07K14/715;;C12N5/078;;C12N5/0786;;C12N5/0789;;C12Q1/68,,0,0,,,,EXPIRED
205,US,A,US 5552490 A,051-943-028-788-13X,1996-09-03,1996,US 43975395 A,1995-05-12,US 43975395 A;;US 30090794 A;;US 3783593 A,1993-03-29,Styrene-isoprene rubber for tire tread compounds,"The subject invention relates to a technique for synthesizing rubbery copolymers of styrene and isoprene. These rubbery copolymers exhibit an excellent combination of properties for utilization in tire tread rubber compounds. By utilizing these styrene-isoprene rubbers in tire treads, tires having improved wet skid resistance can be built without sacrificing rolling resistance or tread wear characteristics. This invention more specifically discloses a process for the synthesis of styrene-isoprene rubbers which exhibit essentially a single glass transition temperature and which are particularly useful in tire tread rubber compounds, said process comprising copolymerizing a monomer mixture containing from about 2 weight percent to about 15 weight percent styrene monomer and from about 85 weight percent to about 98 weight percent isoprene monomer in an organic solvent in the presence of a catalyst system which is comprised of (a) a lithium initiator and (b) a modifier having the structural formula: ##STR1## wherein n represents an integer within the range of 3 to 6, wherein R represents an alkyl group containing from 1 to about 10 carbon atoms, and wherein the molar ratio of the modifier to the lithium initiator is within the range of 2:1 to 40:1.",GOODYEAR TIRE & RUBBER,ZANZIG DAVID J;;SANDSTROM PAUL H;;HUBBELL JOSEPH K;;HSU WEN-LIANG;;HALASA ADEL F;;VERTHE JOHN J A,GOODYEAR TIRE & RUBBER COMPANY THE (1994-08-29),https://lens.org/051-943-028-788-13X,Granted Patent,yes,6,4,2,4,0,C08F236/10;;C08F236/10;;Y02T10/86;;Y02T10/86;;Y10S152/905;;Y10S152/905,C08F2/06;;C08F4/48;;C08F236/10,525/237;;525/232;;524/262;;524/575;;X152209 R,0,0,,,,EXPIRED
206,EP,A1,EP 0905185 A1,060-536-072-733-775,1999-03-31,1999,EP 98117046 A,1998-09-09,US 93116997 A,1997-09-16,Tire tread with elastomers of spatially defined TG's,The invention relates to a tire with a tread. The tread is composed of at least two defined elastomers having Tg's spaced apart by at least 55°C to the exclusion of elastomers having Tg's between -30°C and -85°C. The tread composition can be reinforced with either carbon black or a combination of carbon black and silica reinforcing fillers.,GOODYEAR TIRE & RUBBER,FRANCIK WILLIAM PAUL;;BLOK EDWARD JOHN;;SANDSTROM PAUL HARRY;;VERTHE JOHN JOSEPH ANDRE;;ZANZIG DAVID JOHN;;HALASA ADEL FARHAN,,https://lens.org/060-536-072-733-775,Patent Application,yes,5,14,5,5,0,B60C1/0016;;C08K3/36;;C08K5/372;;C08L9/00;;C08L9/06;;Y10T152/10495;;Y10T152/10495;;C08L9/00;;C08L9/06;;C08K3/36;;B60C1/0016;;C08K5/372,B60C1/00;;C08L9/00;;C08L9/06,,0,0,,,,DISCONTINUED
207,BR,A,BR PI0603777 A,048-476-688-245-829,2007-08-14,2007,BR PI0603777 A,2006-09-11,US 23268505 A,2005-09-22,borracha de estireno-butadieno não aleatória,"BORRACHA DE ESTIRENO-BUTADIENO NãO ALEATóRIA A presente invenção revela um pneumático possuindo uma banda de rodagem que é compreendida de (1) 30 phr a 80 phr de uma borracha de estireno-butadieno não aleatória compreendida de cadeias poliméricas que são derivadas de estireno e 1,3-butadieno, onde cerca de 10% em peso a cerca de 50% em peso das unidades de repetição na borracha de estireno-butadieno são derivados de estireno, onde cerca de 60% em peso a cerca de 90% em peso das unidades de repetição na borracha de estireno-butadieno são derivados de 1,3-butadieno, onde cerca de 30% em peso a cerca de 50% em peso das unidades de repetição de estireno estão nas següências contendo 5 a 20 unidades de repetição de estireno, onde o teor de estireno ligado encontrado na primeira metade das cadeias poliméricas difere do teor de estireno encontrado na segunda metade das cadeias poliméricas em pelo menos 5% em peso, onde a borracha de estireno-butadieno possui um teor de 1,2-vinila que está dentro da faixa de 8% a cerca de 20%, onde a borracha de estireno-butadieno possui um peso molecular médio númerico que está dentro da faixa de 200.000 a 475.000 e onde a borracha de estireno-butadieno possui uma temperatura de transição vítrea que está dentro da faixa de -82°C a - 70°C e (2) 20 phr a 70 phr de cis-1,4-polibutadieno alto. A formulação da banda de rodagem pneumática pode conter opcionalmente sílica e lignina.",GOODYEAR TIRE & RUBBER,HALASA ADEL FARHAN;;HSU WEN-LIANG;;SMITH DAVID MICHAEL;;BUSCH WARREN JAMES;;VERTHE JOHN JOSEPH ANDRE;;JOHNSON SCOTT EDWARDS,,https://lens.org/048-476-688-245-829,Patent Application,no,0,0,7,7,0,B60C1/0016;;B60C1/0016;;C08L9/06;;C08L9/06;;C08F236/10;;C08F236/10;;C08L7/00;;C08L7/00;;C08L9/00;;C08L9/00;;C08L97/005;;C08L97/005;;Y10S152/905;;Y10S152/905,C08F236/10;;C08F236/00,,0,0,,,,DISCONTINUED
208,CA,C,CA 2245355 C,090-773-320-878-381,2007-11-20,2007,CA 2245355 A,1998-08-18,US 93116997 A,1997-09-16,TIRE TREAD WITH ELASTOMERS OF SPATIALLY DEFINED TG'S,The invention relates to a tire with a tread. The tread is composed of at least two defined elastomers having Tg's spaced apart by at least 55.degree.C to the exclusion of elastomers having Tg's between -30.degree. and -85.degree.C. The tread composition can be reinforced with either carbon black or a combination of carbon black and silica reinforcing fillers.,GOODYEAR TIRE & RUBBER,VERTHE JOHN JOSEPH ANDRE;;SANDSTROM PAUL HARRY;;BLOK EDWARD JOHN;;ZANZIG DAVID JOHN;;FRANCIK WILLIAM PAUL;;HALASA ADEL FARHAN,,https://lens.org/090-773-320-878-381,Granted Patent,no,0,0,5,5,0,B60C1/0016;;C08K3/36;;C08K5/372;;C08L9/00;;C08L9/06;;Y10T152/10495;;Y10T152/10495;;C08L9/00;;C08L9/06;;C08K3/36;;B60C1/0016;;C08K5/372,C08L9/00;;B60C1/00;;C08K3/04;;C08L9/06,,0,0,,,,EXPIRED
209,GB,B,GB 2354246 B,052-121-371-817-528,2003-10-01,2003,GB 0020332 A,2000-08-17,US 14960999 P,1999-08-18,Silica-reinforced tire tread rubber,,GOODYEAR TIRE & RUBBER,BLOK EDWARD JOHN;;SANDSTROM PAUL HARRY;;HSU WEN-LIANG;;HALASA ADEL FARHAN;;VERTHE JOHN JOSEPH ANDRE;;DIROSSI RAYMOND ROBERT,,https://lens.org/052-121-371-817-528,Granted Patent,no,4,0,7,7,0,B60C1/0016;;B60C1/0016;;C08L9/00;;C08L9/00;;C08K3/04;;C08K3/04;;C08K3/36;;C08K3/36;;C08K5/0016;;C08K5/0016;;C08L7/00;;C08L7/00;;C08L15/00;;C08L15/00;;Y02T10/86;;Y02T10/86,B60C1/00;;C08L9/00;;C08L15/00,C3M MXC           MXC;;C3M MX1R          MXC;;C3M M127          MXC;;C3M M128          MXC;;C3M M129          MXC;;U1S S1363;;U1S S1845,0,0,,,,EXPIRED
210,CA,A1,CA 2135029 A1,093-653-270-447-104,1996-03-07,1996,CA 2135029 A,1994-11-03,US 30090794 A,1994-09-06,STYRENE-ISOPRENE RUBBER FOR TIRE TREAD COMPOUNDS,"The subject invention relates to a technique for synthesizing rubbery copolymers of styrene and isoprene. These rubbery copolymers exhibit an excellent combination of properties for utilization in tire tread rubber compounds. By utilizing these styrene-isoprene rubbers in tire treads, tires having improved wet skid resistance can be built without sacrificing rolling resistance or tread wear characteristics. This invention more specifically discloses a process for the synthesis of styreneisoprene rubbers which exhibit essentially a single glass transition temperature and which are particularly useful in tire tread rubber compounds, said process comprising copolymerizing a monomer mixture containing from about 2 weight percent to about 15 weight percent styrene monomer and from about 85 weight percent to about 98 weight percent isoprene monomer in an organic solvent in the presence of a catalyst system which is comprised of (a) a lithium initiator and (b) a modifier having the structural formula: <IMG> wherein n represents an integer within the range of 3 to 6, wherein R represents an alkyl group containing from 1 to about 10 carbon atoms, and wherein the molar ratio of the modifier to the lithium initiator is within the range of 2:1 to 40:1.",,ZANZIG DAVID J;;SANDSTROM PAUL H;;HUBBELL JOSEPH K;;HSU WEN-LIANG;;HALASA ADEL F;;VERTHE JOHN J A,,https://lens.org/093-653-270-447-104,Patent Application,no,0,1,1,4,0,,C08F4/48;;C08F236/08;;C08L7/00;;C08L9/00;;C08L9/06,,0,0,,,,DISCONTINUED
211,GB,A,GB 2354246 A,004-426-019-572-599,2001-03-21,2001,GB 0020332 A,2000-08-17,US 14960999 P,1999-08-18,Silica-reinforced tire tread rubber,"A tire comprises a generally toroidal-shaped carcass with an outer circumferential tread, two spaced beads, at least one ply extending from bead to bead and sidewalls extending radially from and connecting said tread to said beads; wherein said tread is adapted to be ground-contacting; wherein the tread is comprised of (1) 5 phr to 40 phr of a polyisoprene rubber selected from the group consisting of natural rubber and synthetic polyisoprene, (2) 20 phr to 60 phr of high vinyl polybutadiene rubber having a glass transition temperature which is within the range of -40{C to 10{C, (3) 20 phr to 60 phr of tin-coupled isoprene-butadiene rubber having a glass transition temperature which is within the range of -90{C to -70{C, (4) 30 phr to 90 phr of silica, (5) 5 phr to 50 phr of carbon black, (6) 2 phr to 50 phr of processing oil and (7) 0.5 phr to 15 phr of a silica coupling agent.",GOODYEAR TIRE & RUBBER,BLOK EDWARD JOHN;;SANDSTROM PAUL HARRY;;HSU WEN-LIANG;;HALASA ADEL FARHAN;;VERTHE JOHN JOSEPH ANDRE;;DIROSSI RAYMOND ROBERT,,https://lens.org/004-426-019-572-599,Patent Application,no,4,2,7,7,0,B60C1/0016;;B60C1/0016;;C08L9/00;;C08L9/00;;C08K3/04;;C08K3/04;;C08K3/36;;C08K3/36;;C08K5/0016;;C08K5/0016;;C08L7/00;;C08L7/00;;C08L15/00;;C08L15/00;;Y02T10/86;;Y02T10/86,B60C1/00;;C08L9/00;;C08L15/00,C3M MXC           MXC;;C3M MX1R          MXC;;C3M M127          MXC;;C3M M128          MXC;;C3M M129          MXC;;U1S S1363;;U1S S1845,0,0,,,,EXPIRED
212,FR,B1,FR 2797636 B1,093-234-185-555-69X,2005-03-04,2005,FR 0009547 A,2000-07-20,US 14960999 P,1999-08-18,PNEUMATIQUE ET FORMULATION DE CAOUTCHOUC UTILISEE POUR SA FABRICATION,,GOODYEAR TIRE & RUBBER,BLOK EDWARD JOHN;;SANDSTROM PAUL HARRY;;HSU WEN LIANG;;HALASA ADEL FARHAN;;VERTHE JOHN JOSEPH ANDRE;;DIROSSI RAYMOND ROBERT,,https://lens.org/093-234-185-555-69X,Granted Patent,no,0,0,7,7,0,B60C1/0016;;B60C1/0016;;C08L9/00;;C08L9/00;;C08K3/04;;C08K3/04;;C08K3/36;;C08K3/36;;C08K5/0016;;C08K5/0016;;C08L7/00;;C08L7/00;;C08L15/00;;C08L15/00;;Y02T10/86;;Y02T10/86,B60C1/00;;C08L9/00;;C08L15/00,,0,0,,,,EXPIRED
213,FR,A1,FR 2797636 A1,072-443-375-066-618,2001-02-23,2001,FR 0009547 A,2000-07-20,US 14960999 P,1999-08-18,Silica reinforced vehicle tire toroidal tread rubber consists of a blend of polyisoprene and other rubbers with a high silica concentration,"The silica-reinforced vehicle tire toroidal tread rubber comprises a blend of polyisoprene rubber 5-40, high-vinyl polybutadiene rubber 20-60, isoprene-butadiene rubber incorporating tin 20-60, silica 30-90, lampblack 5-50, process oil 2-50 and silica-coupling agent 0.5-15 % respectively.",GOODYEAR TIRE & RUBBER,BLOK EDWARD JOHN;;SANDSTROM PAUL HARRY;;HSU WEN LIANG;;HALASA ADEL FARHAN;;VERTHE JOHN JOSEPH ANDRE;;DIROSSI RAYMOND ROBERT,,https://lens.org/072-443-375-066-618,Patent Application,no,3,0,7,7,0,B60C1/0016;;B60C1/0016;;C08L9/00;;C08L9/00;;C08K3/04;;C08K3/04;;C08K3/36;;C08K3/36;;C08K5/0016;;C08K5/0016;;C08L7/00;;C08L7/00;;C08L15/00;;C08L15/00;;Y02T10/86;;Y02T10/86,B60C1/00;;C08L9/00;;C08L15/00,,0,0,,,,EXPIRED
214,BR,A,BR 9803393 A,152-058-723-798-68X,1999-12-14,1999,BR 9803393 A,1998-09-08,US 93116997 A,1997-09-16,Banda de rodagem para pneus com elastómeros de tg's espacialmente definidas.,"""BANDA DE RODAGEM PARA PNEUS COM ELASTÈMEROS DE TG's ESPACIALMENTE DEFINIDAS"". A invenção se refere a um pneu com uma banda de rodagem. A banda de rodagem é composta por pelo menos dois elastómeros definidos com Tg's afastadas em pelo menos 55°C, excluindo-se elastómeros com Tg's entre -30° e 85°C. A composição da banda de rodagem pode ser reforçada com negro-de-fumo ou com uma combinação das cargas de reforço negro-de-fumo e sílica.",GOODYEAR TIRE & RUBBER,FRANCIK WILLIAM PAUL;;BLOK EDWARD JOHN;;SANDSTROM PAUL HARRY;;VERTHE JOHN JOSEPH ANDRE;;ZANZIG DAVID JOHN;;HALASA ADEL FARHAN,,https://lens.org/152-058-723-798-68X,Patent Application,no,0,0,5,5,0,B60C1/0016;;C08K3/36;;C08K5/372;;C08L9/00;;C08L9/06;;Y10T152/10495;;Y10T152/10495;;C08L9/00;;C08L9/06;;C08K3/36;;B60C1/0016;;C08K5/372,B60C1/00;;C08L9/00;;C08L9/06,,0,0,,,,EXPIRED
215,BR,A,BR 0003496 A,085-215-068-078-122,2000-11-28,2000,BR 0003496 A,2000-08-11,US 14960999 P,1999-08-18,Borracha para bandas de rodagem de pneus reforçada com sìlica,"""BORRACHA PARA BANDAS DE RODAGEM DE PNEUS REFORçADA COM SìLICA"" A presente invenção se refere a um composto de banda de rodagem para pneu que é altamente carregado com sílica. Esse composto apresenta as vantagens de combinação da sílica sem a necessidade de SBR de solução. Mais especificamente, as formulações de borracha para banda de rodagem de pneus desta invenção apresentam uma excelente combinação de características de tração, desgaste da banda de rodagem e resistência ao rolamento. A presente invenção apresenta um pneu composto de uma carcaça de formato genericamente toroidal com uma banda de rodagem circunferencial externa, dois talões espaçados, pelo menos uma camada estendendo-se de talão a talão, e flancos estendendo-se radialmente a partir da e conectando a banda de rodagem aos talões; em que a banda de rodagem está adaptada para contato com o chão; em que a banda de rodagem é composta de (1) 5 ppc a 40 ppc de uma borracha de poliisopreno selecionada no grupo que consiste em borracha natural e poliisopreno sintético, (2) 20 ppc a 60 ppc de borracha de polibutadieno de alta vinila, com uma temperatura de transição de vidro que esteja dentro da faixa de -40°C a 10°C, (3) 20 ppc a 60 ppc de borracha de isopreno-butadieno acoplada com estanho, com uma temperatura de transição de vidro que esteja dentro da faixa de -90°C a -70°C, (4) 30 ppc a 90 ppc de sílica, (5) 5 ppc a 50 ppc de negro-de-fumo, (6) 2 ppc a 50 ppc de óleo de processamento e (7) 0,5 ppc a 15 ppc de um agente de acoplamento de sílica.",GOODYEAR TIRE & RUBBER,BLOK EDWARD JOHN;;SANDSTROM PAUL HARRY;;HSU WEN-LIANG;;HALASA ADEL FARHAN;;VERTHE JOHN JOSEPH ANDRE;;DIROSSI RAYMOND ROBERT,,https://lens.org/085-215-068-078-122,Patent Application,no,0,0,7,7,0,B60C1/0016;;B60C1/0016;;C08L9/00;;C08L9/00;;C08K3/04;;C08K3/04;;C08K3/36;;C08K3/36;;C08K5/0016;;C08K5/0016;;C08L7/00;;C08L7/00;;C08L15/00;;C08L15/00;;Y02T10/86;;Y02T10/86,B60C1/00;;C08L9/00;;C08L15/00,,0,0,,,,DISCONTINUED
216,US,B1,US 6429245 B1,098-232-972-787-687,2002-08-06,2002,US 93116997 A,1997-09-16,US 93116997 A,1997-09-16,Tire tread with elastomers of spatially defined Tg's,"
    The invention relates to a tire with a tread. The tread is composed of at least two defined elastomers having Tg's spaced apart by at least 55 C. to the exclusion of elastomers having Tg's between 30 and 85 C. The tread composition can be reinforced with either carbon black or a combination of carbon black and silica reinforcing fillers. 
",GOODYEAR TIRE & RUBBER,FRANCIK WILLIAM PAUL;;BLOK EDWARD JOHN;;SANDSTROM PAUL HARRY;;VERTHE JOHN JOSEPH ANDRE;;ZANZIG DAVID JOHN;;HALASA ADEL FARHAN,GOODYEAR TIRE & RUBBER COMPANY THE (1997-09-15),https://lens.org/098-232-972-787-687,Granted Patent,yes,4,43,5,5,0,B60C1/0016;;C08K3/36;;C08K5/372;;C08L9/00;;C08L9/06;;Y10T152/10495;;Y10T152/10495;;C08L9/00;;C08L9/06;;C08K3/36;;B60C1/0016;;C08K5/372,B60C1/00;;C08L9/00;;C08L9/06,524/262;;524/526;;152/450,1,0,,,Copy of the European Search Report.,EXPIRED
217,US,A,US 5470929 A,143-665-597-321-554,1995-11-28,1995,US 30090794 A,1994-09-06,US 30090794 A;;US 3783593 A,1993-03-29,Process for synthesizing styrene-isoprene rubber,"The subject invention relates to a technique for synthesizing rubbery copolymers of styrene and isoprene. These rubbery copolymers exhibit an excellent combination of properties for utilization in tire tread rubber compounds. By utilizing these styrene-isoprene rubbers in tire treads, tires having improved wet skid resistance can be built without sacrificing rolling resistance or tread wear characteristics. This invention more specifically discloses a process for the synthesis of styrene-isoprene rubbers which exhibit essentially a single glass transition temperature and which are particularly useful in tire tread rubber compounds, said process comprising copolymerizing a monomer mixture containing from about 2 weight percent to about 15 weight percent styrene monomer and from about 85 weight percent to about 98 weight percent isoprene monomer in an organic solvent in the presence of a catalyst system which is comprised of (a) a lithium initiator and (b) a modifier having the structural formula: ##STR1## wherein n represents an integer within the range of 3 to 6, wherein R represents an alkyl group containing from 1 to about 10 carbon atoms, and wherein the molar ratio of the modifier to the lithium initiator is within the range of 2:1 to 40:1.",GOODYEAR TIRE & RUBBER,ZANZIG DAVID J;;SANDSTROM PAUL H;;HUBBELL JOSEPH K;;HSU WEN-LIANG;;HALASA ADEL F;;VERTHE JOHN J A,GOODYEAR TIRE & RUBBER COMPANY THE (1994-08-29),https://lens.org/143-665-597-321-554,Granted Patent,yes,12,7,2,4,0,C08F236/10;;C08F236/10;;Y02T10/86;;Y02T10/86;;Y10S152/905;;Y10S152/905,C08F2/06;;C08F4/48;;C08F236/10,526/181;;526/173;;526/340;;526/204,1,0,,,"Hackh s Chemical Dictionary (Fourth Edition), McGraw Hill Book Company, New York, 286 (1969).",EXPIRED
218,CA,A1,CA 2245355 A1,166-244-267-952-07X,1999-03-16,1999,CA 2245355 A,1998-08-18,US 93116997 A,1997-09-16,TIRE TREAD WITH ELASTOMERS OF SPATIALLY DEFINED TG'S,The invention relates to a tire with a tread. The tread is composed of at least two defined elastomers having Tg's spaced apart by at least 55.degree.C to the exclusion of elastomers having Tg's between -30.degree. and -85.degree.C. The tread composition can be reinforced with either carbon black or a combination of carbon black and silica reinforcing fillers.,GOODYEAR TIRE & RUBBER,FRANCIK WILLIAM PAUL;;VERTHE JOHN JOSEPH ANDRE;;BLOK EDWARD JOHN;;SANDSTROM PAUL HARRY;;ZANZIG DAVID JOHN;;HALASA ADEL FARHAN,,https://lens.org/166-244-267-952-07X,Patent Application,no,0,3,5,5,0,B60C1/0016;;C08K3/36;;C08K5/372;;C08L9/00;;C08L9/06;;Y10T152/10495;;Y10T152/10495;;C08L9/00;;C08L9/06;;C08K3/36;;B60C1/0016;;C08K5/372,B60C1/00;;C08L9/00;;C08L9/06,,0,0,,,,EXPIRED
219,US,B1,US 6350807 B1,182-586-479-700-691,2002-02-26,2002,US 61627000 A,2000-07-14,US 61627000 A;;US 14960999 P,1999-08-18,Silica-reinforced tire tread rubber,"
    The present invention relates to a tire tread compound that is highly loaded with silica. This compound offers the advantages of silica compounding without the need for solution SBR. More specifically, the tire tread rubber formulations of this invention offer an excellent combination of traction, treadwear and rolling resistance characteristics. The subject invention discloses a tire which is comprised of a generally toroidal-shaped carcass with an outer circumferential tread, two spaced beads, at least one ply extending from bead to bead and sidewalls extending radially from and connecting said tread to said beads; wherein said tread is adapted to be ground-contacting; wherein the tread is comprised of (1) 5 phr to 40 phr of a polyisoprene rubber selected from the group consisting of natural rubber and synthetic polyisoprene, (2) 20 phr to 60 phr of high vinyl polybutadiene rubber having a glass transition temperature which is within the range of 40 C. to 10 C., (3) 20 phr to 60 phr of tin-coupled isoprene-butadiene rubber having a glass transition temperature which is within the range of 90 C. to 70 C., (4) 30 phr to 90 phr of silica, (5) 5 phr to 50 phr of carbon black, (6) 2 phr to 50 phr of processing oil and (7) 0.5 phr to 15 phr of a silica coupling agent. 
",GOODYEAR TIRE & RUBBER,BLOK EDWARD JOHN;;SANDSTROM PAUL HARRY;;HSU WEN-LIANG;;HALASA ADEL FARHAN;;VERTHE JOHN JOSEPH ANDRE;;DIROSSI RAYMOND ROBERT,GOODYEAR TIRE & RUBBER COMPANY THE (2001-04-10),https://lens.org/182-586-479-700-691,Granted Patent,yes,2,17,7,7,0,B60C1/0016;;B60C1/0016;;C08L9/00;;C08L9/00;;C08K3/04;;C08K3/04;;C08K3/36;;C08K3/36;;C08K5/0016;;C08K5/0016;;C08L7/00;;C08L7/00;;C08L15/00;;C08L15/00;;Y02T10/86;;Y02T10/86,B60C1/00;;C08L9/00;;C08L15/00,524/493;;152/209.5,0,0,,,,EXPIRED
220,JP,A,JP 2007119739 A,011-415-011-454-475,2007-05-17,2007,JP 2006257537 A,2006-09-22,US 23268505 A,2005-09-22,NON-RANDOM STYRENE-BUTADIENE RUBBER,"<P>PROBLEM TO BE SOLVED: To provide a non-random rubber-like polymer that shows excellent tractive characteristics when compounded in a tire, and to provide a rubber composition and a tire comprised of the composition. <P>SOLUTION: The rubber composition comprises (1) a non-random styrene-butadiene rubber of 30 phr to 80 phr containing a polymer chain derived from styrene and 1,3-butadiene, and having a number average molecular weight within the range of 200,000 to 475,000 and a glass transition temperature within the range of -82°C to -50°C, and (2) a polybutadiene of 20 phr to 70 phr. The compounded material for a tire tread is comprised of the composition, and the compounded material optionally further comprises silica and lignin. <P>COPYRIGHT: (C)2007,JPO&INPIT",GOODYEAR TIRE & RUBBER,HALASA ADEL FARHAN;;HSU WEN-LIANG;;SMITH SR DAVID MICHAEL;;BUSCH WARREN JAMES;;VERTHE JOHN JOSEPH ANDRE;;JOHNSON SCOTT EDWARDS,,https://lens.org/011-415-011-454-475,Patent Application,no,14,10,7,7,0,B60C1/0016;;B60C1/0016;;C08L9/06;;C08L9/06;;C08F236/10;;C08F236/10;;C08L7/00;;C08L7/00;;C08L9/00;;C08L9/00;;C08L97/005;;C08L97/005;;Y10S152/905;;Y10S152/905,C08F236/10;;B60C1/00;;C08K3/36;;C08L9/06;;C08L97/00,,0,0,,,,INACTIVE
221,EP,A2,EP 1770105 A2,179-182-597-836-515,2007-04-04,2007,EP 06120883 A,2006-09-19,US 23268505 A,2005-09-22,Non-random styrene-butadiene rubber,"The present invention discloses a tire having a tread that comprises 30 phr to 80 phr of a non-random styrene-butadiene rubber comprising polymer chains that are derived from styrene and 1,3-butadiene, wherein from 10 weight percent to 50 weight percent of the repeat units in the styrene-butadiene rubber are derived from styrene, wherein from 60 weight percent to 90 weight percent of the repeat units in the styrene-butadiene rubber are derived from 1,3-butadiene, wherein from 30 weight percent to 50 weight percent of the styrene repeat units are in sequences containing 5 to 20 styrene repeat units, wherein the bound styrene content found in the first half of the polymer chains differs from the bound styrene content found in the second half of the polymer chains by at least 5 weight percent, wherein the styrene-butadiene rubber has a 1,2-vinyl content which is within the range of 8 percent to 20 percent, wherein the styrene-butadiene rubber has a number average molecular weight which is within the range of 200,000 to 475,000, and wherein the styrene-butadiene rubber has a glass transition temperature which is within the range of -82°C to - 50°C, and 20 phr to 70 phr of polybutadiene. The tire tread formulation can optionally contain silica and lignin.",GOODYEAR TIRE & RUBBER,HALASA ADEL FARHAN;;HSU WEN-LIANG;;SMITH SR DAVID MICHAEL;;BUSCH WARREN JAMES;;VERTHE JOHN JOSEPH ANDRE;;JOHNSON SCOTT EDWARDS,,https://lens.org/179-182-597-836-515,Patent Application,yes,7,0,7,7,0,B60C1/0016;;C08F236/10;;C08L7/00;;C08L9/00;;C08L9/06;;C08L97/005;;Y10S152/905;;C08L9/06;;B60C1/0016;;C08F236/10;;C08L9/00;;C08L7/00;;C08L97/005;;Y10S152/905,C08F236/10;;C08L9/00;;C08L9/06,,1,1,086-190-854-282-858,10.1002/app.1967.070110819,"G. KRAUS: ""Properties of Randon and Block Copolymers of Butadiene and Styrene. I. Dynamic Properties and Glassy Transition Temperatures"", JOURNAL OF APPLIED POLYMER SCIENCE, vol. 11, 1 January 1967 (1967-01-01), pages 1581 - 1591, XP001105588, DOI: doi:10.1002/app.1967.070110819",DISCONTINUED
222,US,B1,US 7064171 B1,134-456-758-550-458,2006-06-20,2006,US 23268505 A,2005-09-22,US 23268505 A,2005-09-22,Non-random styrene-butadiene rubber,"The present invention reveals a tire having a tread that is comprised of (1) 30 phr to 80 phr of a non-random styrene-butadiene rubber comprised of polymer chains that are derived from styrene and 1,3-butadiene, wherein from about 10 weight percent to about 50 weight percent of the repeat units in the styrene-butadiene rubber are derived from styrene, wherein from about 60 weight percent to about 90 weight percent of the repeat units in the styrene-butadiene rubber are derived from 1,3-butadiene, wherein from about 30 weight percent to about 50 weight percent of the styrene repeat units are in sequences containing 5 to 20 styrene repeat units, wherein the bound styrene content found in the first half of the polymer chains differs from the bound styrene content found in the second half of the polymer chains by at least 5 weight percent, wherein the styrene-butadiene rubber has a 1,2-vinyl content which is within the range of about 8 percent to about 20 percent, wherein the styrene-butadiene rubber has a number average molecular weight which is within the range of 200,000 to 475,000, and wherein the styrene-butadiene rubber has a glass transition temperature which is within the range of −82° C. to −50° C. and (2) 20 phr to 70 phr of polybutadiene. The tire tread formulation can optionally contain silica and lignin.",GOODYEAR TIRE & RUBBER,HALASA ADEL FARHAN;;HSU WEN-LIANG;;SMITH SR DAVID MICHAEL;;BUSCH WARREN JAMES;;VERTHE JOHN JOSEPH ANDRE;;JOHNSON SCOTT EDWARDS,THE GOODYEAR TIRE & RUBBER COMPANY (2005-09-09),https://lens.org/134-456-758-550-458,Granted Patent,yes,14,27,7,7,0,B60C1/0016;;B60C1/0016;;C08L9/06;;C08L9/06;;C08F236/10;;C08F236/10;;C08L7/00;;C08L7/00;;C08L9/00;;C08L9/00;;C08L97/005;;C08L97/005;;Y10S152/905;;Y10S152/905,C08F236/10,526/340;;526/65;;525/192;;525/237;;524/76;;524/575;;152/209.1;;152/905,0,0,,,,INACTIVE
223,EP,A3,EP 1770105 A3,161-475-756-054-365,2009-05-06,2009,EP 06120883 A,2006-09-19,US 23268505 A,2005-09-22,Non-random styrene-butadiene rubber,"The present invention discloses a tire having a tread that comprises 30 phr to 80 phr of a non-random styrene-butadiene rubber comprising polymer chains that are derived from styrene and 1,3-butadiene, wherein from 10 weight percent to 50 weight percent of the repeat units in the styrene-butadiene rubber are derived from styrene, wherein from 60 weight percent to 90 weight percent of the repeat units in the styrene-butadiene rubber are derived from 1,3-butadiene, wherein from 30 weight percent to 50 weight percent of the styrene repeat units are in sequences containing 5 to 20 styrene repeat units, wherein the bound styrene content found in the first half of the polymer chains differs from the bound styrene content found in the second half of the polymer chains by at least 5 weight percent, wherein the styrene-butadiene rubber has a 1,2-vinyl content which is within the range of 8 percent to 20 percent, wherein the styrene-butadiene rubber has a number average molecular weight which is within the range of 200,000 to 475,000, and wherein the styrene-butadiene rubber has a glass transition temperature which is within the range of -82°C to - 50°C, and 20 phr to 70 phr of polybutadiene. The tire tread formulation can optionally contain silica and lignin.",GOODYEAR TIRE & RUBBER,HALASA ADEL FARHAN;;HSU WEN-LIANG;;SMITH DAVID MICHAEL SR;;BUSCH WARREN JAMES;;VERTHE JOHN JOSEPH ANDRE;;JOHNSON SCOTT EDWARDS,,https://lens.org/161-475-756-054-365,Search Report,yes,3,0,7,7,0,B60C1/0016;;B60C1/0016;;C08L9/06;;C08L9/06;;C08F236/10;;C08F236/10;;C08L7/00;;C08L7/00;;C08L9/00;;C08L9/00;;C08L97/005;;C08L97/005;;Y10S152/905;;Y10S152/905,C08F236/10;;C08L9/00;;C08L9/06,,2,1,086-190-854-282-858,10.1002/app.1967.070110819,"KRAUS G ET AL: ""PROPERTIES OF RANDOM AND BLOCK COPOLYMERS OF BUTADIENE AND STYRENE. I. DYNAMIC PROPERTIES AND GLASSY TRANSITION TEMPERATURES"", JOURNAL OF APPLIED POLYMER SCIENCE, NEW YORK, NY, US, vol. 11, 1 January 1967 (1967-01-01), pages 1581 - 1591, XP001105588;;BOTROS S.H., EID M.A. M., NAGEEB Z.A.: ""Thermal stability and dielelctric relaxation of NR/soda lignin and NR/thiolignin composites"", EGYPT J. SOLIDS, vol. 28, no. 1, 2005, pages 67 - 83, XP002520283",DISCONTINUED
224,WO,A2,WO 2023/215741 A2,016-026-209-904-083,2023-11-09,2023,US 2023/0066491 W,2023-05-02,US 202263363963 P,2022-05-02,ORTHOPEDIC INSTRUMENTS AND METHODS,"An orthopedic instrument system includes a burr and a burr guide. The burr guide includes an elongated opening, wherein at least a portion of the elongated opening includes a substantially circular opening having a greater dimension than that of the adjacent portion of the elongated opening. The circular opening is configured to receive at least a portion of the burr therein and therethrough such that the burr may be manipulated along the length of the elongated opening. The burr has a first end opposite a shaft and a second end with the first end being configured to facilitate being releasably coupled to a tool. The second end of the burr has an engagement feature that is configured to cut and/or resurface a bone surface. A method of using the orthopedic instrument system is also disclosed herein.",PARAGON 28 INC,DOGUÉ JOSEPH;;SCHMIDT MICHAEL;;BRINKER LAURA ZAGROCKI;;ALBAYYAT MANSOUR ADEL;;MARTIN BRANDON MICHAEL;;AITKEN MAKENNA;;SEKHADIA DEIP ASHOK;;COMBS TAI JAMES,,https://lens.org/016-026-209-904-083,Patent Application,yes,0,0,2,2,0,A61B17/1775;;A61B2017/1602,A61B17/56,,0,0,,,,PENDING
225,WO,A3,WO 2023/215741 A3,070-661-747-979-905,2023-12-14,2023,US 2023/0066491 W,2023-05-02,US 202263363963 P,2022-05-02,ORTHOPEDIC INSTRUMENTS AND METHODS,"An orthopedic instrument system includes a burr and a burr guide. The burr guide includes an elongated opening, wherein at least a portion of the elongated opening includes a substantially circular opening having a greater dimension than that of the adjacent portion of the elongated opening. The circular opening is configured to receive at least a portion of the burr therein and therethrough such that the burr may be manipulated along the length of the elongated opening. The burr has a first end opposite a shaft and a second end with the first end being configured to facilitate being releasably coupled to a tool. The second end of the burr has an engagement feature that is configured to cut and/or resurface a bone surface. A method of using the orthopedic instrument system is also disclosed herein.",PARAGON 28 INC,DOGUÉ JOSEPH;;SCHMIDT MICHAEL;;BRINKER LAURA ZAGROCKI;;ALBAYYAT MANSOUR ADEL;;MARTIN BRANDON MICHAEL;;AITKEN MAKENNA;;SEKHADIA DEIP ASHOK;;COMBS TAI JAMES,,https://lens.org/070-661-747-979-905,Search Report,yes,7,0,2,2,0,A61B17/1775;;A61B2017/1602,A61B17/17;;A61B17/15;;A61B17/32;;A61B17/90,,0,0,,,,PENDING
226,US,A,US 6084022 A,178-944-613-945-968,2000-07-04,2000,US 93517297 A,1997-09-22,US 93517297 A,1997-09-22,Tire tread compositions containing asymmetrically tin-coupled polybutadiene rubber,"This invention relates to a tire tread compound that is easily processable which can be used to improve the treadwear, rolling resistance and traction characteristics of tires. The tire tread compounds of this invention are a blend of tin-coupled polybutadiene, high vinyl polybutadiene and natural rubber. This blend of low glass transition temperature rubber and high glass transition temperature rubber is surprisingly easy to process which makes the concept of this invention commercially feasible. Thus, the tire tread compounds of this invention can be utilized in making tires having greatly improved traction characteristics and treadwear without sacrificing rolling resistance. These improved properties may be due, in part, to better interaction and compatibility with carbon black and/or silica fillers. The polybutadiene in the blend can be asymmetrical tin-coupled to further improve the cold flow characteristics of the rubber blend. Asymmetrical tin coupling in general also leads to better processability and other beneficial properties. This invention more specifically discloses a tire tread rubber composition which is comprised of (1) from about 20 phr to about 60 phr of tin-coupled polybutadiene rubber, (2) from about 20 phr to about 60 phr of a rubber selected from the group consisting of natural rubber and synthetic polyisoprene and (3) from about 5 phr to about 40 phr of high vinyl polybutadiene rubber.",GOODYEAR TIRE & RUBBER,BLOK EDWARD JOHN;;SANDSTROM PAUL HARRY;;LOSEY CHERYL ANN;;HALASA ADEL FARHAN;;HSU WEN-LIANG;;ZANZIG DAVID JOHN;;VERTHE JOHN JOSEPH ANDRE,GOODYEAR TIRE & RUBBER COMPANY THE (1997-09-22),https://lens.org/178-944-613-945-968,Granted Patent,yes,5,9,7,7,0,B60C1/0016;;C08C19/44;;C08K5/548;;C08L7/00;;C08L9/00;;C08L15/00;;C08L15/005;;C08L21/00;;Y02T10/86;;C08L15/00;;C08L7/00;;C08K5/548;;C08L21/00;;B60C1/0016;;C08L15/005;;C08L9/00;;C08C19/44;;Y02T10/86,B60C1/00;;C08C19/44;;C08J3/26;;C08K5/548;;C08L7/00;;C08L9/00;;C08L15/00;;C08L21/00,524/526;;525/236;;525/237,0,0,,,,EXPIRED
227,US,A,US 6017988 A,012-167-081-598-470,2000-01-25,2000,US 36623699 A,1999-08-03,US 36623699 A;;US 93517297 A,1997-09-22,Tire tread compositions containing asymmetrically tin-coupled polybutadiene rubber and silica coupling agent,"This invention relates to a tire tread compound that is easily processable which can be used to improve the treadwear, rolling resistance and traction characteristics of tires. The tire tread compounds of this invention are a blend of tin-coupled polybutadiene, high vinyl polybutadiene and natural rubber. This blend of low glass transition temperature rubber and high glass transition temperature rubber is surprisingly easy to process which makes the concept of this invention commercially feasible. Thus, the tire tread compounds of this invention can be utilized in making tires having greatly improved traction characteristics and treadwear without sacrificing rolling resistance. These improved properties may be due, in part, to better interaction and compatibility with carbon black and/or silica fillers. The polybutadiene in the blend can be asymmetrical tin-coupled to further improve the cold flow characteristics of the rubber blend. Asymmetrical tin coupling in general also leads to better processability and other beneficial properties. This invention more specifically discloses a tire tread rubber composition which is comprised of (1) from about 20 phr to about 60 phr of tin-coupled polybutadiene rubber, (2) from about 20 phr to about 60 phr of a rubber selected from the group consisting of natural rubber and synthetic polyisoprene and (3) from about 5 phr to about 40 phr of high vinyl polybutadiene rubber.",GOODYEAR TIRE & RUBBER,BLOK EDWARD JOHN;;SANDSTROM PAUL HARRY;;LOSEY CHERYL ANN;;HALASA ADEL FARHAN;;HSU WEN-LIANG;;ZANZIG DAVID JOHN;;VERTHE JOHN JOSEPH ANDRE,GOODYEAR TIRE & RUBBER COMPANY THE (1997-09-22),https://lens.org/012-167-081-598-470,Granted Patent,yes,5,5,7,7,0,B60C1/0016;;C08C19/44;;C08K5/548;;C08L7/00;;C08L9/00;;C08L15/00;;C08L15/005;;C08L21/00;;Y02T10/86;;C08L15/00;;C08L7/00;;C08K5/548;;C08L21/00;;B60C1/0016;;C08L15/005;;C08L9/00;;C08C19/44;;Y02T10/86,B60C1/00;;C08C19/44;;C08J3/26;;C08K5/548;;C08L7/00;;C08L9/00;;C08L15/00;;C08L21/00,524/424;;524/526;;525/236;;525/237,0,0,,,,EXPIRED
228,US,A1,US 2003/0186278 A1,064-547-659-112-061,2003-10-02,2003,US 31630602 A,2002-12-11,US 31630602 A;;US 33925001 P,2001-12-11,Methods for the identification of inhibitors of 1-aminocyclopropane-1-carboxylate oxidase expression or activity in plants,"
   The present inventors have discovered that 1-Aminocyclopropane-1-Carboxylate Oxidase (ACC) is essential for plant growth. Specifically, the inhibition of ACC gene expression in plant seedlings results in reduced and severely stunted growth, and chlorosis. Thus, ACC can be used as a target for the identification of herbicides. Accordingly, the present invention provides methods for the identification of compounds that inhibit ACC expression or activity, comprising: contacting a compound with an ACC and detecting the presence and/or absence of binding between said compound and said an ACC, or detecting a decrease in ACC expression or activity. The methods of the invention are useful for the identification of herbicides. 
",MITCHELL JOSEPH;;ZAYED ADEL;;ASCENZI ROBERT;;BOYES DOUGLAS;;MULPURI RAO;;HOFFMAN NEIL;;KJEMTRUP SUSANNE;;DAVIS KEITH;;HAMILTON CAROL;;WOESSNER JEFFREY;;GORLACH JORN,MITCHELL JOSEPH;;ZAYED ADEL;;ASCENZI ROBERT;;BOYES DOUGLAS;;MULPURI RAO;;HOFFMAN NEIL;;KJEMTRUP SUSANNE;;DAVIS KEITH;;HAMILTON CAROL;;WOESSNER JEFFREY;;GORLACH JORN,PARADIGM GENETICS INC (2002-09-24);;ICORIA INC (2004-04-17),https://lens.org/064-547-659-112-061,Patent Application,yes,5,1,1,1,2,C12Q1/26;;C12Q1/26;;G01N2500/04;;G01N2500/04,C12Q1/26,435/6;;435/25;;504/116.1,0,0,,,,DISCONTINUED
229,EP,A1,EP 0903373 A1,063-053-223-126-554,1999-03-24,1999,EP 98117472 A,1998-09-15,US 93517297 A,1997-09-22,Tire tread compound,"This invention relates to a tire tread compound that is easily processable which can be used to improve the treadwear, rolling resistance and traction characteristics of tires. The tire tread compounds of this invention are a blend of tin-coupled polybutadiene, high vinyl polybutadiene and natural rubber. This blend of low glass transition temperature rubber and high glass transition temperature rubber is surprisingly easy to process which makes the concept of this invention commercially feasible. Thus, the tire tread compounds of this invention can be utilized in making tires having greatly improved traction characteristics and treadwear without sacrificing rolling resistance. These improved properties may be due, in part, to better interaction and compatibility with carbon black and/or silica fillers. The polybutadiene in the blend can be asymmetrical tin-coupled to further improve the cold flow characteristics of the rubber blend. Asymmetrical tin coupling in general also leads to better processability and other beneficial properties. This invention more specifically discloses a tire tread rubber composition which is comprised of (1) from 20 phr to 60 phr of tin-coupled polybutadiene rubber, (2) from 20 phr to 60 phr of a rubber selected from the group consisting of natural rubber and synthetic polyisoprene and (3) from 5 phr to 40 phr of high vinyl polybutadiene rubber.",GOODYEAR TIRE & RUBBER,BLOK EDWARD JOHN;;SANDSTROM PAUL HARRY;;LOSEY CHERYL ANN;;HALASA ADEL FARHAN;;HSU WEN-LIANG;;ZANZIG DAVID JOHN;;VERTHE JOHN JOSEPH ANDRE,,https://lens.org/063-053-223-126-554,Patent Application,yes,2,14,7,7,0,B60C1/0016;;C08C19/44;;C08K5/548;;C08L7/00;;C08L9/00;;C08L15/00;;C08L15/005;;C08L21/00;;Y02T10/86;;C08L15/00;;C08L7/00;;C08K5/548;;C08L21/00;;B60C1/0016;;C08L15/005;;C08L9/00;;C08C19/44;;Y02T10/86,B60C1/00;;C08C19/44;;C08J3/26;;C08K5/548;;C08L7/00;;C08L9/00;;C08L15/00;;C08L21/00,,0,0,,,,DISCONTINUED
230,CA,A1,CA 2246038 A1,155-527-455-976-475,1999-03-22,1999,CA 2246038 A,1998-08-27,US 93517297 A,1997-09-22,TIRE TREAD COMPOUND,"This invention relates to a tire tread compound that is easily processable which can be used to improve the treadwear, rolling resistance and traction characteristics of tires. The tire tread compounds of this invention are a blend of tin-coupled polybutadiene, high vinyl polybutadiene and natural rubber. This blend of low glass transition temperature rubber and high glass transition temperature rubber is surprisingly easy to process which makes the concept of this invention commercially feasible. Thus, the tire tread compounds of this invention can be utilized in making tires having greatly improved traction characteristics and treadwear without sacrificing rolling resistance. These improved properties may be due, in part, to better interaction and compatibility with carbon black and/or silica fillers. The polybutadiene in the blend can be asymmetrical tin-coupled to further improve the cold flow characteristics of the rubber blend. Asymmetrical tin coupling in general also leads to better processability and other beneficial properties. This invention more specifically discloses a tire tread rubber composition which is comprised of (1) from about 20 phr to about 60 phr of tin-coupled polybutadiene rubber, (2) from about 20 phr to about 60 phr of a rubber selected from the group consisting of natural rubber and synthetic polyisoprene and (3) from about 5 phr to about 40 phr of high vinyl polybutadiene rubber.",GOODYEAR TIRE & RUBBER,HALASA ADEL FARHAN;;HSU WEN-LIANG;;ZANZIG DAVID JOHN;;VERTHE JOHN JOSEPH ANDRE;;SANDSTROM PAUL HARRY;;LOSEY CHERYL ANN;;BLOK EDWARD JOHN,,https://lens.org/155-527-455-976-475,Patent Application,no,0,4,7,7,0,B60C1/0016;;C08C19/44;;C08K5/548;;C08L7/00;;C08L9/00;;C08L15/00;;C08L15/005;;C08L21/00;;Y02T10/86;;C08L15/00;;C08L7/00;;C08K5/548;;C08L21/00;;B60C1/0016;;C08L15/005;;C08L9/00;;C08C19/44;;Y02T10/86,B60C1/00;;C08C19/44;;C08J3/26;;C08K5/548;;C08L7/00;;C08L9/00;;C08L15/00;;C08L21/00,,0,0,,,,DISCONTINUED
231,JP,A,JP H11189677 A,177-384-802-786-370,1999-07-13,1999,JP 26854998 A,1998-09-22,US 93517297 A,1997-09-22,TIRE TREAD COMPOUND,"PROBLEM TO BE SOLVED: To obtain a tire tread compd. which can be used for improving the tread abrasion resistance, rolling resistance, and static friction characteristics of a tire and which is easily processible. SOLUTION: This compd. contains from about 20 phr to about 60 phr asymmetric tin-linked polybutadiene rubber, from about 20 phr to about 60 phr rubber selected from natural and synthetic polyisoprene rubbers, and from about 5 phr to about 40 phr high-vinyl polybutadiene rubber. A tire produced by using this compd. has greatly improved static friction characteristics and tread abrasion resistance without detriment to rolling resistance.",GOODYEAR TIRE & RUBBER,BLOK EDWARD JOHN;;SANDSTROM PAUL HARRY;;LOSEY CHERYL ANN;;HALASA ADEL FARHAN;;HSU WEN-LIANG;;ZANZIG DAVID JOHN;;VERTHE JOHN JOSEPH ANDRE,,https://lens.org/177-384-802-786-370,Patent Application,no,0,3,7,7,0,B60C1/0016;;C08C19/44;;C08K5/548;;C08L7/00;;C08L9/00;;C08L15/00;;C08L15/005;;C08L21/00;;Y02T10/86;;C08L15/00;;C08L7/00;;C08K5/548;;C08L21/00;;B60C1/0016;;C08L15/005;;C08L9/00;;C08C19/44;;Y02T10/86,B60C1/00;;C08C19/44;;C08J3/26;;C08K5/548;;C08L7/00;;C08L9/00;;C08L15/00;;C08L21/00,,0,0,,,,PENDING
232,BR,A,BR 9803457 A,014-263-892-595-639,1999-12-14,1999,BR 9803457 A,1998-09-15,US 93517297 A,1997-09-22,Composto para banda de rodagem de pneu.,"""COMPOSTO PARA BANDA DE RODAGEM DE PNEU"". Esta invenção refere-se a um composto para banda de rodagem de penu que é facilmente processável, o qual pode ser usado para aperfeiçoar as características de desgaste da banda de rodagem, resistência ao rolamento e tração dos pneus. Os compostos para banda de rodagem desta invenção são uma combinação de polibutadieno acoplado ao estanho, polibutadieno vinílico superior e borracha natural. A combinação da borracha de temperatura de transição vítrea baixa e a borracha de temperatura de transição vítrea alta é surpreendentemente fácil de ser processada, o que torno o conceito desta invenção comercialmente viável. Assim, os compostos par banda de rodagem de pneus desta invenção podem ser utilizados na fabricação de pneus possuindo características de tração bastante aperfeiçoadas e desgaste da banda de rodagem, sem sacrificar a resistência de rolamento. Estas propriedades aperfeiçoadas podem ser devidas, em parte, a melhor interação e compatibilidade com as cargas de negro de carbono e/ou sílica. O polibutadieno na combinação pode ser acoplado ao estanho assimetricamente, para aperfeiçoar adicionalmente as características de fluxo a frio da combinação de borracha. O acoplamento de estanho assimétrico em geral, também conduz a melhor capacidade de processamento e outras propriedades benéficas. Esta invenção revela, mais especificamente, uma composição de borracha para banda de rodagem que é compreendida de (10 cerca de 20 phr à cerca de 60 phr de borracha de polibutadieno acoplada ao estanho, (2) cerca de 20 phr à cerca de 60 phr de uma borracha selecionada do grupo consistindo de borracha natural e poliisopreno sintético e (3) cerca de 5 phr à cerca de 40 phr de borracha de polibutanideno vinílico superior.",GOODYEAR TIRE & RUBBER,BLOK EDWARD JOHN;;SANDSTROM PAUL HARRY;;LOSEY CHERYL ANN;;HALASA ADEL FARHAN;;HSU WEN-LIANG;;ZANZIG DAVID JOHN;;VERTHE JOHN JOSEPH ANDRE,,https://lens.org/014-263-892-595-639,Patent Application,no,0,0,7,7,0,B60C1/0016;;C08C19/44;;C08K5/548;;C08L7/00;;C08L9/00;;C08L15/00;;C08L15/005;;C08L21/00;;Y02T10/86;;C08L15/00;;C08L7/00;;C08K5/548;;C08L21/00;;B60C1/0016;;C08L15/005;;C08L9/00;;C08C19/44;;Y02T10/86,B60C1/00;;C08C19/44;;C08J3/26;;C08K5/548;;C08L7/00;;C08L9/00;;C08L15/00;;C08L21/00,,0,0,,,,DISCONTINUED
233,US,A,US 6025430 A,083-128-491-990-022,2000-02-15,2000,US 38849199 A,1999-09-02,US 38849199 A;;US 93517297 A,1997-09-22,Tire tread compositions containing asymmetrically tin-coupled polybutadiene rubber,"This invention relates to a tire tread compound that is easily processable which can be used to improve the treadwear, rolling resistance and traction characteristics of tires. The tire tread compounds of this invention are a blend of tin-coupled polybutadiene, high vinyl polybutadiene and natural rubber. This blend of low glass transition temperature rubber and high glass transition temperature rubber is surprisingly easy to process which makes the concept of this invention commercially feasible. Thus, the tire tread compounds of this invention can be utilized in making tires having greatly improved traction characteristics and treadwear without sacrificing rolling resistance. These improved properties may be due, in part, to better interaction and compatibility with carbon black and/or silica fillers. The polybutadiene in the blend can be asymmetrical tin-coupled to further improve the cold flow characteristics of the rubber blend. Asymmetrical tin coupling in general also leads to better processability and other beneficial properties. This invention more specifically discloses a tire tread rubber composition which is comprised of (1) from about 20 phr to about 60 phr of tin-coupled polybutadiene rubber, (2) from about 20 phr to about 60 phr of a rubber selected from the group consisting of natural rubber and synthetic polyisoprene and (3) from about 5 phr to about 40 phr of high vinyl polybutadiene rubber.",GOODYEAR TIRE & RUBBER,BLOK EDWARD JOHN;;SANDSTROM PAUL HARRY;;LOSEY CHERYL ANN;;HALASA ADEL FARHAN;;HSU WEN-LIANG;;ZANZIG DAVID JOHN;;VERTHE JOHN JOSEPH ANDRE,GOODYEAR TIRE & RUBBER COMPANY THE (1999-09-02),https://lens.org/083-128-491-990-022,Granted Patent,yes,5,14,7,7,0,B60C1/0016;;C08C19/44;;C08K5/548;;C08L7/00;;C08L9/00;;C08L15/00;;C08L15/005;;C08L21/00;;Y02T10/86;;C08L15/00;;C08L7/00;;C08K5/548;;C08L21/00;;B60C1/0016;;C08L15/005;;C08L9/00;;C08C19/44;;Y02T10/86,B60C1/00;;C08C19/44;;C08J3/26;;C08K5/548;;C08L7/00;;C08L9/00;;C08L15/00;;C08L21/00,524/526;;525/236;;525/237,0,0,,,,EXPIRED
234,AU,B2,AU 703744 B2,154-114-467-769-244,1999-04-01,1999,AU 1996/063917 A,1996-06-24,GB 9603450 A;;US 56095 P;;US 381895 P;;US 9610778 W,1995-06-27,Pyridinone-thrombin inhibitors,,MERCK & CO INC,SANDERSON PHILIP E;;NAYLOR-OLSEN ADEL M;;DYER DONA L;;VACCA JOSEPH P;;ISAACS RICHARD C A;;DORSEY BRUCE D;;FRALEY MARK E,,https://lens.org/154-114-467-769-244,Granted Patent,no,0,0,7,8,0,A61P7/02;;A61P43/00;;C07D213/64;;C07D213/74;;C07D213/75;;C07D213/76;;C07D401/12;;C07K5/06139,A61K31/44;;A61P7/02;;A61P43/00;;C07D213/64;;C07D213/74;;C07D213/75;;C07D213/76;;C07D401/12;;C07K5/078,,0,0,,,,EXPIRED
235,AU,A,AU 1996/063917 A,192-728-819-292-836,1997-01-30,1997,AU 1996/063917 A,1996-06-24,GB 9603450 A;;US 56095 P;;US 381895 P;;US 9610778 W,1995-06-27,Pyridinone-thrombin inhibitors,,MERCK & CO INC,SANDERSON PHILIP E;;NAYLOR-OLSEN ADEL M;;DYER DONA L;;VACCA JOSEPH P;;ISAACS RICHARD C A;;DORSEY BRUCE D;;FRALEY MARK E,,https://lens.org/192-728-819-292-836,Patent Application,no,0,0,7,8,0,A61P7/02;;A61P43/00;;C07D213/64;;C07D213/74;;C07D213/75;;C07D213/76;;C07D401/12;;C07K5/06139,A61K31/44;;A61P7/02;;A61P43/00;;C07D213/64;;C07D213/74;;C07D213/75;;C07D213/76;;C07D401/12;;C07K5/078,,0,0,,,,EXPIRED
236,US,A,US 5744486 A,113-582-288-853-926,1998-04-28,1998,US 82940697 A,1997-03-31,US 82940697 A;;US 66918996 A,1996-06-24,Pyridinone thrombin inhibitors,Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions and have the following structure: ##STR1## for example: ##STR2##,MERCK & CO INC,SANDERSON PHILIP E;;NAYLOR-OLSEN ADEL M;;DYER DONA L;;VACCA JOSEPH P;;ISAACS RICHARD C A;;DORSEY BRUCE D;;FRALEY MARK E,,https://lens.org/113-582-288-853-926,Granted Patent,yes,3,13,2,2,0,A61K38/00;;C07K5/06139;;C07K5/06139;;A61K38/00,A61K38/00;;C07K5/078,514/318;;546/194;;546/208,1,1,023-175-857-350-704,10.1021/jm00046a016;;7932559;;10.2210/pdb1eas/pdb,"Bernstein, et al., J. Med. Chem., 37, 3313 3326 Nonpeptidic Inhibitors of Human Leukocyte Elastase . . . , 1994.",EXPIRED
237,US,A,US 5668289 A,104-777-302-118-711,1997-09-16,1997,US 66918996 A,1996-06-24,US 66918996 A,1996-06-24,Pyridinone thrombin inhibitors,Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions and have the following structure: ##STR1## for example: ##STR2##,MERCK & CO INC,SANDERSON PHILIP E;;NAYLOR-OLSEN ADEL M;;DYER DONA L;;VACCA JOSEPH P;;ISAACS RICHARD C A;;DORSEY BRUCE D;;FRALEY MARK E,MERCK & CO. INC (1996-06-19),https://lens.org/104-777-302-118-711,Granted Patent,yes,3,59,2,2,0,A61K38/00;;C07K5/06139;;C07K5/06139;;A61K38/00,A61K38/00;;C07K5/078,546/293,1,1,023-175-857-350-704,10.1021/jm00046a016;;7932559;;10.2210/pdb1eas/pdb,"Bernstein, et al., J. Med. Chem., 37, 3313 3326 Nonpeptidic Inhibitors of Human Leukocyte Elastase . . . , 1994.",EXPIRED
238,WO,A1,WO 1997/001338 A1,119-253-687-019-112,1997-01-16,1997,US 9610778 W,1996-06-24,GB 9603450 A;;US 56095 P;;US 381895 P,1995-06-27,PYRIDINONE-THROMBIN INHIBITORS,"Coupounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions and have structure (I), for example (a).",MERCK & CO INC;;SANDERSON PHILIP E;;NAYLOR OLSEN ADEL M;;DYER DONA L;;VACCA JOSEPH P;;ISAACS RICHARD C A;;DORSEY BRUCE D;;FRALEY MARK E,SANDERSON PHILIP E;;NAYLOR-OLSEN ADEL M;;DYER DONA L;;VACCA JOSEPH P;;ISAACS RICHARD C A;;DORSEY BRUCE D;;FRALEY MARK E,,https://lens.org/119-253-687-019-112,Patent Application,yes,2,108,7,8,0,A61P7/02;;A61P43/00;;C07D213/64;;C07D213/74;;C07D213/75;;C07D213/76;;C07D401/12;;C07K5/06139,A61K31/44;;A61P7/02;;A61P43/00;;C07D213/64;;C07D213/74;;C07D213/75;;C07D213/76;;C07D401/12;;C07K5/078,,2,1,023-175-857-350-704,10.1021/jm00046a016;;7932559;;10.2210/pdb1eas/pdb,"J. MED. CHEM., 1994, Vol. 37, BERNSTEIN et al., ""Nonpeptidic Inhibitors of Human Leukocyte Elastase. 3.1 Design, Synthesis, X-Ray Crystallographic Analysis, and Structure-Activity Relationships for a Series of Orally Active 3-Amino-6-Phenylpyridin-2-One Trifluoromethyl Ketones"", pages 3313-3326.;;See also references of EP 0835109A4",PENDING
239,EP,A1,EP 0835109 A1,170-517-928-538-825,1998-04-15,1998,EP 96923399 A,1996-06-24,GB 9603450 A;;US 9610778 W;;US 56095 P;;US 381895 P,1995-06-27,PYRIDINONE-THROMBIN INHIBITORS,,MERCK & CO INC,SANDERSON PHILIP E;;NAYLOR-OLSEN ADEL M;;DYER DONA L;;VACCA JOSEPH P;;ISAACS RICHARD C A;;DORSEY BRUCE D;;FRALEY MARK E,,https://lens.org/170-517-928-538-825,Patent Application,yes,0,0,7,8,0,A61P7/02;;A61P43/00;;C07D213/64;;C07D213/74;;C07D213/75;;C07D213/76;;C07D401/12;;C07K5/06139,A61K31/44;;A61P7/02;;A61P43/00;;C07D213/64;;C07D213/74;;C07D213/75;;C07D213/76;;C07D401/12;;C07K5/078,,0,0,,,,DISCONTINUED
240,CA,A1,CA 2224437 A1,121-141-419-087-667,1997-01-16,1997,CA 2224437 A,1996-06-24,GB 9603450 A;;US 56095 P;;US 381895 P,1995-06-27,PYRIDINONE-THROMBIN INHIBITORS,"Coupounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions and have structure (I), for example (a).",MERCK & CO INC,VACCA JOSEPH P;;SANDERSON PHILIP E;;FRALEY MARK E;;NAYLOR-OLSEN ADEL M;;DYER DONA L;;DORSEY BRUCE D;;ISSACS RICHARD C A,,https://lens.org/121-141-419-087-667,Patent Application,no,0,0,7,8,0,A61P7/02;;A61P43/00;;C07D213/64;;C07D213/74;;C07D213/75;;C07D213/76;;C07D401/12;;C07K5/06139,A61K31/44;;A61P7/02;;A61P43/00;;C07D213/64;;C07D213/74;;C07D213/75;;C07D213/76;;C07D401/12;;C07K5/078,,0,0,,,,DISCONTINUED
241,EP,A4,EP 0835109 A4,072-289-764-826-446,1999-02-03,1999,EP 96923399 A,1996-06-24,GB 9603450 A;;US 9610778 W;;US 56095 P;;US 381895 P,1995-06-27,PYRIDINONE-THROMBIN INHIBITORS,,MERCK & CO INC,SANDERSON PHILIP E;;NAYLOR-OLSEN ADEL M;;DYER DONA L;;VACCA JOSEPH P;;ISAACS RICHARD C A;;DORSEY BRUCE D;;FRALEY MARK E,,https://lens.org/072-289-764-826-446,Search Report,no,1,0,7,8,0,A61P7/02;;A61P43/00;;C07D213/64;;C07D213/74;;C07D213/75;;C07D213/76;;C07D401/12;;C07K5/06139,A61K31/44;;A61P7/02;;A61P43/00;;C07D213/64;;C07D213/74;;C07D213/75;;C07D213/76;;C07D401/12;;C07K5/078,,1,0,,,See also references of WO 9701338A1,DISCONTINUED
242,US,A,US 5872138 A,093-391-342-223-453,1999-02-16,1999,US 92660697 A,1997-09-10,US 92660697 A;;US 2603396 P,1996-09-13,Thrombin inhibitors,A compound which inhibits human thrombin and which has the general structure ##STR1##,MERCK & CO INC,NAYLOR-OLSEN ADEL M;;PONTICELLO GERALD S;;VACCA JOSEPH P;;HUNGATE RANDALL W;;COBURN CRAIG;;PHILLIPS BRIAN T;;LEWIS S D;;FRALEY MARK E,MERCK & CO. INC (1996-10-30),https://lens.org/093-391-342-223-453,Granted Patent,yes,14,44,1,9,0,C07C257/18;;C07D213/73;;C07D213/74;;C07D295/26;;C07D405/12;;C07D213/73;;C07D213/74;;C07D295/26;;C07C257/18;;C07D405/12,C07C257/18;;C07D213/73;;C07D213/74;;C07D295/26;;C07D405/12,514/352;;514/255;;514/637;;544/383;;546/312;;564/245,6,6,009-322-344-338-208;;049-917-404-660-498;;082-212-859-841-769;;005-101-078-984-914;;034-696-567-355-382;;023-175-857-350-704,10.1021/jm00158a024;;3735314;;10.1021/ja00758a035;;10.1021/jm00174a007;;2258899;;10.1021/jm00253a016;;4151968;;10.3109/14756369509040682;;8568568;;10.1021/jm00046a016;;7932559;;10.2210/pdb1eas/pdb,"Johnson RA et al. J. Med Chem. 29(8), pp. 1461 1468, 1986.;;Cohen T and Deets GL. J. Am. Chem. Soc. 94 (3), pp. 932 937, Feb. 1972.;;Efange MN et al. J. Med. Chem. 33 (12), pp. 3133 3138, 1990.;;Archibald JI and Benke GA. J Med. Chem. 17 (7), pp. 736 739, 1974.;;Mack et al., J. Enzyme Inhibition, Design, Synthesis and Biological Activity of Novel Rigid Amidino Phenylalanine . . . , vol. 9, pp. 73 86 (1965).;;Bernstein, et al., J. Med. Chem., 37, 3313 3326 Nonpeptidic Inhibitors of Human Leukocyte Elastase . . . , 1994.",EXPIRED
243,WO,A1,WO 1998/010763 A1,009-457-630-967-847,1998-03-19,1998,US 9715989 W,1997-09-09,GB 9624278 A;;US 2603396 P,1996-09-13,THROMBIN INHIBITORS,A compound which inhibits human thrombin and which has general structure (I) such as formula (a).,MERCK & CO INC;;NAYLOR OLSEN ADEL M;;PONTICELLO GERALD S;;VACCA JOSEPH P;;HUNGATE RANDALL W;;COBURN CRAIG;;PHILLIPS BRIAN T;;LEWIS S D;;FRALEY MARK E,NAYLOR-OLSEN ADEL M;;PONTICELLO GERALD S;;VACCA JOSEPH P;;HUNGATE RANDALL W;;COBURN CRAIG;;PHILLIPS BRIAN T;;LEWIS S D;;FRALEY MARK E,,https://lens.org/009-457-630-967-847,Patent Application,yes,2,36,7,9,0,A61P7/02;;C07D213/73;;C07C257/18;;C07D213/74;;C07D295/26;;C07D405/12,C07D295/22;;A61K31/155;;A61K31/4409;;A61K31/443;;A61K31/4545;;A61K31/495;;A61P7/02;;C07C257/18;;C07D213/16;;C07D213/30;;C07D213/73;;C07D213/74;;C07D295/26;;C07D405/12,,2,1,034-696-567-355-382,10.3109/14756369509040682;;8568568,"J. ENZYME INHIBITION, 1995, Vol. 9, MACK et al., ""Design, Synthesis and Biological Activity of Novel Rigid Amidino-Phenylalanine Derivatives as Inhibitors of Thrombin"", pages 73-86.;;See also references of EP 0927035A4",PENDING
244,EP,A4,EP 0927035 A4,074-933-421-377-64X,2002-11-13,2002,EP 97942415 A,1997-09-09,GB 9624278 A;;US 9715989 W;;US 2603396 P,1996-09-13,THROMBIN INHIBITORS,,MERCK & CO INC,NAYLOR-OLSEN ADEL M;;PONTICELLO GERALD S;;VACCA JOSEPH P;;HUNGATE RANDALL W;;COBURN CRAIG;;PHILLIPS BRIAN T;;LEWIS S D;;FRALEY MARK E,,https://lens.org/074-933-421-377-64X,Search Report,no,6,0,7,9,0,A61P7/02;;C07D213/73;;C07C257/18;;C07D213/74;;C07D295/26;;C07D405/12,C07D295/22;;A61K31/155;;A61K31/4409;;A61K31/443;;A61K31/4545;;A61K31/495;;A61P7/02;;C07C257/18;;C07D213/16;;C07D213/30;;C07D213/73;;C07D213/74;;C07D295/26;;C07D405/12,,8,5,082-212-859-841-769;;001-163-007-522-729;;059-198-887-141-354;;076-974-673-861-220;;026-907-984-003-289,10.1021/jm00174a007;;2258899;;5637194;;10.1021/jm00307a019;;10.1135/cccc19753904;;10.1021/jo01066a030;;10.1007/bf02171857,"EFANGE ET AL: ""Flexible N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Analogues: Synthesis Monamine Oxidase Catalyzed Bioactivation"", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 33, no. 12, 1990, pages 3133 - 3142, XP002119483, ISSN: 0022-2623;;DATABASE CROSSFIRE BEILSTEIN Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; 27 June 1988 (1988-06-27), XP002213631;;JAIN ET AL: ""Chemical and pharmacological investigations of some.omega.-substituted alkylamino-3-aminopyridines"", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 11, no. 1, 1968, pages 87 - 92, XP002093777, ISSN: 0022-2623;;DATABASE WPI Section Ch Week 197734, Derwent World Patents Index; Class C02, AN 1977-60361Y, XP002213632;;PROTIVA M ET AL: ""1-ARYL- AND 1-(ARYLMETHYL)-4-GUANYLPIPERAZINES AND OTHER HETEROCYCLIC AND ALICYCLIC GUANIDINE DERIVATIVES"", COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, ACADEMIC PRESS, LONDON, GB, vol. 40, 1975, pages 3904 - 3923, XP000574972, ISSN: 0010-0765;;WALKER G N ET AL: ""APPLICATION OF SODIUM BOROHYDRIDE, REDUCTION TO SYNTHESIS OF SUBSTITUTED AMINOPIPERIDINES, AMINOPIPERAZINES, AMINOPYRIDINES AND HYDRAZINES"", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 26, no. 8, 14 August 1961 (1961-08-14), pages 2740 - 2747, XP002071843, ISSN: 0022-3263;;MAO S-S: ""FACTOR XA INHIBITORS"", PERSPECTIVES IN DRUG DISCOVERY AND DESIGN, ESCOM SCIENCE PUBLISHERS BV, XX, vol. 1, no. 3, 1993, pages 423 - 430, XP000654087, ISSN: 0928-2866;;See also references of WO 9810763A1",DISCONTINUED
245,AU,A,AU 1997/044117 A,143-656-564-055-873,1998-04-02,1998,AU 1997/044117 A,1997-09-09,GB 9624278 A;;US 2603396 P;;US 9715989 W,1996-09-13,Thrombin inhibitors,,MERCK & CO INC,NAYLOR-OLSEN ADEL M;;PONTICELLO GERALD S;;VACCA JOSEPH P;;HUNGATE RANDALL W;;COBURN CRAIG;;PHILLIPS BRIAN T;;LEWIS S D;;FRALEY MARK E,,https://lens.org/143-656-564-055-873,Patent Application,no,0,0,7,9,0,A61P7/02;;C07D213/73;;C07C257/18;;C07D213/74;;C07D295/26;;C07D405/12,C07D295/22;;A61K31/155;;A61K31/4409;;A61K31/443;;A61K31/4545;;A61K31/495;;A61P7/02;;C07C257/18;;C07D213/16;;C07D213/30;;C07D213/73;;C07D213/74;;C07D295/26;;C07D405/12,,0,0,,,,EXPIRED
246,EP,A1,EP 0927035 A1,133-059-498-766-045,1999-07-07,1999,EP 97942415 A,1997-09-09,GB 9624278 A;;US 9715989 W;;US 2603396 P,1996-09-13,THROMBIN INHIBITORS,,MERCK & CO INC,NAYLOR-OLSEN ADEL M;;PONTICELLO GERALD S;;VACCA JOSEPH P;;HUNGATE RANDALL W;;COBURN CRAIG;;PHILLIPS BRIAN T;;LEWIS S D;;FRALEY MARK E,,https://lens.org/133-059-498-766-045,Patent Application,yes,0,0,7,9,0,A61P7/02;;C07D213/73;;C07C257/18;;C07D213/74;;C07D295/26;;C07D405/12,C07D295/22;;A61K31/155;;A61K31/4409;;A61K31/443;;A61K31/4545;;A61K31/495;;A61P7/02;;C07C257/18;;C07D213/16;;C07D213/30;;C07D213/73;;C07D213/74;;C07D295/26;;C07D405/12,,0,0,,,,DISCONTINUED
247,CA,A1,CA 2264037 A1,028-287-732-398-278,1998-03-19,1998,CA 2264037 A,1997-09-09,GB 9624278 A;;US 2603396 P;;US 9715989 W,1996-09-13,THROMBIN INHIBITORS,A compound which inhibits human thrombin and which has general structure (I) such as formula (a).,MERCK & CO INC,HUNGATE RANDALL W;;LEWIS S D;;COBURN CRAIG;;PHILLIPS BRIAN T;;NAYLOR-OLSEN ADEL M;;VACCA JOSEPH P;;PONTICELLO GERALD S;;FRALEY MARK E,,https://lens.org/028-287-732-398-278,Patent Application,no,0,0,7,9,0,A61P7/02;;C07D213/73;;C07C257/18;;C07D213/74;;C07D295/26;;C07D405/12,C07D295/22;;A61K31/155;;A61K31/4409;;A61K31/443;;A61K31/4545;;A61K31/495;;A61P7/02;;C07C257/18;;C07D213/16;;C07D213/30;;C07D213/73;;C07D213/74;;C07D295/26;;C07D405/12,,0,0,,,,DISCONTINUED
248,AU,B2,AU 725403 B2,165-585-499-298-862,2000-10-12,2000,AU 1997/044117 A,1997-09-09,GB 9624278 A;;US 2603396 P;;US 9715989 W,1996-09-13,Thrombin inhibitors,,MERCK & CO INC,NAYLOR-OLSEN ADEL M;;PONTICELLO GERALD S;;VACCA JOSEPH P;;HUNGATE RANDALL W;;COBURN CRAIG;;PHILLIPS BRIAN T;;LEWIS S D;;FRALEY MARK E,,https://lens.org/165-585-499-298-862,Granted Patent,no,1,0,7,9,0,A61P7/02;;C07D213/73;;C07C257/18;;C07D213/74;;C07D295/26;;C07D405/12,C07D295/22;;A61K31/155;;A61K31/4409;;A61K31/443;;A61K31/4545;;A61K31/495;;A61P7/02;;C07C257/18;;C07D213/16;;C07D213/30;;C07D213/73;;C07D213/74;;C07D295/26;;C07D405/12,,0,0,,,,EXPIRED
249,EP,A1,EP 3753600 A1,152-707-605-278-824,2020-12-23,2020,EP 20189096 A,2015-10-30,US 201462073766 P;;US 201562142895 P;;US 201562156152 P;;EP 15791220 A;;US 2015/0058505 W,2014-10-31,SYSTEMS FOR TREATING HYDROCEPHALUS,"An implantable shunt (200) for treating hydrocephalus having one or more cerebrospinal fluid (CSF) intake openings in a distal portion of the shunt, a valve (209) disposed in a proximal portion of the shunt, and a lumen (207) extending between the one or more CSF intake openings and the valve, the shunt (200) being configured for implantation in a patient such that the one or more CSF intake openings disposed within the cerebellopontine (CP) angle cistern, a body (203) of the shunt (200) is disposed within the inferior petrosal sinus (102), and the proximal portion (204) of the shunt (200) is disposed within or proximate to the jugular vein (106), such that CSF flows from the CP angle cistern to the jugular vein (106) via the shunt lumen (207).
",CEREVASC INC,HEILMAN CARL;;MALEK ADEL M;;BHANDARI AYAN A;;CERIER JEFFREY C;;CRUZ AMOS G;;GORDON JOSEPH;;JOHNSON THOMAS R;;MARTIN GREGORY T;;O'KEEFE JONATHAN B;;REZAC DAVID A;;ROBINSON TIMOTHY W;;SIWINSKI SHANE;;TING JOSEPH;;TOYJANOVA JENNET;;ZIEGLER ANDREW,,https://lens.org/152-707-605-278-824,Patent Application,yes,10,0,30,30,0,A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M27/006;;A61M39/24;;A61M2210/06;;A61M2039/2426;;A61M2039/242;;A61M27/006;;A61B17/3401;;A61B17/3478;;A61M27/006;;A61B6/12;;A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M25/10;;A61M39/24;;A61M2039/242;;A61B34/20;;A61B18/14;;A61B2018/1425;;A61B18/1477;;A61B2018/00446;;A61B2018/00619;;A61M2210/06;;A61B18/1492;;A61M2039/2426,A61M27/00,,0,0,,,,PENDING
250,EP,A1,EP 3212275 A1,169-572-115-004-005,2017-09-06,2017,EP 15791220 A,2015-10-30,US 201462073766 P;;US 201562142895 P;;US 201562156152 P;;US 2015/0058505 W,2014-10-31,SYSTEM FOR TREATING HYDROCEPHALUS,,CEREVASC LLC,HEILMAN CARL;;MALEK ADEL M;;BHANDARI AYAN A;;CERIER JEFFREY C;;CRUZ AMOS G;;GORDON JOSEPH;;JOHNSON THOMAS R;;MARTIN GREGORY T;;O'KEEFE JONATHAN B;;REZAC DAVID A;;ROBINSON TIMOTHY W;;SIWINSKI SHANE;;TING JOSEPH;;TOYJANOVA JENNET;;ZIEGLER ANDREW,"CEREVASC, INC., AUBURNDALE, US (2020-10-14);;CEREVASC, INC. (2020-10-14)",https://lens.org/169-572-115-004-005,Patent Application,yes,0,0,30,30,0,A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M27/006;;A61M39/24;;A61M2210/06;;A61M2039/2426;;A61M2039/242;;A61M27/006;;A61B17/3401;;A61B17/3478;;A61M27/006;;A61B6/12;;A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M25/10;;A61M39/24;;A61M2039/242;;A61B34/20;;A61B18/14;;A61B2018/1425;;A61B18/1477;;A61B2018/00446;;A61B2018/00619;;A61M2210/06;;A61B18/1492;;A61M2039/2426,A61M27/00,,0,0,,,,ACTIVE
251,WO,A1,WO 2016/070147 A1,172-407-690-157-429,2016-05-06,2016,US 2015/0058505 W,2015-10-30,US 201462073766 P;;US 201562142895 P;;US 201562156152 P,2014-10-31,METHODS AND SYSTEMS FOR TREATING HYDROCEPHALUS,"An implantable shunt for treating hydrocephalus having one or more cerebrospinal fluid (CSF) intake openings in a distal portion of the shunt, a valve disposed in a proximal portion of the shunt, and a lumen extending between the one or more CSF intake openings and the valve, the shunt being configured for implantation in a patient such that the one or more CSF intake openings disposed within the cerebellopontine (CP) angle cistern, a body of the shunt is disposed within the inferior petrosal sinus (IPS), and the proximal portion of the shunt is disposed within or proximate to the jugular vein (JV), such that CSF flows from the CP angle cistern to the JV via the shunt lumen.",CEREVASC LLC,HEILMAN CARL;;MALEK ADEL M;;BHANDARI AYAN A;;CERIER JEFFREY C;;CRUZ AMOS G;;GORDON JOSEPH;;JOHNSON THOMAS R;;MARTIN GREGORY T;;O'KEEFE JONATHAN B;;REZAC DAVID A;;ROBINSON TIMOTHY W;;SIWINSKI SHANE;;TING JOSEPH;;TOYJANOVA JENNET;;ZIEGLER ANDREW,,https://lens.org/172-407-690-157-429,Patent Application,yes,6,23,30,30,0,A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M27/006;;A61M39/24;;A61M2210/06;;A61M2039/2426;;A61M2039/242;;A61M27/006;;A61B17/3401;;A61B17/3478;;A61M27/006;;A61B6/12;;A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M25/10;;A61M39/24;;A61M2039/242;;A61B34/20;;A61B18/14;;A61B2018/1425;;A61B18/1477;;A61B2018/00446;;A61B2018/00619;;A61M2210/06;;A61B18/1492;;A61M2039/2426,A61M27/00,,0,0,,,,PENDING
252,EP,B1,EP 3212275 B1,019-241-741-721-268,2020-08-05,2020,EP 15791220 A,2015-10-30,US 201462073766 P;;US 201562142895 P;;US 201562156152 P;;US 2015/0058505 W,2014-10-31,SYSTEM FOR TREATING HYDROCEPHALUS,,CEREVASC LLC,HEILMAN CARL;;MALEK ADEL M;;BHANDARI AYAN A;;CERIER JEFFREY C;;CRUZ AMOS G;;GORDON JOSEPH;;JOHNSON THOMAS R;;MARTIN GREGORY T;;O'KEEFE JONATHAN B;;REZAC DAVID A;;ROBINSON TIMOTHY W;;SIWINSKI SHANE;;TING JOSEPH;;TOYJANOVA JENNET;;ZIEGLER ANDREW,"CEREVASC, INC., AUBURNDALE, US (2020-10-14);;CEREVASC, INC. (2020-10-14)",https://lens.org/019-241-741-721-268,Granted Patent,yes,4,0,30,30,0,A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M27/006;;A61M39/24;;A61M2210/06;;A61M2039/2426;;A61M2039/242;;A61M27/006;;A61B17/3401;;A61B17/3478;;A61M27/006;;A61B6/12;;A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M25/10;;A61M39/24;;A61M2039/242;;A61B34/20;;A61B18/14;;A61B2018/1425;;A61B18/1477;;A61B2018/00446;;A61B2018/00619;;A61M2210/06;;A61B18/1492;;A61M2039/2426,A61M27/00,,0,0,,,,ACTIVE
253,US,A1,US 2016/0136398 A1,103-883-540-139-545,2016-05-19,2016,US 201514929066 A,2015-10-30,US 201514929066 A;;US 201462073766 P;;US 201562142895 P;;US 201562156152 P,2014-10-31,METHODS AND SYSTEMS FOR TREATING HYDROCEPHALUS,"Methods for treating hydrocephalus using a shunt, the shunt having one or more CSF intake openings in a distal portion, a valve disposed in a proximal portion of the shunt, and a lumen extending between the one or more CSF intake openings and the valve, the method comprises deploying the shunt in a body of a patient so that the distal portion of the shunt is at least partially disposed within a CP angle cistern, a body of the shunt is at least partially disposed within an IPS of the patient, and the proximal portion of the shunt is at least partially disposed within or proximate to a JV of the patient, wherein, after deployment of the shunt, CSF flows from the CP angle cistern to the JV via the shunt lumen at a flow rate in a range of 5 ml per hour to 15 ml per hour.",CEREVASC LLC,HEILMAN CARL;;MALEK ADEL M;;BHANDARI AYAN A;;CERIER JEFFREY C;;CRUZ AMOS G;;GORDON JOSEPH;;JOHNSON THOMAS R;;MARTIN GREGORY T;;O'KEEFE JONATHAN B;;REZAC DAVID A;;ROBINSON TIMOTHY W;;SIWINSKI SHANE;;TING JOSEPH;;TOYJANOVA JENNET;;ZIEGLER ANDREW,CEREVASC INC (2015-05-12),https://lens.org/103-883-540-139-545,Patent Application,yes,0,41,30,30,0,A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M27/006;;A61M39/24;;A61M2210/06;;A61M2039/2426;;A61M2039/242;;A61M27/006;;A61B17/3401;;A61B17/3478;;A61M27/006;;A61B6/12;;A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M25/10;;A61M39/24;;A61M2039/242;;A61B34/20;;A61B18/14;;A61B2018/1425;;A61B18/1477;;A61B2018/00446;;A61B2018/00619;;A61M2210/06;;A61B18/1492;;A61M2039/2426,A61M27/00;;A61B6/12;;A61M25/00;;A61M25/01;;A61M25/09;;A61M25/10;;A61M39/24,,0,0,,,,DISCONTINUED
254,CN,A,CN 107148293 A,032-034-393-711-707,2017-09-08,2017,CN 201580058807 A,2015-10-30,US 201462073766 P;;US 201562142895 P;;US 201562156152 P;;US 2015/0058505 W,2014-10-31,Methods and systems for treating hydrocephalus,"An implantable shunt for treating hydrocephalus having one or more cerebrospinal fluid (CSF) intake openings in a distal portion of the shunt, a valve disposed in a proximal portion of the shunt, and a lumen extending between the one or more CSF intake openings and the valve, the shunt being configured for implantation in a patient such that the one or more CSF intake openings disposed within the cerebellopontine (CP) angle cistern, a body of the shunt is disposed within the inferior petrosal sinus (IPS), and the proximal portion of the shunt is disposed within or proximate to the jugular vein (JV), such that CSF flows from the CP angle cistern to the JV via the shunt lumen.",CEREVASC LLC,HEILMAN CARL;;MALEK ADEL M;;BHANDARI AYAN A;;CERIER JEFFREY C;;CRUZ AMOS G;;GORDON JOSEPH;;JOHNSON THOMAS R;;MARTIN GREGORY T;;O'KEEFE JONATHAN B;;REZAC DAVID A;;ROBINSON TIMOTHY W;;SIWINSKI SHANE;;TING JOSEPH;;TOYJANOVA JENNET;;ZIEGLER ANDREW,,https://lens.org/032-034-393-711-707,Patent Application,no,2,3,30,30,0,A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M27/006;;A61M39/24;;A61M2210/06;;A61M2039/2426;;A61M2039/242;;A61M27/006;;A61B17/3401;;A61B17/3478;;A61M27/006;;A61B6/12;;A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M25/10;;A61M39/24;;A61M2039/242;;A61B34/20;;A61B18/14;;A61B2018/1425;;A61B18/1477;;A61B2018/00446;;A61B2018/00619;;A61M2210/06;;A61B18/1492;;A61M2039/2426,A61M27/00;;A61M25/00;;A61M25/01;;A61M25/09;;A61M39/24,,0,0,,,,ACTIVE
255,JP,A,JP 2019193826 A,034-038-145-503-475,2019-11-07,2019,JP 2019116178 A,2019-06-24,US 201462073766 P;;US 201562142895 P;;US 201562156152 P,2014-10-31,METHOD AND SYSTEM FOR HYDROCEPHALUS TREATMENT,"To provide a shunt for hydrocephalus treatment configured to be arranged within an inferior petrosal sinus (IPS) of a patient.SOLUTION: An embeddable shunt 200 relating to hydrocephalus treatment comprises: one or more cerebrospinal fluid (CSF) intake openings in a distal portion 202 of the shunt; a valve 209 disposed in a proximal portion 204 of the shunt; and a lumen 207 extending between the one or more CSF intake openings and the valve. In the shunt, the one or more CSF intake openings are disposed within a cerebellopontine (CP) angle cistern 138, the body 203 of the shunt is disposed within the inferior petrosal sinus (IPS) 102 of the patient, and the proximal portion of the shunt is disposed within or proximate to a jugular vein (JV) 106 of the patient. As a result, the shunt is embedded in the patient such that CSF flows from the CP angle cistern to the JV via the shunt lumen.SELECTED DRAWING: Figure 3",CEREVASC LLC,CARL HEILMAN;;ADEL M MALEK;;AYAN A BHANDARI;;JEFFREY C CERIER;;AMOS G CRUZ;;JOSEPH GORDON;;THOMAS R JOHNSON;;GREGORY T MARTIN;;JONATHAN B O'KEEFE;;DAVID A REZAC;;TIMOTHY W ROBINSON;;SHANE SIWINSKI;;JOSEPH TING;;JENNET TOYJANOVA;;ANDREW ZIEGLER,,https://lens.org/034-038-145-503-475,Patent Application,no,4,0,30,30,0,A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M27/006;;A61M39/24;;A61M2210/06;;A61M2039/2426;;A61M2039/242;;A61M27/006;;A61B17/3401;;A61B17/3478;;A61M27/006;;A61B6/12;;A61M25/0067;;A61M25/0108;;A61M25/0155;;A61M25/09;;A61M25/10;;A61M39/24;;A61M2039/242;;A61B34/20;;A61B18/14;;A61B2018/1425;;A61B18/1477;;A61B2018/00446;;A61B2018/00619;;A61M2210/06;;A61B18/1492;;A61M2039/2426,A61M25/00;;A61M1/00,,0,0,,,,ACTIVE
256,WO,A2,WO 2004/101761 A2,148-117-055-168-22X,2004-11-25,2004,US 2004/0014733 W,2004-05-12,US 43622303 A,2003-05-12,METHODS FOR THE IDENTIFICATION OF INHIBITORS OF CAX1-LIKE Ca<+2>/H+ANTIPORTER ACTIVITY IN PLANTS,"The present inventors have discovered that CAX1 -like H+/Ca+2 antiporter is essential for plant growth. Specifically, the inhibition of CAX1-like H+/Ca+2 antiporter gene expression in plant seedlings results in reduced growth and abnormal development. Thus, CAX1-like H+/Ca+2 antiporter is useful as a target for the identification of herbicides. Accordingly, the present invention provides methods for the identification of herbicides by measuring the activity of a CAX 1 -like H+/Ca+2 antiporter in the presence and absence of a compound, where an alteration of CAX 1 -like H+/Ca+2 antiporter activity in the presence of the compound indicates the compound as a candidate for a herbicide.",PARADIGM GENETICS INC;;DEZWAAN TODD M;;GUO LINING;;DAVIS KEITH;;ZAYED ADEL;;KJEMTRUP SUSANNE;;BOYES DOUGLAS;;WARRICK BRENDA;;MITCHELL CAMERON JOSEPH;;ASCENZI ROBERT;;HAMILTON CAROL;;WOESSNER JEFFREY;;GORLACH JORN;;HOFFMAN NEIL;;MULPURI RAO,DEZWAAN TODD M;;GUO LINING;;DAVIS KEITH;;ZAYED ADEL;;KJEMTRUP SUSANNE;;BOYES DOUGLAS;;WARRICK BRENDA;;MITCHELL CAMERON JOSEPH;;ASCENZI ROBERT;;HAMILTON CAROL;;WOESSNER JEFFREY;;GORLACH JORN;;HOFFMAN NEIL;;MULPURI RAO,,https://lens.org/148-117-055-168-22X,Patent Application,yes,0,1,3,3,0,C12Q1/025;;G01N33/6872;;G01N33/6872;;C12Q1/025,C12N/;;C12Q1/00;;C12Q1/02;;G01N33/68,,0,0,,,,PENDING
257,US,A1,US 2004/0229208 A1,175-665-186-824-043,2004-11-18,2004,US 43622303 A,2003-05-12,US 43622303 A,2003-05-12,Methods for the identification of inhibitors of CAX1-like Ca+2/H+ antiporter activity in plants,"
    The present inventors have discovered that CAX1-like H/Ca ² antiporter is essential for plant growth. Specifically, the inhibition of CAX1-like H/Ca ² antiporter gene expression in plant seedlings results in reduced growth and abnormal development. Thus, CAX1-like H/Ca ² antiporter is useful as a target for the identification of herbicides. Accordingly, the present invention provides methods for the identification of herbicides by measuring the activity of a CAX1-like H/Ca ² antiporter in the presence and absence of a compound, where an alteration of CAX1-like H/Ca ² antiporter activity in the presence of the compound indicates the compound as a candidate for a herbicide. 
",TODD M. DEZWAAN;;GUO LINING;;DAVIS KEITH;;ZAYED ADEL;;KJEMTRUP SUSANNE;;BOYES DOUGLAS;;WARRICK BRENDA;;MITCHELL JOSEPH CAMERON;;ASCENZI ROBERT;;HAMILTON CAROL;;WOESSNER JEFFREY;;GORLACH JORN;;HOFFMAN NEIL;;MULPURI RAO,TODD M DEZWAAN;;GUO LINING;;DAVIS KEITH;;ZAYED ADEL;;KJEMTRUP SUSANNE;;BOYES DOUGLAS;;WARRICK BRENDA;;MITCHELL JOSEPH CAMERON;;ASCENZI ROBERT;;HAMILTON CAROL;;WOESSNER JEFFREY;;GORLACH JORN;;HOFFMAN NEIL;;MULPURI RAO,PARADIGM GENETICS INC (2003-07-22);;ICORIA INC (2004-04-17),https://lens.org/175-665-186-824-043,Patent Application,yes,0,1,3,3,7,C12Q1/025;;G01N33/6872;;G01N33/6872;;C12Q1/025,C12N/;;C12Q1/00;;C12Q1/02;;G01N33/68,435/4,0,0,,,,DISCONTINUED
258,US,A1,US 2004/0265836 A1,165-304-396-063-928,2004-12-30,2004,US 61015603 A,2003-06-30,US 61015603 A,2003-06-30,Methods for the identification of inhibitors of C4 Long Chain Base Hydroxylase activity in plants,"
    The present inventors have discovered that LCBH is essential for plant growth. Specifically, the inhibition of LCBH gene expression in Arabidopsis results in reduced growth and abnormal development. Thus, LCBH is useful as a target for the identification of herbicides. Accordingly, the present invention provides methods for the identification of herbicides by measuring the activity of a LCBH in the presence and absence of a compound, where an alteration of LCBH activity in the presence of the compound indicates the compound as a candidate for a herbicide. 
",TODD M. DEZWAAN;;GUO LINING;;DAVIS KEITH;;ZAYED ADEL;;KJEMTRUP SUSANNE;;BOYES DOUGLAS;;WARRICK BRENDA;;MITCHELL JOSEPH CAMERON;;ASCENZI ROBERT;;HAMILTON CAROL;;WOESSNER JEFFREY;;GORLACH JORN;;HOFFMAN NEIL;;MULPURI RAO,TODD M DEZWAAN;;GUO LINING;;DAVIS KEITH;;ZAYED ADEL;;KJEMTRUP SUSANNE;;BOYES DOUGLAS;;WARRICK BRENDA;;MITCHELL JOSEPH CAMERON;;ASCENZI ROBERT;;HAMILTON CAROL;;WOESSNER JEFFREY;;GORLACH JORN;;HOFFMAN NEIL;;MULPURI RAO,PARADIGM GENETICS INC (2003-10-03);;ICORIA INC (2004-04-17),https://lens.org/165-304-396-063-928,Patent Application,yes,1,0,3,3,10,C12Q1/6895;;C12Q2600/158;;C12Q1/6895;;C12Q2600/158,A01N63/00;;A61K38/00;;C12N15/00;;C12N15/09;;C12Q/;;C12Q1/34;;C12Q1/68,435/6,0,0,,,,DISCONTINUED
259,WO,A3,WO 2004/101761 A3,085-111-358-378-944,2006-07-06,2006,US 2004/0014733 W,2004-05-12,US 43622303 A,2003-05-12,METHODS FOR THE IDENTIFICATION OF INHIBITORS OF CAX1-LIKE Ca+2/H+ANTIPORTER ACTIVITY IN PLANTS,"The present inventors have discovered that CAX1 -like H+/Ca+2 antiporter is essential for plant growth. Specifically, the inhibition of CAX1-like H+/Ca+2 antiporter gene expression in plant seedlings results in reduced growth and abnormal development. Thus, CAX1-like H+/Ca+2 antiporter is useful as a target for the identification of herbicides. Accordingly, the present invention provides methods for the identification of herbicides by measuring the activity of a CAX 1 -like H+/Ca+2 antiporter in the presence and absence of a compound, where an alteration of CAX 1 -like H+/Ca+2 antiporter activity in the presence of the compound indicates the compound as a candidate for a herbicide.",PARADIGM GENETICS INC;;DEZWAAN TODD M;;GUO LINING;;DAVIS KEITH;;ZAYED ADEL;;KJEMTRUP SUSANNE;;BOYES DOUGLAS;;WARRICK BRENDA;;MITCHELL CAMERON JOSEPH;;ASCENZI ROBERT;;HAMILTON CAROL;;WOESSNER JEFFREY;;GORLACH JORN;;HOFFMAN NEIL;;MULPURI RAO,DEZWAAN TODD M;;GUO LINING;;DAVIS KEITH;;ZAYED ADEL;;KJEMTRUP SUSANNE;;BOYES DOUGLAS;;WARRICK BRENDA;;MITCHELL CAMERON JOSEPH;;ASCENZI ROBERT;;HAMILTON CAROL;;WOESSNER JEFFREY;;GORLACH JORN;;HOFFMAN NEIL;;MULPURI RAO,,https://lens.org/085-111-358-378-944,Search Report,yes,1,0,3,3,0,C12Q1/025;;G01N33/6872;;G01N33/6872;;C12Q1/025,C12Q1/00;;C12N/;;C12Q1/02;;G01N33/68,,3,3,089-343-246-110-837;;100-993-926-856-983;;101-764-588-777-082,pmc38751;;8710949;;10.1073/pnas.93.16.8782;;10.1016/s0378-1119(00)00390-5;;11080595;;10.1016/s0021-9258(19)38713-7;;2351660,"HIRSCHI ET AL.: ""CAX1, and H+/Ca2+antiporter from Arabidopsis"", PROC. NATL. ACAD. SCI. USA, vol. 93, August 1996 (1996-08-01), pages 8782 - 8786, XP002998098;;SHIGAKI ET AL.: ""Characterization of CAX-like genes in plants: implications for functional diversity"", GENE, vol. 257, 2000, pages 291 - 298, XP004224851;;BLACKFORD ET AL.: ""Voltage Sensitivity of H+/Ca2+ Antiport in Higher Plant Tonoplast Suggests a Role in Vascular Calcium Accumulation"", J. BIOL. CHEM., vol. 265, 15 June 1990 (1990-06-15), pages 9617 - 9620, XP002998099",PENDING
260,US,B1,US 6770452 B1,030-503-216-943-95X,2004-08-03,2004,US 40281803 A,2003-03-28,US 40281803 A,2003-03-28,Methods for the identification of inhibitors of serine acetyltransferase activity in plants,"
    The present inventors have discovered that serine acetyltransferase (SAT) is essential for plant growth. Specifically, the inhibition of SAT gene expression in plant seedlings results in reduced growth and altered pigmentation. Thus, SAT is useful as a target for the identification of herbicides. Accordingly, the present invention provides methods for the identification of herbicides by measuring the activity of an SAT in the presence and absence of a compound, wherein an alteration of SAT activity in the presence of the compound indicates the compound as a candidate for a herbicide. 
",PARADIGM GENETICS INC,RICE JOHN W;;GUO LINING;;DAVIS KEITH;;ZAYED ADEL;;ASCENZI ROBERT;;MITCHELL JOSEPH CAMERON;;RIGGSBEE DANIEL N;;BOYES DOUGLAS;;MULPURI RAO;;HOFFMAN NEIL;;KJEMTRUP SUSANNE;;HAMILTON CAROL;;WOESSNER JEFFREY;;GORLACH JORN,PARADIGM GENETICS INC (2003-06-02);;ICORIA INC (2004-04-17),https://lens.org/030-503-216-943-95X,Granted Patent,yes,1,0,3,3,11,C12N9/1029;;C12N15/8261;;C12N15/8274;;C12Q1/48;;G01N2333/91057;;G01N2500/02;;Y02A40/146;;C12N9/1029;;G01N2333/91057;;C12Q1/48;;C12N15/8261;;G01N2500/02;;C12N15/8274;;Y02A40/146,C12N9/10;;C12N15/82;;C12Q1/48,435/15;;435/69.2;;435/193,10,10,016-416-690-895-323;;022-847-510-160-461;;048-728-226-777-327;;006-919-866-087-998;;054-561-149-838-733;;054-156-960-691-380;;005-484-329-746-517;;055-490-942-289-590;;039-864-862-754-388;;084-560-554-362-808,10.1093/pcp/pce078;;11427682;;11388466;;10.1271/bbb.65.865;;10.1016/s0378-1119(00)00399-1;;11080593;;10.1271/bbb.64.1874;;11055390;;10993149;;10.1271/bbb.64.1628;;9692924;;10.1046/j.1432-1327.1998.2550235.x;;9830017;;10.1074/jbc.273.49.32739;;10.1074/jbc.275.1.461;;10617639;;11168407;;10.1046/j.1432-1327.2001.01920.x;;10.1046/j.1365-313x.2000.00743.x;;10849350,"Noji, Masaaki et al., Serine Acetyltransferase Involved in Cysteine Biosynthesis from Spinach: Molecular Cloning, Characterization and Expression Analysis of cDNA Encoding a Plastidic Isoform. Plant Cell Physiol, 42(6): 627-634 (2001).;;Mino, Koshiki et al., Increase in the Stability of Serine Acetyltransferase from Escherichia coli Against Cold Inactivation and Proteolysis by Forming a Biendzyme Complex, Biosci. Biotechnol. Biochem., 65(4), 865-874, 2001.;;Urano, Yasuomi et al., Molecular Cloning and Functional Characterization of cDNAs Encoding Cysteine Synthase and Serine Acetyltransferase That May Be Responsible For High Cellular Cysteine Content in Allium Tuberosum, Gene, 257(2), 269-277, (2000).;;Mino, Koshiki et al., Characteristics of Serine Acetyltransferase From Escherichia coli Deleting Different Lengths of Amino Acid Residues from the C-Terminus, Biosci. Biotechnol. Biochem., 64(9) 1874-1880, 2000.;;Mino, Koshiki et al., Effects of Bienzyme Complex Formation of Cysteine Synthetase from Escherichia coli on Some Properties and Kinetics, Biosci. Biotechnol. Biochem., 64(8), 1628-1640, 2000.;;Droux, Michel et al., Interactions Between Serine Acetyltransferase and O-Acetylserine (Thiol) Lyase in Higher Plants-Structural and Kinetic Properties of the Free and Bound Enzymes, Eur. J. Biochem., 255, 235-245 (1998).;;Noji, Masaaki et al., Isoform-dependent Differences in Feedback Regulation And Subcellular Localization of Serine Acetyltransferase Involved in Cysteine Biosysynthesis from Arabidopsis thaliana, The Journal of Biological Chemistry, vol. 273, pp. 32739-32745, Issue of Dec. 4, 1998.;;Hindson, VJ et al., Serine Acetyltransferase from Escherichia coli is a Dimer of Trimers, The Journal of Biological Chemistry, vol. 275, No. 1, Issue of Jan., pp 461-466, 2000.;;Wirtz, Markus et al., The Cysteine Synthase Complex From Plants, Eur. J. Biochem, 268, 686-693, 2001.;;Harms, Karsten et al., Expression of a Bacterial Serine Acetyltransferase in Transgenic Potato Plants Leads to Increased Levels of Cysteine and Glutathione, The Plant Journal, 22(4), 335-343, 2000.",EXPIRED
261,CA,A1,CA 3162186 A1,108-674-365-362-774,2021-02-18,2021,CA 3162186 A,2020-08-12,US 201962885375 P;;US 202063030053 P;;US 202063055919 P;;CA 2020051100 W,2019-08-12,SYSTEM AND METHOD OF SEMI-AUTONOMOUS CLEANING OF SURFACES,"A system and method can be provided for detecting the status of one or more components and/or systems of, for example, a manual, semi-autonomous, or fully autonomous cleaning device or the like. Embodiments described herein relate to a system that provides semi-autonomous cleaning of surfaces by a semi-autonomous cleaning device. The system provides for improved reliable obstacle detection and avoidance, improved sensing, improved design, improved failure detection, advanced diagnostics and expandability capabilities.",AVIDBOTS CORP,MOLINA CABRERA PABLO ROBERTO;;CHOI YOOHEE;;COCA FLORIN;;FAKIH ADEL;;PARK BONGKYUN;;YE WEILONG;;RASHEED UMER;;BAJWA BHAVNIT SINGH;;FRASER CAMERON SCOTT REIDLINGER;;LEE KENNETH KING HO;;MCLENNAN DUNCAN CHAMPAN;;DUCHESNE THOMAS JOSEPH;;HAYTON BREANNA MAY;;GORZKOWSKI IGOR;;HYDE JOHN JAMES SAMUEL;;BERSENEV ALEXANDER;;BABOOLAL RAVI;;GUPTA DHROV;;GRANDIN THOMAS,,https://lens.org/108-674-365-362-774,Patent Application,no,0,0,7,9,0,G05D1/0272;;G05D1/0248;;G05D1/0274;;A47L11/305;;A47L11/4038;;A47L11/4011;;A47L11/4044;;A47L11/4055;;G01B11/2545;;G01B11/245;;G06V20/10;;G06V10/25;;G06V10/82;;G06F18/00;;G05D1/0251;;G05D1/0274;;G06V20/58;;A47L11/305;;A47L11/4008;;A47L11/4011;;A47L11/4038;;A47L11/4044;;A47L11/4066;;A47L11/4088;;A47L2201/04;;G06V10/25;;G06V10/82;;G06V20/10,A47L11/40;;A47L11/29;;B08B13/00;;B25J9/18;;B25J19/02;;B25J19/04;;G01B11/14;;G01M13/00;;G06V10/25;;H04W4/38,,0,0,,,,PENDING
262,EP,A1,EP 4013279 A1,044-161-759-877-611,2022-06-22,2022,EP 20851459 A,2020-08-12,US 201962885375 P;;US 202063030053 P;;US 202063055919 P;;CA 2020051100 W,2019-08-12,SYSTEM AND METHOD OF SEMI-AUTONOMOUS CLEANING OF SURFACES,,AVIDBOTS CORP;;MOLINA CABRERA PABLO ROBERTO,CHOI YOOHEE;;COCA FLORIN;;FAKIH ADEL;;PARK BONGKYUN;;YE WEILONG;;RASHEED UMER;;BAJWA BHAVNIT SINGH;;FRASER CAMERON SCOTT REIDLINGER;;LEE KENNETH KING HO;;MCLENNAN DUNCAN CHAPMAN;;DUCHESNE THOMAS JOSEPH;;HAYTON BREANNA MAY;;GORZKOWSKI IGOR;;HYDE JOHN JAMES SAMUEL;;BERSENEV ALEXANDER;;BABOOLAL RAVI;;GUPTA DHROV;;GRANDIN THOMAS;;MOLINA CABRERA PABLO ROBERTO,,https://lens.org/044-161-759-877-611,Patent Application,yes,0,0,7,9,0,G05D1/0272;;G05D1/0248;;G05D1/0274;;A47L11/305;;A47L11/4038;;A47L11/4011;;A47L11/4044;;A47L11/4055;;G01B11/2545;;G01B11/245;;G06V20/10;;G06V10/25;;G06V10/82;;G06F18/00;;G05D1/0251;;G05D1/0274;;G06V20/58;;A47L11/305;;A47L11/4008;;A47L11/4011;;A47L11/4038;;A47L11/4044;;A47L11/4066;;A47L11/4088;;A47L2201/04;;G06V10/25;;G06V10/82;;G06V20/10,A47L11/40;;A47L11/29;;B08B13/00;;B25J9/18;;B25J19/02;;B25J19/04;;G01B11/14;;G01M13/00;;G06V10/25;;H04W4/38,,0,0,,,,PENDING
263,WO,A1,WO 2021/026649 A1,155-128-272-726-985,2021-02-18,2021,CA 2020051100 W,2020-08-12,US 201962885375 P;;US 202063030053 P;;US 202063055919 P,2019-08-12,SYSTEM AND METHOD OF SEMI-AUTONOMOUS CLEANING OF SURFACES,"A system and method can be provided for detecting the status of one or more components and/or systems of, for example, a manual, semi-autonomous, or fully autonomous cleaning device or the like. Embodiments described herein relate to a system that provides semi-autonomous cleaning of surfaces by a semi-autonomous cleaning device. The system provides for improved reliable obstacle detection and avoidance, improved sensing, improved design, improved failure detection, advanced diagnostics and expandability capabilities.",AVIDBOTS CORP;;MOLINA CABRERA PABLO ROBERTO,MOLINA CABRERA PABLO ROBERTO;;CHOI YOOHEE;;COCA FLORIN;;FAKIH ADEL;;PARK BONGKYUN;;YE WEILONG;;RASHEED UMER;;BAJWA BHAVNIT SINGH;;FRASER CAMERON SCOTT REIDLINGER;;LEE KENNETH KING HO;;MCLENNAN DUNCAN CHAPMAN;;DUCHESNE THOMAS JOSEPH;;HAYTON BREANNA MAY;;GORZKOWSKI IGOR;;HYDE JOHN JAMES SAMUEL;;BERSENEV ALEXANDER;;BABOOLAL RAVI;;GUPTA DHROV;;GRANDIN THOMAS,,https://lens.org/155-128-272-726-985,Patent Application,yes,11,3,7,9,0,G05D1/0272;;G05D1/0248;;G05D1/0274;;A47L11/305;;A47L11/4038;;A47L11/4011;;A47L11/4044;;A47L11/4055;;G01B11/2545;;G01B11/245;;G06V20/10;;G06V10/25;;G06V10/82;;G06F18/00;;G05D1/0251;;G05D1/0274;;G06V20/58;;A47L11/305;;A47L11/4008;;A47L11/4011;;A47L11/4038;;A47L11/4044;;A47L11/4066;;A47L11/4088;;A47L2201/04;;G06V10/25;;G06V10/82;;G06V20/10,A47L11/40;;A47L11/29;;B08B13/00;;B25J9/18;;B25J19/02;;B25J19/04;;G01B11/14;;G01M13/00;;G06V10/25;;H04W4/38,,1,0,,,See also references of EP 4013279A4,PENDING
264,US,A1,US 2022/0265110 A1,140-190-477-264-246,2022-08-25,2022,US 202017650678 A,2020-08-12,US 202017650678 A;;US 201962885375 P;;US 202063030053 P;;US 202063055919 P;;CA 2020051100 W,2019-08-12,SYSTEM AND METHOD OF SEMI-AUTONOMOUS CLEANING OF SURFACES,"A system and method can be provided for detecting the status of one or more components and/or systems of, for example, a manual, semi-autonomous, or fully autonomous cleaning device or the like. Embodiments described herein relate to a system that provides semi-autonomous cleaning of surfaces by a semi-autonomous cleaning device. The system provides for improved reliable obstacle detection and avoidance, improved sensing, improved design, improved failure detection, advanced diagnostics and expandability capabilities.",AVIDBOTS CORP,MOLINA CABRERA PABLO ROBERTO;;CHOI YOOHEE;;COCA FLORIN;;FAKIH ADEL;;PARK BONGKYUN JAKE;;YE WEILONG;;RASHEED UMER;;BAJWA BHAVNIT SINGH;;FRASER CAMERON SCOTT REIDLINGER;;LEE KENNETH KING HO;;MCLENNAN DUNCAN CHAPMAN;;DUCHESNE THOMAS JOSEPH;;HAYTON BREANNA MAY;;GORZKOWSKI IGOR;;HYDE JOHN JAMES SAMUEL;;BERSENEV ALEXANDER;;BABOOLAL RAVI;;GUPTA DHROV;;GRANDIN THOMAS,AVIDBOTS CORP (2022-01-14),https://lens.org/140-190-477-264-246,Patent Application,yes,0,5,7,9,0,G05D1/0272;;G05D1/0248;;G05D1/0274;;A47L11/305;;A47L11/4038;;A47L11/4011;;A47L11/4044;;A47L11/4055;;G01B11/2545;;G01B11/245;;G06V20/10;;G06V10/25;;G06V10/82;;G06F18/00;;G05D1/0251;;G05D1/0274;;G06V20/58;;A47L11/305;;A47L11/4008;;A47L11/4011;;A47L11/4038;;A47L11/4044;;A47L11/4066;;A47L11/4088;;A47L2201/04;;G06V10/25;;G06V10/82;;G06V20/10,A47L11/40;;A47L11/30;;G05D1/02;;G06V10/25;;G06V20/58,,0,0,,,,PENDING
265,AU,A1,AU 2020/330380 A1,006-218-168-915-424,2022-03-03,2022,AU 2020/330380 A,2020-08-12,US 201962885375 P;;US 202063030053 P;;US 202063055919 P;;CA 2020051100 W,2019-08-12,System and method of semi-autonomous cleaning of surfaces,"A system and method can be provided for detecting the status of one or more components and/or systems of, for example, a manual, semi-autonomous, or fully autonomous cleaning device or the like. Embodiments described herein relate to a system that provides semi-autonomous cleaning of surfaces by a semi-autonomous cleaning device. The system provides for improved reliable obstacle detection and avoidance, improved sensing, improved design, improved failure detection, advanced diagnostics and expandability capabilities.",AVIDBOTS CORP;;MOLINA CABRERA PABLO,MOLINA CABRERA PABLO ROBERTO;;CHOI YOOHEE;;COCA FLORIN;;FAKIH ADEL;;PARK BONGKYUN;;YE WEILONG;;RASHEED UMER;;BAJWA BHAVNIT SINGH;;FRASER CAMERON SCOTT REIDLINGER;;LEE KENNETH KING HO;;MCLENNAN DUNCAN CHAPMAN;;DUCHESNE THOMAS JOSEPH;;HAYTON BREANNA MAY;;GORZKOWSKI IGOR;;HYDE JOHN JAMES SAMUEL;;BERSENEV ALEXANDER;;BABOOLAL RAVI;;GUPTA DHROV;;GRANDIN THOMAS,,https://lens.org/006-218-168-915-424,Patent Application,no,0,0,7,9,0,G05D1/0272;;G05D1/0248;;G05D1/0274;;A47L11/305;;A47L11/4038;;A47L11/4011;;A47L11/4044;;A47L11/4055;;G01B11/2545;;G01B11/245;;G06V20/10;;G06V10/25;;G06V10/82;;G06F18/00;;G05D1/0251;;G05D1/0274;;G06V20/58;;A47L11/305;;A47L11/4008;;A47L11/4011;;A47L11/4038;;A47L11/4044;;A47L11/4066;;A47L11/4088;;A47L2201/04;;G06V10/25;;G06V10/82;;G06V20/10,A47L11/40;;A47L11/29;;B08B13/00;;B25J9/18;;B25J19/02;;B25J19/04;;G01B11/14;;G01M13/00;;G06V10/25;;H04W4/38,,0,0,,,,PENDING
266,EP,A4,EP 4013279 A4,150-681-966-158-54X,2023-09-06,2023,EP 20851459 A,2020-08-12,US 201962885375 P;;US 202063030053 P;;US 202063055919 P;;CA 2020051100 W,2019-08-12,SYSTEM AND METHOD OF SEMI-AUTONOMOUS CLEANING OF SURFACES,,AVIDBOTS CORP;;MOLINA CABRERA PABLO ROBERTO,CHOI YOOHEE;;COCA FLORIN;;FAKIH ADEL;;PARK BONGKYUN;;YE WEILONG;;RASHEED UMER;;BAJWA BHAVNIT SINGH;;FRASER CAMERON SCOTT REIDLINGER;;LEE KENNETH KING HO;;MCLENNAN DUNCAN CHAPMAN;;DUCHESNE THOMAS JOSEPH;;HAYTON BREANNA MAY;;GORZKOWSKI IGOR;;HYDE JOHN JAMES SAMUEL;;BERSENEV ALEXANDER;;BABOOLAL RAVI;;GUPTA DHROV;;GRANDIN THOMAS;;MOLINA CABRERA PABLO ROBERTO,,https://lens.org/150-681-966-158-54X,Search Report,no,3,0,7,9,0,G05D1/0272;;G05D1/0248;;G05D1/0274;;A47L11/305;;A47L11/4038;;A47L11/4011;;A47L11/4044;;A47L11/4055;;G01B11/2545;;G01B11/245;;G06V20/10;;G06V10/25;;G06V10/82;;G06F18/00;;G05D1/0251;;G05D1/0274;;G06V20/58;;A47L11/305;;A47L11/4008;;A47L11/4011;;A47L11/4038;;A47L11/4044;;A47L11/4066;;A47L11/4088;;A47L2201/04;;G06V10/25;;G06V10/82;;G06V20/10,A47L11/29;;A47L11/40;;B08B13/00;;B25J9/18;;B25J19/02;;B25J19/04;;G01B11/14;;G01M13/00;;H04W4/38,,1,0,,,See also references of WO 2021026649A1,PENDING
